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1. Abstract 
The goal of eliminating tuberculosis (TB) by 2050 depends on the development of 
improved TB diagnostics, drugs and vaccines. Advances in these areas require a deep 
understanding of the disease and its causative agent, Mycobacterium tuberculosis (M. 
tb). Mycobacterial species that cause TB in humans and other mammalian hosts are 
grouped within the M. tb complex. Development of powerful technologies such as 
next-generation sequencing and microarrays opened up new avenues for comparative 
and functional genomics of the M. tb complex. Due to the large and increasingly 
complex datasets generated from these technologies, the bottleneck in biological 
investigation has shifted from data generation to analysis. The objectives of this 
thesis were to establish and employ strategies for the analysis, integration, and 
interpretation of high-throughput sequencing and microarray datasets using a range 
of bioinformatics and statistical tools.  
In the area of comparative genomics, we assessed the genetic diversity in the M. tb 
complex using various methods, such as SNP (single nucleotide polymorphism) 
genotyping, automated Sanger sequencing and next-generation sequencing. In a 
study comparing the genomes of the virulent M. bovis and M. bovis BCG vaccine 
strains, we identified a set of SNPs that were common to all BCG strains, and could 
provide novel insights on the molecular basis of BCG attenuation. In another study, 
we surveyed the genetic variation in the highly immunodominant esx gene family 
among clinical isolates of M. tb and identified sequence polymorphisms in known T-
cell epitopes on Esx proteins that could affect their immunogenicity. We exploited 
the power of next-generation sequencing to detect sequence variation among M. tb 
strains that could result in phenotypic differences. By comparing the genomes of 
drug-resistant mutants with the sensitive wild-type strain we were able to identify 
the target of the anti-TB drug, pyridomycin. Using a similar approach we identified 
a mutation that makes M. tb strains incapable of producing PDIMs (phthiocerol 
dimycocerosates), which are cell wall associated lipids involved in M. tb virulence. 
In the area of functional genomics, we mapped genome-wide binding sites for 
transcription factors using chromatin immunoprecipitation followed by hybridization 
to microarrays (ChIP-on-chip) or sequencing (ChIP-seq), and performed 
transcription profiling by means of high-throughput cDNA sequencing (RNA-seq). 
We carried out a comprehensive study to characterize the whole transcriptome of M. 
tb in exponential and stationary phases of growth, and understand the genome-wide 
dynamics of two key components of the transcription machinery, namely, RNA 
polymerase and NusA. By systematic integration of the ChIP-seq and RNA-seq data, 
we identified a set of transcription units (TU) in the M. tb genome, and mapped 
their putative promoters. Analysis of RNAP and NusA binding across the promoter 
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and body of TUs and their correlation with transcription uncovered new functional 
aspects of the transcriptional complex in M. tb. We also exploited the ChIP-on-chip 
and ChIP-seq technologies to define the regulon of the M. tb sigma factor F, and 
gain a better understanding of the regulatory role of the nucleoid associated protein, 
EspR.   
 
Altogether, this thesis has improved our knowledge of the evolution, physiology and 
virulence of the M. tb complex. In addition, we have established next generation 
sequencing as a powerful tool for comparative and functional studies, with potential 
applications in the clinical setting. 
 
Keywords: Mycobacterium tuberculosis, genomics, transcriptomics, ChIP-seq, RNA-
seq, ChIP-on-chip, microarrays, next-generation sequencing, tuberculosis, 
bioinformatics, single nucleotide polymorphisms 
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Résumé 
L’objectif d’éradiquer la tuberculose (TB) pour 2050 dépend du développement de 
nouveaux tests diagnostiques, d’agents antimycobactériens et de vaccins. Les progrès 
dans ces domaines nécessitent une bonne compréhension de la maladie et de l’agent 
infectieux en cause, Mycobacterium tuberculosis (M. tb). Les espèces de 
mycobactéries responsables de la tuberculose chez l’homme et chez d’autres 
mammifères forment le “complexe M. tb”. Le développement de technologies très 
performantes telles que les puces à ADN et le séquençage à haut débit a ouvert la 
voie de la génomique comparative et fonctionnelle du « complexe M. tb ». En raison 
de la masse considérable et de la complexité des données générées par ces nouvelles 
technologies, l’étape limitante en génonique aujourd’hui n’est plus l’obtention de 
données mais leur analyse. Les objectifs de cette thèse étaient d’établir et d’utiliser 
des méthodes d’analyse, d’intégration, et d’interprétation des données des puces à 
ADN et du séquençage à haut débit en s’appuyant sur un panel d’outils statistiques 
et bio-informatiques. 
 
Dans le domaine de la génomique comparative, nous avons étudié la diversité 
génétique du complexe M.tb en utilisant diverses méthodes telles que le génotypage 
de polymorphismes mononucléotidiques (SNP), le séquençage automatisé Sanger et le 
séquençage de nouvelle génération à haut débit. L’étude comparative des génomes 
d’une souche de M. bovis virulente et de souches de M. bovis BCG atténuées nous a 
permis d’identifier un certain nombre de SNPs communs à toutes les souches BCG, 
révélant de nouvelles bases moléculaires pouvant être à l’origine de l’atténuation des 
souches. Dans une autre étude nous avons examiné la variation génétique des gènes 
de la famille esx, chez des isolats cliniques de M. tb.  Nous avons identifié des 
polymorphismes dans des épitopes connus de lymphocytes T qui pourraient affecter 
l’immunogénicité des protéines Esx. Nous avons également exploité la puissance du 
séquençage à haut débit pour détecter des variations de séquence entre des souches 
de M. tb dans le but de découvrir des mutations responsables de différences 
phénotypiques. En comparant les génomes de la souche sauvage M. tb H37Rv et d’un 
mutant résistant à la pyridomycine, nous avons pu identifier la protéine cible de cet 
antibiotique, la protéine InhA. Par la même approche, nous avons mis en évidence 
une mutation responsable d’un défaut de production de PDIM, un lipide associé à 
l’enveloppe de la bactérie et qui contribue à la virulence de M. tuberculosis.  
  
Dans le domaine de la génomique fonctionnelle, nous avons cartographié à l’échelle 
du génome les sites de liaison à l’ADN de facteurs de transcription par la technique 
d’immunoprécipitation de la chromatine suivie d’hybridation de puces à ADN 
(ChIP-on-chip) ou de séquencage (ChIP-seq) et nous avons étudié le transcriptome 
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de M. tb par séquencage d’ADNc à haut débit (RNA seq). Nous avons réalisé une 
étude globale visant à caractériser le transcriptome complet de M. tb en phases de 
croissance exponentielle et stationnaire et à comprendre la dynamique de deux 
facteurs clés de la machinerie transcriptionnelle à savoir l’ARN polymérase et le 
facteur de transcription NusA. En intégrant de façon systématique les données 
obtenues par ChIP-seq et RNA-seq, nous avons identifié une série d’unités 
transcriptionnelles dans le génome de M. tb et localisé leurs promoteurs putatifs. 
L’analyse des sites de liaison de l’ARN polymérase et de NusA au niveau des 
promoteurs et des corps principaux des unités de transcription corrélée à l’activité 
transcriptionnelle a mis en évidence de nouveaux aspects fonctionnels du complexe 
de transcription. Nous avons également exploité les technologies de ChIP-on-chip et 
ChIP-seq pour définir le régulon du facteur sigma F et approfondir les connaissances 
sur le rôle régulateur de EspR, une protéine associée aux nucléoides. 
 
Globalement, les études décrites dans cette thèse ont amélioré nos connaissances sur 
l’évolution, la physiologie et la virulence du complexe M. tb. De plus, nous avons 
établi le séquençage de nouvelle génération comme un outil performant pour réaliser 
des études comparatives et fonctionnelles ayant des applications cliniques. 
 
Mots-clés: Mycobacterium tuberculosis, génomique , transcriptomicque ChIP-seq, 
RNA-seq, ChIP-on-chip, microarrays, séquençage à haut débit , tuberculose, 
bioinformatique, polymorphismes mononucléotidiques  
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2. Background 
2.1 Tuberculosis 
Tuberculosis (TB) is a chronic infectious disease that has afflicted humans for 
thousands of years. Mycobacterium tuberculosis (M. tb), the bacterium that 
causes TB is an obligate human pathogen. It is transmitted by aerosols 
containing infectious M. tb released from the lungs of infected individuals 
upon coughing. TB predominantly affects the lungs, but can occur in any 
tissue. An infection with M. tb can lead to one of three possible outcomes: 
(Glickman & Jacobs 2001; Young et al. 2009)  
1) a minority of infected individuals develop rapidly progressive disease, 
referred to as ‘active’ primary TB. Active disease is a chronic wasting illness 
characterized by fever, weight loss and cough (in the case of pulmonary 
infection) that could lead to death. 
2) the majority of infected individuals develop a clinically ‘latent’ TB 
infection (LTBI) characterized by an effective acquired immune response and 
absence of disease symptoms.  
3) a small proportion of the ‘latently’ infected individuals, especially those 
who are immunosuppressed, may develop ‘active’ disease at a later stage, 
which is referred to as ‘post-primary’ TB. 
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2.1.1 History of the Disease 
Archaeological evidence from Egyptian mummies indicated manifestation of 
TB as early as 5000 BC (Schaaf & Zumla 2009). TB was designated “The 
Captain of all the Men of Death” as it continued to claim lives through the 
ages (Daniel 2006). In the 18th and 19th centuries, TB reached epidemic 
proportions in Europe and North America and was referred to as “The Great 
White Plague” (Dubos 1952). On March 24, 1882, the German scientist 
Robert Koch changed the course of TB history when he identified 
Mycobacterium tuberculosis (M. tb) as the causative agent of TB. The 
discovery of the tubercle bacillus paved the way for great advances in the 
areas of TB diagnosis, prevention and control.  
 
In 1907 Clemens von Pirquet developed the tuberculin skin test for 
diagnosing TB and used it to demonstrate latent TB infection in 
asymptomatic children (Daniel 2006). In 1908, Albert Calmette and Camille 
Guérin began their efforts to attenuate Mycobacterium bovis (a close relative 
of M. tb), which finally led to the development of the BCG (Bacille Calmette-
Guérin) vaccine in 1921 (Calmette 1931).  BCG remains the most widely used 
vaccine in the world. In the decades that followed, a therapeutic revolution 
took place with the discoveries of para-amino salicylic acid (PAS) in 1943 and 
streptomycin in 1944 (Daniel 2006; Zumla et al. 2009). In 1952, Isoniazid 
became the first oral anti-TB drug, followed by rifampicin in 1963 (Girling et 
al. 1976; Daniel 2006). Short-course chemotherapy regimens developed in the 
early 1970s proved to be highly efficient in the treatment of TB (Schaaf & 
Zumla 2009; Zumla et al. 2009; Girling et al. 1976).  
 
Even before the introduction of BCG and chemotherapy, improvements in the 
socioeconomic conditions and living standards had led to a decrease in the 
 9  
death toll from TB in the Western world. As tuberculosis was no longer 
considered a threat to developed countries funding for tuberculosis research 
declined. However, at the same time, TB assumed greater prevalence in many 
poor and developing countries. There was a global resurgence of TB by the 
late 1980s primarily due to the arrival and spread of HIV infection and the 
emergence of drug resistant strains of M. tb. This combined with the 
increased immigration from high-incidence countries, the deterioration in the 
quality of TB control, and intermittent adherence to treatment fuelled the 
TB epidemic further (Murray 2004; Zumla et al. 2009). In the 1990s, it was 
estimated that one-third of the world’s population had been infected with M. 
tb (LTBI) putting these individuals at risk of developing active TB at a later 
stage (Dye et al. 1999). HIV infection was identified as the most powerful risk 
factor for progression of TB from latency to active disease, along with 
diabetes, old age, malnutrition, and other factors leading to 
immunosuppression (Aaron et al. 2004; Corbett et al. 2006; Lawn & Zumla 
2011).  
 
The World Health Organization (WHO) declared TB a global emergency in 
1993, and re-established its TB control program by promoting the Directly 
Observed Therapy Short-Course (DOTS) strategy in 1994. The DOTS 
strategy relies on efficient case detection, standardized chemotherapy, 
uninterrupted drug supply, standardized recording and reporting systems and 
government commitment in order to cope with the high burden of TB (Schaaf 
& Zumla 2009; Espinal et al. 1999). In 2001, the Stop TB Partnership 
(http://www.stoptb.org) was established with the goal of eliminating TB as a 
public health problem. Led by the WHO and involving nearly 1000 
organizations worldwide, the partnership outlined a global plan to halve TB 
prevalence and mortality by 2015 and to eliminate TB as a public health 
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problem by 2050 (Stop TB Partnership, 2006).  
 
Despite the growing number of local, national and international research and 
TB control initiatives in the past decade TB is still among the top causes of 
death and morbidity worldwide, especially in the low- and mid-income 
countries.  
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2.1.2 Epidemiology of Tuberculosis 
TB remains a global pandemic, killing someone approximately every 25 
seconds. In 2010 there were an estimated 8.8 million cases of TB and 1.4 
million estimated deaths caused by TB. The highest incidence rate was 
observed in sub-Saharan Africa (Figure 1), reflecting the high prevalence of 
HIV-infection in this region (Figure 2) (Raviglione et al. 2012). Over 80% of 
the worldwide TB burden is borne by 22 low-income and middle-income 
countries, with the majority of the estimated cases occurring in Asia (59%) 
and Africa (26%). The five countries with largest number of incident cases in 
2010 were India, China, South Africa, Indonesia, and Pakistan (World Health 
Organisation, 2011b) (Figure 1). Although it appears that TB rates in North 
America and most western European countries have reached record lows, the 
number of cases in some metropolitan areas, such as London, has doubled in 
the past 10 years (Raviglione et al. 2012) (Figure 1). HIV-associated TB 
presents a formidable challenge, accounting for 1.1 million of the total TB 
cases in 2010. The African region accounts for the highest proportion (82%) 
of TB cases co-infected with HIV (Figure 2). 
 
Figure 1. Estimated tuberculosis incidence in 2010 (WHO, 2011b). 
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Figure 2. Estimated HIV prevalence in new cases of TB in 2010 (WHO, 2011b). 
 
Another major threat to TB control is the emergence of drug-resistant M. tb 
strains. Drug-resistant TB is widespread and found in all countries surveyed 
by the WHO. Multidrug-resistant TB (MDR-TB) is caused by bacteria that 
are resistant to two of the first-line anti-TB drugs (rifampicin and isoniazid). 
In 2010, the top five countries in terms of total numbers of MDR cases were 
India, China, the Russian Federation, South Africa, and Bangladesh. 
Estimates for the incidence of drug-resistant tuberculosis are difficult to 
obtain due to insufficient laboratory facilities for drug susceptibility testing in 
most endemic countries (Raviglione et al. 2012). Of the expected 250,000 
MDR-TB cases in 2009, only 24,511 were reported to have enrolled for 
treatment (WHO Stop TB Department, 2011d). In 2010, the estimated 
prevalence of MDR-TB rose to 650,000 cases among which only 46,000 
enrolled for treatment. These data reveal the urgent need for improving the 
diagnosis and management of drug-resistant tuberculosis, especially in 
resource-poor countries. Extensively drug-resistant TB (XDR-TB) is a serious 
threat to global health caused by bacterial strains that are resistant to the 
two first-line drugs (rifampicin and isoniazid) and to second-line drugs 
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(fluoroquinolones and injectable aminoglycosides) (WHO Stop TB 
Department, 2011d). Globally, there are an estimated 25,000 annual cases of 
XDR-TB. A total of 69 countries have reported at least one case of XDR-TB 
(Migliori et al. 2007; N Sarita Shah 2011). The situation is worse in Eastern 
Europe where 10% of all MDR-TB cases are extensively drug-resistant.  
 
Since 1995, 46 million people have been successfully treated and up to 6.8 
million lives have been saved through the Stop TB Strategy (Raviglione et al. 
2012). To eliminate TB as a public health problem by 2050, the global 
incidence must fall at a rate of 16% annually over the next four decades 
(Lönnroth et al. 2009). Unfortunately, the rate of decline in TB incidences 
has been very slow, at less than 1% since 2002, stressing the need for 
intensifying efforts to combat TB.  
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2.1.3 Methods for TB Control and Challenges 
In spite of substantial advances in TB control, and a steady decline in the 
global TB incidence in the last decade, the disease still represents an 
unacceptable burden of human suffering and death in the world. Elimination 
of TB can only be achieved by intensifying basic and operational research in 
the three key areas, namely, effective and faster-acting anti-TB drugs, more 
sensitive and specific diagnostic tests and a universally efficacious vaccine 
(Cole 2002a; Zumla et al. 2009). The Stop TB Partnership and WHO created 
the TB Research Movement to support and stimulate fundamental research 
on tuberculosis. The result was a roadmap for global TB research – a list of 
the main research priorities that need to be addressed to help us get closer to 
the goal of TB elimination (Stop TB Partnership, 2011c). This section will 
summarize the important recent developments in global research efforts for 
TB control (Lawn & Zumla 2011; Raviglione et al. 2012) along with the key 
research priorities identified in the International Roadmap for TB research 
and selected review publications in areas of diagnostics (Wallis et al. 2010), 
vaccine (Brennan 2012; Kaufmann & Hussey 2010), and drug (Zumla, Hafner, 
et al. 2012a; Sala & Hartkoorn 2011) development.  
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2.1.3.1 Diagnosis 
The last few years have seen substantial progress in the development of new 
diagnostic tools for TB. In 2007, WHO recommended liquid culture systems 
for TB diagnosis and for drug-susceptibility testing owing to their increased 
sensitivity and reduced delays in obtaining results compared to the use of 
solid media. The following year, molecular line probe assays (LPAs) based on 
reverse hybridization technology were approved for detection of drug 
resistance in smear-positive patients (Morgan et al. 2005; Ling, Zwerling, et 
al. 2008b). The most promising development in TB diagnostics came in 2010 
with the introduction of nucleic acid amplification tests (NAATs) (Ling, 
Flores, et al. 2008a). The GeneXpert MTB/RIF assay is a quick (< 2 hours), 
automated diagnostic test that can detect M. tb and resistance to rifampicin 
(RIF) (Helb et al. 2010). It has been endorsed by WHO and adapted on a 
wide scale over the last couple of years (Boehme et al. 2010).  
 
For the past century, the primary diagnosis of LTBI was carried out using 
the tuberculin skin test. Unfortunately, this test is unable to distinguish 
individuals infected with M. tb from those exposed to other mycobacteria, 
including those immunized with M. bovis BCG. About a decade ago, 
interferon gamma (IFN-!) release assays (IGRA) were developed for 
diagnosing latent TB infection based on the release of IFN-
! triggered by immunodominant M.tb antigens such as ESAT-6 and CFP-10 
(Pai et al. 2008). QuantiFERON-TB Gold (Mazurek et al. 2001) and the T-
SPOT.TB (Meier et al. 2005) tests are commercially available IGRAs that 
can detect latent TB but have a reduced specificity for diagnosing active TB.  
 
Despite the recent progress in the field of diagnostics, most of the high-
burden, resource-poor countries rely on the inaccurate and relatively 
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antiquated methods such as direct smear microscopy, chest radiography and 
tuberculin skin testing. The diagnostics pipeline is still missing a simple, 
rapid, inexpensive point-of-care test for active tuberculosis that can work in 
high-burden settings without the need for sophisticated equipment or 
laboratory infrastructure. The existing diagnostic tests are also restricted in 
their ability to diagnose latent TB infection, predict progression of disease 
and, most importantly, to rapidly screen and detect MDR-TB, XDR-TB, and 
HIV-associated TB. At present, the major research priorities for diagnostics 
development are: 
(1) Identify and evaluate new host- and pathogen-specific biomarkers that 
can be used to discriminate between active and latent TB from infected 
samples. 
(2) Devise affordable, rapid, simple and multi-functional diagnostic platforms 
that can be appropriately used in high-burden settings.  
(3) Combine new and existing diagnostic tests in order to detect various 
forms of TB (drug-sensitive, drug-resistant, LTBI) in various population 
settings and at all health-care levels.  
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2.1.3.2 Treatment 
The current DOTS treatment regimen for drug-sensitive TB lasts for six 
months and involves administration of four drugs, isoniazid, rifampicin, 
pyrazinamide and ethambutol for the first two months followed by four 
months of isoniazid and rifampicin. A key feature of the DOTS regimen is 
giving the drugs under direct observation to ensure completion of therapy in 
order to prevent relapse of the disease and minimize the likelihood of 
spreading drug resistance. Although this makes the therapy highly effective, 
its lengthy duration represents a challenge, especially in most developing 
countries where adherence to treatment is often poor. For TB patients 
infected with MDR-TB strains, or those who are intolerant to first-line drugs, 
there are second-line drugs such as fluoroquinolones, amikacin and 
kanamycin. The regimens currently used for MDR- and XDR-TB are long, 
toxic, expensive and of limited efficacy (Zumla, Abubakar, et al. 2012b). 
Given the high prevalence of HIV-associated TB infection, it is also important 
to consider potential interactions of anti-TB drugs with drugs used in anti-
retroviral therapy (ART).  
 
Currently, the development pipeline has over a dozen new or repurposed anti-
TB drugs in clinical trails or in preclinical development (Cole & Riccardi 
2011). Phase 3 trials to investigate whether the current regimen can be 
shortened to four months by replacing ethambutol or isoniazid with 
gatifloxacin or moxifloxacin are also in progress (Figure 3). For the treatment 
of LTBI, three month regimens of rifapentine and isoniazid have yielded good 
results (Sterling et al. 2011). Keeping the drug pipeline’ filled is essential for 
further progress in TB treatment.  
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Figure 3. Development Pipeline for new tuberculosis drugs (Stop TB Partnership, 
2012; Raviglione et al. 2012) 
*Ongoing projects without a lead compound series. †Combination regimens 
 
There is an urgent need to develop TB regimens that can cure all forms of 
TB, that are safe and compatible with ART and effective against LTBI. This 
calls for greater emphasis in understanding the fundamental aspects of M. tb 
biology, its interaction with the host and its life cycle. At present, the major 
research priorities in the field of TB drug development are: 
(1) Identify the mechanisms of action of anti-TB drugs that are currently 
being used or being developed.  
(2) Develop models of M. tb metabolism and physiology, and understand 
persistence mechanisms of the bacilli. 
(3) Understand the relation between active and latently persisting bacilli and 
develop drugs that specifically target LTBI. 
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2.1.3.3 Prevention 
Since 1921, Mycobacterium bovis bacillus Calmette-Guérin (BCG) has been 
the only vaccine used against tuberculosis. It is a live attenuated vaccine that 
was derived upon 230 repeated subcultures of a strain of Mycobacterium bovis 
on potato slices soaked in glycerol and ox bile, leading to the in vitro 
accumulation of mutations and ultimately attenuation (Calmette 1931). Over 
4 billion people have been vaccinated with BCG so far making it the most 
widely used vaccine in the world (Kaufmann & Hussey 2010). BCG is 
effective against severe forms of TB in children (Trunz et al. 2006), but it 
offers very little protection against adult pulmonary TB, the most prevalent 
form of the disease (Fine 1995). In addition, BCG is not recommended for use 
in children diagnosed as HIV-positive owing to the risk of disseminated BCG 
disease. There is a dire need for new vaccines that are safe in HIV-infected 
children and adults, and effective against all age groups and populations. At 
present there are at least 12 TB vaccine candidates in clinical trials (Figure 
3) with the aim of either replacing or enhancing the existing BCG vaccine 
(Kaufmann & Hussey 2010). The vaccine candidates can be classified into 4 
main types (Brennan 2012; Kaufmann & Hussey 2010): 
(1) prime vaccines, to be given as a replacement to BCG, (2) booster vaccines 
to be given weeks, or years after vaccination with BCG or its replacement, 
prior to TB exposure, (3) post-infection vaccines to target latent infection or 
prevent re-activation in those who have been pre-exposed to TB, (4) 
immunotherapy vaccines to be given as an adjunct to chemotherapy (Figure 
3) (Brennan 2012). 
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Figure 4. Global TB Vaccine Pipeline in 2011 (Stop TB Partnership, 2011a). 
 
The objective of fundamental research in vaccine development is to 
understand how to manipulate the host immune response to control M. tb 
infection and disease. Therefore, it is critical to identify components of the 
host immune system that are required for elimination of the bacteria. At 
present, the major research priorities in the area of vaccine development are: 
(1) Evaluate and compare immune responses to BCG and to new vaccines in 
different populations and age groups.  
(2) Understand host-pathogen interactions during disease progression and to 
determine components of the host’s immune system that lead to elimination 
of M. tb and prevent reactivation of LTBI. 
(3) Identify immunodominant antigens that are associated with different 
metabolic states of M. tb. 
  
Global TB Vaccine Pipeline 
AdAg85A 
McMaster University 
Hybrid-I+CAF01 
SSI, TBVI 
H56+IC31 
SSI, Aeras, Intercell 
Hyvac 4/ AERAS-404 
+IC31 
SSI, sanofi-pasteur, 
Aeras, Intercell 
AERAS-422 
Aeras 
M72+AS01 
GSK, Aeras 
VPM 1002 
Max Planck, Vakzine 
Projekt Mgmt, TBVI 
Hybrid-1+IC31 
SSI, TBVI, EDCTP, 
Intercell 
 
RUTI 
Archivel Farma, S.L. 
 
 
MVA85A/ 
AERAS-485 
Oxford-Emergent 
Tuberculosis 
Consortium (OETC), 
Aeras 
AERAS-402/ 
Crucell Ad35 
Crucell, Aeras 
Mw [M. indicus pranii 
(MIP)] 
Dept of Biotechnology 
(India), M/s. Cadila 
 
 
Phase II Phase III Phase IIb Phase I 
Source:  Tuberculosis Vaccine Candidates – 2011 
  Prime 
  Boost 
  Post-infection 
  Immunotherapy 
                   TB Vaccine Types 
Viral-vectored: MVA85A, AERAS-402, AdAg85A 
Protein/adjuvant: M72, Hybrid-1, Hyvac 4, H56 
rBCG: VPM 1002, AERAS-422 
Killed WC or Extract: Mw, RUTI 
 2 1  
 
2.2 Mycobacterium tuberculosis (M. tb) 
Mycobacterium tuberculosis (M. tb), the causative agent of TB in humans, is 
an aerobic, slow-growing, acid-fast, rod-shaped bacterium. The genus 
Mycobacterium is within the order Actinomycetales that comprises a large 
number of well-characterized species, several of which are associated with 
human and animal disease. Other human pathogens include, Mycobacterium 
leprae, the cause of leprosy, Mycobacterium ulcerans, the causative agent of 
Buruli ulcer, and Mycobacterium avium, which is an opportunistic pathogen 
often reported to be involved in HIV-infection (Horsburgh 1991). 
 
M. tb has a slow doubling time of approximately 24 hours and takes three to 
four weeks to form colonies in vitro. In humans, it undergoes a complex life 
cycle, which can involve a dormant or latent phase where metabolism is 
thought to be greatly reduced as the bacteria are contained within 
granulomas, organised arrangements of immune cells. The dormant bacteria 
can reactivate to cause full-blown disease many years later, following 
immunosuppression or aging. The slow replication rate and ability to persist 
in a latent state contribute to the chronic nature of TB infection. A 
characteristic feature of mycobacteria is their extremely resilient cell envelope 
that contains a rich variety of lipids such as mycolic acids, glycolipids, and 
polysaccharides. This unique cell wall is also responsible for the acid fast 
staining property of mycobacteria.  
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2.2.1 The Mycobacterium tuberculosis complex 
Mycobacterial species that cause TB in humans and other mammalian hosts 
are collectively known as tubercle bacilli and are grouped within the 
Mycobacterium tuberculosis complex (MTBC). In humans, TB is primarily 
caused by M. tuberculosis and M. africanum (sub-Saharan Africa). In 
addition, several animal-adapted members of MTBC have been identified. 
These include, M. bovis (cattle) and its attenuated derivative M. bovis BCG 
(vaccine strain), M. microti (voles and other small rodents), M. pinnipedii 
(seals and sea lions), and M. caprae (goats and sheep) (Schaaf & Zumla 
2009). 
 
The genomic revolution in the last decade has facilitated the application of a 
variety of powerful tools, such as large-scale transcriptomics, proteomics, 
comparative genomics, and structural genomics studies in the field of TB 
research that have led to great advances in our understanding of the biology 
and pathogenesis of the tubercle bacilli.  
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2.2.2 Genome Biology of M. tb H37Rv 
In 1998, the paradigm reference strain H37Rv became the first fully 
sequenced M. tb strain (S. Cole et al. 1998). The circular M. tb H37Rv 
genome consists of 4,411,532 bp and displays a high G+C content of 65% 
(Figure 5). It contains over 4000 protein-coding and 50 stable RNA genes, 
using around 91% of its potential coding capacity. It displays a gene density 
at one gene per kilobase, which is comparable to other prokaryotes. Genes are 
evenly distributed on the forward and reverse strands, and 59% of the 
transcription is in the same polarity as the replication fork. More than half of 
the coding sequences in M. tb have arisen from gene duplication or domain-
shuffling events (Tekaia et al. 1999). 
 
Analysis of the genome sequence highlighted several characteristics of the 
biochemistry, physiology, genetics and immunology of M. tb. Being the most 
widely used strain in TB research, continued efforts have been carried out (S. 
T. Cole & Barrell 1998; J.-C. Camus et al. 2002b; J. Camus et al. 2002a; Lew 
et al. 2011) to maintain an accurate and up-to-date genome annotation of M. 
tb H37Rv using a combination of bioinformatics, data mining, comparative 
genomics, scientific literature and manual curation. For over 10 years, the 
TubercuList database (Lew et al. 2011) (http://tuberculist.epfl.ch) has been 
providing access to gene-based annotation for M. tb H37Rv. The current 
release (R25 – April 2012) contains 4095 annotated features, which includes 
4022 protein genes and 73 RNAs (tRNAs, ribosomal RNAs, small RNAs, 
stable RNAs). 
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Figure 5. Circular map of the chromosome of M. tuberculosis H37Rv (S. Cole et al. 
1998).  
The outer circle shows the scale in megabases, with 0 representing the origin of replication. 
The first ring from the exterior denotes the positions of stable RNA genes (tRNAs are blue, 
and others are pink) and the direct-repeat region (pink cube); the second ring shows the 
coding sequence by strand (clockwise, dark green; anticlockwise, light green); the third ring 
depicts repetitive DNA (insertion sequences, orange; 13E12 REP family, dark pink; prophage, 
blue); the fourth ring shows the positions of the PPE family members (green); the fifth ring 
shows the positions of the PE family members (purple, excluding PGRS); and the sixth ring 
shows the positions of the PGRS sequences (dark red). The histogram (center) represents the 
G+C content, with <65% G+C in yellow and >65% G+C in red (S. Cole et al. 1998). 
 
The M. tb genes have been broadly classified into eleven functional categories 
(Table 1). The genome sequence highlighted several characteristics of the 
biology of M. tb, which have been summarized below for each functional 
category.  
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Table 1. Broad classification of M. tb genes according to the TubercuList database  
         (Lew et al. 2011) 
Category Function Number of  features % of total 
0 Virulence, detoxification, and adaptation 238 5.8 
1 Lipid metabolism 272 6.6 
2 Information pathways 242 5.9 
3 Cell wall and cell processes 773 18.9 
4 Stable RNAs 73 1.8 
5 Insertion seqs and phages 147 3.6 
6 PE/PPE proteins 168 4.1 
7 Intermediary metabolism and respiration 936 22.9 
8 Unknown 16 0.4 
9 Regulatory proteins 198 4.8 
10 Conserved hypotheticals 1032 25.2 
 
Virulence, detoxification, and adaptation 
This functional category includes a number of virulence factors, heat shock 
proteins, also known as molecular chaperones, oxidative stress response 
proteins, and toxin-antitoxin systems. An important group of M. tb virulence 
factors involved in host cell invasion is the mammalian cell entry (mce) 
protein family. The M. tb H37Rv genome contains four mce operons that are 
similar in sequence and organization. Inactivation of certain mce genes has 
been shown to reduce the ability of M. tb to invade and/or persist in host 
cells, resulting in attenuation of M. tb virulence in mice (Gioffré et al. 2005). 
Homologs of Mce proteins are found in pathogenic as well as non-pathogenic 
mycobacteria suggesting that their function might not be limited to cell entry 
(F. Zhang & Xie 2011).  
 
The M. tb genome has evolved strategies to counteract the toxic effects of 
oxidative damage. These include production of compounds like mycothiol, 
and enzymes, superoxide dimutase (SodAB) and catalase (KatG). The katG 
 2 6  
gene encodes catalase and peroxidase, which have been shown to be involved 
in growth and persistence of M. tb in mice and guinea pigs (Manca et al. 
1999). KatG is also essential for activation of isoniazid (INH). Resistance to 
INH has often been associated with mutations in the katG gene (Y. Zhang et 
al. 1992).  
 
It is interesting to note that more than half the CDSs (52%) annotated in this 
functional category belong to the toxin-antitoxin (TA) locus. TA systems 
typically consist of a two-gene operon encoding a toxin protein that targets 
an essential cellular function and an antitoxin that counteracts the effects of 
the toxin (van Embden et al. 1993; Gerdes et al. 2005). At present, 62 pairs 
of TA genes are annotated in the M. tb H37Rv genome, nearly all of which 
are conserved among the MTBC, but absent from species outside of this 
complex (Lew et al. 2011). The largest family of TA systems, VapBC encodes 
toxins that act by inhibiting translation via mRNA cleavage. A subset of TA 
systems has been shown to be induced in response to stress and implicated in 
M. tb pathogenesis and adaptation (Ramage et al. 2009).  
 
Lipid metabolism 
M. tb devotes 8% of its coding capacity to lipid biosynthesis and lipid 
degradation. There are representatives of almost every known lipid 
biosynthetic system encoded in the M. tb genome, including homologues of 
enzymes found in mammals and plants. The M. tb genome contains roughly 
250 enzymes involved in fatty acid metabolism, compared to only 50 in 
Escherichia coli. A large proportion of these encode components of fatty acid 
oxidation systems, including the canonical FadA/FadB "-oxidation complex, 
revealing the importance of degradation of host-cell lipids in intracellular 
survival of M. tb (S. Cole et al. 1998). Mycobacteria are unique among 
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bacteria, as they possess both a mammalian type fatty acid synthase I (FASI) 
enzyme as well as a bacterial type fatty acid synthase II (FASII). These 
enzymes are involved in the synthesis of mycolic acids, which are key 
components of the mycobacterial cell wall (S. Cole et al. 1998). While the 
FASs are involved in biosynthesis of primary metabolites, there is another 
family of genes known as the polyketide synthases (PKSs), which often 
catalyze the formation of secondary metabolites. The pps gene cluster 
(ppsABCDE) and the mas gene cluster produce phthiocerol and mycocerosic 
acid that esterify to form phthiocerol dimycocerosate (PDIM), which is one of 
the most abundant cell wall-associated lipids (S. Cole et al. 1998). Over the 
years, M. tb lipids have also been shown to play key roles in virulence and 
pathogenesis of the bacillus. 
 
Information pathways 
This functional class comprises genes involved in the fundamental cellular 
processes, such as DNA replication, DNA repair, transcription and 
translation. About 40% of the genes in this category encode ribosomal 
proteins, which make up subunits of the ribosome in conjunction with 
ribosomal RNA. A number of commonly used TB drugs target functions 
belonging to this category. For example, rifampin targets the DNA-dependent 
RNA polymerase RpoB, fluoroquinolones target DNA gyrase, and 
streptomycin targets the ribosomal protein RpsL (Schaaf & Zumla 2009). 
 
The prokaryotic core RNA polymerase (RNAP) is composed of four distinct 
subunits, ", "!, #, and an $ dimer. The fifth subunit is the % factor, which can 
associate reversibly with core RNAP to form the holoenzyme. It provides the 
promoter recognition function by directing the holoenzyme to specific genes. 
Bacterial genomes generally encode a principal % factor that is involved in 
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transcription of housekeeping genes, and a variable number of alternative % 
factors. The M. tb genome encodes 13 % factors, each with its own specificity. 
The principal % factor, SigA is essential for general transcription of 
housekeeping genes, while the other % factors (SigB to SigM) are nonessential 
(S. Cole et al. 1998). One common mechanism by which % factors are 
regulated is inhibition by proteins referred to as anti-% factors. Anti-% factors 
for SigE, SigH, SigL, SigK and SigF have been annotated in the M. tb 
genome (Lew et al. 2011). The sigB gene encodes an alternative-principal 
% factor, which is induced under various stress conditions. SigF is a stress 
response sigma factor, which is required for full virulence of M. tb (Lee et al. 
2008). The ten other %  factors are classified as extracytoplasmic function 
% factors, which control a variety of functions in response to specific 
extracellular environmental signals, such as, nutrient starvation (SigD), heat 
stock (SigE), antibiotic exposure (SigJ), and oxidative stress (SigH) (S. Cole 
et al. 1998; Manganelli et al. 2004).  
 
Cell wall and cell processes 
Given the distinctive architecture and composition of the mycobacterial cell 
wall, it is not surprising that M. tb devotes a significant proportion (19%) of 
its genes to cell wall and cell processes (Lew et al. 2011). This functional class 
contains genes involved in cell wall biosynthesis, along with lipoproteins, 
transmembrane- and membrane-associated proteins, and secreted proteins. 
The M. tb cell wall is composed of peptidoglycan (PG) and arabinogalactan 
(AG), which form the cell wall core (mAGP) by attaching to mycolic acids 
(Brennan 2003).  In addition there are a number of cell wall-associated lipids, 
such as phosphatidyl-myoinositol mannosides (PIMs) and lipoglycans, termed 
lipomannan (LM) and lipoarabinomannan (LAM) (Brennan 2003). In 
addition to their physiological role these cell wall components also play an 
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immunomodulatory role by interacting with receptors of the host immune 
system (Brennan 2003; Mishra et al. 2011). Many of the proteins involved in 
biosynthesis of cell wall components in M. tb are essential for its survival and 
therefore represent excellent drug targets (Sassetti et al. 2003). Ethambutol is 
a first-line TB drug which blocks the synthesis of arabinogalactan, whereas 
cycloserine, a second-line TB drug, inhibits peptidoglycan synthesis (Schaaf & 
Zumla 2009). 
 
An important family of genes in this functional class encodes specialized 
secretion systems, known as type VII secretion systems (T7SS), which enable 
transport of extracellular proteins across the cell wall. M. tb possesses five 
T7SS, named ESX-1 to ESX-5, which display a conserved genomic 
organization characterized by the presence of tandem gene pairs encoding 
ESX family proteins located immediately downstream of PE/PPE genes 
(Abdallah et al. 2007). The ESX-1 system encodes and secretes the prototypic 
ESX proteins, namely the 6 kDa early secreted antigenic target, ESAT-6 
(EsxA) and the 10 kDa culture filtrate protein, CFP-10 (EsxB), which are 
involved in host-pathogen interactions and play a crucial role in M. tb 
virulence (Alderson et al. 2000). Incidentally, ESX-1 is also conserved in other 
pathogenic mycobacteria such as M. leprae and M. marinum. Loss of the 
region of difference 1 (RD1) containing the ESX-1 locus contributes to the 
attenuation of the vaccine strains of M. bovis BCG (Pym et al. 2002). Of the 
other systems, ESX-5 is known to be necessary for the secretion of PE and 
PPE proteins in M. marinum (Abdallah et al. 2008) and plays a similar role 
in M. tb, where its disruption results in loss of PPE protein secretion, altered 
cell wall integrity and attenuation (Bottai et al. 2012). ESX-3 is essential for 
in vitro growth and may be involved in iron/zinc homeostasis (Siegrist et al. 
2009).  
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Stable RNAs 
This category is dedicated to the genes encoding functional RNA molecules in 
M. tb. It presently contains 73 genes encoding ribosomal RNAs, tRNAs, small 
RNAs and other stable RNAs (Figure 5). Most eubacteria usually contain 
several copies of the ribosomal operon located close to the origin of 
replication, in order to exploit the gene-dosage effect obtained during 
replication. In contrast, M. tb has a single ribosomal RNA operon, located 
1500 kb from the origin of replication (Bercovier et al. 1986). It is likely that 
this contributes to the slow-growth of mycobacteria. Genes encoding tRNAs 
in M. tb recognize 43 of 61 possible sense codons. Over the last few years, a 
number of small non-coding RNAs have been identified in M. tb, including, 
anti-sense transcripts and intergenic small RNAs (sRNAs) (Arnvig & Young 
2009). While functional characterization of sRNAs in M. tb has only been 
recently initiated, some sRNAs have been found at increased abundance 
during stress conditions, infection or in the stationary phase, implicating their 
involvement in host adaptation and virulence (Arnvig & Young 2012; 
DiChiara et al. 2010).  
 
Insertion sequences and phages 
About 3.5% of the M. tb genome is composed of insertion sequences (IS), 
prophages, and a family of repetitive sequences, which exhibit some 
characteristics of mobile genetic elements (Figure 5). There are 56 copies of IS 
elements belonging to at least nine different families, some of which are 
highly similar to those found in other actinomycetes. The most abundant IS 
elements in the M. tb genome are IS6110 (16 copies) and IS1081 (6 copies). 
While most IS elements are stable, IS6110 frequently transposes, and can lead 
to inactivation of genes upon insertion or deletion of chromosomal fragments 
as a result of homologous recombination. The IS6110 copy number can vary 
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from 0-25 between M. tb strains, therefore making them useful molecular 
markers for genotyping strains from the MTBC (van Embden et al. 1993; 
Prod'hom et al. 1997). There are two prophage-like elements, phiRv1 and 
phiRv2, in the genome of M. tb, which share a similar genetic organization 
and are both over 10 kb in length. The phiRv1 prophage is absent in the M. 
bovis BCG vaccine strain. The functional class also includes seven copies of a 
repetitive sequence referred to as REP13E12 or the ‘13E12’ family (Figure 5).  
 
PE/PPE proteins 
The most prominent multi-gene families in M. tb, which are unique to 
mycobacteria, encode the glycine-rich PE and PPE proteins. These genes 
account for 10% of the coding capacity of the M. tb genome (Figure 5). PE 
and PPE members share a conserved N-terminal domain with characteristic 
Pro-Glu (PE) or Pro-Pro-Glu (PPE) motifs and can be divided into 
subfamilies according to the homology and presence of characteristic motifs in 
their C-terminal domains. The largest of these subfamilies contains multiple 
copies of polymorphic GC-rich repetitive sequences at the C-terminal end, 
and is called the PE_PGRS family of proteins. The second largest is the 
major polymorphic tandem repeat or MPTR PPE family. A subset of the PE 
and PPE genes is associated with the ESX loci, which encode components of 
type VII secretion systems.  It has been suggested that the PE and PPE 
proteins may contribute to antigenic variation by interfering with the T-cell 
immune responses (Ramakrishnan et al. 2000).  
 
Intermediary metabolism and respiration 
Around 23% of genes belong to this class, making it the largest functional 
category (excluding conserved hypothetical proteins) in the M. tb genome. 
The abundance of genes in this category, and their functional diversity reflect 
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the high metabolic capacity of M. tb. Genes necessary for synthesis of all 
essential amino acids, vitamins and enzyme co-factors are present in M. tb. In 
addition it can synthesize enzymes necessary for the anabolic pentose 
phosphate pathway, the catabolic Kreb’s cycle, glycolysis, and the glyoxylate 
cycle (S. Cole et al. 1998). It contains electron transport chains using 
oxidative phosphorylation, as well as several anaerobic electron transport 
chains. These include gene clusters that encode nitrate reductase (narGHJI), 
nitrite reductase (nirBD), and fumarate reductase (frdABCD) (S. Cole et al. 
1998; Schaaf & Zumla 2009). It has been demonstrated that the capacity for 
anaerobic respiration might contribute to M. tb virulence (Stermann et al. 
2004). Several studies have suggested that M. tb switches its intermediary 
metabolism from carbon sources such as glucose and glycerol to fatty acids 
and host lipids during the course of infection (Schnappinger et al. 2003; 
Muñoz-Elías et al. 2006). The ability of the bacillus to adapt its metabolism 
to the number of different environments, such as the lung, the macrophage, 
and the granuloma, plays a key role in its pathogenesis.  
 
Regulatory proteins 
Gene expression in M. tb is controlled at the level of transcription initiation 
by a diverse array of regulatory elements. The M. tb genome encodes about 
200 regulatory proteins, which include eleven two-component systems, five 
unpaired response regulators, eleven protein kinases and over 100 putative 
transcriptional regulators (S. Cole et al. 1998). The eukaryotic-like 
serine/threonine protein kinases (STPKs), namely, pknA, pknB and pknD-
pknL have been found to be involved in various processes including cell 
growth, morphology, molecular transport, as well as transcription regulation 
(Sharma et al. 2006; Kumar et al. 2009). M. tb encodes eleven complete two-
component systems, including the DosR (DevR) and DosS (DevS) system, 
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which controls the expression of a number of genes that are induced during 
hypoxia and in response to nitric oxide stress. Another two-component 
system, encoding PhoP and PhoR has been demonstrated to be essential for 
the virulence of M. tb. PhoP positively regulates the biosynthesis of virulence-
associated lipids, and also affects the function of ESX-1 through the espA-
espC-espD locus, which is crucial for ESX-1 function and virulence (Frigui et 
al. 2008). EspR is an important transcriptional regulator that upregulates 
ESX-1 activity by binding upstream of the espA-espC-espD locus (Raghavan 
et al. 2008). In addition, a number of transcription regulator genes have been 
shown to be expressed in M. tb upon infection. 
 
Unknown & Conserved hypotheticals 
Due to the increasing availability of complete mycobacterial genome 
sequences and scientific literature mining, the proportion of unknown CDSs 
and conserved hypothetical proteins in the M. tb genome has been steadily 
decreasing. However, approximately one quarter of the CDSs still fall into 
these two categories. The ‘Conserved hypothetical proteins’ category refers to 
CDSs that are conserved in closely related species of the MTBC, or in other 
mycobacteria, such as, M. smegmatis and M. marinum, that are not members 
of the MTBC. The ‘Unknown’ category refers to genes with no known 
orthologues and includes only 16 CDSs, at present.  
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2.2.3 Comparative and Functional Genomics of the M. tb complex 
The availability of complete genome sequences of M. tb H37Rv and related 
strains combined with advances in high-throughput experimental technologies 
have led to tremendous advances in our knowledge of the evolution, 
population biology, and virulence of M. tb, which has been applied to the 
development of new diagnostic tests, better drugs and vaccines against TB. 
As of August 2012, the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/) and the European Bioinformatics Institute 
(http://www.ebi.ac.uk/) databases hold complete genome sequences for 48 
mycobacterial strains and partial sequences (scaffolds/contigs) for 33 strains. 
Whole genome sequences for several clinical and laboratory strains of M. tb 
and other members of the MTBC are available (Table 2). 
 
Table 2. List of completely sequenced genomes of MTBC members 
 Organism Genome size 
(MB) 
No. of 
Genes 
Mycobacterium tuberculosis str. Erdman ATCC 35801 4.39 4,246 
Mycobacterium tuberculosis CDC5079 4.40 3,695 
Mycobacterium tuberculosis CDC5180 4.41 3,638 
Mycobacterium tuberculosis CDC1551 4.40 4,293 
Mycobacterium tuberculosis CTRI-2 4.40 4,001 
Mycobacterium tuberculosis F11 4.42 3,998 
Mycobacterium tuberculosis H37Ra 4.42 4,084 
Mycobacterium tuberculosis H37Rv 4.41 4,062 
Mycobacterium tuberculosis KZN 605 4.40 4,071 
Mycobacterium tuberculosis KZN 1435 4.40 4,107 
Mycobacterium tuberculosis KZN 4207 4.39 4,191 
Mycobacterium tuberculosis RGTB327 4.38 3,739 
Mycobacterium tuberculosis RGTB423 4.41 3,670 
Mycobacterium tuberculosis UT205 4.42 3,814 
Mycobacterium bovis AF2122/97 4.35 4,001 
Mycobacterium bovis BCG str. Mexico 4.35 4,031 
Mycobacterium bovis BCG str. Pasteur 1173P2 4.37 4,033 
Mycobacterium bovis BCG str. Tokyo 172 4.37 4,027 
Mycobacterium africanum GM041182 4.39 3,983 
(Source: NCBI and EBI databases) 
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2.2.3.1 Genotyping of the M. tb complex 
Discrimination between strains of pathogenic bacteria is crucial from an 
epidemiological perspective. In the 1990s, advances in the field of molecular 
biology led to the development of DNA-fingerprinting methods, which relied 
on strain-specific molecular markers, in order to identify and differentiate 
between strains of the MTBC. Molecular ‘strain typing’ or genotyping tools 
have been used to study disease outbreaks and transmission (Small et al. 
1994), to assess the relative contributions of reinfection and reactivation to 
disease (van Rie et al. 1999), and to address a number of other issues relevant 
to TB control. Several countries routinely collect genotyping data as part of 
their TB surveillance programs. Three of the most commonly used genotyping 
methods are described below, and the genetic elements that are used as 
strain-specific markers in these methods are summarized in Figure 6. 
 
 
Figure 6. Schematic representation of the genetic basis of genotyping techniques.  
Modified from (Nicol & Wilkinson 2008)) The circular chromosome of the reference strain M. 
tb H37Rv is shown together with examples of major genetic elements used for strain 
genotyping. For clarity, only one mycobacterial interspersed repetitive unit (MIRU) locus 
and one insertion sequence (IS6110) are shown.  
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IS6110-based RFLP and ligation-mediated PCR 
The repetitive, mobile insertion sequence IS6110 is present in the genomes of 
the MTBC in varying numbers of copies (Figure 6). Most members carry 
between 5-20 copies at different positions, although some strains with one or 
zero IS6110 copies have also been identified. The IS6110-based restriction 
fragment length polymorphism (RFLP) technique makes use of the variation 
in the number and genomic position of IS6110 elements to generate strain-
specific hybridization patterns (van Embden et al. 1993). A major drawback 
of the RFLP procedure is that it is the time-consuming and expensive. The 
preferred alternative is ligation-mediated PCR which uses one primer specific 
for IS6110 and a second specific for a linker ligated to SalI-restricted genomic 
DNA, making it faster and cheaper compared to RFLP (Prod'hom et al. 
1997).  
 
MIRU-VNTR typing 
Multiple loci on the genome of MTBC strains contain variable numbers of 
tandem repeats (VNTRs) known as the mycobacterial interspersed repetitive 
units (MIRUs) (Supply et al. 1997). MIRU-typing is based on the 
polymorphisms observed in 41 VNTRs ranging from 40-100 bp dispersed on 
the genome of the MTBC (Figure 6). The number of repeats observed at 12, 
15 or 24 selected MIRU loci can be used for genotyping using a PCR-based 
method (Supply et al. 2000). As the length of the repeats is known, the 
number of repeats at each locus is combined to generate a unique numerical 
code. The discriminatory power of MIRU-VNTR analysis is typically 
proportional to the number of loci evaluated. The 24-locus system of tandem 
repeats has been proposed as a high-resolution tool to capture the genetic 
diversity of strains (Supply et al. 2006).  
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Spoligotyping 
MTBC strains contain a genomic region known as the Direct Repeat (DR) 
region that consists of 36 bp repeats interspersed by 43 unique spacer DNA 
sequences of 35-41 bp (Groenen et al. 1993) (Figure 6). The DR locus is a 
representative of the Clustered Regulatory Short Palindromic Repeats 
(CRISPR) family, which has been shown to confer resistance against viruses 
and bacteriophages in bacteria and archaea (Sorek et al. 2008). In the MTBC 
strains, loss of spacers can occur due to homologous recombination or 
transposition of IS6110 insertion sequences (Legrand et al. 2001). Spacer 
oligonucleotide typing or spoligotyping is a PCR-based reverse hybridization 
technique that exploits the variation in the spacers within the conserved DRs 
in order to differentiate MTBC strains (Kamerbeek et al. 1997). The results 
are represented as a 43-digit binary string constructed on the basis of the 
presence or absence of spacers. Spoligotyping has low discriminatory power 
compared to the two other typing methods, but it is widely used because it is 
easy to perform, and highly reproducible.   
 
Centralized databases have been constructed to store DNA fingerprinting 
data for TB using a standardized nomenclature in order to facilitate 
comparison of data from different epidemiological studies and enable 
researchers to analyze the genetic diversity and biogeographic distribution of 
MTBC strains across the world (Shabbeer et al. 2012). The two main 
repositories of M. tb genotyping data are, SpolDB4, which contains close to 
40,000 spoligo patterns for MTBC isolates from more than 120 countries 
(Brudey et al. 2006), and MIRU-VNTRplus, which is a highly curated 
database containing detailed profiles (IS6110 RFLP fingerprint, spoligotype, 
24-locus MIRU profile, etc.) of 186 strains representing all MTBC lineages 
(Allix-Béguec et al. 2008). 
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It has been shown that different strains of M. tb have distinctive 
epidemiological and clinical characteristics in terms of pathogenicity, clinical 
representation and varying behaviour in animal models (Lopez et al. 2003). 
Given the importance of pathogen variation in the outcome of infection and 
disease, understanding the evolution of a pathogen can allow for better 
epidemiological predictions. Genotyping methods have a propensity for 
convergent evolution which limits their use for phylogenetics and strain 
classification (Comas et al. 2009). Availability of the whole genome sequence 
of M. tb H37Rv and the development of DNA microarray technology offered 
new opportunities to study strain diversity in the MTBC by comparative 
genomics (S. V. Gordon et al. 1999; Behr et al. 1999; S. T. Cole 2002b).  
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2.2.3.2 Genetic diversity in the M. tb complex 
Whole genome comparison allowed us to infer the impact of processes such as 
mutation, deletion, duplication and selection on the evolution of the MTBC. 
Soon after the completion of the genome of M. tb H37Rv (H37Rv), sequences 
of the clinical strain M. tb CDC1551 (CDC1551) (Fleischmann et al. 2002), 
and the causative agent of bovine TB, M. bovis AF2122/97 (Garnier 2003) 
became available. DNA sequence data can also be exploited to study the 
nature and strength of selective forces shaping the genetic diversity within 
populations. Proteins are generally highly conserved and therefore amino acid 
substitutions are primarily driven by positive functional selection. 
Identification of proteins under such selective pressure may lead to 
unravelling of important virulence mechanisms as well as the genetic events 
that lead to variable forms of disease caused by the same organism. 
 
Most of the comparative genomics studies have been performed on the 
canonical laboratory strains H37Rv, H37Ra, and M. tb Erdman, the reference 
clinical strains CDC1551 and M. tb HN878, and the vaccine strain M. bovis 
BCG. Genome comparison revealed that members of the MTBC share 99.9% 
identity at the DNA level as well as identical 16s rRNA (Brosch et al. 2002; 
Fleischmann et al. 2002). Single nucleotide polymorphisms (SNPs) and large 
sequence polymorphisms (LSPs), such as chromosomal deletions, are the main 
source of inter-strain variability. 
 
The CDC1551 strain, is a highly transmissible clinical isolate that caused a 
TB outbreak in a rural area of the United States in the 1990s (Valway et al. 
1998). The strain was capable of inducing greater immunoreactivity, and was 
less virulent compared to M. tb H37Rv in animal models (Manca et al. 2001). 
The complete genome of CDC1551 was sequenced in order to identify 
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polymorphisms with potential relevance to disease, pathogenesis, immunity 
and evolution. Comparison of H37Rv and CDC1551 revealed 86 InDels 
(longer than 10 bp) and 1075 SNPs, of which 579 were nonsynonymous, 
presenting important leads to associate genotypic changes with phenotypic 
differences (Fleischmann et al. 2002).  
 
M. tb H37Ra is the avirulent counterpart of the virulent strain H37Rv and 
both strains were derived from their virulent parent H37, which was 
originally isolated from a patient with chronic pulmonary TB (Brosch et al. 
1999). The H37Ra genome is highly similar to that of H37Rv with only 198 
SNPs that occur between H37Ra and H37Rv (Zheng et al. 2008). In fact, 119 
of them are identical between H37Ra and CDC1551 and 3 are due to H37Rv 
strain variation, leaving only 76 H37Ra-specific SNPs that affect 32 genes 
(Garnier 2003). It was later shown that the attenuation in virulence in H37Ra 
was primarily due to a nonsynonymous mutation in the phoP gene leading to 
the inactivation of the positive transcriptional regulator PhoP (Frigui et al. 
2008).  
 
The genome sequence of M. bovis was found to be 99.95% identical to the 
genomes of H37Rv and CDC1551, but the genome size was slightly smaller 
due to a number of deletions. Direct comparison of 2,504 coding sequences 
(CDS) across the three genomes revealed that approximately 1600 M. bovis 
CDS are identical to H37Rv and CDC1551 respectively. There were about 
2400 SNPs between M. bovis and the two M. tb strains, of which roughly 800 
were nsSNPs (Fleischmann et al. 2002). This analysis highlighted the 
conservation of gene sequence across the MTBC, and also the divergence of 
M. bovis and M. tb.  
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Comparison of virulent and avirulent or attenuated MTBC strains made it 
possible to identify genetic differences that might explain the molecular 
mechanisms of pathogenicity. Comparison of genome sequences of the vaccine 
strain M. bovis BCG Pasteur 1173P2 (BCG Pasteur) with H37Rv, CDC1551, 
and M. bovis AF2122/97 uncovered LSPs that led to the loss of 133 genes in 
BCG Pasteur (Behr et al. 1999; Brosch et al. 2007). There were only 736 
SNPs between the two M. bovis isolates, and around 2400 SNPs between 
BCG and M. tb strains. 
 
Further insights on the virulence determinants came from comparison of M. 
tb with M. leprae, the causative agent of leprosy. M. leprae is an obligate 
intracellular pathogen that essentially displays the same cellular tropism and 
host range as the tubercle bacillus. The M. leprae genome has undergone 
massive gene decay as a result of extreme reductive evolution, leaving only 
1604 functional protein-coding genes in the leprosy bacillus (S. T. Cole et al. 
2001). The minimal gene set retained by M. leprae despite the massive gene 
decay suggests that these gene functions are essential for M. leprae and 
possibly for other pathogenic mycobacteria. In silico comparisons among the 
1439 genes common to M. tb and M. leprae revealed a set of 219 “core” genes 
unique to mycobacteria making them potential targets for developing specific 
anti-mycobacterial drugs (Marmiesse et al. 2004).   
 
The MTBC is considered to be clonal and there is little evidence for on-going 
horizontal transfer in members of this complex (Supply et al. 2003; Smith et 
al. 2003; Hirsh et al. 2004), therefore variations occur almost exclusively by 
genomic mutations. SNPs occur at a very low rate of 1 per 2000-4000bp in 
the MTBC. LSPs represent irreversible genetic events in the evolution of the 
MTBC. Each strain has roughly 200 intergenic SNPs that can potentially 
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alter gene expression, 500 genes that are affected by at least one nsSNP, and 
100 genes that are lost or inactivated due to LSPs (Fleischmann et al. 2002; 
Tsolaki et al. 2004; Ernst et al. 2007). 
 
There is clear evidence that SNPs and LSPs both contribute to strain 
variability, for example, most of the drug-resistance mutations are due to 
SNPs (Y. Zhang et al. 1992; Ramaswamy et al. 2000; Cavusoglu et al. 2002), 
and LSPs have been shown to be responsible for variability in virulence of M. 
tb strains (Marmiesse et al. 2004). SNPs are distributed throughout the 
genome and have a low reverse mutation rate and homoplasy index, which 
makes them ideal to investigate genetic diversity (Comas et al. 2009). In a 
study of genomic deletions within clinical isolates of M. tb, mycobacterial 
clones shared the same genomic deletions (LSPs), suggesting that deletions 
could be used as evolutionary marker (Mostowy et al. 2002).  
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2.2.3.3 Evolutionary scenario for the M. tb complex 
Studies have made use of LSPs, together with SNPs and repetitive element 
patterns (spoligotypes) to decipher the genealogy of the MTBC (Ernst et al. 
2007; Brosch et al. 2002; Mostowy et al. 2002; Kamerbeek et al. 1997). In this 
approach, the successive and unidirectional loss of DNA in representative 
strains reveals the order in which members of the complex descended from 
their ancient common ancestor. 
 
Large sequence polymorphisms (LSPs) between MTBC members were first 
identified using techniques such as subtractive hybridization (Mahairas et al. 
1996), bacterial artificial chromosome (BAC) arrays (Brosch et al. 1998; S. V. 
Gordon et al. 1999), microarrays (Behr et al. 1999), and pulsed-field gel 
electrophoresis (S. V. Gordon et al. 1999; Brosch et al. 1999). These studies 
uncovered 14 regions of difference (RD1 to RD14), ranging in size from 2 to 
12.7 kb, that were absent from M. bovis BCG strains relative to the M. tb 
H37Rv genome.  The RD1 region, in particular, is absent from all BCG 
strains, but present in all members of the MTBC. It was later shown to be 
the primary attenuation event in the derivation of M. bovis BCG from M. 
bovis (Pym et al. 2002). Comparison of other members of the MTBC with M. 
tb H37Rv revealed six regions, including, five H37Rv-specific deletions (RvD1-
RvD5) and one M.tb specific deletion (TbD1). The TbD1 region, which is 
characterized by the absence of a 2 kb fragment truncating genes mmpS6 and 
mmpL6, is the only genomic region present in M. bovis and absent from the 
M. tb strains. Based on sequence comparison of 26 structural genes across 
over 800 isolates from the MTBC, Sreevatsan et al. identified two high 
frequency polymorphisms in the genes katG and gyrA that could be used to 
classify MTBC strains into three principal genetic groups (PGGs) (Sreevatsan 
et al. 1997). Brosch et al. examined the distribution of 20 variable regions (14 
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RD, 5 RvD, TbD1) across 100 diverse strains belonging the MTBC. In 
addition, sequences of five genes, namely, oxyR, pncA, katG, gyrA and 
mmpl6, were also analyzed for all the strains as these genes had been shown 
to vary between different tubercle bacilli (Sreevatsan et al. 1996; Scorpio et 
al. 1997; Sreevatsan et al. 1997; Brosch et al. 2002).  
 
An evolutionary pathway of the tubercle bacilli was proposed based on the 
presence or absence of conserved deleted regions and sequence polymorphisms 
in the five genes (Figure 7). The M. tb strains can be divided into two groups, 
“ancestral” and “modern”, based on the presence or absence of the TbD1 
region. All strains of the PGG-2 and PGG-3 as defined by Sreevatsan et al. 
belong to “modern” M. tb strains. The loss of RD9 corresponds to a major 
divergence leading to a main lineage encompassing M. africanum and all 
animal-adapted members of the MTBC. Successive deletions led to M. 
microti, M. pinnipedii, M. caprae, M. bovis and eventually, M. bovis BCG. 
The evolutionary scheme was refined later on to include another molecular 
marker in the pks15/1 gene which is responsible for the production of an 
immunomodulatory phenolic glycolipid (PGL) (Marmiesse et al. 2004). A 7 
bp deletion, inactivating the pks15/1 gene was observed in all “modern” M. tb 
strains, whereas a 6 bp deletion that had on the function of the pks15/1 gene 
occurred in the M. africanum ! M. bovis lineage. The 6 bp deletion occurred 
after the RD9 and before RD10 deletion suggesting that it arose 
independently from the 7 bp deletion. It was also shown that spoligotypes of 
the RD9 deleted lineage could also be used as phylogenetic markers, and the 
resulting phylogeny was congruent to the one based on LSPs, suggesting that 
recombination is rare or absent between strains of this lineage (Smith et al. 
2006).  
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Figure 7. New evolutionary scheme of the MTBC from Ernst et al (Ernst et al. 
2007).  
This is a refined evolutionary scheme after Brosch et al., based on informative markers, such 
as RD regions, SNPs, and spoligotype spacers (Brosch et al. 2002; Marmiesse et al. 2004; 
Smith et al. 2006).  
 
The evolutionary scheme highlighted that M. tb and M. bovis, as well as 
other members of the MTBC have evolved from a common ancestor. 
Additionally, they confirmed that members of the MTBC show a clonal 
population structure, with very little horizontal gene transfer.  
 
The use of regions of difference (RDs), SNPs, and strain-specific deletions and 
duplications, also allowed the construction of the BCG genealogy, which 
classified the BCG strains into four major groups (Figure 8). After the 
original BCG vaccine was derived in 1921, it was distributed to different 
laboratories across the world, which maintained their own daughter strains by 
passaging, until the introduction of archival seed lots in the 1960s.  
Comparative genomics uncovered regions of difference and SNPs between the 
daughter strains, dividing them into early strains represented by BCG Japan, 
Birkhaug, Sweden and Russia, and late strains, including BCGs Pasteur, 
Danish, Glaxo and Prague (Mahairas et al. 1996; S. V. Gordon et al. 1999; 
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Mostowy 2003). The most prominent genomic polymorphisms in the M. bovis 
BCG Pasteur strain were two large tandem duplications, DU1 (! 26 kb) and 
DU2 (! 36 kb), making it partially diploid for 58 genes (Brosch et al. 2007). 
Sequence comparison of M. bovis BCG Pasteur with other BCG strains, 
showed that, DU1 is restricted to BCG Pasteur, while four forms of DU2 
existed, DU2-1 is confined to early BCG vaccines, whereas DU2-III and DU2-
IV occur in late vaccines (Brosch et al. 2007).  
 
 
Figure 8. Refined genealogy of BCG vaccines (Brosch et al. 2002). 
The scheme shows the position of genetic markers identified in this work, RD markers, some 
strain-specific deletions, SNPs, and the distribution of vaccines into the four groups. 
 
A number of successive studies employed SNPs and LSPs as phylogenetically 
informative markers to infer a robust M. tb phylogeny from analysis of 
globally sampled M. tb isolates, and obtained comparable results. Knowledge 
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of the genetic population structure can yield an association between M. tb 
lineages and important traits such as clinical phenotypes, transmissibility, 
likelihood of drug resistance, and adaptation to distinct human populations.   
 
Baker et al. investigated SNPs in seven housekeeping genes (katG, gyrA, 
rpoB, oxyR, ahpC, pncA, and rpsL), and identified 36 synonymous SNPs, 
which allowed them to construct a phylogenetic tree that divided the strains 
into four distinct groups (I – IV) (Baker et al. 2004). Gutacker et al. used 
insilico whole genome comparisons to identify 36 synonymous SNPs in 5069 
clinical isolates, and defined nine main lineages (Gutacker et al. 2002). Filliol 
et al. used the same strategy to identify 159 synonymous SNPs in 219 M. tb 
and M. bovis isolates, which led to ten major groupings, including a lineage 
specific to M. bovis (Filliol et al. 2006). Gagneux et al. obtained similar 
findings by using phylogenetically informative LSPs to screen a global sample 
of 857 clinical isolates of M. tb from 80 countries (Gagneux et al. 2006). 
 
In addition to defining a robust phylogeny, these studies also demonstrated a 
strong association between the phylogenetic lineages and particular 
geographical regions. Given the clonal population structure of the MTBC, the 
selectively neutral sequence variation (sSNPs) was chromosomally linked to 
the selected genetic variation (nsSNPs), resulting in perfectly congruent 
phylogenetic trees using sSNPs and nsSNPs (Gutacker et al. 2002).  
 
Evaluation of the global phylogenies inferred from the aforementioned 
studies, together with the analysis of the large spoligotyping database 
(Brudey et al. 2006) led to the identification of six main strain lineages of M. 
tb and M. africanum that are associated with particular geographic regions 
(Table 2). 
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Table 2. Comparison of terminology and molecular markers for the six main lineages of M. tb 
and M. africanum strains.  
Criteria Lineage 1 Lineage 2 Lineage 3 Lineage 4 Lineage 5 Lineage 6 
SNP 
Sreevatsan  
et al. 
PGG 1 PGG 1 PGGs 2 & 3 PGG 1 PGG 1 PGG 1 
SNP 
Baker et al. Lineage IV Lineage I Lineage III Lineage II Not done Not done 
LSP 
Gagneux  
et al. 
Indo-
Oceanic 
lineage 
East Asian 
lineage 
East 
African-
Indian 
lineage 
Euro-American 
lineage 
West 
African 
lineage I 
West 
African 
lineage II 
SNP 
Gutacker 
 et al. 
Cluster I Cluster II Cluster II.A Cluster III-VII Not done Not done 
SNP 
Filliol et al. 
Cluster 
group 1 
Cluster 
group 2 
Cluster 
group 3a 
Cluster group  
3b-6b Not done Not done 
Spoligotyping 
Brudey et al. EAI Beijing CAS 
Haarlem, LAM,  
T, X AFRI2 AFRI1 
Geographical 
Association 
East Africa, 
Southeast 
Asia, South 
India 
East Asia, 
Russia, 
South Africa 
East Africa, 
North India, 
Pakistan 
Americas, Europe, 
North Africa, 
Middle east 
Ghana, 
Benin, 
Nigeria, 
Cameroon 
Senegal, 
Guinea-
Bissau, 
The Gambia 
 
Hershberg et al. (2008) performed an in-depth survey of the genetic diversity 
in MTBC by de novo sequencing 89 genes in a global collection of 108 
human-adapted MTBC strains. This analysis refined the previous MTBC 
phylogeny and also suggested an association between the genetic diversity in 
human-adapted MTBC strains and ancient human migrations out of Africa, 
as well as more recent population movements in the past few hundred years. 
Deeper insight into the MTBC phylogeny has been obtained from next-
generation sequencing (NGS) studies. Comas et al. (2010) carried out whole 
genome re-sequencing of 20 strains representative of the six M. tb lineages, 
and established a comprehensive MTBC phylogeny based on 9,037 variable 
common nucleotide positions. Schürch et al. (2010) successfully reconstructed 
the phylogeny of the M. tb Beijing genotype family based on NGS data from 
six Beijing strains. The impact of NGS on M. tb research, especially in the 
areas of molecular epidemiology and phylogenetic analysis has been 
elaborated in Section 2.2.4. 
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2.2.3.4  Overview of functional genomics 
Comparative genomics has provided us with a catalogue of genomic diversity 
in the form of mutations, deletions, duplications and their impact on the 
evolution of the MTBC.  In particular, the identification of genes or loci that 
differ between virulent and avirulent or attenuated strains of M. tb can allow 
us to identify the molecular mechanisms of pathogenicity, and also provide 
leads for the development of new therapies for the disease. The aim of 
functional genomics is to understand the functional consequences of the 
genetic diversity at the levels of genes, transcripts and proteins using a 
genome-wide approach. This section will highlight the functional genomic 
approaches used for studying gene expression and transcription regulation in 
the MTBC and their contribution to improving our understanding of M. tb 
biology and pathogenesis.  
 
The development of DNA microarray technology was a major breakthrough 
in the study of gene expression and regulation. It enabled researchers to move 
beyond the study of individual genes and proteins to the functioning of the 
entire system. Microarrays have been a very important tool for identification 
of genes expressed under a variety of growth conditions as well as for 
elucidation of the function of regulatory proteins by mutation analysis. 
 
Genome-wide expression profiling of M. tb has been used to address the basic 
question – how does M. tb survive and thrive in the host? Typically, 
expression analysis compares the level of RNA transcripts in two pools of 
bacteria grown in different conditions by hybridization to microarrays or 
takes advantage of isogenic mutant and wild-type strains. The rationale 
behind studying the changes in gene expression assumes that the changes 
reflect the importance of genes in responding to the environment.  Also, genes 
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that are specifically expressed during infection or co-regulated with known 
virulence genes are likely to be candidate virulence genes.  
 
Another application of microarrays is to characterize the role of transcription 
factors in gene regulation. Traditionally this was done by comparing 
expression profiles for wild-type and regulatory mutant strains. However, this 
approach is unable to distinguish between primary and secondary regulatory 
effects, in cases where one regulator controls the expression of the gene for 
another. A powerful alternative was introduced by combining chromatin 
immunoprecipitation with DNA microarrays, known as the ChIP-on-chip 
technology. In this approach, proteins in contact with DNA are chemically 
cross-linked and the DNA is fragmented by sonication or enzymatic digestion. 
The cross-linked proteins are immunoprecipitated with antibodies specific for 
the proteins of interest. The immunoprecipitated DNA is then reverse cross-
linked, purified, labelled, and hybridized to microarrays in order to detect 
enrichment of the sequences bound by the proteins.   
 
The pathogenesis of M. tb involves a complex interaction with the host. In 
order to establish a successful infection the pathogen must adapt and survive 
the plethora of stresses encountered in the host by fine-tuning gene 
expression. Indeed, M. tb has an impressive repertoire of transcription 
regulators, including 13 sigma factors that recognize different classes of 
promoter and nearly 200 regulatory proteins that respond to environmental 
cues or physiological changes. Many of these environmental cues are relayed 
via reversible protein phosphorylation cascades catalysed by serine-threonine 
protein kinases or two-component systems (S. Cole et al. 1998). 
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Initial transcriptomic studies focused on capturing the transcription in in 
vitro conditions that might mimic in vivo situations. Hypoxia is thought to be 
a key factor in triggering latency in vivo. Microarray studies identified over 
100 genes whose expression is rapidly altered by defined hypoxic conditions 
(Sherman et al. 2001). A similar approach was used to identify genes affected 
by nitric oxide stress, which is known to inhibit bacterial respiration (Voskuil 
et al. 2003). Interestingly, the set of genes found to be induced by hypoxia as 
well as nitric oxide stress were later shown to be regulated by DosR 
(Dormancy survival regulatory), and are collectively known as the DosR or 
dormancy regulon. A combination of microarrays and proteomics was used to 
investigate the response of M. tb to nutrient starvation. This provided 
evidence for slowdown of the transcription apparatus, energy metabolism, 
lipid biosynthesis, and cell division in addition to the induction of genes that 
may play a role in maintaining long-term survival of M. tb (Betts et al. 2002). 
The first in vivo microarray-based analysis of the M. tb transcriptome 
identified genes that are differentially expressed in naive and activated 
macrophage phagosomes in mice. The findings indicate that the 
intraphagosomal environment is rich in lipids, poor in iron and carbohydrates, 
and a strong source of oxidative and nitrosative stress (Schnappinger et al. 
2003).  
 
Genome-wide expression profiling has also been used to study drug-induced 
alteration of the M. tb transcriptome. Some of the drugs that have been 
studied in this manner include isoniazid, thiolactomycin, triclosan, and 
tetrahydrolipstatin (M. Wilson et al. 1999; Betts et al. 2003; Waddell et al. 
2004). Another extensive study used genome-wide expression profiling to map 
adaptability of M. tb to diverse environmental changes (different drug types) 
that interrupt metabolism in different ways (Boshoff et al. 2004). It was 
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observed that distinct transcriptional signatures were generated upon 
treatment with particular drug types, which can be used to identify the target 
of an inhibitor whose mode of action is unknown. 
 
Sassetti and colleagues developed a novel use for microarrays to identify 
essential genes in M. tb at the whole genome level. The method involved 
construction of transposon mutant libraries, followed by the transposon site 
hybridization (TraSH) to map sites of transposon insertions and identify 
genes required for growth. They reported that 614 M. tb genes are required in 
vitro, and 194 are required for in vivo growth in the mouse model (Sassetti et 
al. 2003).  
 
A number of transcriptional regulators have been studied using microarrays. 
Regulatory mutants for the iron-dependent repressor protein, IdeR, the DNA 
repair protein (Rodriguez et al. 2002) and DosR, the hypoxic response 
regulator (H.-D. Park et al. 2003), have been used to define regulons for these 
proteins. The so-called dormancy regulon comprises 48 genes controlled by 
DosR, which binds to DNA following phosphorylation by one of two cognate 
sensor kinases (Roberts et al. 2004; Saini et al. 2004). A number of sigma 
factors have also been implicated in virulence based on microarray analysis. 
For example, SigE has been shown to contribute to pathogen survival 
following severe distinct stresses. SigE regulates the expression of genes 
involved in maintenance of the cell wall, and was shown to be upregulated in 
M. tb after phagocytosis (Manganelli et al. 2001; Schnappinger et al. 2003).  
 
Recently, the ChIP-on-chip technology has been used to define the regulons 
of several transcription regulators in M. tb, including, BlaI, which responds to 
"-lactam antibiotics (Sala et al. 2009), Lsr2, which is a nucleoid-associated 
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protein that regulates M. tb virulence (B. R. G. Gordon et al. 2010), and the 
stationary phase sigma factor, SigF (Hartkoorn et al. 2012). 
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2.2.4 Impact of high-throughput sequencing on M. tb research 
Technological breakthroughs in the field of sequencing in the last few years 
have transformed biological research. These technologies are collectively 
referred to as ‘next-generation’ sequencing (NGS) technologies, which perform 
high-throughput sequencing to generate whole genome data at an 
unprecedented scale and speed. Sequencing based genomics has several 
advantages compared to microarray analysis: 
1) Microarrays require a priori knowledge of the genome, whereas NGS data 
can also be assembled de novo. 
2) Cross-hybridization between similar sequences restricts the use of 
microarray analysis to non-repetitive fractions of the genome. NGS offers 
single-nucleotide resolution and demonstrates a greater ability to distinguish 
between isoforms, and reveal sequence variants.  
3) Competitive hybridization on microarrays is a relative measure, while 
quantification of signal from NGS approaches is a direct measure, based on 
counting sequence tags, making it better for detection of transcripts produced 
at high as well as low levels.   
4) Microarrays require more starting material (micrograms) compared to high 
throughput sequencing (nanograms). 
 
The massive sequence output, relatively low cost per base considering the 
small genome size of M. tb, and the ability to generate large quantities of 
data make NGS an attractive choice for re-sequencing microbial genomes. 
The major applications of NGS in M. tb research have been in genome re-
sequencing. NGS has allowed the detection of genetic diversity in the MTBC 
at an unprecedented resolution. NGS has been applied in studies on 
evolution, transmission and treatment of M. tb. SNP typing from NGS has 
been used to estimate selective pressures on antigens (Comas et al. 2010), to 
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characterize of MDR- and XDR-TB strains (Ioerger et al. 2009), to identify 
mutations responsible for drug resistance (Hartkoorn 2012), and to establish a 
refined phylogeny of closely related M. tb strains (Schürch 2011). Based on 
NGS data, Niemann et al. (2009) uncovered a significant amount of genetic 
diversity in drug sensitive and MDR isolates of M. tb exhibiting identical 
IS6110-RFLP patterns, which may have important clinical implications. In 
addition, NGS provides a powerful alternative to gene expression microarrays 
in the form of RNA-seq, which can be used for mapping and quantifying 
transcripts in biological samples. For detecting small RNAs, preferential 
isolation via size selection or small RNA-enrichment can be performed. After 
sequencing, reads are aligned to a reference genome, compared with known 
transcript sequences, or assembled de novo to construct a transcription map 
of the genome. RNA-seq has been successfully applied to identify non-coding 
and small RNAs in the M. tb transcriptome (Arnvig & Young 2009; Pellin et 
al. 2012).  
 
An alternative to ChIP-on-chip technology is the ChIP-seq technology, where 
chromatin immunoprecipitated DNA is subjected to NGS sequencing instead 
of being hybridized to microarrays. The obtained reads can be mapped to the 
reference genome of interest to generate a high-resolution, genome-wide 
protein-binding map. The higher resolution offered by ChIP-seq is evident by 
its capacity to identify novel binding sites and confirm previously identified 
binding sites and sequence motifs. ChIP-seq has been used in M. tb to define 
the regulons, and study the genome-wide distribution of EspR (Blasco et al. 
2012), which is a regulator of the ESX-1 secretion system, and LexA, which is 
a key regulator of the DNA damage (SOS) response (Smollett et al. 2012). 
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3. Overview of Methods 
 
The overall objectives of this thesis were to analyse genome-wide datasets 
generated from the application of microarray and next-generation sequencing 
technologies in comparative and functional genomics of the M. tb complex. 
The work carried out as part of this thesis can be classified into three main 
research areas: 
 
1) Comparative genomics 
- Assessment of the genetic diversity in the esx gene family among M. tb 
clinical isolates from SNP data generated using automated Sanger sequencing.  
- Analysis of SNP distribution in M. bovis and M. bovis BCG strains by SNP-
genotyping and phylogenetic clustering. 
2) Global transcription and its regulation  
- Integration of ChIP-seq and RNA-seq data to study global transcription and 
dynamics of the transcription machinery in M. tb.  
- Identification of genome-wide transcription factor binding sites using ChIP-
seq and ChIP-on-chip data.  
3) Whole-genome re-sequencing (High-throughput SNP typing) 
- SNP and InDel (insertions and deletions) detection from whole-genome re-
sequencing data to identify genetic mutations responsible for drug resistance 
in M. tb, and contributing to phenotypic differences between M. tb strains.  
 
This chapter will focus on the microarray and next generation sequencing 
approaches used in this thesis. It includes a brief description of the nature of 
the data generated by these technologies followed by an overview of the 
bioinformatics strategies for data analysis. 
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3.1 Microarrays 
A ‘microarray’ refers to a collection of thousands of probes or oligonucleotide 
fragments bound to a solid-surface support that hybridize to target molecules, 
which are fluorescently labelled. The result of successful hybridization 
between the labelled target and the immobilized probe is an increase of 
fluorescence intensity over a background level, which can be measured using a 
fluorescent scanner. Oligonucleotide microarrays usually contain probes for 
annotated genes, whereas tiling arrays consist of partially overlapping or non-
overlapping probes that span the entire genome. Many commercial 
oligonucleotide arrays and custom printed cDNA microarrays are now 
available (Harshman & MARTÍNEZ-A 2002; Harrington et al. 2000). 
 
As described in the previous chapters, microarrays have been widely used for 
expression profiling of M. tb and more recently in studying protein-DNA 
interactions (ChIP-on-chip). In cDNA microarrays, mRNA from biological 
samples is reverse-transcribed into cDNA and labelled separately with two 
fluorescent dyes Cy3 (green) and Cy5 (red). Upon hybridization of the cDNA 
to the array, the relative fluorescent intensities are measured and captured to 
produce a composite image. The image is then used to decipher the 
hybridization efficiency of each spot on the microarray, which correlates to 
the relative abundance of the target gene in the sample of interest 
(Trachtenberg et al. 2012). 
 
Microarray analysis starts with the assessment and quantification of the 
image acquired after the reaction on the microarray surface. The first step 
involves use of image analysis software to assess the quality of the image 
acquired upon scanning of the hybridized microarray. Poor quality spots are 
flagged and removed in order to improve the accuracy of the subsequent 
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analysis. The images are then transformed into numerical values representing 
the Cy3 and Cy5 intensities for each spot. Most commercial microarray 
scanners provide software to handle image processing; there are several 
additional image-processing packages available (Harshman & MARTÍNEZ-A 
2002; Quackenbush 2001; Harrington et al. 2000).  
 
The next step is data normalization, which attempts to compensate for the 
systematic variation resulting from the technology rather than from biological 
differences in the samples. These include differences in labelling, detection, 
hybridization or washing procedures, and in the quantity of the samples 
examined (Trachtenberg et al. 2012; Smyth & Speed 2003; López-Campos et 
al. 2012). Several normalization strategies have been proposed for microarray 
data; these methods can be broken into two groups, linear and non-linear 
methods (D. L. Wilson et al. 2003).   
 
1) Linear methods rely on the concept that the bias introduced during the 
experiments can be summarized by means of a “global” constant or scaling 
factor; therefore, the intensities are corrected for global multiplicative effects. 
There are different ways to calculate the global normalization constant 
(mean, median, Z-score), which is used to re-scale the intensity for each probe 
in the array (D. L. Wilson et al. 2003; López-Campos et al. 2012). 
 
2) Non-linear methods are more commonly used when normalizing two-colour 
cDNA microarrays. This Loess/LOWESS normalization methods stem from 
the Magnitude versus Amplitude plot (MA plot), where M is the log intensity 
ratio (difference in expression values) and A is the average log intensity for 
each spot (Figure 9A). MA plots are used to visualize the intensity-dependent 
ratio of raw microarray data. A normalization curve is fitted to this MA plot 
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by using the Loess method which performs local regression. The fits based on 
the normalization curve are subsequently subtracted from the M values 
(Figure 9B). Loess/LOWESS normalization algorithms correct for sub-array 
spatial variation and for intensity-dependent artifacts (Allison et al. 2006).  
 
 
Figure 9. MA-plot of microarray data, A) before, and B) after LOESS normalization. 
 
After normalization, the data are typically reported as an ‘expression ratio’ 
for microarrays or an ‘enrichment ratio’ for ChIP-on-chip. These ratios are 
usually log transformed (usually to the base 2), as it results in treating 
differential up-regulation and down-regulation equally, and also has a 
continuous mapping space ((Smyth & Speed 2003; M. Wilson et al. 1999). 
 
The R/Bioconductor framework provides a lot of open source packages that 
implement most of the normalization methods (Gentleman et al. 2004). While 
preliminary data processing and standard normalization methods are common 
to most microarray datasets, the downstream analysis and data interpretation 
vary depending on the type of experiment, i.e. transcription profiling or 
ChIP-on-chip, as they answer different biological questions. 
  
MA-plot before normalization MA-plot after normalization 
A) B) 
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1) In the case of microarrays, the next step is to identify differentially 
expressed genes under two experimental conditions. Most published studies 
tend to use a post-normalization cut-off of two-fold increase or decrease, 
although there is no firm theoretical basis for selecting this level as significant 
(Harshman & MARTÍNEZ-A 2002; Quackenbush 2001; Harrington et al. 
2000). There are several approaches for reporting the degree of reliability of 
the differential expression results. These include the t-test and its variants, 
which compare the di!erence in the mean expression levels between the two 
groups, taking into account the variability of the data (Trachtenberg et al. 
2012; Pan 2002). Another widely used approach is to report the false 
discovery rate (FDR) (Quackenbush 2001; Benjamini & Hochberg 1995). It is 
an estimate of the fraction of false positives within the resulting differentially 
expressed elements. One of the most common software applications for FDR 
control is the SAM (statistical analysis of microarrays) tool (Smyth & Speed 
2003; Tibshirani 2006; López-Campos et al. 2012). 
 
2) In the case of ChIP-on-chip, the next step is peak detection and 
localization of binding sites.  It is important to consider certain features of 
the ChIP-on-chip technique for effective data analysis. Prior to 
immunoprecipitation of enriched DNA, the ChIP procedure involves 
sonication, which generates DNA fragments ranging from 300 to 700 bp. 
Therefore, the sheared DNA fragments can bind to several adjacent probes on 
the microarray (average probe length is 60bp) introducing a positive 
correlation among probe hybridization densities. This feature is termed as the 
‘neighbour effect’ and results in high enrichment ratios centered over the site 
of protein-DNA interaction and spanning several genomically adjacent probes 
(Figure 10).  
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Figure 10. The neighbour effect in ChIP-chip data.  
After IP enrichment, DNA fragments bound by the protein of interest will be of varying 
lengths. Spot ‘A’ contains the actual binding, as seen by the high enrichment ratio (black = 
high ratio, white = low ratio). Spots B and C, which are within 1 kb of the binding site will 
also be enriched. Spot B will have a higher Cy5/Cy3 ratio then spot C, since the binding site 
is closer to the B element. The two D spots are too far from the binding site to be enriched. 
(Buck & Lieb 2004).  
 
Regions containing a cluster of peaks are more likely to be true binding sites 
than a single peak. Considering this characteristic of ChIP-chip data, a 
powerful method for peak detection is the sliding window approach. A 
window of selected size is slid across a region of the genome and the average 
log2 ratio of all the probes falling within the window is determined. The 
window is then moved downstream and the calculation is repeated iteratively 
for the entire length of the genome (Figure 11). A confidence value is assigned 
for each peak based on the number of independent probes used to construct 
the peak (D. L. Wilson et al. 2003; Buck & Lieb 2004; López-Campos et al. 
2012). For functional interpretation of the ChIP-chip data, the predicted 
binding regions are linked to the genome annotation to identify the genes 
associated with the peaks (Figure 11). 
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Figure 11. ChIP-on-chip data visualization. 
ChIP-on-chip results for the BlaI (Rv1846c) protein of M. tb represented as a plot of the 
enrichment ratios for each probe calculated as sliding window averages against the genomic 
position of the probes (Sala et al. 2009). The genes showing high enrichment have been 
annotated. 
 
Most transcription factors recognize specific DNA sequence patterns in their 
target sites, known as motifs. Comparison of DNA sequences retrieved from 
all the binding regions can help identify conserved motifs. Tools like MEME 
(Bailey et al. 2009), Gibbs Motif Sampler (Thompson et al. 2005) can be used 
for a de novo motif search. The genome-wide datasets be can visualized in the 
context of the genome annotation using stand-alone browsers such as Artemis 
(Carver et al. 2012) or online browsers like the UCSC genome browser 
(Dreszer et al. 2012).   
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Since Rv1846c-like proteins usually control their own expression, we expected to 
obtain a high signal in the intergenic region upstream of this gene. Analysis of the 
probes in the rv1846c gene locus revealed an enrichment ratio of 2.8, which is just 
below the arbitrary cut-off that was selected.  
Fig. 7 shows a plot of the enrichment ratios obtained using the sliding window 
method against the genomic location of the probes. We can deduce that the 
arbitrary cut-off of 3 needs to be lowered (to at least 2.8) in order to incorporate the 
rv1846c locus which is expected to show positive enrichment. 
 
Fig. 7 A plot of the enrichment ratios for each probe calculated as sliding window averages against 
the genomic position of the probes. The genes showing high enrichment have been annotated.  
 
Pr liminary data analysis reve l d a mall but highly si nific nt subset of genes. 
Several additional steps can be proposed to enha ce the accuracy and r liability of 
the results.  
There were several probe sequences that showed intensity ratios lower than the 
negative controls. These probes were not eliminated from the above analysis. 
However, for subsequent analysis, the negative controls could be used as a 
reference to study the effects of base composition on non-specific binding of DNA 
fragments to the probes. The negative controls could be grouped based on their % 
GC content and this could be plotted against the average enrichment ratio for each 
group. Grouping of probes in the array would also reveal if the same subset of 
probes showed consistently lower intensity signals as compared with the negative 
controls. Probes with extremely low levels of fluorescence intensities could be 
eliminated to avoid artifacts generated by using the IP to genomic DNA ratio as a 
measure of enrichment.  
An important consideration for determination of a threshold for the enrichment ratio 
is measurement of the number of false positives or false negatives that might 
occur. Permutation tests can be useful to evaluate random expectation of the error 
rate and calculate the number of false positives that could be expected for a certain 
cut-off.  
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3.2 Next-generation Sequencing 
The wave of next generation sequencing technologies started with the 
development of the 454 pyrosequencing by Roche, followed by the Solexa 
sequencing-by-synthesis, which was commercialized by Illumina, and the 
ligation-based SOLiD sequencing by Applied Biosystems. The technologies 
from Roche and Illumina are most widely used, although new platforms are 
now emerging, such as single-molecule sequencing by Pacific Biosciences, and 
the Ion Torrent semiconductor-based pH sequencing by Life Technologies 
(Mardis 2008; Metzker 2009; Pareek et al. 2011) .  
 
A common characteristic of all NGS platforms is that they do not rely on the 
Sanger sequencing chemistry. Instead they sequence clonally amplified DNA 
fragments or single DNA molecules in a flow cell in a massively parallel 
fashion. This is done using a step-wise iterative process or in a continuous 
real-time manner (Voelkerding et al. 2009). All sequencers produce megabases 
to gigabases of nucleotide sequence output in the form of reads: sequences of 
single-letter base calls plus a numeric quality score (Phred score) for each 
base call (Ewing & Green 1998). The major differences between these 
platforms lie in the specifics of the DNA sequencing reaction, the resulting 
read length, sequencing accuracy and throughput per run (Metzker 2009). A 
broad comparison of the NGS technologies is shown in Table 3. 
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Table 3. Comparison of NGS technologies by Dunne et al (Dunne et al. 2012).  
Generationa Chemistry Platform 
Throughput 
per run 
(bases) 
Error rate 
(Phred 
score) 
Read 
length 
Second Pyrosequencing Life Sciences 454 450 Mb Q30
b 450 
Second 
Dye 
termination/ 
synthesis 
Illumina 
Solexa 120,000 Mb Q15
b 
2 x 150 
paired 
Second Ligation AB SOLiD 20,000 Q27b 50 
Third Semiconductor Ion Torrent 10-100 Mb Q15-Q20 est. 100 
Third Direct detection 
Pacific 
Biosciences 
RS 
75 Mb, 
estimate Unknown 
1,500 
est. 
aWith “first generation” single-chain sequencing (Sanger dideoxy chain termination 
sequencing) as reference, “second generation” sequencing analyzes an ensemble of DNA 
molecules simultaneously by wash and scan techniques, and “third generation” sequencing 
interrogates molecules without the need to halt between read steps.  
bEstimated Phred score, Q0"10 log10(P("n/s), where s is the observed signal and n is the 
length of the homopolymer that produced the signal, serves here as a common-denominator 
indicator of sequence quality that is familiar from low-throughput dideoxy or Sanger 
sequencing. A score of 20 is equivalent to an error rate of 1 in 100 bases. 
 
All the NGS performed as part of this thesis made use of the Illumina 
sequencing technology (http://www.Illumina.com), which will be reviewed 
here in more detail. The Solexa/Illumina Genome Analyzer sequencing 
workflow (Figure 12) begins with fragmentation of genomic DNA and 
addition of adapter sequences to the ends of the fragments. The DNA 
molecules are attached to a slide and clonally amplified using the bridge 
amplification method. The sequencing reaction makes use of reversible 
terminator nucleotides, the fluorescently labelled nucleotides contain a 
termination moiety that prevents addition of other nucleotides to the 
synthesized strand such that only one nucleotide incorporation event occurs 
per fragment population per sequencing cycle. Post-incorporation fluorescence 
is recorded at the end of each cycle. This method generates short sequencing 
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reads of 36 – 100 bp, and an overall sequence output of around one billion 
base pairs per analytical run. The majority of published NGS papers to date 
have described methods using the short sequence data, produced with the 
Genome Analyzer. 
 
 
Figure 12. Illumina/Solexa Genome Analyzer sequencing (Voelkerding et al. 2009) 
Adapter-modified, single-stranded DNA is added to the flow cell and immobilized by 
hybridization. Bridge amplification generates clonally amplified clusters. Clusters are 
denatured and cleaved; sequencing is initiated with addition of primer, polymerase (POL) 
and 4 reversible dye terminators. Postincorporation fluorescence is recorded. The fluor and 
block are removed before the next synthesis cycle. 
  
Fig. 2. Illumina Genome Analyzer sequencing.
Adapter-modified, single-stranded DNA is added to the flow cell and immobilized by hybridization. Bridge amplification
generates clonally amplified clusters. Clusters are denatured and cleaved; sequencing is initiated with addition of primer,
polymerase (POL) and 4 reversible dye terminators. Postincorpo ation fluorescence is recorded. The fluor and block are removed
before the next synthesis cycle.
Reviews
644 Clinical Chemistry 55:4 (2009)
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The applications of Illumina/Solexa sequencing in M. tb research can be 
classified into three main categories: 1) Whole genome re-sequencing to 
catalogue genetic variants such as SNPs and InDels, 2) RNA-seq for 
transcriptome profiling by sequencing cDNA, and 3) ChIP-seq to elucidate 
binding sites of individual transcription regulators, or study the genome-wide 
distribution of global transcription factors such as RNA polymerase.  Analysis 
and interpretation of the vast amounts of data generated by NGS requires a 
multi-step strategy involving the use of bioinformatics and statistical tools, 
which needs to be tailored to address the different biological applications of 
this technology.   
 
The first step common to all NGS data is alignment or de novo assembly of 
the sequence reads. Most alignment algorithms construct auxiliary data 
structures, called indices, either for the reference or the reads, which allow 
fast mapping of the reads to the genome sequence. Some of the commonly 
used alignment tools are, MAQ (H. Li et al. 2008a), Bowtie (Langmead et al. 
2009), SOAP (R. Li et al. 2008b), etc. De novo assembly of short reads is 
more challenging given the minimal overlap between the reads. Some of the 
currently used de novo assembly programs are Velvet (Zerbino & Birney 
2008), SSAKE (Warren et al. 2007), and ABySS (Simpson et al. 2009), all of 
them employ principles of graph theory. The choice of alignment parameters 
affects the results of the mapping procedure. These parameters include, the 
number of mismatches allowed for mapping, the maximum number of distinct 
matches allowed per sequence read, and the seed length (minimum portion of 
the read to be used to establish a candidate mapping site for a read).  
 
Accurate alignment of sequence reads is of utmost importance in the case of 
variant-discovery. At least two factors can lead to incorrect read alignment. 
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The first one concerns the problem of mapping reads accurately to repetitive 
sequences. For example, given the high amount of repetitive DNA in the M. 
tb genome, a sequence read could map equally well to more than one genomic 
site. The second one involves the introduction of sequencing errors or 
mutations, which could lead to placement of the read at the wrong site. 
Usually, reads that align equally well at multiple sites can be randomly 
distributed to the sites or in some cases discarded, depending on the 
alignment software used. In de novo assembly these reads are typically 
discarded which leads to gaps in coverage and multiple aligned read groups 
(contigs) (Voelkerding et al. 2009). Based on the base-calling confidence 
scores, alignment programs estimate the likelihood of sequencing errors and 
calculate the probability of a read being mapped to the wrong place, known 
as the alignment score (H. Li et al. 2008a). Many alignment programs provide 
extended capabilities for SNP and InDel calling which take into consideration 
the alignment score and the sequencing depth for filtering low quality 
variants (H. Li et al. 2008a; R. Li et al. 2008b). Once the SNPs and/or InDel 
variants have been identified they need to be mapped to the genome sequence 
and analyzed in the context of the genome annotation. Polymorphisms 
occurring in protein-coding genes can be characterized as non-synonymous or 
synonymous based on whether they have an impact on the resulting amino 
acid or not.  
 
Interpretation of the ChIP-seq and RNA-seq datasets requires further 
processing. Once the reads are mapped to the reference genome, the 
alignments are usually transformed to genomic densities, namely tags-to-
positions maps (e.g. SAM files (H. Li et al. 2009)) which are in turn 
converted into count-per-position data (e.g. WIG files (Dreszer et al. 2012)), 
i.e. the read depth at every genomic position. WIG files can be used for 
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visualizing the NGS data aligned on the genome using tools such as the 
UCSC genome browser (Dreszer et al. 2012) or the Integrative Genome 
Viewer (Thorvaldsdóttir et al. 2012).  
 
Most NGS experiments involve analysis of data from at least two or more 
biological/technical replicates. Different samples can yield significantly 
different numbers of unique mapped reads depending on the amount of 
starting material, the sequencing error rate, the severity of amplification 
biases, etc. Therefore, a normalization step is included to make sure results 
from different datasets are comparable. In most cases, each dataset is 
normalized to the total mapped reads. 
 
In the case of RNA-seq data, the expression level for each transcript is 
determined by the total number of reads mapping to the transcript. A 
commonly used measure to determine the relative expression level of a 
transcript is RPKM (Reads per Kilobase of transcript per Million mapped 
reads) (Fang et al. 2012). As RPKM considers the length of the transcript, it 
enables comparison among different transcripts in the same dataset. As with 
most expression profiling experiments, RNA-seq is used to identify 
differentially expressed transcripts between different experimental conditions. 
A number of statistical methods have been proposed to detect differentially 
expressed genes from a counts table. These methods differ in their underlying 
data distribution and handling of biological replicates. Two of the commonly 
used methods include DEGSeq (Wang et al. 2009) and edgeR (Anders & 
Huber 2010), which are based on negative binomial distribution.  
 
An additional processing step is required for ChIP-seq data, prior to 
estimation of binding-sites. As fragments are sequenced at the 5# end, the 
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locations of mapped reads form two distributions, one on the forward strand 
and the other on the reverse strand, with a consistent distance between the 
peaks of the distributions (Rougemont & Naef 2012). In order to identify 
enriched regions, a combined profile of the two strands is calculated usually 
by shifting each distribution towards the centre (Figure 13). Programs like 
MACS (Lun et al. 2009), QuEST (Valouev et al. 2008) can perform peak 
detection in ChIP-seq data. Once the peaks are identified, motif searches can 
be performed using tools like MEME (Bailey et al. 2009) or Gibbs Motif 
Sampler (Thompson et al. 2005).  
 
Figure 13. Strand-specific profiles at enriched sites in the ChIP-seq experiment (P. J. 
Park 2009). 
 
Nature Reviews | Genetics
Protein or
nucleosome
of interest
Short reads
are aligned
Distribution of tags
is computed
Reference genome
Peak identification
can be performed
on either profile
Profile is generated from 
combined tags
For example, each mapped 
location is extended 
with a fragment of
estimated size
Fragments are added
3?Positive strand5?
3? Negative strand 5?
5? ends of
fragments are
sequenced
Figure 5 | Strand-specific profiles at enriched sites. DNA fragments from a 
chromatin immunoprecipitation experiment are sequenced from the 5? end. 
Therefore, the alignment of thes  tags to the genome r sults in two peaks (one on 
each strand) that flank the binding location of the protein or nucleosome of interest. 
This strand-specific pattern can be used for the optimal detection of enriched 
regions. To create an approximate distribution of all fragments, each tag location can 
be extended by an estimated fragment size in the appropriate orientation and the 
number of fragments can be counted at each position.
Poisson model
A probability distribution that 
is often used to model the 
number of random events in a 
fixed interval. Given an average 
number of events in the 
interval, the probability of a 
given number of occurrences 
can be calculated.
alignment, as all subsequent results are based on the 
aligned reads. Owing to the large number of reads, the 
use of conventional alignment algorithms can take hun-
dreds or thousands of processor hours; therefore, a new 
generation of aligners has been developed57, and more 
are expected soon. Every aligner is a balance between 
accuracy, speed, memory and flexibility, and no aligner 
can be best suited for all applications. Alignment for 
ChIP–seq should allow for a small number of mis-
matches due to sequencing errors, SNPs and indels or 
the difference between the genome of interest and the 
reference genome. This is simpler than in RNA–seq, 
for example, in which large gaps corresponding to 
introns must be considered. Popular aligners include: 
Eland, an efficient and fast aligner for short reads that 
was developed by Illumina and is the default aligner on 
that platform; Mapping and Assembly with Qualities 
(MAQ)58, a widely used aligner with a more exhaustive 
algorithm and excellent capabilities for detecting SNPs; 
and Bowtie59, an extremely fast mapper that is based 
on an algorithm that was originally developed for file 
compression. These methods use the quality score that 
accompanies each base call to indicate its reliability. For 
the SOLiD di-base sequencing technology, in which two 
consecutive bases are read at a time, modified aligners 
have been developed60,61. Many current analysis pipe-
lines discard non-unique tags, but studies involving the 
repetitive regions of the genome27,62–64 require careful 
handling of these non-unique tags.
Identification of enriched regions. After sequenced 
reads are aligned to the genome, the next step is to iden-
tify regions that are enriched in the ChIP sample relative 
to the control with statistical significance.
Several ‘peak callers’ that scan along the genome 
to identify the enriched regions are currently 
available24,26,38,48,65–70. In early algorithms, regions were 
scored by the number of tags in a window of a given 
size and then assessed by a set of criteria based on fac-
tors such as enrichment over the control and minimum 
tag density. Subsequent algorithms take advantage of 
the directionality of the reads71. As shown in FIG. 5, the 
fragments are sequenced at the 5? end, and the loca-
tions of mapped reads should form two distributions, 
one on the positive strand and the other on the negative 
strand, with a consistent distance between the peaks of 
the distributions. In these methods, a smoothed pro-
file of each strand is constructed65,72 and the combined 
profile is calculated either by shifting each distribution 
towards the centre or by extending each mapped position 
into an appropriately oriented ‘fragment’ and then 
adding the fragments together. The latter approach 
should result in a more accurate profile with respect to 
the width of the binding, but it requires an estimate 
of the fragment size as well as the assumption that 
fragment size is uniform.
Given a combined profile, peaks can be scored in sev-
eral ways. A simple fold ratio of the signal for the ChIP 
sample relative to that of the control sample around the 
peak (FIG. 3B) provides important information, but it is 
not adequate. A fold ratio of 5 estimated from 50 and 10 
tags (from the ChIP and control experiments, respec-
tively) has a different statistical significance to the same 
ratio estimated from, for example, 500 and 100 tags. 
A Poisson model for the tag distribution is an effective 
approach that accounts for the ratio as well as the abso-
lute tag numbers27, and it can also be modified to account 
for regional bias in tag density due to the chromatin 
structure, copy number variation or amplification bias67. 
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The high spatial resolution of ChIP-seq makes it more efficient at identifying 
over-represented DNA sequence motifs compared to the ChIP-on-chip 
method. 
 
The scheme below summarizes the technologies and experimental methods 
used, the nature of the biological datasets, and examples of the results 
obtained as part of this thesis.  
 
 
Figure 14. Overview of analysis strategies. 
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4. Results and Discussion 
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List of Publications 
 
1. Garcia Pelayo MC*, Uplekar S*, Keniry A, Mendoza Lopez P, Garnier T, Nunez 
Garcia J, Boschiroli L, Zhou X, Parkhill J, Smith N, Hewinson RG, Cole ST & 
Gordon SV. A comprehensive survey of single nucleotide polymorphisms (SNPs) 
across Mycobacterium bovis strains and M. bovis BCG vaccine strains refines the 
genealogy and defines a minimal set of SNPs that separate virulent M. bovis 
strains and M. bovis BCG strains. Infect. Immun. 77, 2230–2238 (2009). 
2. Uplekar S, Heym B, Friocourt V, Rougemont J & Cole ST. Comparative 
genomics of Esx genes from clinical isolates of Mycobacterium tuberculosis 
provides evidence for gene conversion and epitope variation. Infect. Immun. 79, 
4042–4049 (2011). 
3. Hartkoorn RC, Sala C, Uplekar S, Busso P, Rougemont J & Cole ST. Genome-
wide definition of the SigF regulon in Mycobacterium tuberculosis. J Bacteriol. 
194, 2001-9 (2012). 
4. Blasco B, Chen JM, Hartkoorn R, Sala C, Uplekar S, Rougemont J, Pojer F & 
Cole ST. Virulence regulator EspR of Mycobacterium tuberculosis is a nucleoid-
associated protein. PLoS Pathog. 8, e1002621 (2012). 
5. Kirksey MA, Tischler AD, Siméone R, Hisert KB, Uplekar S, Guilhot C & 
McKinney JD. Spontaneous phthiocerol dimycocerosate-deficient variants of 
Mycobacterium tuberculosis are susceptible to gamma interferon-mediated 
immunity. Infect. Immun. 79, 2829–2838 (2011). 
6. Massouras A, Hens K, Gubelmann C, Uplekar S, Decouttere F, Rougemont J, 
Cole ST & Deplancke B. Primer-initiated sequence synthesis to detect and 
assemble structural variants. Nat. Methods 7, 485–486 (2010). 
7. Chen JM, Uplekar S, Gordon SV, Cole ST. A Point Mutation in cycA Partially 
Contributes to the D-cycloserine Resistance Trait of Mycobacterium bovis BCG 
Vaccine Strains. PLoS ONE, 2012. 
8. Hartkoorn RC, Sala C, Neres J, Pojer F, Magnet SJ, Mujherjee R, Uplekar S, 
Boy-Rottger S, Altmann KH, & Cole ST. Towards a new tuberculosis drug: 
Pyridomycin – Nature’s Isoniazid. EMBO Molecular Medicine, July 2012 
 
Accepted 
 
9. Uplekar S, Rougemont J, Cole ST & Sala C. High-resolution transcriptome and 
genome-wide dynamics of RNA polymerase and NusA in Mycobacterium 
tuberculosis. Nucleic Acids Research.   

 7 2  
4.1. Comparative Genomics 
 
4.1.1 A comprehensive survey of single nucleotide polymorphisms 
(SNPs) across M. bovis strains and M. bovis BCG vaccine strains 
Contribution: Analysis of the SNP dataset, assessment of the SNP 
distribution across different M. bovis BCG and M. bovis strains, construction 
of SNP based phylogenies, and phylogenetic analysis to quantify the selection 
pressure on the BCG strains. 
 
Mycobacterium bovis bacille Calmette-Guérin (BCG) is the only available 
vaccine against tuberculosis and the most widely used vaccine in the world. 
While BCG protects children effectively against early manifestations of TB, 
its success in adults is debatable. The protective efficacy against adult 
pulmonary TB ranges from 0-80%. One of the factors contributing to the 
variable efficacy of BCG could be the heterogeneity of the BCG daughter 
strains. After the original BCG vaccine was derived in 1921, it was 
distributed to different laboratories across the world, which maintained their 
own daughter strains by passaging, until the introduction of archival seed lots 
in the 1960s. The widespread distribution and subsequent subcultures led to 
the generation of a number of daughter strains named after their geographical 
origin (hence, BCG Russia, BCG Denmark, etc.) (Oettinger et al. 1999). The 
protective efficacy of the different BCG daughter strains has been shown to 
vary in both laboratory models (Lagranderie et al. 1996) and epidemiological 
studies (Davids et al. 2006). In order to promote the development of TB 
vaccines, it is necessary to improve our understanding of the genetic 
mechanisms of BCG attenuation and how they translate into variation in the 
efficacy of individual vaccine strains. Subtractive hybridization, and later 
comparative hybridization using DNA microarrays revealed a region of 
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difference (RD1) encoding the ESX-1 protein secretion system that is absent 
from all BCG strains and shown to play a major role in the attenuation of 
BCG (Mahairas et al. 1996; Lewis et al. 2003). However, the re-introduction 
of ESX-1 in BCG did not restore full virulence (Pym et al. 2002), suggesting 
the involvement of other attenuating mutations.  
 
The evolutionary scheme based on strain-specific genetic markers divides 
BCG vaccine strains into four main sub-groups (Behr et al. 1999; Brosch et 
al. 2007). Comparison of the whole genome sequences of M. bovis BCG 
Pasteur (Brosch et al. 2007) with the virulent M. bovis 2122/97 (Garnier 
2003) enabled high-resolution detection of sequence polymorphisms between 
the two strains. Of the 736 SNPs identified between the two strains, 56% 
were non-synonymous (nsSNPs) and could have functional consequences on 
the genes they affected (Brosch et al. 2007). All BCG strains contain a 
frameshift mutation in the phoT gene; inactivation of phoT in M. bovis 
attenuates the strain, and so this phoT mutation may also contribute to the 
loss of virulence of BCG (Collins 2003). SNPs unique to some BCG strains 
have also been shown to have functional consequences. For example, the sigK 
gene of BCG Pasteur has incurred a missense mutation in its start codon 
leading to a reduced expression of the major antigens MPB70 and MPB83 in 
this strain (Charlet et al. 2005). These data clearly indicate that SNPs have 
played a significant role in the attenuation of BCG. However, in order to 
discover SNP candidates that are likely to be responsible for the attenuation 
of BCG we need to consider SNPs that differentiate all attenuated BCG 
strains from virulent M. bovis strains.  
  
 7 4  
We employed a high-throughput SNP screening methodology, the Sequenom 
genotyping platform, (Sequenom Inc., San Diego, CA) to map all SNPs 
identified between BCG Pasteur and M. bovis 2122/97 across a selection of 
M. bovis isolates and BCG daughter strains. Informative data sets were 
obtained for 658 SNPs from 21 virulent M. bovis strains from UK and France, 
and 13 BCG daughter strains. The distribution of SNPs across the British, 
French and BCG lineages allowed clustering of these strains to generate a 
linear phylogeny that was consistent with the geographical origin of the 
strains and previous evolutionary schemes for BCG. Our data has refined the 
previous genealogies of BCG by revealing a closer relationship between BCG 
Tice and BCG Pasteur than was previously appreciated, and also positioning 
BCG Beijing within the group of BCG Denmark-derived strains.  
 
We identified a minimal set of 115 nsSNPs SNPs between virulent M. bovis 
strains and all BCG strains, affecting important functions such as 
transcriptional regulation and central metabolism, which might impact on 
virulence. In conclusion, the SNPs identified from our study provide a rich 
source of genetic variation that can be mapped to functional differences across 
BCG strains and provide further insight on the molecular basis for the 
attenuation of BCG.  
 
Last year, Orduna et al. sequenced the whole genome of the BCG Mexico 
1931 using 454 pyrosequencing. The aim of their study was to characterize 
the genomic and immune proteomic profile of the BCG vaccine strain used in 
Mexico. Comparison of the BCG Mexico sequence with the genomes of BCG 
Pasteur and BCG Tokyo revealed 33 SNPs, of which 23 were also reported in 
our BCG analysis. The results were consistent with our SNP-based 
phylogeny, which placed BCG Mexico 1931 in the same group as BCG Tice.  
 7 5  
Two recent publications have characterized the functional effect of some of 
the nsSNPs identified in our study between the virulent M. bovis and the 
attenuated BCG strains, 
1) Mendoza Lopez et. al (2010) analysed the nsSNP in BCG3145, which is a 
global gene regulator belonging to the SARP (Streptomyces antibiotic 
regulatory protein) family of proteins. The SNP replaces a highly 
conserved glutamic residue at position 159 with glycine (E159G), in the 
bacterial transcriptional activation (BTA) domain of BCG3145. 
Microarray analysis of transcriptome changes upon overexpression of 
BCG3145 and Rv3124 (orthologue of BCG3145 in M. tb H37Rv) revealed 
that the two proteins were positive regulators of molybdopterin 
biosynthesis. Based on this study, Rv3124 was renamed moaR1 as it was 
found to regulate expression of the moa1 locus. The E159G mutation in 
BCG3145 was shown to decrease, but not abolish, the ability of the 
regulator to induce expression of the moa1 locus (Mendoza Lopez et al. 
2010).  
2) Chen et. al (2012) studied the nsSNP in the cycA gene of all BCG strains 
that results in a glycine to serine substitution at position 122 (G122S) in 
the CycA protein, which is an amino acid transporter. CycA is involved 
in the uptake of the antibiotic D-cycloserine. Compared to wild-type M. 
tb and M. bovis, BCG has been found to be more resistant to growth 
inhibition by D-cycloserine (DCS). Using genetic approaches, it was 
shown that a merodiploid strain of BCG expressing M. tb CycA had 
increased sensitivity to DCS. In addition, M. smegmatis strains 
heterologously expressing either M. tb or M. bovis CycA but not BCG 
CycA were rendered more sensitive to DCS. These findings demonstrate 
that the BCG cycA SNP partially contributes to DCS resistance in the 
vaccine strain (Chen et al. 2012).  
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Refines the Genealogy and Defines a Minimal Set of SNPs That
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To further unravel the mechanisms responsible for attenuation of the tuberculosis vaccine Mycobacterium
bovis BCG, comparative genomics was used to identify single nucleotide polymorphisms (SNPs) that differed
between sequenced strains of Mycobacterium bovis and M. bovis BCG. SNPs were assayed in M. bovis isolates
from France and the United Kingdom and from different BCG vaccines in order to identify those that arose
during the attenuation process which gave rise to BCG. Informative data sets were obtained for 658 SNPs from
21 virulentM. bovis strains and 13 BCG strains; these SNPs showed phylogenetic clustering that was consistent
with the geographical origin of the strains and previous schemes for BCG genealogies. The data revealed a
closer relationship between BCG Tice and BCG Pasteur than was previously appreciated, while we were able
to position BCG Beijing within a grouping of BCG Denmark-derived strains. Only 186 SNPs were identified
between virulent M. bovis strains and all BCG strains, with 115 nonsynonymous SNPs affecting important
functions such as global regulators, transcriptional factors, and central metabolism, which might impact on
virulence. We therefore refine previous genealogies of BCG vaccines and define a minimal set of SNPs between
virulent M. bovis strains and the attenuated BCG strain that will underpin future functional analyses.
Mycobacterium bovis bacillus Calmette-Gue´rin (BCG) is the
only vaccine available against tuberculosis and is the most
widely used vaccine in the world. It was derived by the repeated
subculture of a strain of Mycobacterium bovis on potato slices
soaked in glycerol and ox bile (10), leading to the in vitro
accumulation of mutations and ultimately attenuation. Despite
the widespread use of BCG, the precise genetic lesions that led
to attenuation are not defined. Furthermore, the success of
BCG led to its distribution from the Institut Pasteur to labo-
ratories around the world, each of which continued the sub-
culturing process, thereby leading to the generation of a num-
ber of daughter strains named after their geographical origin
(hence BCG Tokyo, BCG Russia, etc.). The protective efficacy
of these strains has been shown to vary in both laboratory
models and epidemiological studies (6, 18, 36).
As BCG is the only vaccine currently available against
tuberculosis, there is a clear need to understand the molec-
ular basis of attenuation and variable efficacy afforded by
BCG. The first study that attempted to identify mutations
linked to attenuation was performed by Mahairas and col-
leagues, who identified three deletions, RD1 to RD3, from
the genome of BCG strain Connaught (39). The RD1 locus
was shown to be deleted from all BCG strains but present in
all virulent strains of M. bovis and Mycobacterium tubercu-
losis studied. Subsequent work has shown that this deletion
played a major role in the attenuation of BCG (38, 46).
However, complementation of BCG with RD1 does not
restore virulence to wild-type levels, suggesting that other
attenuating mutations exist. Indeed, all BCG strains contain
a frameshift mutation in the phoT gene; inactivation of phoT
in M. bovis attenuates the strain, and so this phoT mutation
may also contribute to the loss of virulence of BCG (15).
This observation demonstrates that single nucleotide poly-
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morphisms (SNPs) may play a significant part in the atten-
uation of BCG.
A major step toward defining the molecular basis of atten-
uation in BCG was the completion of the genome sequence of
M. bovis BCG Pasteur (9). Genomic comparison of BCG Pas-
teur withM. bovis 2122/97 (22) identified a range of mutational
differences, including deletions, duplications, and SNPs. In fur-
ther work the configuration of two large duplications, DU1 and
DU2, was shown to vary across BCG daughter strains, in a
manner that was congruent with the previous BCG phylogeny
defined by Behr and colleagues using deletions (7, 9, 41).
From the complete chromosome sequences, 736 SNPs were
identified between the BCG Pasteur vaccine strain and the
virulent M. bovis strain 2122/97 (9). However, only those SNPs
that are unique to all BCG strains are good candidates for
mutations involved in the attenuation of BCG; such SNPs
presumably occurred during the attenuation of BCG after it
was derived from wild-type M. bovis. The ideal experiment
would be a comparison using the chromosome of the wild-type
progenitor from which BCG strains were derived; unfortu-
nately, this strain is unavailable. The M. bovis 2122/97 strain is
derived from the clonal complex of M. bovis common in the
British Isles (provisionally called Eu1 [53]), while the BCG
strain is derived from the French lineage, which is phyloge-
netically distinct from the Eu1 clonal complex. Many of the 736
SNPs that differ between BCG Pasteur and M. bovis 2122/97
may be lineage specific to either BCG or the Eu1 clonal complex
and therefore unlikely to be involved in the attenuation of BCG.
To identify those SNPs that are unique to BCG strains and
therefore possible candidates for the attenuation of BCG, we
mapped the phylogenetic position of all SNPs identified be-
tween M. bovis 2122/97 and BCG Pasteur across a population
of United Kingdom and French M. bovis isolates, as well as
BCG daughter strains. We used a high-throughput SNP
screening methodology to screen hundreds of SNPs across the
population and generated a distribution of SNPs across British,
French, and BCG M. bovis strains.
It has previously been shown that some SNPs unique to
BCG have functional effects: a nonsynonymous SNP (nsSNP)
in themmaA3 gene, which encodes a mycolic acid methyltrans-
ferase, results in the loss of methoxymycolic acids from late
strains of BCG (5); an SNP in sigK leads to reduced synthesis
of MPB83 and MPB70 in late BCG strains (11); and an SNP in
the pykA gene reverts a null mutation in M. bovis and allows
BCG to grow on glycerol (33). Finally, SNPs in the cyclic AMP
receptor protein (CRP) transcriptional regulator in some BCG
strains affect the binding of the regulator to DNA (4, 30).
Following these examples, we highlight SNPs that may impact
on phenotypic differences between virulent M. bovis and BCG.
MATERIALS AND METHODS
SNP identification. The sequences of M. bovis 2122/97 and M. bovis BCG
Pasteur were compared using the DIFFSEQ application from the EMBOSS
package (http://emboss.sourceforge.net/). This tool is less complex than many
genome comparison tools but can be used here, as the two genomes are entirely
colinear. This allowed three classes of mutations to be identified: (i) transitions
and transversions; (ii) insertions or deletions (InDels); and (iii) “block” substi-
tutions, where a block of sequence of !1 bp replaces another. The InDels were
further subdivided into two groups, the mIns and mDels, which are the insertions
or deletions of a single base, respectively. We defined SNPs as the total number
of transitions and transversions (736) plus the mIns and mDels (46), which gave
a total of 782 positions to be investigated. Each SNP was initially verified by
checking the original sequence trace files from the BCG Pasteur and M. bovis
2122/97 sequencing projects.
Bacterial strains. Strains are shown in Table 1, with a spoligotype phylogeny
shown in Fig. 1 to illustrate the relationships across the strains. British M. bovis
strains were selected from the VLA Weybridge strain collection to represent the
British M. bovis population structure. French isolates were selected from the
strain collection of the Agence Franc¸aise de Se´curite´ Sanitaire des Aliments
(AFSSA), such that the spoligotype of the strain was the same as that of BCG
(SB0120, as defined by the international M. bovis spoligotype database [www
.mbovis.org]). BCG daughter strains were obtained from the VLA Weybridge
strain collection, Marcel Behr (McGill University, Montreal, Canada), or the
Statens Serum Institut (Copenhagen, Denmark). A total of 34 strains were
examined.
Molecular typing. Strains were typed by both spoligotyping and variable-
number tandem repeat (VNTR) (ETR-A to -F) typing. Spoligotyping and
VNTR were performed as described previously (21, 32).
Sequenom genotyping. Genotyping was performed with IPLEX chemistry, on
the Sequenom genotyping platform (Sequenom Inc., San Diego, CA). During the
IPLEX reaction, oligonucleotide primers anneal directly adjacent to the SNP of
interest. Allele-specific extension products are then produced by single base
extension of the oligonucleotide with terminator nucleotides, each of unique
mass. Multiplexed IPLEX assays of between 1 and 28 assays per plex were
designed to detect 701 single nucleotide base changes using the Sequenom Assay
Design v3.0.2.0 package. Genomic DNA was extracted from BCG and other M.
bovis strains using a standard cetyltrimethylammonium bromide method and
diluted in Tris-EDTA to a final concentration of 4 ng/"l. SNP-containing loci
were amplified from genomic DNA by PCR. Unincorporated nucleotides were
removed by treatment with shrimp alkaline phosphatase, followed by the IPLEX
extension reaction, per the manufacturer’s instructions. The allele-specific prod-
ucts resulting from the IPLEX reaction were desalted through the addition of an
anion-exchange resin and then analyzed by matrix-assisted laser desorption ion-
ization–time of flight mass spectrometry. Genotypes were assigned in real time
and then evaluated using the SpectroCALLER and SpectroACQUIRE software
(Sequenom), respectively. Selected SNPs were confirmed using standard capil-
lary sequencing.
Phylogenetic analysis. SNP calls were parsed to extract SNPs specific to each
strain and concatenated into a single 701-bp sequence. Sequence alignment was
carried out using ClustalW, and phylogenetic analyses were performed using the
MEGA 4.0 software. Discrepancies in the data (i.e., call rates lower than 100%
or ambiguous calls) were replaced by “?” for the purposes of alignment. Dis-
tance-based analysis was conducted by applying the neighbor-joining algorithm
using the number of nucleotide differences. A consensus parsimony tree was
generated using the maximum parsimony method with bootstrapping.
dN/dS estimations. The sequence of the common ancestor (anc1) of the
British lineage and the French lineage was reconstructed at the polymorphic sites
using the M. tuberculosis H37Rv strain as an outgroup. The reconstructed an-
cestral sequence was then compared to the sequence found in strain 2253 (a
representative of the British lineage, SB0134 [Table 1]), and the ratio of the
number of nonsynonymous to synonymous changes per site (dN/dS ratio) was
calculated for 48 synonymous and nonsynonymous mutations that had happened
during the descent of this strain from anc1 to its divergence from the lineage that
led to the M. bovis sequenced strain 2122. In a similar way the dN/dS ratio was
calculated for 87 synonymous and nonsynonymous mutations in strain F1.2
(representing the French lineage, SB0120 [Table 1]) that happened between
anc1 and the divergence of F1.2 from the lineage that leads to BCG Pasteur.
Finally, the dN/dS ratio was calculated for 161 synonymous and nonsynonymous
mutations between the divergence of strain F1.2 and BCG Russia in the lineage
leading to BCG Pasteur. dN/dS ratios were calculated with the S.T.A.R.T 2
package (31) using the Nei-Gojobori method and the Jukes-Cantor correction
(43).
RESULTS
Sequenom analysis. SNPs were queried using oligonucleo-
tides that anneal #1 from the base of interest; allele-specific
extension products were then analyzed via matrix-assisted laser
desorption ionization mass spectrometry to identify the base at
each SNP position across the panel of strains (Fig. 2). From the
total of 736 SNPs, 35 SNPs failed and 20 gave ambiguous calls
(i.e., many strain-calls missing or both alleles called at the same
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locus); this gave a total of 681 SNPs that gave usable data. Of
these 681 SNPs, 23 were called as invariant across BCG Pas-
teur and otherM. bovis strains, suggesting errors in the original
genome sequences. However these 23 SNPs were contained
within repeated sequences such as IS1081, REP13E12, and
PE-PGRS genes, suggesting that the Sequenom method may
also be at fault. To determine whether the sequence or Seque-
nom calls were correct, we examined the original sequence
trace files for the BCG Pasteur and M. bovis 2122/97 genome
sequences. This confirmed that 14 of the 23 invariant SNPs
were indeed point mutations between BCG Pasteur and M.
bovis 2122/97; four SNPs appeared to be errors in M. bovis,
while the remaining five SNPs could not be called because of
poor sequence reading coverage. As we could not determine
the distribution of these 23 SNPs across the remaining strains,
they were excluded from the analysis. Hence, we obtained
informative data from 658 SNPs. The complete results for all
of the 701 SNPs that gave data (including ambiguous calls) are
shown in Table S1 in the supplemental material, while the
distribution of SNPs across the functional classification of
BCG genes is shown in Fig. S1 in the supplemental material.
Phylogenetic analysis. The phylogenetic distribution of
SNPs allowed the strains to be clustered into related groupings,
FIG. 1. Spoligotype phylogeny of M. bovis strains. The figure de-
picts relationships across the M. bovis strains used in this study based
solely on spoligotype. Strain numbers are shown clustered into their
spoligotype designations (“SB” numbers, based on the internationalM.
bovis spoligotype database at www.mbovis.org). SB0120 is the most
repleteM. bovis spoligotype pattern, with all other patterns used in this
study derivatives of this pattern. Branch lengths are not phylogeneti-
cally informative and are shown merely for the purposes of clustering
related strains.
TABLE 1. Strains used in this study
M. bovis strain Source Spoligotype VNTR Comment
Non-BCG strains
2122/97 VLA Weybridge, United Kingdom SB0140 8555*33.1 Genome-sequenced strain
F1.2 AFSSA, Alfort, France SB0120 5654*33.1 French clinical isolate
F3 AFSSA, Alfort, France SB0120 5553*33.1 French clinical isolate
F4 AFSSA, Alfort, France SB0120 5554*43.1 French clinical isolate
F5 AFSSA, Alfort, France SB0120 5554*33.1 French clinical isolate
F6 AFSSA, Alfort, France SB0120 5554*33.1 French clinical isolate
F7 AFSSA, Alfort, France SB0120 NDa French clinical isolate
F8 AFSSA, Alfort, France SB0120 4554*33.1 French clinical isolate
F9 AFSSA, Alfort, France SB0120 5554*33.1 French clinical isolate
F10 AFSSA, Alfort, France SB0120 5554*33.1 French clinical isolate
F11 AFSSA, Alfort, France SB0120 5554*33.1 French clinical isolate
F12 AFSSA, Alfort, France SB0120 5554*33.1 French clinical isolate
F13 AFSSA, Alfort, France SB0120 5554*33.1 French clinical isolate
F14 AFSSA, Alfort, France SB0120 5554*33.1 French clinical isolate
2253 VLA Weybridge, United Kingdom SB0134 3534*33.1 United Kingdom clinical isolate
1766 VLA Weybridge, United Kingdom SB0134 3534*33.1 United Kingdom clinical isolate
681 VLA Weybridge, United Kingdom SB0129 6554*23.1 United Kingdom clinical isolate
1198 VLA Weybridge, United Kingdom SB0140 6554*33.1 United Kingdom clinical isolate
1094 VLA Weybridge, United Kingdom SB0140 7554*33.1 United Kingdom clinical isolate
393 VLA Weybridge, United Kingdom SB0140 7554*33.1 United Kingdom clinical isolate
AN5 VLA Weybridge, United Kingdom SB1417 6554*33.2 Tuberculin production strain
BCG strains
Pasteur VLA Weybridge, United Kingdom SB0120 556233.1 Genome-sequenced strain
Sweden Marcel Behr, McGill University, Canada SB0120 5553*33.1 Vaccine strain
Tokyo VLA Weybridge, United Kingdom SB0120 5553*33.1 Vaccine strain
Denmark Statens Serum Institut, Denmark SB0120 5552/3*33.1 Vaccine strain
Tice Marcel Behr, McGill University, Canada SB0120 555233.1 Vaccine strain
Frappier Marcel Behr, McGill University, Canada SB0120 555133.1 Vaccine strain
Glaxo VLA Weybridge, United Kingdom SB0120 5553*33.1 Vaccine strain
Russia VLA Weybridge, United Kingdom SB0120 ND Vaccine strain
Beijing China Agricultural University SB0120 ND Vaccine strain
Connaught VLA Weybridge, United Kingdom SB0120 ND Vaccine strain
Birkhaug Marcel Behr, McGill University, Canada SB0120 ND Vaccine strain
Prague Marcel Behr, McGill University, Canada SB0120 ND Vaccine strain
Moreau Marcel Behr, McGill University, Canada SB0120 ND Vaccine strain
a ND, not determined.
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showing as expected that M. bovis strains isolated in Britain,
those isolated in France, and BCG daughter strains formed
three distinct clades (Fig. 3). As the SNPs were selected on
comparison of the genomes of BCG Pasteur and M. bovis
2122/97, it should be noted that we generated a “linear” phy-
logeny, with these two strains being most distant from each
other and all other strains falling between them.
The SNP phylogeny recapitulated BCG genealogies pro-
posed using deletions or duplications (7, 9). Hence, “early”
(pre-1927) or “late” (post-1927) BCG strains group together,
although the SNPs did not allow the resolution of DU2 groups
I and II as defined by Brosch et al. (9). BCG strains Russia,
Tokyo, and Moreau (group I) and Sweden and Birkhaug
(group II) clustered together. DU2 group III (BCG strains
Denmark, Glaxo, Beijing, and Prague) formed a discrete
group, with 10 SNPs distinguishing them from groups I and II.
One SNP separated BCG Connaught/Frappier from group II,
while seven SNPs separated these strains from BCG Tice.
Finally, BCG Pasteur had eight strain-specific SNPs. One SNP,
a 1-bp insertion at position 842687 (mIns-842687; see Table S1
in the supplemental material), was present in BCG Pasteur and
BCG Beijing only. As this SNP is homoplasic, the Sequenom
results were verified using standard sequencing and confirmed
to be correct. Whether this indicates a selective pressure at this
locus is unclear.
BCG Beijing was included in our SNP analysis as this strain
had so far, to our knowledge, not been genetically studied. It
was known, however, that BCG Beijing was derived from BCG
Denmark and shows protective efficacy similar to that of BCG
Denmark in animal models (56). The SNP analysis showed, as
expected, that it belonged to the DU2-III group with BCG
strains Denmark, Prague, and Glaxo. However, comparative
genomic hybridization (data not shown) using an M. tubercu-
losis complex microarray (25) revealed that BCG Beijing had
the characteristic RD-Denmark locus intact (41). Hence, it
would appear that BCG Beijing was derived from a BCG
Danish seed-lot before the RD-Denmark deletion had oc-
curred. Using high-resolution NimbleGen arrays, Leung et al.
also recently screened the genomes of BCG Beijing and 12
other BCG strains for InDels and also placed BCG Beijing in
the BCG Denmark-derived clade (37).
The M. bovis progenitor attenuated by Calmette and Gue´rin
is not available, having been lost from the Institut Pasteur
archives. Therefore, we selected a panel of French M. bovis
strains on the basis that they had the same spoligotype as BCG
(SB0120) and similar VNTR profiles. Hence, the SNP screen
showed minimal variation between the 13 French M. bovis
strains. However, they were distinguished from the British
strains by 158 SNPs and from BCG by 186 SNPs; we will deal
below with the functional implications of these latter 186 SNPs.
The British strains were chosen on the basis of our detailed
knowledge of the population structure of M. bovis, with mo-
lecular types SB0129, SB0134, and SB0140 representing the
major groups of M. bovis in Britain (Fig. 1). In agreement with
previous phylogenies of M. bovis based on spoligotypes and
VNTR (53, 57), types SB0129 and SB0134 are more closely
related to French strains than to the SB0140 clonal complex.
The sequenced strain, 2122/97, showed 66 unique SNPs com-
pared to other strains with the same SB0140 pattern.
One hundred fifty-eight SNPs separated all of the French
strains from all of the British M. bovis strains. Using BLASTn
(3), we determined the status of each of these SNPs in an
outgroup, the genome sequence of M. tuberculosis H37Rv, to
establish where the SNPs occurred in the evolution of the
British and French lineages (Fig. 3). This analysis showed that
53 SNPs had occurred during the evolution of the British M.
bovis branch (to SB0134), with 105 SNPs on the French branch.
Hence, it appears that the British SB0134 strains are more
FIG. 2. Sequenom output. Images of the MassARRAY TyperAnalyzer v3.3 software (Sequenom) output for two samples. (a) Mass spectrom-
etry output for BCG Pasteur, highlighting a T allele call for SNP GS34910, which is at BCG genome position 565209, located at the start of the
sigK gene. (b) Mass spectrometry output for BCG Russia SNP GS34910, showing a C allele call for this SNP. This SNP gives rise to the differential
expression of the SigK regulon between early and late BCG strains.
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similar to the common ancestor of the British-French lineage
(anc1 in Fig. 3) than to the French strains selected in this study.
Determining the ratio of synonymous and nonsynonymous
mutations per site between sequences (dN/dS ratio) can indi-
cate the strength and direction of selection. Purifying selection
is normally stronger on nonsynonymous changes, reducing the
dN/dS ratio and giving values of !1; in contrast, positive or
directional selection would give values for dN/dS of"1. Strains
of BCG have been cultured in vitro for long periods, and
therefore, dN/dS calculations may reveal differences in selec-
tion pressures between in vivo and in vitro growth. Calcula-
tions of dN/dS ratios gave values of 0.48 for anc1 (Fig. 3) to
strain 2253 (SB0134, 48 SNPs), 0.68 from anc1 to strain F1.2
(SB0120, 87 SNPs), and 0.63 for the branch between the di-
vergence of the F1.2 wild strain and the divergence of BCG
Russia (161 SNPs). For such closely related strains, the inter-
pretation of high dN/dS values is complex and the values are
open to several interpretations (48). Nevertheless, two conclu-
sions can be reached from our data. First, there appears to be
no evidence for increased relaxed selection during the in vitro
cultivation of BCG strains compared to in vivo-isolated M.
bovis strains (0.63 in vitro versus 0.68 in vivo). Second, the
relatively high dN/dS ratios are further evidence for relaxed
purifying selection within theM. tuberculosis complex, presum-
ably in response to a low effective population size (53). This
latter point has been elegantly demonstrated by Hershberg et al.
(29), who performed a multilocus sequencing analysis on a world-
wide collection of 108 M. tuberculosis complex strains. The aver-
age pairwise dN/dS ratio across these strains for 370 SNPs was
0.57, comparable to the values that we obtained and, they con-
cluded, likely a consequence of reduced selective constraint.
Interestingly, the ugpAEBC region contains SNPs that dif-
ferentiate the British, French, and BCG lineages. For example,
taking theM. bovis 2122/97 genome sequence as the reference,
SNP mIns-3095955 is a 1-bp insertion in ugpA that is present in
SB0134 and SB0120 M. bovis (i.e., including BCG); this poly-
morphism is in fact a 1-bp deletion from type SB0129, AN5,
and M. bovis 2122/97 that frameshifts ugpA; hence, SNP mIns-
3095955 delineates SB0129 and its descendants. Similarly, SNP
3093642 is an nsSNP in ugpB found only in the British SB0140
clonal complex. Finally, SNPs 3092465 and 3093840 are found
only in BCG strains (see Table S1 in the supplemental mate-
FIG. 3. Distribution of SNPs across British, French, and BCG lineages. A linear phylogeny is shown, where the sequenced strains that were used
to derive the SNPs, M. bovis 2122/97 and BCG Pasteur, lie at the extremes. Numbers of SNPs that separate each grouping are shown. Branch
lengths are not phylogenetically informative; the figure shows merely the clustering of strains generated by the SNP analysis.
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rial). Hence, focused sequencing of these SNPs provides a simple
way to cluster British, French, and BCG strains. Possible func-
tional implications of these mutations are discussed below.
Functional inferences. Of the 186 SNPs identified between
virulentM. bovis strains and BCG, 115 are nonsynonymous and
55 are synonymous, 13 are intergenic, and three are located in
pseudogenes. While synonymous SNPs (sSNPs) may have
functional consequences in rare cases (34), nsSNPs, frame-
shifts, or intergenic SNPs that affect gene expression or protein
structure are the most likely source of phenotypic variation.
Virulence. In a global analysis of genes required for in vivo
survival, Sassetti and Rubin identified 194 major candidate
genes (50); eight of these genes contain nsSNPs in BCG (Table
2). While many of these nsSNPs encode conservative amino
acid substitutions, some may have functional consequences.
For example, kdpD encodes the histidine kinase sensor of the
two-component system KdpDE that regulates turgor pressure
and potassium homeostasis. The BCG kdpD allele contains
two nsSNPs, P83S and N776D, the latter of which is a conser-
vative substitution. The N-terminal domain of KdpD contains
two Walker nucleotide binding motifs which are important in
ATP binding (27). While the P83S substitution does not dis-
rupt these motifs, the P83 residue is conserved across KdpD
homologues in many bacterial species (27). Functional analysis
of the BCG KdpD protein is therefore warranted.
The SenX3 histidine kinase is also implicated in virulence
(44, 50) and contains an F109S mutation; its linked response
regulator, the RegX3 protein, also contains an nsSNP (A18T).
The RegX3 mutation occurs at an alanine residue which is
conserved across many similar two-component regulators. The
function of SenX3-RegX3 in M. bovis BCG is unknown, but in
Mycobacterium smegmatis SenX-RegX regulates the expres-
sion of the high-affinity pstSCAB phosphate uptake system (23,
24). If SenX3-RegX3 also functions in phosphate control in
BCG, and as the pst high-affinity system appears to be non-
functional in BCG, the accumulation of mutations in the
senX3-regX3 locus may be indicative of relaxed selection acting
at this locus.
It is worth noting that the pks12 gene, which encodes a man-
nosyl-!-1-phosphoisoprenoid synthase (40), contains 11 nsSNPs
between BCG and other M. bovis strains; however, only one of
these SNPs, S2964R, is present in all BCG strains but absent from
all other M. bovis strains studied. Furthermore, there is no evi-
dence of any structural difference between the mannosyl-!-1-
phosphoisoprenoid synthases synthesized by BCG and those syn-
thesized byM. tuberculosis (40), suggesting that this accumulation
of nsSNPs in pks12 has no functional effect.
Lesions in metabolism. The M. bovis genome encodes 17
cytochrome P450 oxidase (CYP) enzymes, with an 18th gene,
the CYP142 gene, frameshifted (22). All BCG strains contain
a frameshifted CYP123 gene, with an extended C-terminal
portion that would be expected to disrupt correct protein fold-
ing and function. The role of mycobacterial CYP enzymes is
still being elucidated, but they are expected to be integral to
lipid metabolism. The function of CYP123 is unknown, but it
was found to be upregulated in response to heat stress (55).
The genes for three further CYP enzymes, the CYP126,
CYP128, and CYP135B1 genes, contain nsSNPs, but their
functional consequences are unknown. CYP128 was shown to
be essential for in vitro growth of M. tuberculosis (49), so
presumably the L203F substitution present in the BCG protein
has no major functional effects.
M. bovis andM. bovis BCG strains cannot catabolize alanine
due to a frameshift mutation in the aldA gene, which encodes
alanine dehydrogenase. Chen and colleagues have also shown
that BCG strains exhibit defects in serine metabolism, with
BCG Pasteur and Frappier being unable to catabolize serine
(12). The genetic basis for this defect in serine catabolism
remains unidentified; indeed, sdaA, which encodes serine
deaminase, is identical between M. bovis and M. bovis BCG
strains, which suggests a regulatory defect (12). Analysis of
SNPs that are shared between BCG Frappier and Pasteur did
not reveal any obvious candidates that would explain the serine
catabolism phenotype.
The M. tuberculosis complex contains three systems for the
biosynthesis of trehalose, namely, the OtsAB, TreS, and
TreXYZ systems (14, 42). It appears that the OtsAB system is
the principal pathway for trehalose biosynthesis in M. tubercu-
losis; inactivation of the TreXYZ system had no in vitro or in
vivo effect on growth (42). TheM. bovis 2122/97 strain contains
an internal deletion in the treY gene that leads to an inactive
protein product (22, 26); however, this mutation is present only
in strains that are closely related to 2122/97. It is surprising,
therefore, that all BCG strains have an independent mutation
in the TreXYZ system, with treZ frameshifted. Hence, the
same biosynthetic pathway is mutated in both wild-type viru-
lent M. bovis and in vitro-attenuated BCG. As the TreXYZ
pathway is not required for virulence, its loss may simply reflect
the removal of biosynthetic redundancy.
TABLE 2. Genes defined as essential in vivo by transposon site hybridization that contain nsSNPs across all BCG strainsc
Gene Rv coding sequence BCG coding sequence SNP Function
nrp Rv101 BCG0134 L1365M Nonribosomal peptide synthase
senX3 Rv0490 BCG0531 F109S Two-component sensor
kdpD Rv1028c BCG1085c P83S; N776Da Two-component sensor
murI Rv1338 BCG1400 R154L Glutamate racemase
lysX Rv1640c BCG1679c D769Ea Lysyl-tRNA synthase
pks12 Rv2048c BCG2067c S2964R Mannosyl-!-1-phosphoisoprenoid synthase
fadE22 Rv3061c BCG3086c K488Ea,b; S497Cb Acyl coenzyme A dehydrogenase
Rv3335c Rv3335c BCG3406c A86Va Integral membrane protein
Rv3616c Rv3616c BCG3680c A4Va ESX-1 secreted antigen
a Conservative substitution.
b Position with reference to H37Rv protein sequence as M. bovis 2122/97 allele is frameshifted.
c Transposon site hybridization was performed as described previously (50).
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Growth on glycerol. A key metabolic selection placed on the
M. bovis progenitor of BCG was the utilization of glycerol as a
carbon source. We have previously shown that M. bovis strains
contain an nsSNP in the gene encoding pyruvate kinase (pykA)
that prevents the conversion of phosphoenolpyruvate to pyru-
vate and hence blocks glycolysis from feeding into the tricar-
boxylic acid cycle (22, 33). BCG strains all contain an
Asp220Glu mutation that restores activity to pyruvate kinase,
a mutation that was selected by the glycerol-based medium
used by Calmette and Gue´rin.
In a chemostat analysis of Escherichia coli strains grown on
glycerol, mutations in glpK (encoding glycerol kinase) that in-
creased enzyme efficiency were selected for (28). The glpK
gene of M. bovis 2122/97 is frameshifted, while that of BCG is
in frame (22, 33). This latter mutation was not, however, se-
lected for during BCG’s in vitro growth, as French and related
British M. bovis strains have an in-frame glpK; hence, it is
merely a mutation in M. bovis 2122/97. The bovine tuberculin
production strain, M. bovis AN5, was included in our SNP
screen since, like BCG, it is a glycerol-adapted strain of M.
bovis (45); SNPs shared between BCG and AN5 may favor
growth of M. bovis on glycerol. However, apart from the pre-
viously described Asp220Glu mutation in pykA we could iden-
tify only one homoplasic SNP shared between BCG and AN5
(SNP 1369616), which was located in the gene for PPE18.
However, it appears unlikely that this represents a glycerol-
adaptive mutation.
As noted above, the ugpAEBC locus contains a number of
SNPs with functional consequences. Hence, ugpA is frame-
shifted in British type SB0129 and the SB0140 clonal complex
because of a 1-bp insertion; the resulting protein will not lo-
calize correctly in the membrane and is therefore nonfunc-
tional. All BCG strains have an independent null mutation in
the same operon, with ugpB containing an in-frame stop codon,
and they also contain an nsSNP in ugpC. Hence, in British and
BCG lineages the UgpAEBC transporter is nonfunctional.
This is interesting because ugpAEBC encodes a glycerol-3-
phosphate transporter that in related actinobacteria is respon-
sive to phosphate starvation (35); hence, BCG contains null
mutations in both the high-affinity Pst phosphate uptake sys-
tem and the Ugp system. This may reflect BCG’s in vitro
growth conditions but will undoubtedly impair in vivo phos-
phate acquisition and hence may be implicated in attenuation.
Transcriptional regulators. Comparison of the transcrip-
tomes of M. bovis 2122/97 and BCG Pasteur revealed that 133
genes showed a minimum twofold difference in expression
across the strains (9). It is probable that some of these expres-
sion differences reflect differences between the United King-
dom and French clades of M. bovis rather than a difference
between virulent and attenuated strains. However, the genes
for three transcriptional regulators, BCG3734, BCG3145, and
BCG2507c, show nsSNPs across all BCG strains compared to
virulent M. bovis strains, mutations which may explain global
expression differences between M. bovis BCG and M. bovis.
BCG3734 encodes the CRP, a global gene regulator. Previ-
ous work has shown that there are two nsSNPs in BCG3734
compared to the M. bovis and M. tuberculosis genes, which
encode E178K and L47P substitutions (54). These mutations
have been shown to enhance the binding of BCG CRP to its
DNA binding sites (4, 30); however, this enhanced binding
does not appear to play a role in attenuation of BCG (30).
The LuxR family regulator BCG2507c contains an N-termi-
nal adenylate/guanylate cyclase catalytic domain, a putative
ATPase domain (COG3903 superfamily), and a C-terminal
helix-turn-helix domain. The D535E mutation in BCG2507c
falls in the ATPase domain; as it is a conservative substitution,
its functional consequences are expected to be minimal.
BCG3145 is a member of the AfsR/DnrI/SARP (Streptomy-
ces antibiotic regulatory protein) class of transcriptional regu-
lators. This class also contains EmbR, the regulator of three
arabinosyltransferases that are the targets of the front-line
tuberculosis drug ethambutol (8). The structure of EmbR has
been elucidated, revealing DNA binding, bacterial transcrip-
tional activation (BTA), and forkhead-associated domains (1).
While BCG3145 lacks the forkhead-associated domain, the
E159G mutation in BCG3145 mutates to glycine a conserved
glutamic acid residue located in a tetratricopeptide repeat in
the BTA domain (region T3). Tetratricopeptide repeat do-
mains are associated with protein-protein interactions (16),
and a conserved core (helices T1 to T7) of the BTA domain
seems to be required for proper function of SARP family
proteins (1, 51). Hence, the E159G mutation may affect the
ability of BCG3145 to regulate transcription.
Cycloserine resistance.Growth on D-cycloserine can be used
to differentiate M. bovis from M. bovis BCG strains, with M.
bovis being sensitive to 0.02 mg/ml cycloserine while M. bovis
BCG strains are resistant. The molecular basis for this pheno-
type is unknown. The emergence of cycloserine resistance is
usually due to mutations in the alrA gene encoding alanine
racemase or the ddlA gene encoding D-alanyl-D-alanine ligase
(20); however, the sequences of alrA and ddlA inM. bovis BCG
and other M. bovis strains are identical, as are their expression
levels (9). The other possibility is that the cycloserine trans-
porter CycA (which also transports D-serine, D-alanine, and
glycine) is defective for cycloserine transport in BCG. CycA
does in fact contain an nsSNP across all BCG strains, intro-
ducing a G122S mutation. It is noteworthy that in all se-
quenced mycobacterial CycA proteins this position is occupied
by glycine or sometimes, in other bacteria, by alanine. David
showed that resistance to cycloserine in M. tuberculosis can be
due to defective transport of the antibiotic (17), and so it is
tempting to speculate that the G122S mutation plays some role
in the inherent cycloserine resistance of BCG. This would also
suggest that BCG may be defective in D-alanine, glycine, and
D-serine transport, but this has not been reported.
DISCUSSION
Phylogenetic relationships based on SNPs identified by com-
paring two sequenced strains will inevitably place these latter
strains as most distant in any phylogeny (2, 58). Phylogenies
with these characteristics can therefore be deemed “prese-
lected” or “linear” phylogenies. This is evident in our phylog-
eny (Fig. 3). However, this does not invalidate the resulting
tree; our prior knowledge of the population structure of M.
bovis allowed us to select strains which encompass the diversity
within the population and to address our primary question of
which SNPs were acquired during the initial derivation of
BCG. Indeed, the SNP phylogeny is congruent with trees con-
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structed using spoligotyping and deletion typing (52, 53). The
one divergence from previous trees is the positioning of BCG
Tice and Frappier; BCG Tice and Pasteur shared six SNPs not
seen in Frappier, hence placing Tice closer to BCG Pasteur. In
a previous schema BCG Frappier had been positioned closer
to BCG Pasteur than Tice (9). However, Rosenthal is known to
have mixed BCG Pasteur with BCG Tice in the early 1950s to
correct for overattenuation (19). From the SNP data presented
here, it appears that this mixture of BCG Tice and BCG Pasteur
resolved as a variant of BCG Pasteur. In a recent DNA array-
based comparative study of BCG vaccine strains, Leung et al.
note that BCG Tice has a distinctive duplication (DU-Tice), pro-
viding a further marker to differentiate BCG Tice (37).
We describe a range of SNPs with putative functional effects
in this study. While it is straightforward to ascribe functional
effects to SNPs that, for example, frameshift genes, predicting
the impact of intergenic SNPs or nsSNPs is problematic. We
have therefore been conservative in our interpretation of the
SNP data and instead see them as the basis for focused exper-
imental validation. Furthermore, we are mindful that 35 SNP
detection reactions did not generate usable data, as is common
in high-throughput projects. Hence, it is possible that informa-
tive SNPs are missing from the data set presented here, but
future scans will revisit these SNPs.
What are the implications of this research for the BCG
vaccine? The fact that BCG daughter strains are genetically
distinct is evident from our study and previous work; however,
how these genetic differences translate into variation in vaccine
efficacy requires considerable functional analyses. Indeed, clar-
ity is first needed on the question of the efficacy of BCG
substrains. In a recent review of published data on the efficacy
of different BCG strains in human and animal studies, Ritz and
colleagues showed that BCG Pasteur, Denmark, and Glaxo
were associated with better protection against challenge in the
mouse model while BCG Denmark appeared the best in
guinea pig models (47). However, standardization of animal
protocols for such variables as the dose and route of vaccine
administration, interval between immunization and challenge,
and dose and route of challenge strain(s) is needed if true
head-to-head comparisons of BCG daughter strains are to be
made. Similarly, results from human studies suggest that there
are distinct differences in immunogenicity across BCG strains,
although the lack of standardization across trials again com-
plicates interpretation. For example, in a study of neonatal
vaccination in Mexico using BCG strains Brazil, Denmark, and
Japan, it appeared that BCG Japan was the least immunogenic
(59); however, in a South African study of neonatal vaccination
using BCG strains Japan and Denmark, BCG Japan was more
immunogenic than BCG Denmark (18).
Against this background it is difficult to connect genetic
differences in BCG strains to vaccine efficacy. However, this is
not to say that linkages cannot be made, once clear phenotypes
are defined. An elegant example of the link between BCG
genotype and phenotype was provided by Leung et al. (37),
who disclosed a deletion in the BCG Moreau strain that ex-
plained the lack of phenolic glycolipid and phthiocerol dimy-
cocerosates from this strain (13). As these latter lipids are
potent immunomodulators, their absence from BCG Moreau
may explain the lack of BCG-associated complications re-
ported with this strain (13). Hence, the SNP differences de-
fined herein will provide a rich source of genetic variation that
can be mapped to functional differences across BCG strains.
Using high-throughput SNP screening, we have therefore
identified SNPs that refine the phylogeny of British and French
M. bovis strains, confirm previous genealogies of BCG vac-
cines, and define a minimal set of SNPs between virulent M.
bovis strains and the attenuated BCG. These SNPs will there-
fore facilitate future studies of M. bovis phylogeography and
the molecular basis for the attenuation of BCG.
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4.1.2 Comparative genomics of esx genes from clinical isolates of  
M. tb 
Contribution: Analysis of the SNP data, assessment of the SNP distribution 
across the esx family and across different lineages of M. tb, mapping the SNP 
data to known Esx epitopes, phylogenetic analyses to quantify the selection 
pressure acting on the esx genes, and testing for gene conversion. 
 
In humans, CD4+ and CD8+ T-cells confer protective immunity against M. tb 
by mediating antigen-specific immune responses. Several secreted proteins 
from M. tb contain short peptide fragments bearing epitopes that bind to 
major histocompatibility complex (MHC) molecules, which are recognized by 
T-cells (Andersen et al. 1991). In order to evade the host immune system, 
variants of pathogens emerge, with alterations in epitope regions recognized 
by critical host immune cells. 
 
The Esx family of M. tb comprises 23 proteins (EsxA to EsxW) involved in 
the host-pathogen interactions of M. tb. Two of its members, EsxA or ESAT-
6 (early secretory antigenic target of 6 kDa) and EsxB or CFP-10 (culture 
filtrate protein of 10 kDa), are among the most frequently recognized T-cell 
antigens from M. tb (Andersen et al. 1995). There are 11 pairs of tandem 
genes encoding paralogous Esx proteins on the M. tb H37Rv genome. Five of 
the tandem esx gene pairs are contained within the conserved ESX-1 to ESX-
5 genetic loci, encoding components of type VII secretion systems (Abdallah 
et al. 2007). The 13 esx genes (six gene pairs and a singleton) that are not 
part of the conserved ESX loci have arisen from singular duplication events 
(Gey Van Pittius et al. 2001). Consequently, the Esx family can be classified 
into the Mtb9.9, QILSS, and TB10.4 subfamilies based on high sequence 
identity. The TB10.4 subfamily comprises EsxH, which is a component of the 
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ESX-3 locus, and two of its paralogs (Skjøt et al. 2002). The Mtb9.9 and 
QILSS subfamilies have five members each that include gene duplicates of 
EsxN and EsxM, respectively, both of which belong to the ESX-5 locus. 
These gene duplicates show a striking level of amino acid similarity (93 to 
98%), indicating recent duplication from part of the ESX-5 locus (Gey Van 
Pittius et al. 2001). 
 
The strong antigenic properties of some of the Esx proteins have been utilized 
in the development of diagnostic tests (EsxA and EsxB) and protein-based 
vaccines (EsxH). Antigenic epitopes in several Esx proteins have been 
characterized experimentally. Despite the high level of sequence conservation 
in the Esx family, there is heterogeneity in T-cell responses to different Esx 
antigens. On the one hand, there is evidence of cross reactivity between 
highly similar epitopes in duplicated proteins from the QILSS and Mtb9.9 
subfamilies, but on the other hand, even single-residue differences in the 
epitope sequences have been shown to alter the responder frequencies to these 
antigens. For example, it has been shown that human CD4+ T-cell lines 
specific for EsxL (G22 and L23) fail to recognize peptides from EsxN (A22 
and S23) and EsxV (G22 and S23), all of which are from the Mtb9.9 
subfamily (Alderson et al. 2000).  
 
The aim of this study was to characterize sequence diversity in esx genes 
isolated from clinical M. tb samples in order to identify substitutions that 
may impact immunogenicity. A total of 108 clinical strains isolated from TB 
patients at Hôpital Ambroise Paré in Boulogne-Billancourt, France were 
included in this study.  MIRU-VNTR typing revealed that the clinical strains 
represented the main geographical lineages of M. tb. Sequencing of the esx 
genes from the clinical samples was carried out using the automated Sanger 
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sequencing method and the sequences obtained were compared to the M. tb 
reference strain H37Rv in order to detect nucleotide variation. A total of 109 
unique SNPs were observed in the clinical dataset, 59 of which were 
nonsynonymous.  
 
Assessment of the SNP distribution across the Esx proteins indicated high 
genetic variability in the Mtb9.9 and QILSS subfamilies, and more 
conservation in the ESX-1 to ESX-4 loci. Comparison of the DNA sequences 
of variable esx genes provided clear evidence for gene conversion events 
between duplicated paralogous genes in the QILSS and Mtb9.9 subfamilies. 
Mapping the SNPs to known Esx epitopes revealed that the majority of the 
nonsynonymous SNPs occurred in regions of the gene coding for known 
epitopes. We identified a nonsynonymous SNP (E68K) in EsxB present in 18 
clinical isolates belonging to different lineages. This substitution occurs within 
a known human T-cell epitope and may influence responses to EsxB peptides 
that are used in commercially available diagnostic tests for TB. Estimation of 
the dN/dS ratio (ratio of synonymous and nonsynonymous mutations per 
site) suggested that some of the Esx epitopes might be under positive 
selection. In conclusion, our work revealed a number of previously unknown 
sequence polymorphisms in the Esx family, some of which may have an 
impact on the immunogenicity of the corresponding proteins. 
 
In a previous investigation, Comas et al. uncovered more than 9,000 SNPs by 
whole-genome sequencing of 21 strains using the Illumina genome analyzer. 
Combining the SNP data with the epitope information from the IEDB 
database, they estimated low dN/dS values indicating that human T-cell 
epitopes are under purifying selection and are highly conserved (Comas et al. 
2010). On the contrary, our study has reported that the some of the 
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immunodominant Esx proteins are highly polymorphic, in part because of 
high level of recombination. For technical reasons, we believe that Comas et 
al. have underestimated the amount of variation in the Esx family. One of 
the limitations of the Illumina technology is sequence assembly and 
identification of SNPs in repetitive regions due to the short lengths of the 
sequence reads. This could mask any polymorphisms generated due to gene 
conversion events in duplicated paralogous genes, due to erroneous mapping 
of short reads. The use of Sanger sequencing with primers specific for the 
highly similar esx genes helped us overcome the pitfalls of short read 
sequencing technology. As we report lineage-specific sequence polymorphisms 
within the Esx family, comparative gene expression studies of clinical isolates 
by Homolka et. al (2010) have shown lineage-specific transcription patterns in 
response to host-derived stimuli. 
 
Mathematical modelling analyses by Cohen et al. (2008) suggest that a failure 
to consider mycobacterial strain diversity could have a significant negative 
impact on vaccine efficacy, due to strain replacement by M. tb variants not 
targeted by the vaccine. Therefore, characterization of the molecular and 
phenotypic differences and similarities between clinical isolates is a crucial 
component in the design of new control measures. 
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The 23-membered Esx protein family is involved in the host-pathogen interactions of Mycobacterium tuber-
culosis. These secreted proteins are among the most immunodominant antigens recognized by the human
immune system and have thus been used to develop vaccines and immunodiagnostic tests for tuberculosis (TB).
Gene pairs for 10 Esx proteins are contained in the ESX-1 to ESX-5 loci, encoding type VII secretion systems.
A subset of Esx proteins can be further classified into the Mtb9.9, QILSS, and TB10.4 subfamilies. To survey
genetic diversity in the Esx family and its potential for antigenic variation, we sequenced all esx genes from 108
clinical isolates of M. tuberculosis from different clades by using a targeted approach. A total of 109 unique
single nucleotide polymorphisms (SNPs) were observed, and 59 of these were nonsynonymous. Some of the
resultant amino acid substitutions affect known Esx epitopes, including two in the EsxB (CFP-10) and EsxH
(TB10.4) antigens. Assessment of the SNP distribution across the Esx proteins revealed high genetic variabil-
ity, especially in the Mtb9.9 and QILSS subfamilies, and more conservation in the ESX-1 to ESX-4 loci.
Comparison of the DNA sequences of variable esx genes provided clear evidence for recombination events
between different genes in the same strain, some of which are predicted to truncate the corresponding protein.
Many of these polymorphisms escape detection by ultrahigh-throughput sequencing using short sequence
reads, as such approaches cannot distinguish between closely related genes. The esx gene family is dynamic,
and sequence changes likely lead to immune variation.
Development of an effective tuberculosis (TB) control strat-
egy requires detailed understanding of the biology of Myco-
bacterium tuberculosis and its interaction with human hosts. In
humans, CD4! and CD8! T cells are known to mediate anti-
gen-specific immune responses that are essential for conferring
protective immunity against M. tuberculosis (7, 36). Several
secreted proteins from mycobacteria have been shown to in-
duce strong cellular immune responses due to the presence of
short peptide fragments bearing epitopes that bind to major
histocompatibility complex (MHC) molecules, which are rec-
ognized by T lymphocytes (7).
Two of the most frequently recognized T cell antigens from
M. tuberculosis are the small secreted proteins EsxA or
ESAT-6 (early secretory antigenic target of 6 kDa) and EsxB
or CFP-10 (culture filtrate protein of 10 kDa), the prototypes
of the Esx family (6). Genes encoding ESAT-6 (esxA) and
CFP-10 (esxB) are located directly adjacent to each other and
known to be cotranscribed (10). Analysis of the genome se-
quence of M. tuberculosis H37Rv revealed 11 pairs of tandem
genes encoding paralogous Esx proteins located immediately
downstream of the PE/PPE genes (15, 48). The esx family has
23 members (11 gene pairs and a singleton, esxQ) named esxA
to esxW. Although the level of sequence identity varies be-
tween the Esx proteins (35% to 98%), all of them belong to the
WXG100 family, which is characterized by a size of "100
amino acids and the presence of a Trp-Xaa-Gly (W-X-G)
motif (37).
EsxA and EsxB interact to form a 1:1 heterodimer, which
appears to be essential for their secretion (10, 43). Proteins
encoded by two other paralogous gene pairs, EsxR-EsxS and
EsxH-EsxG, also form 1:1 complexes, suggesting that this may
be typical of all Esx protein couplets (8, 32). Five of the 11
tandem gene pairs are contained within conserved genetic loci
ESX-1 to ESX-5, encoding components of a type VII secretory
apparatus (Table 1) (2, 26, 48). The ESX-1 system, which is
responsible for the secretion of EsxA and EsxB, has been
extensively studied due to its important role in M. tuberculosis
pathogenesis (11, 12, 27). Loss of the region of difference 1
(RD1) containing the ESX-1 locus contributes to the attenu-
ation of the vaccine strains Mycobacterium bovis BCG and
Mycobacterium microti (12, 40, 41). Of the other systems,
ESX-5 is known to be necessary for the secretion of PE and
PPE proteins in Mycobacterium marinum and for macrophage
subversion (3, 4). ESX-3 is essential for in vitro growth and may
be involved in iron/zinc homeostasis (44), while the functions
of ESX-2 and ESX-4 remain unknown. Comparative genomic
analysis suggested that the ESX loci in mycobacteria resulted
from a series of duplication events, where ESX-4 was the
progenitor (26).
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The 13 esx genes that are not part of the ESX-1 to ESX-5
loci seem to have arisen from singular duplication events (26).
Consequently, the Esx family can be classified into distinct
subfamilies based on high sequence identity between certain
members (Table 1). The TB10.4 subfamily comprises esxH,
which is a component of the ESX-3 locus, and two of its
paralogs (45). The Mtb9.9 (31) and QILSS (48) subfamilies
have 5 members each that include gene duplicates of esxN and
esxM, respectively, both of which belong to the ESX-5 locus.
These gene duplicates show a striking level of amino acid
similarity (93 to 98%), indicating recent duplication from part
of the ESX-5 locus (26). Comparative proteomics between M.
tuberculosis H37Rv and the attenuated strain M. tuberculosis
H37Ra revealed the absence of some EsxM and EsxN paralogs
in M. tuberculosis H37Ra (28). Along with the ESX-1 system,
two other loci, encoding paralogs of EsxM and EsxN, have
been deleted from the vaccine strain M. bovis BCG: the RD5
and RD8 loci comprising esxP-esxO and esxW-esxV, respec-
tively (9, 28).
The identification of EsxA and EsxB as potent T cell anti-
gens prompted several immunological studies in different an-
imal models and humans (1, 6, 21, 42, 49), and it has been
shown that other Esx proteins also display antigenic qualities
(12). ESAT-6 and CFP-10 have been utilized in the develop-
ment of diagnostic tests that can distinguish between infected
and vaccinated individuals (33, 49), while EsxH (TB10.4) has
been used to obtain a fusion protein-based subunit vaccine
(20). Furthermore, antigenic epitopes in several Esx proteins
have been characterized experimentally. Investigation of
TB10.4 paralogs revealed unique antigenic epitopes in the
three proteins despite the high sequence similarity (!75%)
(45). Interestingly, the Mtb9.9 subfamily proteins, which dis-
play an even higher degree of amino acid similarity (!93%),
have also been shown to induce heterogeneous human T cell
responses (5).
The success of M. tuberculosis as a pathogen has been due
largely to its ability to survive in spite of a host immune re-
sponse. In order to evade the host immune system, variants of
pathogens emerge, with alterations in epitope regions recog-
nized by critical host immune cells. Despite the high level of
sequence conservation in the Esx family, there is heterogeneity
in T cell responses to different Esx antigens. The aim of this
study was to characterize sequence diversity in esx genes iso-
lated from clinical M. tuberculosis samples in order to identify
substitutions that may impact immunogenicity.
MATERIALS AND METHODS
TB patients. The clinical strains used in this study were isolated from tuber-
culosis patients at Hoˆpital Ambroise Pare´ in Boulogne-Billancourt, France, over
a period of 3 years from 2001 to 2004. A total of 103 patients were included,
among whom 58 were male and 45 were female. The patient ages ranged from
12 to 96 years, with a median age of 38 years. Localization of tuberculosis was
pulmonary in 84 cases and extrapulmonary in the remaining 19 cases (pleural TB,
3 cases; lymphatic TB, 8 cases; bone and joint TB, 3 cases; meningitis, 2 cases;
miliary TB, 2 cases; digestive TB, 1 case). The HIV status was unknown for 31
patients, 67 patients tested HIV negative, and 5 patients tested HIV positive.
Strains. With the exception of two patients, one single isolate per patient was
included in this study. For one of the patients, 2 isolates were included, which
had been isolated at a 3-week interval, while for another patient, 5 isolates were
included, which had been isolated over a period of 3 years. The respiratory
samples were decontaminated by the N-acetyl-cysteine–NaOH method. Routine
laboratory procedures included microscopic examination after fluorescence
staining and culture on solid Lowenstein-Jensen (Bio-Rad, Marnes-la Coquette,
France) and liquid (MGIT; Becton Dickinson, Le Pont-de-Claix, France) media.
Solid media were maintained at 37°C for 3 months and examined for growth once
a week. The MGIT media were incubated in the Bactec MGIT 960 system and
examined as soon as a positive signal was emitted. In the case of negativity, the
liquid cultures were maintained in the MGIT system for 45 days. Species iden-
tification was done using the commercially available Accuprobe system (bioMe´ri-
eux, Marcy l’Etoile, France), and antibiotic susceptibility testing was carried out
with the Bactec MGIT 960 system.
Molecular typing. For molecular typing, a loopful of Lowenstein-Jensen cul-
ture was suspended in 150 "l of Tris-EDTA (TE) buffer and heated at 95°C for
15 min. This crude lysate was used for PCRs. The M. tuberculosis H37Rv refer-
ence strain was included for control purposes. Amplification of the direct repeat
(DR) regions and hybridization for spoligotyping were carried out as previously
described (30), and hybridization profiles were expressed using the octal code
and compared with the database, SpolDB4, to determine the corresponding
spoligo international types (14). Amplification of the mycobacterial interspersed
repetitive-unit (MIRU) loci for MIRU–variable-number tandem-repeat
(VNTR) typing was carried out as described in the past (47). The fragment sizes
of the amplification products were estimated by agarose gel electrophoresis in
relation to molecular weight markers, and the number of MIRU copies was
determined with reference to the MIRU-VNTR allele table (see Table S1 in the
supplemental material).
PCR and sequencing. Fragments bearing all esx genes were amplified using the
sets of primers listed in Table S2A in the supplemental material. Amplification
was performed using 25 "l of ReddyMix PCR Master Mix (Thermo Fisher
Scientific, Inc.) and 1 "l of each primer (10 pmol). Dideoxy sequencing of the
amplified gene fragments was carried out on both strands with the BigDye
Terminator cycle sequencing kit (Applied Biosystems, Foster City, CA), using
the primers listed in Table S2B in the supplemental material, and with an ABI
3700 DNA analyzer.
TABLE 1. Overview of the esx family of M. tuberculosisa
Conserved ESX
locus
esxA (ESAT-6) paralogs esxB (CFP-10) paralogs
Inside the ESX
locus Outside the ESX locus
Inside the ESX
locus Outside the ESX locus
ESX-1 esxA (rv3875) esxB (rv3874)
ESX-2 esxC (rv3890c) esxD (rv3891c)
ESX-3 esxH (rv0288) esxR (rv3019c), esxQb (rv3017c) esxG (rv0287) esxS (rv3020c)
ESX-4 esxT (rv3444c) esxU (rv3445c)
ESX-5 esxN (rv1793) esxI (rv1037c), esxL (rv1198), esxO
(rv2346c), esxV (rv3619c)
esxM (rv1792) esxJ (rv1038c), esxK (rv1197),
esxP (rv2347c), esxW
(rv3620c)
None esxEc (rv3904c) esxFc (rv3905c)
a Bold, TB10.4 subfamily; underlined, Mtb9.9 subfamily; bold and underlined, QILSS subfamily.
b esxQ does not occur in tandem with a cfp-10 homologue.
c esxE and esxF show no significant homology to any conserved ESX loci.
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SNP detection. Sequences of esx genes from the clinical strains were compared
with the corresponding sequences from the M. tuberculosis reference strain
H37Rv. The positions of variant nucleotides were recorded as single nucleotide
polymorphisms (SNPs) using the BLAST function on the TubercuList website
(http://tuberculist.epfl.ch). By comparison of the amino acid resulting from the
substitution with the reference amino acid sequence, these SNPs were further
characterized as being synonymous (sSNPs; no change in amino acid) or non-
synonymous (nsSNPs; resulting in an amino acid change).
Epitope identification. A total of 93 peptides belonging to the Esx proteins
comprising human T cell epitopes and major histocompatibility complex (MHC)-
binding peptides were obtained from the Immune Epitope Database and Anal-
ysis Resource (50) (see Table S3 in the supplemental material). The database
was accessed on 20 July 2010 (http://www.immuneepitope.org/).
Phylogenetic analysis. Comparison of the synonymous substitution rate per
site (dS) to the nonsynonymous substitution rate per site (dN) via the ratio ! "
dN/dS allows quantification of selection pressures on codon alignments. The
number of SNPs observed in individual esx genes was not sufficient to determine
a gene-specific dN/dS ratio from our data set. Instead, we concatenated all the
codons containing SNPs to generate a single sequence for each isolate, which was
used for subsequent analysis. Phylogenetic trees were obtained using the
PHYLIP package (22) by implementing the neighbor-joining algorithm based on
distances calculated under the K80 model. The neighbor-joining tree topologies
and the sequence alignment were subjected to codon-based likelihood analysis
using the CODEML (51) program in the PAML package (52). The M0 model
was used to estimate a single ! ratio for all branches of the tree.
In order to screen for recombination, the genetic algorithm recombination
detection (GARD) tool (38) was used, which is available on the web server of the
HyPhy package (39) (http://www.datamonkey.org/). GARD searches for putative
recombination breakpoints using a multiple-sequence alignment and generates
the phylogenies for each nonrecombinant segment in order to assess a goodness
of fit based on the Akaike information criterion (AIC) and AICc (AIC derived
from a maximum likelihood model fit to each segment) (46). Information from
all the fitted models is combined to assign a level of support to the placement of
breakpoints and for different phylogenies inferred among nonrecombinant seg-
ments.
RESULTS
Diversity of bacterial strains. A total of 108 clinical samples
were included in this study to investigate the genetic diversity
in the 23 genes constituting the esx family. Recent clinical
isolates were used in order to assess the current situation and
avoid possible sequence biases that could have been intro-
duced in heavily passaged laboratory strains. The clinical iso-
lates originated from different geographical locations in Eu-
rope, North Africa, America, and Asia and represented 75
different spoligo international types. MIRU-VNTR typing re-
vealed the distribution of the isolates across different genotypic
families, representing the main geographical lineages of M.
tuberculosis (24). A subset of the isolates could be identified as
members of the Beijing (6 isolates), Haarlem and Haarlem-like
(23 isolates), East African Indian (EAI; 6 isolates), Latin
American (LAM; 4 isolates), West African (7 isolates), and
East African (4 isolates) families, representing the breadth of
genomic diversity in the species (see Table S1 in the supple-
mental material). One of the clinical isolates was an M. bovis
strain. The esx gene sequences obtained from the clinical sam-
ples and the M. tuberculosis reference strain H37Rv were com-
pared in order to detect any variation at the nucleotide level.
Gene sequences of esx from the attenuated strain H37Ra are
identical to those of H37Rv (53).
Comparative esx genomics of clinical isolates. In the entire
clinical data set, a total of 797 substitutions were identified,
corresponding to 109 unique SNPs across the 23 esx genes,
each of which occurred in one or several isolates (see Table S4
in the supplemental material). Analysis of the 109 SNPs re-
vealed 50 sSNPs and 59 nsSNPs. Based on the spoligotype and
MIRU-VNTR information available for the clinical isolates,
we investigated whether the highly prevalent SNPs were spe-
cific to any of the geographical lineages represented in our data
set (see Table S1 and Fig. S1 in the supplemental material).
Interestingly, three SNPs in esxV, including two nsSNPs, Q20L
and S23L, and an sSNP in codon 57, occurred in 74 isolates
which belonged to different lineages. The high prevalence of
these SNPs in the clinical data set indicates that these positions
in esxV are lineage markers. An E68K substitution in EsxB
(CFP-10) was observed in 19 isolates, mostly belonging to the
Haarlem, Haarlem-like, and LAM families, all of which rep-
resent the Euro-American lineage (24). On the other hand,
there were also several SNPs with a very low prevalence that
appeared to be specific to particular strains or lineages. The
onlyM. bovis isolate in the data set showed two nsSNPs, M82V
in EsxE and W58stop in EsxF, which were not observed in the
other isolates. These were confirmed to be M. bovis specific
upon comparison with the genome sequences of M. bovis
AF2122/97 and M. bovis BCG Pasteur 1173P2 (13, 25).
SNPs involving stop codons can have a significant impact on
the structure and function of a protein. Apart from EsxF, two
other esx genes had substitutions that introduced stop codons.
These include EsxL, containing a Q76stop, which was observed
in three isolates, and EsxW, containing a Q59stop, which was
observed in one isolate. In contrast to EsxW, a stop59Q sub-
stitution in EsxM was present in nine clinical isolates. Another
nsSNP, A71S in EsxH, was seen in only two isolates, both of
which represented West African lineages (I and II). Three out
of six Beijing strains harbored an nsSNP, P63S in EsxU, that
was not present in any of the other isolates.
SNP distribution across esx genes. Analysis of 108 clinical
isolates revealed SNPs in 19 of the 23 esx genes. Sequences for
esxA, esxC, esxT, and esxS for all clinical isolates were invariant.
The distribution of the SNPs was not uniform across the esx
family members (Fig. 1). Grouping of the esx genes into their
subfamilies revealed that the four secretion systems ESX-1 to
ESX-4 displayed a low level of variation in general and a
strikingly low level of synonymous substitutions. On the other
hand, genes belonging to the Mtb9.9 and the QILSS subfam-
ilies, including the ESX-5 system, accounted for the majority of
the variation, displaying a large number of sSNPs as well as
nsSNPs. On average, from whole-genome comparisons of two
strains of M. tuberculosis (such as H37Rv and CDC1551 [23]),
FIG. 1. Distribution of nonsynonymous (red) and synonymous
(blue) SNPs across 23 esx genes. Brackets indicate genes encoded in
the ESX-1 to ESX-4 loci and members of the Mtb9.9, QILSS, and
TB10.4 subgroups.
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the SNP frequency is 1 per 4.1 kb. In contrast, in our esx data
set, the frequency compared to H37Rv ranges from a median
of 1 per kb to a maximum of 3 per kb depending on the clinical
isolate examined.
To estimate the incidence of SNPs across the clinical data
set, while accounting for lineage-specific polymorphisms, we
divided the clinical isolates into groups based on the lineage
information. The isolates that could not be successfully geno-
typed were considered one separate group. The frequency of
occurrence of an SNP was calculated separately for each lin-
eage and represented as the average of SNP frequency per
lineage. SNPs were grouped together based on the gene in
which they occurred (Fig. 2). As seen with the number of
polymorphisms, SNPs in the Mtb9.9 and QILSS genes were
present in a large number of clinical isolates. In contrast, SNPs
in genes encoded in the ESX-1 to ESX-4 loci and the TB10.4
paralogs were observed in very few isolates. Due to differences
in the proportion of SNPs observed in different esx subfamilies,
we carried out phylogenetic analysis separately on the two
main classes of esx genes: the ESX-5 paralogs (Mtb9.9 and
QILSS members) and components of the ESX-1 to ESX-4 loci.
Gene conversion in ESX-5 paralogs. A particular feature of
SNPs observed in esx genes belonging to the Mtb9.9 and
QILSS subfamilies was the cooccurrence of two or more SNPs
in neighboring codons. All the isolates containing an sSNP in
codon 40 of esxJ also had an sSNP substitution in codon 41.
The same was true for sSNPs in codons 6 and 8 of esxL. The
highly prevalent Q20L and S23L SNPs in esxV occurred in over
70% of the clinical isolates, all of which harbored an sSNP in
codon 57 of esxV. Reciprocal substitutions, Q59stop and
stop59Q, were also seen in the esxM and esxW genes.
Sequences for esxP from 17 clinical isolates contained an
sSNP in the second codon followed by an nsSNP (T3S) in the
third codon (Fig. 3A). The resulting codons in the esxP clinical
sequences were identical to the M. tuberculosis H37Rv se-
quences of the paralogous genes esxK, esxJ, and esxM from the
QILSS subfamily. The nucleotide sequences in esxP, esxK, and
esxJ are also identical for 108 bp downstream of the SNPs.
Sequences up to 80 bp upstream of the SNPs, including the
intergenic regions, are identical only between esxP and esxK
(Fig. 3A). The esxK sequences of the 17 clinical isolates andM.
tuberculosis H37Rv were identical, but note that in one other
clinical isolate, codons 40, 41, and 42 all contain the same
sSNPs as those present in esxP of M. tuberculosis H37Rv. We
subjected the 17 esxK and esxP sequences to a recombination
screen using the GARD tool. The results revealed the pres-
ence of one significant recombination breakpoint at the sev-
enth position (codon 3) and two suggestive potential break-
points between codons 40 and 42 (Fig. 3B).
Phylogenetic analysis. In order to calculate the ! (dN/dS)
ratio to quantify the selective pressure acting on the esx genes,
we chose the random-site model, which accounts for variable
selective pressures across codons and can detect amino acid
residues under either positive or negative selection. Analysis of
codon alignments, including SNPs observed in all esx genes,
gave a low ! of 0.35, because the dS value of the ESX-5
paralogs is very high. Mtb9.9 and QILSS genes harbor 46 of the
50 sSNPs which are observed in a large proportion of the
clinical isolates. However, the codon-based analysis assumes a
single tree topology for the whole alignment and does not
account for recombination. Therefore, we generated a codon
alignment for SNPs in esx genes belonging to the ESX-1 to
ESX-4 loci and reanalyzed them using CODEML. The esti-
mated ! value of 1.66 (dN/dS " 1) indicated diversifying se-
lection in this subset of esx genes.
SNPs occurring in Esx epitopes. In order to identify
whether any of the SNPs observed in our clinical data set
could impact the immunogenicity of the Esx proteins, we
searched the IEDB database for experimentally confirmed
human T cell and MHC-binding peptides specific to the Esx
family. A total of 93 peptides were obtained, 80 of which
comprised overlapping peptides that belonged to EsxA and
EsxB and spanned the entirety of these proteins. Sequence
alignments of the EsxA (excluding EsxQ due to a low level
of sequence homology to other EsxA paralogs) and EsxB
paralogs (Fig. 4) highlight the antigenic epitopes and posi-
tions of all the SNPs observed in the clinical data set. There
were 3 sSNP and 15 nsSNPs occurring in known epitope
regions. Excluding the 80 epitopes from EsxA and EsxB, 9 of
the 13 known epitopes in the other Esx proteins had at least
one or more SNPs (Table 2). Mtb9.9 genes, which harbored
12 of the 18 SNPs, were overrepresented. The correspond-
ing proteins share an MHC-binding peptide, MIRAQA
[GA][SL]LEA, at positions 16 to 26 that is subject to se-
FIG. 2. Incidence of synonymous (A) and nonsynonymous (B) SNPs
in 23 esx genes seen across 108 clinical isolates. Each pattern in the bars
indicates a unique SNP, and the height of each bar correlates with the
average frequencies per lineage.
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quence variation. Interestingly, three of the Mtb9.9 pro-
teins, EsxI, EsxV, and EsxO, showed a Q20L polar-to-non-
polar substitution. One of the two variable positions in the
MHC-binding peptide reflected an amino acid change, S23L
in EsxI and EsxV, and a reverse L23S change in EsxO. In
fact, we were able to identify several recurring positions
both inside and outside known epitopes (Fig. 4) at which
SNPs were observed in two or more Esx proteins.
FIG. 3. Putative recombination between esxP and esxK genes. (A) Schematic representation of sequence variation in esxK and esxP from M.
tuberculosis H37Rv and esxP sequences from clinical isolates. The M. tuberculosis H37Rv sequences for esxK and esxP are identical except at the
positions indicated with circles (silent polymorphisms) and rectangles (amino acid differences). Positions of the SNPs observed in esxP from 17
clinical isolates are color coded depending on their similarity to the corresponding gene in M. tuberculosis H37Rv. Nucleotide sequences up to 80
bp upstream of the gene are also identical in esxP and esxK. (B) Plot and summary of GARD results showing the location of the putative
recombination breakpoint. !AICc indicates improvement of the AICc score compared to that of the model with zero breakpoints. Significance of
the difference in topologies between the partitions to the left and right of the breakpoint is indicated with P values for both sides.
FIG. 4. Multiple sequence alignment of EsxB (CFP-10) and EsxA (ESAT-6) paralogs from M. tuberculosis H37Rv. Positions containing nonsynony-
mous (red boxes) and synonymous (blue boxes) changes have been annotated for each protein. Known immune epitope regions are highlighted in yellow.
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DISCUSSION
In this study, all 23 esx genes from 108 clinical samples were
sequenced in order to identify substitutions that may have an
impact on the immunogenicity or function of Esx proteins. A
total of 797 substitutions corresponding to 109 distinct SNPs
were observed in the entire clinical data set. Our analysis
indicated that esx genes encoded within the ESX-1 to ESX-4
loci displayed less variation overall than the esx genes located
outside these loci. EsxA and EsxB have been most extensively
studied owing to their crucial role in M. tuberculosis pathogen-
esis and applications in the development of vaccines and diag-
nostics. A past study by Musser et al. involving sequencing of
24 important M. tuberculosis antigens from 16 clinical strains
revealed no variation in EsxA and EsxB sequences (35). The
commercially available gamma interferon (IFN-!) release as-
says (IGRA) used for diagnosing TB, QuantiFERON gold test
(33), and T-SPOT.TB (34) employ peptides from ESAT-6
(EsxA) and CFP-10 (EsxB). While no sequence variation has
yet been observed in EsxA, there is an amino acid substitution
(E68K) in EsxB present in 18 of the 108 strains representing
diverse lineages. This substitution occurs within a known hu-
man T cell epitope, so it may influence responses to EsxB
peptides in the IGRA. Although the strains containing the
EsxB SNP represent different lineages, they also share three
sSNPs in codons 6 and 8 of EsxL and codon 57 of EsxV.
A more recent study by Davila et al. to assess the genetic
diversity of EsxA and EsxH genes among 88 clinical isolates
revealed no variation in either of the two genes (17), and this
is essentially in agreement with our findings (Table 2). Our
results showed that three out of five EsxA paralogs encoded by
the ESX-1 to ESX-5 loci were invariant across the entire clin-
ical data set. There was also an absence of silent substitutions
in the esx components of the ESX-1 to ESX-4 loci with the
exception of esxD. Interestingly, the majority of the nsSNPs
occur in regions of the gene coding for known epitopes. Our
estimation of dN/dS (" # 1.66) indicated that some of these
epitopes might be under positive selection. These findings are
in contrast with those in a recent publication by Comas et al.
demonstrating the hyperconservation of human T cell epitopes
among 21 strains representing the six main geographical lin-
eages of M. tuberculosis (16). Their investigation uncovered
more than 9,000 SNPs by whole-genome sequencing of 21
strains using the Illumina genome analyzer. Using the epitope
information from the IEDB database, they estimated low "
values (dN/dS $ 1) in antigens compared to those for essential
and nonessential genes.
For technical reasons, we believe that Comas et al. (16) have
underestimated the amount of variation in the Esx family. One
of the limitations of the Illumina technology is sequence as-
sembly and identification of SNPs in repetitive regions due to
the short lengths of the sequence reads. This could mask any
polymorphisms generated due to gene conversion events in
duplicated paralogous genes, due to erroneous mapping of
short reads. This includes genes in the Mtb9.9 and QILSS
subfamilies. Our study involved traditional sequencing with
primers specific for the different esx genes and significantly
longer sequence reads than those generated by the Illumina
technology and thus avoids this pitfall. Interestingly, one of the
three outliers in the Comas et al. study was esxH, which dis-
played a high level of variation in epitope regions (dN/dS% 1).
Members of the Mtb9.9 and QILSS subfamilies show the
highest levels (93 to 98%) of amino acid identity among the
Esx family. Although several immunogenic epitopes were lo-
cated in regions of 100% sequence identity, some of the major
immunodominant epitopes were also identified in regions of
sequence diversity in proteins from the Mtb9.9 and QILSS
subfamilies. A recent study by Jones et al. confirmed that the
Esx proteins, whose genes were not part of the ESX-1 to
ESX-5 loci, showed similar levels of immunogenicity to the Esx
proteins from the ESX-1 to ESX-5 loci (29). Strikingly, even
single-residue differences in the epitope sequences altered the
responder frequencies to these antigens. The amino acid res-
idues critical for antigenicity include T58 for the QILSS sub-
family and G22 and S23 for the Mtb9.9 subfamily. In the
TABLE 2. SNPs affecting known epitope regions
Protein SNP Type of change
Amino acid sequencea No. of
isolatesT cell epitope MHC-II binding
EsxB E68K Acidic to basic KQELDEISTNIRQAG 19
EsxG A56T Nonpolar to polar AAHARFVAA 1
EsxH A71S Nonpolar to polar AMEDLVRAYHAMSSTHEA 2
EsxQ S90A Polar to nonpolar RCRRALRQIGVLERPVGDSS 1
EsxQ L76P Nonpolar to nonpolar RCRRALRQIGVLERPVGDSS 1
EsxR W58C Nonpolar to polar YQGWQTQWNQALEDLVRAYQ 3
EsxI S23L Polar to nonpolar MIRAQAGSL 1
EsxI Q20L Polar to nonpolar MIRAQAGSL 13
EsxL Q20L Polar to nonpolar MIRAQAGLL 1
EsxN 24 Synonymous DAHGAMIRAQAASLE 4
EsxN 83 Synonymous KVQAAGNNMAQTDSA 1
EsxO L23S Nonpolar MIRAQAGLL 6
EsxO G22A Polar to nonpolar MIRAQAGLL 6
EsxO A21P Nonpolar to nonpolar MIRAQAGLL 1
EsxO 20 Synonymous MIRAQAGLL 1
EsxO A12D Nonpolar to acidic DAHGAMIRAQAGLLE 1
EsxV S23L Polar to nonpolar MIRAQAGSL 77
EsxV Q20L Polar to nonpolar MIRAQAGSL 74
a Obtained from the IEDB resource (49). Amino acids from codons containing nsSNPs are underlined, and sSNPs are italicized.
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clinical data set, we observed an A58T mutation in EsxP and
EsxK and a converse T58A substitution in EsxW. S23L substi-
tutions in EsxI and EsxV and L23S and G22A substitutions in
EsxO were also found in several isolates. A study using human
CD4! T cells performed by Alderson et al. demonstrated that
T cell lines specific for EsxL (G22 and L23) failed to recognize
peptides from EsxN (A22 and S23) and EsxV (G22 and S23)
(5). On the other hand, peptide fragments from EsxV, which is
absent inM. bovis, have been shown to induce IFN-" responses
in cattle infected with TB (29), suggesting cross-reactivity be-
tween highly similar epitopes in duplicated proteins. The con-
servation of silent as well as nonsynonymous SNPs between
paralogs and orthologs of the Mtb9.9 family, as seen in esxP
and esxM, respectively, suggests that even minor variation
within the Mtb9.9 and QILSS families could significantly alter
the length and expression of this protein subfamily. Based on
the clinical SNPs, we were able to provide evidence for puta-
tive recombination between esxK and esxP. It is possible that
gene conversion events may occur between other duplicated
paralogous genes in the QILSS and Mtb9.9 subfamilies. Gene
conversion has been described in members of the PE-PGRS
gene family in M. bovis, where homogenotization has been
reported for genesMb1485 andMb1487 (19). Frequent homol-
ogous recombination events in the highly repetitive PE/PPE
multigene families with a potential role in antigenic variability
have been described in M. tuberculosis (18), and the present
work indicates that the esx gene family is also dynamic.
Amino acid substitutions encoded by duplicated genes may
allow for genetic drift, by regulating expression of the func-
tionally similar protein paralogs that differ in their immuno-
dominant epitopes. Although in silico prediction of T cell bind-
ing epitopes is possible, we included only the experimentally
confirmed epitope data in our analysis. With the exception of
EsxA and EsxB, there is very little or no epitope data in IEDB
for other members of the Esx family. As new Esx epitopes are
identified in the future, we should be able to assess the role of
the other nsSNPs observed in our clinical data set. In conclu-
sion, our analysis of esx genes has revealed a number of pre-
viously unknown sequence polymorphisms in the highly immu-
nogenic Esx family, including some in known epitope regions,
which may affect the immunogenicity of the corresponding
protein. This is the case with EsxB (CFP-10) and EsxH
(TB10.4) and has implications for the fields of vaccines and
diagnostics.
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4.2 Global Transcription and its Regulation 
 
4.2.1 High-resolution transcriptome and genome-wide dynamics of 
RNA polymerase and NusA in M. tb 
Contribution: Processing, quantification, visualization, and comparison of 
datasets, design and implementation of a workflow for identification of 
transcriptional units upon integration of the ChIP-seq and RNA-seq data, 
qualitative analyses to study global patterns of RNAP and NusA distribution 
across the TUs. 
 
The ability of M. tb to adapt to the numerous environments it encounters in 
the host is reflected by the complexity of its regulatory machinery. Gene 
expression in M. tb is primarily controlled at the level of transcription 
initiation by a diverse array of regulatory elements, which interact with RNA 
polymerase (RNAP). In order to fully understand M. tb pathogenesis, it is 
important to decipher how regulatory proteins control gene expression in 
different developmental and environmental conditions, and to locate where 
they bind to the genome. NusA is an essential modulator of gene expression 
that binds directly to RNAP and has been shown to play a role in elongation, 
pausing, termination and anti-termination of transcription.  
 
Previous studies in Escherichia coli (Mooney et al. 2009) and Bacillus subtilis 
(Ishikawa et al. 2010) have made use of ChIP-on-chip (chromatin 
immunoprecipitation followed by hybridization to microarrays) technology to 
study the genome-wide distribution of RNAP and NusA and elucidate the 
dynamics of the transcriptional complex. We used a novel high-resolution 
approach involving a combination of two complementary techniques to 
investigate the assembly, distribution and activity of the transcriptional 
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complex throughout the M. tb genome.  
 
The genome-wide dynamics of the transcriptional complex in M. tb was 
investigated by carrying out chromatin immunoprecipitation experiments 
followed by high-throughput sequencing (ChIP-seq) in M. tb H37Rv, using 
antibodies specific for the "-subunit, RpoB of polymerase (RNAP), and for 
the transcriptional regulator NusA. To correlate the occupancy of the 
transcriptional complex with its activity, the global transcriptome was 
determined by using a strand-specific RNA-seq approach. ChIP-seq and 
RNA-seq data were obtained for exponential (Exp) as well as stationary 
(Stat) phase cultures. The physiological differences between the two growth 
phases are a result of major changes in transcriptional regulation.  The 
availability of the ChIP-seq and RNA-seq datasets from two different growth 
conditions allowed us to compare transcription profiles in the two conditions 
and correlate the differences in activity of the transcriptional complex with 
RNA production.   
 
All datasets were mapped to the H37Rv genome sequence and quantitative 
analysis was based on the genomic features annotated in the TubercuList 
database (http://tuberculist.epfl.ch) which comprises 4019 protein coding 
sequences (CDS), 73 genes encoding ribosomal RNAs, small RNAs (sRNAs), 
tRNAs and other stable RNAs, 3080 intergenic regions (defined as regions 
flanked by two non-overlapping features). The level of ChIP-seq enrichment 
for each feature was determined as the ratio of the number of ChIP reads to 
the number of Input DNA (control sample) reads mapping to the feature. In 
the case of RNA-seq, there was a striking abundance of reads mapping to the 
ribosomal RNA operon (> 95%) in both exponential and stationary phases. 
Therefore, each dataset was normalized to the number of reads remaining 
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after subtracting the number of ribosomal RNA operon reads from the total 
number of mapped reads. The gene expression values were quantified in terms 
of RPM (reads per million) which can be defined as the total number of reads 
mapping to the feature divided by feature length (in bp) normalized to the 
number of remaining reads (in millions). 
 
ChIP-seq results showed that RNAP and NusA occur ubiquitously across the 
genome, with NusA mirroring RNAP distribution in both the exponential and 
stationary phases of growth. Comparison of the transcriptome profiles in 
exponential and stationary phases across different functional categories (based 
on TubercuList) revealed an abundance of stable RNAs and information 
pathways in both phases of growth. The stationary phase profile was similar 
to the expression profile observed in the nutrient starvation condition, that 
has been previously characterized (Betts et al. 2002). There was a clear 
under-representation of genes involved in intermediary metabolism and 
respiration in the stationary phase. The high resolution and accuracy offered 
by RNA-seq helped us to uncover anti-sense and intergenic transcripts 
corresponding to previously un-annotated features. These independent 
features were confirmed by the presence of RNAP and NusA at their 
promoters and could also be validated by alternative methods. 
 
A systematic workflow was designed to identify transcription units (TUs) 
across the genome based on the RNA-seq data and map putative promoters 
based on enrichment of RNAP and NusA at the start of these units. This led 
to the identification of 606 high-quality TUs that were widely distributed 
along the M. tb genome. Analysis of RNAP and NusA binding across the 
promoter and body of TUs and their correlation with transcription uncovered 
interesting biological aspects of the transcriptional complex in M. tb. 
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Generally, promoter-proximal peaks for RNAP and NusA were observed, 
followed by a decrease in signal strength reflecting transcriptional polarity. A 
significant association between expression levels and the presence of NusA 
throughout the gene body was demonstrated, confirming the peculiar 
transcription-promoting role of NusA. We also observed that increased NusA 
occupancy in the body on the unit contributes to higher levels of 
transcription. The whole-genome distribution of the TUs revealed a strong 
bias in the expression levels with respect to the direction of the replication 
forks. The majority of the highly transcribed TUs were localized on the 
leading strand showing that DNA polymerase and RNAP proceed in the same 
direction through most of the highly expressed features in the in vitro 
conditions tested. 
 
Using a combination of the two high-throughput approaches, we have 
obtained an unprecedented depth of information on the transcription profile 
of M. tb genes during exponential and stationary phases of growth, and also 
offered new insights on the biological roles of RNAP and NusA in promoting 
transcription. 
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Abstract  
 
To construct a regulatory map of the genome of the human pathogen, 
Mycobacterium tuberculosis, we applied two complementary high-resolution 
approaches: strand-specific RNA-seq, to survey the global transcriptome, and 
ChIP-seq, to monitor the genome-wide dynamics of RNA polymerase (RNAP) 
and the antiterminator NusA.  Although NusA does not bind directly to DNA, 
but rather to RNAP and/or to the nascent transcript, we demonstrate that 
NusA interacts with RNAP ubiquitously throughout the chromosome and that 
its profile mirrors RNAP distribution in both the exponential and stationary 
phases of growth.  Generally, promoter-proximal peaks for RNAP and NusA 
were observed, followed by a decrease in signal strength reflecting 
transcriptional polarity.  Differential binding of RNAP and NusA in the two 
growth conditions correlated with transcriptional activity as reflected by RNA 
abundance.  Indeed, a significant association between expression levels and the 
presence of NusA throughout the gene body was detected, confirming the 
peculiar transcription-promoting role of NusA.  Integration of the datasets 
pinpointed transcriptional units, mapped promoters and uncovered new anti-
sense and non-coding transcripts.  Highly expressed transcriptional units were 
situated mainly on the leading strand, despite the relatively unbiased 
distribution of genes throughout the genome, thus helping the replicative and 
transcriptional complexes to align. 
Introduction 
 
In order to adapt and survive in a range of different environments, 
Mycobacterium tuberculosis, the etiologic agent of human tuberculosis (TB), 
has to fine-tune gene expression to support active growth, to survive periods 
of non-replicating persistence and to cope with the plethora of stresses 
encountered within the host (1-3). 
In prokaryotes, regulation of gene expression mainly takes place at the 
transcriptional level, and this is particularly evident in M. tuberculosis that 
has 13 sigma factors, which direct RNA polymerase (RNAP) core enzyme to 
defined subsets of promoters, and nearly 200 potential transcriptional 
regulators (4). One particular class of regulators is represented by proteins 
affecting pausing, termination and anti-termination of transcription, the best 
characterized of them being NusA. 
NusA is an essential RNAP- and RNA-binding modulator of gene 
expression, present in all bacteria whose genomes have been sequenced so far, 
and was named N-utilizing substance after the phage l N-protein mediated 
anti-termination process (5). Its role in preventing termination at ribosomal 
RNA operons was first demonstrated in the paradigm organism Escherichia 
coli, where the ability of NusA to bind to nut-like sites (Box A, B and C) and 
to protect the nascent naked transcript from Rho-dependent termination has 
been proved (6). Likewise, more recent studies in M. tuberculosis confirmed 
that this mechanism is conserved among different bacterial species (7). 
Conversely, NusA has also been implicated in pausing and termination at 
intrinsic or Rho-independent terminator sequences (8,9).  Cardinale et al. 
later demonstrated that the protein plays a pivotal role in Rho-dependent 
silencing of foreign DNA in E. coli (10). This multi-functionality is reflected 
in the crystal structures of the Thermotoga maritima and M. tuberculosis 
NusA proteins, which have a multidomain organization. The protein is in fact 
composed of an N-terminal RNAP-binding domain, connected through a 
flexible linker to the S1, KH1 and KH2 RNA-binding motifs (11,12).  
In a comprehensive study aimed at understanding the dynamics of the 
transcriptional complex in E. coli, Mooney and colleagues demonstrated the 
genome-wide association of RNAP with NusA as RNA synthesis occurs and 
the enzyme moves away from the promoter (13). In addition, RNAP 
promoter-proximal peaks coincide with the distribution of NusA, therefore 
indicating that RNAP peaks reflect elongating rather than stalled 
transcriptional complexes. Recent work performed in Bacillus subtilis showed 
that, contrary to E. coli RNAP, the enzyme is distributed evenly from the 
promoter throughout the coding sequence in this species and does not 
generate promoter-proximal signals (14).  
Whole-genome research conducted thus far in M. tuberculosis has 
focused on the final product of transcriptional regulation, the RNA, and has 
analyzed the differential expression of genes in specific growth conditions by 
microarrays (15-17). More recently, deep sequencing was applied to 
transcriptomic profiling and revealed the existence of previously unknown 
small RNAs whose expression changes during the transition from exponential 
to stationary phase, and may undergo deregulation during infection (18).  
However, little is known of the molecular mechanisms taking place at the 
DNA level and there is no genome-wide description of the RNAP and NusA 
interaction with the chromosome in different growth phases. In this work, we 
used two complementary, single-nucleotide resolution approaches, namely 
ChIP-seq and RNA-seq, to investigate the assembly, distribution and activity 
of the transcriptional complex throughout the M. tuberculosis genome. 
  
Cluster Generation Kit v3 and TruSeq SBS Kit v3 (for NusA ChIP-seq). Data 
were processed with the Illumina Pipeline Software v1.60 (for RNAP ChIP-
seq), v1.70 (for input samples), v1.80 (for NusA ChIP-seq). 
 
Genome annotation 
All analyses in this study were carried out using the M. tuberculosis 
H37Rv annotation from the TubercuList database 
(http://tuberculist.epfl.ch/). There are 4019 protein coding sequences (CDS) 
currently annotated in the genome, 73 genes encoding for stable RNAs, small 
RNAs and tRNAs. In order to quantify protein occupancy and transcription 
across the entire genome, 3080 intergenic regions (regions flanked by two non-
overlapping CDS) were included, resulting in a total of 7172 features.  
 
ChIP-seq data analysis 
The single-ended sequence reads generated from ChIP-seq experiments 
were aligned to the M. tuberculosis H37Rv genome (NCBI accession 
NC_000962.2) using Bowtie (48) allowing up to 3 mismatches and up to 10 
hits per read. Since the samples were sequenced using different protocols 
resulting in varied read lengths (38 – 50 nt) all the raw datasets were trimmed 
to 38 bases to enable unbiased comparison of experiments. Bowtie results were 
converted into SAM/BAM format using samtools (49). A custom perl script 
was then used to obtain the per-base coverage normalized to the total number 
of mapped reads for each dataset. The script also shifted (by 80 bp) and 
merged the read counts for forward and reverse strands to generate wig files 
containing single ChIP-seq profiles that were visualized on the UCSC Genome 
Browser Mycobacterium tuberculosis H37Rv 06/20/1998 Assembly (50). To 
compute the read count (RC) for each feature, the number of reads mapping 
to all positions in the feature were summed up and normalized to feature 
length. The final read count for each feature was determined as the mean of 
the read counts of both replicates. To determine the level of ChIP-seq 
enrichment for each feature, an enrichment ratio (ER) was calculated by 
dividing the read count for the ChIP-seq sample by the read count for the 
Input (control) sample.  
 
RNA extraction 
Forty milliliters of either exponential or stationary phase M. 
tuberculosis cultures were pelleted and cells were flash frozen in liquid 
nitrogen and stored at -80°C until use. Bacteria were re-suspended in 1 ml 
Trizol (Invitrogen) and added to a 2-ml screw-cap tube containing 0.5 ml 
zirconia beads (BioSpec Products). Cells were disrupted by bead-beating twice 
for 1 minute with a 2-minute interval on ice. The cell suspension was then 
transferred to a new tube, where chloroform-isoamylalcohol (24:1) extraction 
was performed. RNA was precipitated by adding 1/10 volume of sodium 
acetate (2 M, pH 5.2) and 0.7 volume of isopropanol, washed with 70% 
ethanol, air-dried and resuspended in DEPC-treated water. DNase treatment 
was carried out twice using RQ1 RNase-free DNase (Promega), following the 
manufacturer’s recommendations, and the reactions were subsequently cleaned 
up by phenol-chloroform extraction and ethanol precipitation. RNA was 
stored at -80°C in DEPC-treated water. Amount and purity of RNA were 
determined spectrophotometrically, integrity of RNA was assessed on 1% 
agarose gel. 
 
Library preparation for RNA-seq analysis and Illumina high-throughput 
sequencing  
100 ng of total RNA from exponential and stationary phase were mixed 
with 5x Fragmentation buffer (Applied Biosystems), incubated for 4 minutes 
at 70°C and then transferred immediately on ice. RNA was purified using 
RNAClean XP beads (Beckman Coulter), according to the manufacturer’s 
recommendations, and subsequently treated with Antarctic phosphatase (New 
England Biolabs). RNA was then re-phosphorylated at the 5’-end with 
polynucleotide kinase (New England Biolabs) and purified with Qiagen 
RNeasy MinElute columns. In order to ensure strand-specificity, v1.5 sRNA 
adapters (Illumina) were ligated at the 5’- and 3’-ends using RNA ligase. 
Reverse transcription was carried out using SuperScript III Reverse 
Transcriptase (Invitrogen) and SRA RT primer (Illumina). Twelve cycles of 
PCR amplification using Phusion DNA polymerase were then performed and 
the library was finally purified with AMPure beads (Beckman Coulter) as per 
the manufacturer’s instructions. A small aliquot (2.5 ml) was analyzed on 
Invitrogen Qubit and Agilent Bioanalyzer prior to sequencing on Illumina 
Genome Analyzer IIx using the TruSeq SR Cluster Generation Kit v3 and 
TruSeq SBS Kit v3. Data were processed with the Illumina Pipeline Software 
v1.82. 
 
RNA-seq data analysis 
The single-ended sequence reads generated from RNA-seq experiments 
were aligned to the M. tuberculosis H37Rv genome (NCBI accession 
NC_000962.2) using Bowtie (48) allowing 1 mismatch and no more than 5 
hits per read. Since the samples were sequenced using different protocols 
resulting in varied read lengths (40 – 50 nt) the raw datasets were trimmed to 
38 bases to enable unbiased comparison of the experiments. Bowtie results 
were converted into SAM/BAM format using samtools (49). Preliminary 
analysis revealed a striking abundance of reads mapping to the ribosomal 
RNA operon (over 95%) in all samples. Consequently, the datasets were 
normalized to the number of remainder reads i.e. subtracting the number of 
ribosomal RNA operon reads from total number of mapped reads for each 
dataset. The gene expression values were quantified in terms of RPM (reads 
per million) which can be defined as the total number of reads mapping to the 
feature divided by feature length (in bp) normalized to the number of 
remaining reads (in millions). The normalization factor was also used to 
generate wig files that were visualized on the UCSC Genome Browser (50). 
The mean RPM value was determined for the experimental replicates. The 
MA-plot was generated using a python script where the average expression in 
the exponential and stationary phase samples was plotted against the log2 
fold-change between the two conditions. Analysis of differential expression 
was carried out using the DESeq package (51). 
 
Transcriptional unit (TU) quantification 
 Enrichment of RNAP and NusA in TUs was quantified separately for 
the promoter and the body of the TU. The first feature was considered as the 
promoter, while the remaining features represented the body. The TU body 
read count and enrichment ratio were computed as the mean of the RCs and 
ERs for all features in the TU. The level of transcription of the TU was 
calculated as the average RPM of all features (including promoter) in the TU.  
 
Reverse transcription  
Two micrograms of M. tuberculosis RNA were incubated with 50 ng 
random primers and 1 mM dNTPs at 65°C for five minutes. After cooling on 
ice, 40 U RNase inhibitor, 10 mM DTT, 1x reaction buffer, 5 mM MgCl2 and 
200 U SuperScript III reverse transcriptase (Invitrogen) were added in a final 
volume of 20 ml. A control reaction without reverse transcriptase was 
included as control. Reactions were incubated at room temperature for ten 
minutes, at 50°C for one hour and at 55°C for one hour. Reverse transcriptase 
was inactivated by incubation at 80°C for two minutes. RNase H treatment 
was carried out for twenty minutes at 37°C with 1 ml RNase H (Invitrogen). 
cDNA was stored at -20°C. 
 
Quantitative PCR (qPCR) for ChIP-seq and RNA-seq data validation 
All PCR primers were designed using Primer3 software 
(http://frodo.wi.mit.edu/primer3/). The 20 ml PCR reaction consisted of 1X 
Sybr Green PCR Master Mix (Applied Biosystems), 0.1 mM of each primer 
and 1 ml of cDNA or IP DNA from immunoprecipitation reactions. Reactions 
were carried out in duplicate in an Applied Biosystems 7900HT Sequence 
Detection System with the following protocol: denaturation at 95°C for 10 
min, 40 cycles of denaturation at 95°C for 15 sec, annealing and extension at 
60°C for 40 sec with data collection. Melting curves were constructed to 
ensure that only one amplification product was obtained. 
Parallel reactions using different amounts of H37Rv chromosomal DNA 
were performed for each primer set in order to obtain the standard curve 
correlating the threshold cycle with the number of template molecules. The 
resulting equation was used to quantify the number of target molecules in the 
unknown samples. 
In the case of qPCR for RNA-seq data confirmation, normalization was 
obtained to the total amount of RNA used in the reverse transcription 
reaction, as previously described (23). Results were expressed as the log2 ratio 
of the number of molecules determined in the exponential phase vs. the 
number of molecules in the stationary phase and correlated with the log2 ratio 
obtained with RPM values. 
Regarding the qPCR for ChIP-seq data validation, the number of 
target molecules was normalized to the Input sample, after subtraction of the 
background represented by the mock-IP (no antibody control). Results were 
expressed as the log2 enrichment ratio of the IP DNA vs. Input and correlated 
with the log2 enrichment ratio calculated as described earlier. 
 
Statistical analysis 
Statistical analyses were performed with the statistical language R and 
various Bioconductor packages (52) (http://www.bioconductor.org). Several 
plots were created using GraphPad Prism 5 software (www.graphpad.com). 
Custom Perl and Python scripts were developed by members of the EPFL 
Bioinformatics and Biostatistics core Facility. Correlations between replicates 
were based on Pearson’s product moment correlation coefficient. The 
Wilcoxon signed-rank test (Mann-Whitney U test) was used to assess the 
differences between exponential and stationary phase values for the same set 
of features.  
 
Data access 
The ChIP-seq and RNA-seq datasets have been deposited in NCBI's 
Gene Expression Omnibus (53) under accession number GSE40862. 
  
Results 
 
General strategy 
The genome-wide dynamics of the transcriptional complex in M. 
tuberculosis was investigated by carrying out chromatin immunoprecipitation 
experiments followed by deep sequencing (ChIP-seq) using antibodies specific 
for a core component of RNA polymerase (RNAP), the beta subunit RpoB, 
and for the transcriptional regulator NusA. To correlate the occupancy of the 
transcriptional complex with its activity, the global transcriptome was 
determined by using a strand-specific RNA-seq approach. ChIP-seq and RNA-
seq data were obtained from exponential (Exp) and stationary (Stat) phase 
cultures. All datasets were mapped to the H37Rv genome sequence and 
further analyses were based on the annotation from the TubercuList database 
(http://tuberculist.epfl.ch) which comprises 4019 protein coding sequences 
(CDS), 73 genes encoding ribosomal RNAs, small RNAs (sRNAs), tRNAs and 
other stable RNAs.  There are 3080 intergenic regions (IG), defined as regions 
flanked by two non-overlapping features, of which 2283 are !30 bases in 
length.  
 
The genome-wide distribution of RNAP and NusA in M. 
tuberculosis 
ChIP-seq experiments for RNAP and NusA, and sequencing of the 
Input DNA, were performed in duplicate and the results are summarized in 
Supplementary Table S1. Supplementary Table S2 shows the correlation 
coefficients for the biological replicates, confirming the extremely high 
reproducibility of the Input and NusA datasets and, to a lesser extent, of the 
RNAP results.  
Inspection of RNAP data, displayed on the UCSC genome browser, 
revealed that signals were present along the entire genome although 
prominent accumulation of the enzyme at the putative promoter regions was 
detected in both of the conditions tested (promoter-proximal peaks). This is 
illustrated in Figure 1, where a global view of a 1 MB portion of the genome 
is shown (Figure 1A) together with three representative transcriptional units 
(Figure 1B-D). The NusA binding profile appeared to qualitatively match the 
RNAP distribution. Indeed, upon closer inspection of the RNAP and NusA 
tracks, extensive overlap was observed in both growth phases, as evidenced 
from the correlation reported in Supplementary Figure S1, thus proving that, 
although NusA does not bind to DNA directly, it is part of the transcriptional 
complex and associates with RNAP. 
Head-to-head comparison of the Exp and Stat datasets was possible by 
calculation of the enrichment ratios relative to the Input sample (ER) for 
RNAP and NusA for each genomic feature. Results are reported in 
Supplementary Table S4. Approximately the same number of features was 
found to be enriched (ER ! 2) in Exp and Stat (1117 and 1062, respectively) 
and, in both phases, most of the signals were identified in IG regions (> 60% 
vs. < 40% inside CDSs and RNA-encoding genes), where promoter sequences 
are most likely present. The strongest peaks were detected at the promoters of 
the ribosomal RNA operon rrn (Figure 1B), the ribosomal protein operons, 
the ATP synthase (Figure 1C), PDIM biosynthesis and nadABC gene clusters 
in Exp phase, and preceding genes encoding sRNA and tRNAs. In both 
growth conditions, most of the regions showed enrichment for either RNAP 
and NusA together or RNAP only, whilst NusA alone was detected for a small 
fraction of signals (193 and 107 features in Exp and Stat, respectively). 
Independent support for the ChIP-seq findings was obtained by quantitative 
PCR (qPCR) for a subset of CDSs and IGs, selected in order to cover a broad 
range of ER values (Supplementary Figure S2).  
 
Figure 1. ChIP-seq profiles of RNAP and NusA and transcriptional levels measured 
by RNA-seq. (A) UCSC genome browser view of ChIP-seq (CS) profiles for RNAP 
and NusA and RNA-seq (RS) profiles on forward (Fwd) and reverse (Rev) strands 
across a 1 MB region of the M. tuberculosis H37Rv genome in Exponential (Exp) and 
Stationary (Stat) phases. The scale and the genome coordinates are reported at the 
top. (B) Profile of the ribosomal RNA operon in Exp and Stat phases. (C) Profile of 
the ATP synthase operon in Exp phase. (D) Profile of the rv1285 to rv1286 region in 
Stat phase. The scale for the number of reads is on the y-axis. 
 
Detailed examination of the whole-genome profiles revealed 
unexpectedly high densities for RNAP and NusA at the end of convergent 
genes or inside CDSs, suggesting the existence of new features. For instance, 
these are the cases of the peak between rv3661 and rv3662c or the peak inside 
ino1 where, indeed, new sRNAs have been recently identified (18). In 
addition, the genomic regions encoding the putative excisionases of prophages 
phiRv1 and phiRv2 exhibited exceptionally high ER values for both RNAP 
and NusA, mainly in the Exp growth phase (21 and 7 for RNAP and NusA 
respectively for rv1584c, 17 and 6.7 for RNAP and NusA respectively for 
rv2657c). Deeper understanding of these peaks and of the entire ChIP-seq 
dataset was possible upon transcriptomic profiling as described later. 
 
Deep RNA-seq analysis 
To correlate the presence of RNAP and NusA, inferred from ChIP-seq, 
with transcriptional activity, global transcriptomic analysis was performed by 
deep sequencing, RNA-seq. More than 98% of the sequence tags could be 
mapped to the annotated CDSs in the sense orientation, whilst less than 2% 
was attributed to the anti-sense orientation, thereby confirming the strand-
specific nature of the protocol. The correlation coefficient for biological 
replicates revealed high reproducibility (r2 > 0.95) and further mapping 
statistics are reported in Supplementary Table S3. As expected, most of the 
reads aligned to rrn in both Exp and Stat phases and there was a clear 
predominance of stable RNAs such as sRNAs, tRNAs, the RNA component of 
RNAse P and the tmRNA ssr under both growth conditions. The remaining 
reads could be assigned to CDSs on both strands in almost equal proportion 
and these provided sufficient coverage for quantification purposes. RPM 
(Reads Per Million reads aligned) values represent the unit chosen to allow 
comparison of the expression levels and these are presented in Supplementary 
Table S5 for all of the features in the sense and anti-sense orientation, in the 
two growth conditions. 
 
Codon usage and tRNAs 
Measuring tRNA expression levels was informative in terms of 
understanding genome biology and generating confidence in the quantitation 
procedure.  We counted the occurrence of each codon in every CDS then 
multiplied this count by the value of gene expression obtained by RNA-seq 
(RPM) before summing these expression values across the whole genome to 
yield a per-codon “expression level”. This codon usage was then compared with 
the expression of the corresponding tRNA. Figure 2A shows a clear correlation 
between these two metrics in the Exp condition (with highly similar results in 
the Stat phase). Notably, AT-rich codons generally tend to be under-used as 
opposed to their GC-rich alternatives with the cognate tRNAs being 
considerably more abundant. 
 
 
Figure 2. RNA-seq results. (A) Correlation between tRNA abundance and codon 
usage. (B) Distribution of genes transcribed in exponential and stationary phases 
across functional categories as defined in the TubercuList database 
(http://tuberculist.epfl.ch/) relative to the proportion observed in the M. 
tuberculosis H37Rv genome. (C) Magnitude-Amplitude-plot in which the mean 
(log10) expression value for each gene in exponential and stationary phase samples is 
plotted against the expression ratio (log2) between the two samples. Differentially 
expressed genes are colored in green. The inset box indicates some of the genes 
induced in stationary phase. rv1954A indicates the anti-sense transcribed feature 
rv1954. 
 
Comparison of the Exp vs. Stat phase transcriptomes 
Grouping CDSs into functional categories according to TubercuList 
facilitated comparison of the total transcriptome in Exp and Stat phases. The 
box-and-whisker plots in Supplementary Figure S3 show that all categories 
are represented in both conditions, although the RPM dynamic range is 
higher in Exp phase, in particular for the lipid metabolism, information 
pathways and PE-PPE groups. On the contrary, features belonging to the 
virulence, detoxification and unknown subgroups are more enriched in Stat 
phase. Figure 2B illustrates the relative abundance of each category in terms 
of the proportion of genes with expression level (RPM) !1, the value chosen 
as cutoff. There is enrichment of genes involved in information pathways 
(p<10-4 in Exp and Stat, Fisher’s exact test) and an abundance of stable 
RNAs (p<10-4 in Exp and p<10-21 Stat, Fisher’s exact test) in both Exp and 
Stat phases. There is also a clear underrepresentation of genes belonging to 
intermediary metabolism and respiration (p<10-7) in the Stat phase. 
Closer inspection of the differentially expressed genes revealed a Stat 
profile similar to the nutrient starvation condition previously described by 
Betts and colleagues (15), with down-regulation of the ATP synthase gene 
cluster, the nad genes, the housekeeping sigma factor sigA, the ribosomal 
protein operons, cell wall and cell membrane functions. By contrast, specific 
features induced in the Betts model were also found to be up-regulated in Stat 
phase, such as lat, rv0188, usfY, hsp, and the cys operon, while a steep 
increase in the expression level of the sigma factors sigB and sigE was 
observed (Figure 2C).  Genes rv1954c and rv2660c had been reported as 
induced in starvation conditions (15) and our data confirmed this but in the 
anti-sense orientation. In addition, the high resolution provided by deep 
sequencing allowed the quantification of small transcripts, namely mcr11, 
reported as inducible in Stat phase (18), the recently discovered gene mymT 
(19) and the sRNA encoded in the intergenic region between rv3661 and 
rv3662c whose expression increases significantly in Stat phase (18). 
To validate the quantification method, twelve features covering a broad 
range of RPM values were selected for quantitative reverse transcription PCR 
(qRT-PCR) analysis. Results are reported in Supplementary Figure S4 and 
confirm the good correlation (r2 > 0.91) between the Exp/Stat ratio 
calculated from RPM values and the corresponding figures obtained from 
qRT-PCR, thus justifying the use of RPM values for absolute comparisons 
between the different growth phases.  
 
Correlation between the RNAP and NusA profiles and 
transcription 
The availability of the ChIP-seq and RNA-seq datasets from two 
different growth conditions allowed correlation studies to understand the 
relationship between the presence of the transcriptional complex and RNA 
production. For this purpose, features with RNAP or NusA ER ! 2 and with 
RPM ! 1 were selected. From the histogram reported in Figure 3 it is evident 
that most of the features enriched in RNAP and NusA in Exp phase were also 
associated with transcription (89%). A smaller percentage of features with ER 
! 2 for RNAP but no detectable NusA were transcribed (71%), suggesting 
that, indeed, the presence of NusA in the transcriptional complex favors 
transcription. The values changed markedly in the Stat phase, where a 
reduced number of features enriched in both RNAP and NusA was found to 
be transcribed (76%). Even more relevant, less than half of the RNAP-only 
containing signals were associated with RPM values greater than 1. Overall, 
the vast majority of the RNAP- and/or NusA-enriched features in Exp phase 
were also expressed, whereas approximately half of those enriched in Stat 
were associated with detectable transcripts, indicating that RNAP and NusA 
interact with the genome but are not involved in active transcriptional 
activity during the Stat condition. Regarding the NusA-only containing peaks 
(often intragenic), most of them correlated with a transcript at least in Exp 
phase, thereby leaving a small number (42) with unusual NusA binding.  
 
Figure 3. Overlap between enriched (ER ! 1) and transcribed (RPM ! 1) features 
in exponential and stationary phases. Stacked bar charts show the total number of 
features enriched with RNAP, NusA and both (RNAP as well as NusA) in the two 
phases. Blue stacks represent the proportion of enriched features that are also 
transcribed.  
 
Most of the surprising signals previously reported for ChIP-seq could 
be explained upon direct comparison with the RNA-seq results. In the next 
section we will describe two subsets of these peculiar features: those 
corresponding to anti-sense and to intergenic transcription. Importantly, this 
information allowed refinement of the existing M. tuberculosis genome 
annotation (4). 
 
Unusual ChIP-seq peaks reflect anti-sense transcription in M. 
tuberculosis 
As mentioned earlier, less than 2% of the RNA-seq reads mapped to 
the anti-sense orientation as compared to the existing annotation. 
Quantification uncovered 134 anti-sense transcribed features in Exp phase and 
41 in Stat phase (Supplementary Table S6), the majority of which could be 
explained as RNAs that are much longer than the corresponding annotated 
CDS, thereby generating anti-sense transcripts to the following, reverse-
oriented, feature. In this section, we will not provide details of these but 
rather focus on the anti-sense RNAs that are transcribed independently. Upon 
clustering them into functional categories, two groups appeared prominent, 
the “Insertion sequences and phages” and the “Unknown” categories, where a 
>2- or 3-fold increase was noticed compared to their abundance in the 
genome, respectively.  
The top-scoring feature in Exp phase is the anti-sense transcript inside 
the gene ino1. Interestingly, this region contains one of the features that was 
unexpectedly highly enriched in RNAP and NusA ChIP-seq studies 
(Supplementary Figure S5A).  
A closer look into the fraction of RNAP- and NusA-enriched features 
with no corresponding sense transcript revealed that some of these were 
associated with an anti-sense RNA. This is exemplified by rv0842, where 
RNAP and NusA densities at the beginning of the gene do not correlate with 
expression of the CDS but rather with transcription of an anti-sense RNA 
that extends in the upstream region (Supplementary Figure S5B). 
Furthermore, an anti-sense transcript was mapped inside the phiRv1 
excisionase-encoding gene rv1584c. Its expression level increased in Exp and 
was reduced to the background level in Stat phase. On the contrary, no 
obvious explanation could be obtained for the RNAP peak inside the phiRv2 
gene rv2657c. RNAP and NusA may just be “sitting” there without 
transcribing (at least in the conditions tested) or the transcript could be 
undetectable because of stability issues. Finally, curious RNAP and NusA 
peaks were detected at the end of rv0061. After looking at the transcriptomic 
profile, these signals could be associated with anti-sense transcription of the 
whole CDS (Supplementary Figure S5C), thereby allowing re-annotation of 
this open reading frame as rv0061c, encoding a protein similar to M. marinum 
MMAR_3839, with 76% identity in 112 amino acid overlap. 
Concerning the Stat condition, the top-scoring anti-sense RNA was 
noted inside rv3684. Accordingly, RNAP and NusA peaks are high in this 
position, thus cross-validating the finding (Supplementary Figure S6A). The 
genomic region encompassing the end of rv1734c was found to be highly 
transcribed in the anti-sense orientation in Stat phase (Supplementary Figure 
S6B). Correspondingly, the NusA density profile increases in this condition.  
 
Intergenic ChIP-seq densities as hallmarks of intergenic transcripts  
Within the 2283 IG regions of at least 30 bases in length, 1153 showed 
an RPM ! 1. We could identify most of these as part of transcriptional units 
as described later, IGs constituting the 5’- or 3’-UTR of flanking genes (12%) 
and “anti-sense IGs” (2%), i.e. IG regions transcribed in the opposite sense to 
both of the flanking CDSs (Supplementary Table S6). 
Examples of long 5’-UTRs are represented by rv3219 (Supplementary 
Figure S7A) and by the rv3648c mRNA (Supplementary Figure S7B). The 
latter feature, expressed at high levels in the Exp growth phase (20), showed 
high enrichment ratios for RNAP and NusA and suggested the existence of 
attenuation mechanisms in controlling gene expression.  
Other examples include IG regions transcribed as independent features. 
This is the case of the IG at the end of the convergent genes rv3661 and 
rv3662c: an sRNA (18), highly induced in Stat phase, is encoded here and this 
is corroborated by enrichment of both RNAP and NusA in the ChIP-seq data.  
The last type of IG directs anti-sense transcripts with respect to both 
of the flanking genes and therefore representing independent features such as 
sRNAs. The top-scoring instance is the IG between rv1144 and rv1145, where 
an sRNA was identified and high ER values for both RNAP and NusA were 
calculated (Supplementary Figure S7C).  
 
Integration of ChIP-seq and RNA-seq datasets 
In order to provide more quantitative correlation patterns between the 
dynamics of RNAP and NusA and transcription levels, a subset of well-known 
highly expressed transcriptional units (TUs) was selected. Specifically, 24 
ribosomal protein operons, comprising a total of 75 CDSs and 57 IGs, 
represented the test set in the systems biology approach described hereafter. 
The level of transcription and enrichment of RNAP and NusA were quantified 
for each operon, with the “operon promoter” being defined as the first feature 
of the TU (usually an IG), and the “body” representing the remaining 
features. RNA-seq data showed that the majority of these TUs were expressed 
in both Exp (21 out of 24) and Stat (18 out of 24) growth conditions as long, 
continuous transcripts but the RPM values were significantly higher in the 
Exp compared to the Stat phase (p<10-6, Wilcoxon signed-rank test, Figure 
4A). Promoter regions of all transcribed TUs showed a median ER greater 
than two for RNAP as well as NusA (the latter in Exp phase only). These 
values were considerably different in the body of the TUs: the median ER of 
RNAP and NusA was reduced, confirming the presence of the promoter-
proximal peaks mentioned earlier rather than homogeneous distribution of the 
transcriptional complex throughout the operon. Interestingly, a significant 
higher level of NusA in Exp phase compared to Stat was detected in the body 
(p<10-4), whereas the RNAP ER in the operon body did not vary between the 
two conditions.  
 
Figure 4. Box plots showing the distribution of RNAP and NusA in the promoter 
and body of transcriptional units (TUs) along with the transcription levels (RPM). 
(A) Ribosomal protein operons. (B) TUs expressed in exponential phase only and (C) 
TUs expressed in stationary phase only. P-values for comparison of different groups 
are based on the Wilcoxon signed-rank test.  
 
Altogether, these results suggest that increased NusA occupancy in the 
operon body contributes to higher levels of transcription in the Exp compared 
to the Stat growth phase. In addition, the criteria that define a TU (i.e. 
promoter at the first feature and uninterrupted RNA) and the patterns 
identified with this subgroup of operons were applied to and examined in a 
larger dataset, as described below. 
 
Genome-wide TU identification  
An algorithm (Figure 5A) was designed to discover TUs using the 
genome-wide ChIP-seq and RNA-seq profiles. Genomic features, including 
CDS and IGs, that displayed NusA or RNAP ER ! 2 and RPM ! 1 in at least 
one of the two growth phases were used as input. Features with RPM ! 1 
were split into two groups based on the strand that was associated with 
higher RPM values. The forward and reverse sets of features were then sorted 
according to the genomic order and grouped into TUs. A TU was defined as a 
set of two or more consecutive features that are transcribed in the same 
direction and controlled by a promoter located at the first feature. Following 
the identification of transcription boundaries for all operons by means of 
RNA-seq data, promoters were mapped based on the RNAP and NusA ER. If 
the highest ER value was observed at the first feature, it was considered as a 
possible promoter. If the feature showing maximum ER did not correspond to 
the first one, the TU was split into two separate units at that feature, and 
promoter identification was repeated. This ensured that all TUs displayed a 
uniform organization characterized by enrichment of RNAP/NusA at the 
promoter and an uninterrupted transcript from the start to the end of the 
unit. Of the 817 continuous transcripts identified from RNA-seq, 606 were 
associated with significant promoter enrichment (ER !2) and therefore 
defined as “high-quality TUs”. Of these, 301 were mapped on the forward 
strand and 305 on the reverse strand (Supplementary Table S7). Basic 
features of these TUs are reported in Figure 5. 323 of these were single-gene 
units, while the remainder comprised between 2 and 12 genes. The largest 
TUs were represented by the ATP synthase operon, the ESX-3 locus (eccA3 
to eccE3), and two ribosomal protein operons (from rpsJ to rpsQ and from 
rplN to rplO). 268 operons were transcribed in both Exp and Stat phases, 
while 272 were transcribed only in the Exp phase and 17 only in the Stat 
phase, for instance the latter included lipX-PPE17, rv2557-rv2558, usfY, lat, 
cysD, rv2660c. Importantly, all of the previously described ribosomal protein 
operons were correctly identified with the developed workflow, underscoring 
the validity of the algorithm.  
To appraise differences in RNAP and NusA distribution between Exp 
and Stat phase, the same parameters used for the characterization of the 
ribosomal protein operons were employed. Specifically, the RNAP and NusA 
ER values in the promoter and body of two subsets, namely the top 17 TUs 
transcribed in Exp phase only (Figure 4B) and the 17 TUs that were 
transcribed in Stat phase only (Figure 4C), were compared. The RPM and ER 
figures for those transcribed in Exp phase mirrored the observations made in 
the case of ribosomal protein operons (Figure 4A and 4B). Once again, the 
level of NusA in the body was significantly higher in Exp vs. Stat phase 
(p<10-4, Wilcoxon signed-rank test). However, in contrast to what was 
observed for ribosomal protein operons, the RNAP ER in the TU body was 
also significantly increased in Exp phase (p< 10-2), consistent with the lack of 
expression in Stat phase. Regarding the TUs transcribed in Stat phase only, 
complementary patterns to those in Figure 4B were observed (Figure 4C). 
Indeed, the levels of RNAP and NusA in the operon body were higher in the 
Stat phase compared to the Exp phase (p< 10-3 and 10-4, respectively) 
reflecting the difference in transcription between the two conditions. In 
conclusion, it is noteworthy that Exp phase-only and Stat phase-only 
transcribed TUs displayed RNAP ER at the promoters in both growth 
conditions, irrespective of the transcriptional levels, supporting the notion of a 
stationary enzyme in the non-transcribed phase. 
 
Figure 5. Integration of ChIP-seq and RNA-seq data to map transcriptional units 
(TUs). (A) Workflow for TU identification. (B) Distribution of TU composition. (C) 
TU expression levels in Exp and Stat conditions. (D) Median traveling ratios (TR) 
for RNAP and NusA in Exp and Stat phases and RNAP:NusA ratio at the TU 
promoters and bodies. 
 
Transition from transcription initiation to elongation is rate limiting  
The rate of transition from transcription initiation to elongation was 
measured as the ratio of the RNAP and NusA ER in the body relative to the 
corresponding promoter ER. This value defines the traveling ratio (TR) and 
the medians for all of the TUs are reported in Figure 5D. The TR for RNAP 
was around 0.5, reflecting the presence of promoter-proximal peaks and 
implying that the transition from initiation to elongation is a rate-limiting 
step at most transcribed regions. The TR for NusA was slightly higher (0.75), 
conveying the idea that NusA-containing transcriptional complexes move 
more efficiently from the promoter throughout the TU. Further support for 
this concept came from the calculated RNAP:NusA ratio at promoters and in 
gene bodies. Indeed, this was in favor of RNAP at promoter regions and close 
to 1 in bodies, suggesting that a proportion of RNAP molecules, probably not 
associated with NusA, contacts the promoter but either does not progress or 
leaves abortively. 
 
Global RNAP and NusA profiles throughout the TUs 
Global profiles for RNAP and NusA were obtained by averaging the 
read counts for all of the identified TUs. Two highly expressed and enriched 
loci, namely rrn and the sRNA mcr11, were excluded from the analysis, so as 
to avoid a biased output. The TUs were split into two groups based on their 
genomic orientation and each one was divided into 100 equal sized bins. The 
average number of reads for RNAP and NusA was calculated within each bin 
and the mean for all operons was used to generate a single operon profile. The 
average enrichment in 50 bp regions flanking each TU was also included. 
Figure 6A presents the averaged forward and reverse profiles for RNAP and 
NusA in both phases of growth. Prominent enrichment was evident close to 
the start of the TUs on both strands, as pointed out earlier, and the average 
level of RNAP was higher than that of NusA in agreement with the 
previously calculated ratios. The decrease in the level of RNAP and NusA 
along the operon body reflects the polarity of transcription. Since half of the 
identified operons are transcribed in both Exp and Stat phases, the profiles 
for RNAP and NusA in the two phases almost coincide.  
 
Figure 6. Global RNAP and NusA profiles of the transcriptional units. (A) 
Averaged profiles for RNAP and NusA across forward and reverse TUs. The y-axis 
indicates the average number of reads, the x-axis the genomic position with an 
arbitrary length for the TU. (B) Averaged RNAP and NusA profiles at promoter 
regions for RNAP-enriched transcribed features. (C) Averaged RNAP and NusA 
profiles at promoter regions for RNAP-enriched non-transcribed features. The legend 
is provided on top. 
 
Finally, detailed promoter profiles were generated for transcribed TUs 
as follows: the average number of reads per nucleotide was calculated for the 
RNAP and NusA datasets in an interval spanning 200 bp centered at the 
maximum of the RNAP peak for each promoter (i.e. the first feature of the 
TU). The forward and reverse strand results were merged to generate a single 
Exp and Stat phase profile for RNAP and NusA (Figure 6B). The averaged 
plots not only confirmed enrichment of NusA at promoters, but also its co-
localization with RNAP in both Exp and Stat phase. As a control, a subset of 
features enriched with RNAP (in both Exp and Stat phases) but not 
associated with transcription was chosen and the analysis repeated. Unlike the 
profile observed for transcribed TUs, the NusA enrichment around the RNAP 
peak was much lower for non-transcribed features and did not display the 
same shape nor co-localize with the RNAP peak (Figure 6C), thereby 
confirming NusA as a transcription promoting factor in M. tuberculosis in 
both of the experimental conditions tested. 
Discussion 
 
Our aim was to map the genome of the major human pathogen, M. 
tuberculosis, by systematically studying the activity of the transcriptional 
complex and its interaction with DNA. Using high-resolution ChIP-seq 
analyses we demonstrated the ubiquitous association of RNAP and NusA with 
the genome and the significant overlap of the two binding profiles, thus 
confirming that NusA is part of the RNAP complex. ChIP-seq was an 
extremely powerful tool to monitor NusA, a protein which does not interact 
directly with DNA but rather with RNAP and/or with the nascent transcript. 
Quantitative reproducibility between biological replicates was 
extremely high in the case of NusA in both of the conditions tested, whereas a 
reduced correlation was noted for RNAP. This could be the consequence of a 
lower affinity of the monoclonal antibody against RpoB as compared to the 
polyclonal NusA anti-serum or could result from intrinsic higher variability of 
the RNAP dynamics on the M. tuberculosis genome caused by non-specific or 
random interactions of the enzyme with DNA, as previously reported in E. 
coli (21,22). Interactions between the transcriptional complex and DNA might 
be stronger when NusA is present, thus explaining the increased 
reproducibility of the NusA profiles. Indeed, the density of RNAP only-
containing peaks was found to be less reproducible than that of peaks 
associated with NusA, supporting our hypothesis.  
In addition to ChIP-seq, RNA-seq was exploited to obtain a global 
view of transcriptional regulation in M. tuberculosis and to explain unusual 
peaks observed in the ChIP-seq profiles. Quantification of RNA-seq results by 
RPM values with normalization to the total number of reads allowed absolute 
comparison of the conditions tested, in a way that resembles microarray-based 
transcriptomic approaches, where total fluorescence was used as normalizing 
factor (23). The Stat profile was similar to that of a starved culture (15) and 
hallmarks of this condition were readily identified. Discrepancies with 
previously published studies can be explained by the different culture 
conditions utilized. In our model, a four-week old M. tuberculosis culture may 
mimic the starvation condition since all of the nutrients have been consumed. 
Importantly, the deep sequencing transcriptomic experiments reported 
here exhibited striking strand specificity, with a minor portion of the sequence 
tags (< 2%) mapping to the CDSs in anti-sense orientation. We therefore 
considered this anti-sense transcription as genuine and exploited the data to 
improve the M. tuberculosis genome annotation (4). As an illustration, the 
CDS rv0061 was renamed rv0061c following the results of this work. Several 
anti-sense transcripts mapped by RNA-seq found additional confirmation by 
ChIP-seq profiling. BLAST analysis performed on the top-scoring anti-sense-
transcribed features revealed that some of them are specific to the MTB 
complex (e.g. rv1374c, rv1734c), whereas others, like ino1, showed more than 
85% conservation at the nucleotide level in other mycobacterial species such 
as M. marinum, M. smegmatis and M. leprae, suggesting that the anti-sense 
RNA encoded there might be conserved. Curiously, two features (rv2660c and 
rv1954c) that were described as induced upon starvation (15) were also found 
to be up-regulated in Stat phase but in the anti-sense orientation. The strand-
specificity of RNA-seq uncovered this discrepancy, whilst previously used 
PCR-based microarrays did not allow correct strand identification (15). 
Ironically, Rv2660c has been proposed as part of a multi-subunit TB vaccine 
(24) even though its gene is transcribed in the opposite direction. 
Intergenic transcription and corresponding RNAP/NusA ER added 
further value. A number of long 5’-UTRs has been identified, such as those of 
whiB1 (rv3219) and of cspA (rv3648c), suggesting the existence of cis-
regulatory elements affecting transcription elongation or attenuation 
mechanisms, including those mediated by riboswitches. To date, some of these 
have been predicted or validated in M. tuberculosis (25-27). The presence of 
NusA at these genomic positions confirms the role of this protein in the 
transcription attenuation process, in agreement with earlier studies (28,29). 
The single-nucleotide resolution conferred by RNA-seq allowed the 
identification of intergenic sRNAs and independent confirmation by ChIP-seq 
was obtained. Most of the previously described small transcripts (18,30-32) 
were easily recognized in our study and some of the discrepancies encountered 
could be related to different culture conditions or sequencing methodologies. 
Prediction of the conservation and of the functional role carried out by these 
transcripts remains elusive, given the reduced sequence identity occurring in 
IGs among the various mycobacterial species. 
A major strength of our work lies in the combination of ChIP-seq with 
RNA-seq technologies, and therefore the cross-validation of the respective 
datasets. Approximately the same number of features was found to be 
enriched in RNAP and/or NusA in the two conditions tested but there was 
good correlation with transcription in Exp phase only. On the contrary, 
roughly half of the RNAP/NusA signals were associated with RNA in Stat 
phase. Overall, while on the one hand RNA stability effects cannot be ruled 
out, on the other these data suggest a model where RNAP and NusA bind 
throughout the M. tuberculosis genome but their activity might be impeded 
by the lack of additional transcription factors and/or by the lack of nutrients, 
especially in Stat phase. It has been reported that approximately 23% of the 
RNAP signals in growing E. coli were not associated with RNA, thus leading 
to the definition of “poised” RNAP (33). This is similar to the percentage 
(21%) of RNAP- and/or NusA-enriched features that do not correspond to a 
transcript in Exp phase in our study. Indeed, RNAP sitting on promoter 
sequences has to undergo several steps of abortive initiation and requires the 
presence of activators, such as GreA (34), and/or small molecules (35) or a 
particular DNA topology (36) in order to proceed fruitfully. A recent study 
identified transcription start site associated RNAs in Mycoplasma pneumoniae 
that overlap RNAP pausing sites (37). These small RNA molecules may exist 
in M. tuberculosis as well, thus explaining some of the unusual RNAP and/or 
NusA peaks that were not associated with a detectable transcript. Since the 
results of RNA-seq and RNAP ChIP-seq are not necessarily the same in M. 
tuberculosis, care should be taken with replacing transcriptomic profiling by 
detection of RNAP binding sites. Indeed, RNA studies (and nowadays 
powerful deep transcriptomic profiling) represent the gold standard for gene 
expression analysis.  
The NusA-only containing signals deserve some discussion. The 
majority of these peaks were associated with RNA either in the same or in the 
neighboring feature whereas only 42 signals could not be correlated to 
transcription. Technical reasons could explain why RNAP was not detected 
above the background, for instance immunoprecipitation might be difficult 
because the epitope is masked by other transcription factors or by intricate 
chromatin structures in those regions.  
Integration of ChIP-seq and RNA-seq data in a systems biology 
context provided the most relevant output to this work. Based on the criteria 
defined with the ribosomal protein operons (i.e. presence of an RNAP/NusA 
peak at the first feature and a continuous transcript throughout the TU) we 
developed an algorithm that identified 606 high-quality TUs widely 
distributed along the M. tuberculosis genome. More TUs may be present on 
the chromosome but will have escaped identification since our algorithm was 
based on data generated in vitro in specific growth conditions. This is the first 
study of its kind to have performed genome-wide TU identification relying on 
empirical data rather than on predictions as done previously (38). We could 
confirm those TUs for which experimental evidence in the literature exists, for 
example the furA-katG operon (39), the yrbE1A-mce1F locus (40), the pstB-
pstA2 unit (41) and the rv3134c-devS operon (42).  Our approach is 
complementary to the transcriptional start sites (TSS) mapping developed in 
Helicobacter pylori by means of a differential RNA-seq method (43). While 
the latter procedure allows precise identification of the 5’-end of primary 
transcripts, the combination of RNAP/NusA ChIP-seq and RNA-seq provides 
a more dynamic view of the interactions of the transcriptional complex with 
the genome and circumvents potential technical issues related to RNA 
stability. 
By studying RNAP and NusA binding across TUs and their correlation 
with transcription, we established some common patterns in both growth 
phases that shed light on the biology of the transcriptional complex in M. 
tuberculosis. Firstly, promoter-proximal peaks for RNAP (and, to a lesser 
extent, for NusA) were recognized in the global TU profile. These signals may 
correspond to RNAP trapped at promoters before promoter clearance (i.e. 
abortive initiation), represent pause sites or result from premature 
transcription termination or attenuation mechanisms. Similar findings were 
previously described in E. coli (13), where the simultaneous occurrence of 
RNAP and NusA peaks allowed the classification of those promoter-proximal 
signals as elongating (EC) rather than stalled complexes. Given the strong 
analogy with our results, we infer that this is the case for M. tuberculosis as 
well, thus revealing Actinobacteria to be more similar to Proteobacteria than 
to the Firmicute B. subtilis (14) in the mechanistic basis of gene expression. 
Secondly, significant abundance of NusA in the body of the transcribed TUs 
was observed, underlining its role in promoting transcription by anti-
termination processes. In addition, the traveling ratio (TR) for RNAP was 
found to be <1, suggesting that the transition from initiation to elongation is 
a rate-limiting step in M. tuberculosis as well, similarly to E. coli (33,44). 
Slightly different from the RNAP TR, the TR for NusA was 0.75, suggesting 
that NusA-containing complexes move through the TUs faster. Indeed, the 
ratio between RNAP and NusA ER at promoters was in favor of RNAP, as 
witnessed by the global promoter profile, indicating that a proportion of the 
RNAP molecules does not associate with NusA and probably does not move 
along the genes. Overall, the importance of NusA in promoter clearance was 
also highlighted, since features lacking the NusA peak in the corresponding 
RNAP enrichment were not expressed. Finally, a striking polarity in the 
distribution of RNAP and NusA was noticed in the TU profiles. 
 
Figure 7. Circular genome view of the transcription profiles for transcriptional units 
in exponential and stationary phases. Ori indicates the origin of replication. The 
outermost blue circle represents CDSs on the forward strand, followed by the 
exponential phase expression profile for TUs on the forward strand in orange, the 
stationary phase expression profile for TUs on the forward strand in blue. The green 
circle represents CDSs on the reverse strand, followed by the exponential phase 
expression profile for TUs on the reverse strand in orange and the stationary phase 
expression profile for TUs on the reverse strand in blue. Genomic coordinates are 
marked at every 1 MB. Red arrows indicate the direction of the replication forks. 
Some of the highly transcribed loci are highlighted in yellow and annotated. 
 
The whole-genome distribution of the TUs (Figure 7) revealed a strong 
bias in the expression levels with respect to the direction of the replication 
forks. The majority of the highly transcribed TUs were localized on the 
leading strand thus resulting in an image where the M. tuberculosis 
chromosome is split into two non-symmetrical halves with the replication 
terminus located tentatively at ~2.1 MB. Interestingly, while the orientation 
of the CDSs in the H37Rv genome is only slightly biased (59% with the same 
polarity as DNA replication, (4)), their expression levels are more affected, as 
confirmed by applying a Kolmogorov-Smirnov test to the cumulative RPM 
along each strand resulting in a p <10-10 (Supplementary Figure S8). This is 
different from what was observed in other bacteria, such as E. coli (45) and 
B. subtilis (46), where the orientation bias is more pronounced. Our genome-
wide transcriptional study shows that in a slow-growing pathogenic bacterium 
the DNA and RNA polymerases proceed in the same direction through most 
of the highly expressed features thus avoiding potential collisions. 
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4.2.2 Genome-wide definition of the SigF Regulon in M. tb  
Contribution: Processing of raw data, normalization, filtering, quantification 
and integration of the ChIP-on-chip and microarray results.   
 
In order to adapt and survive the multitude of stresses imposed by the host 
immune system, M. tb employs a large number of transcriptional regulators 
to effectively control its gene expression. The M. tb genome encodes 13 
putative sigma factors that modulate gene expression by directly altering the 
promoter preference of RNA polymerase (S. Cole et al. 1998). The primary 
sigma factor, SigA is essential for general transcription of housekeeping genes, 
while the other sigma factors (SigB to SigM) are nonessential and generally 
respond to various environmental and physiological stresses to help fine-tune 
expression of specific genes (Manganelli et al. 2004). 
 
SigF is a stationary-phase stress response sigma factor required for full 
virulence of M. tb. Studies in M. bovis BCG showed induction of the sigF 
gene in response to cold shock, hypoxia and nitrogen depletion, but these 
findings could not be replicated in M. tb, suggesting differences in regulation 
of sigF between the two species. Although sigF is nonessential for bacterial 
growth in vitro and occurs as a pseudogene in M. leprae it is conserved in 
most mycobacterial species. Several approaches have been used to identify 
genes requiring SigF for their expression, but there is little agreement 
between the findings from these studies. However, all of them indicate that 
SigF controls its own transcription.  
 
In this study, a combination of two genome-wide approaches was used to 
define the SigF regulon: ChIP-on-chip (chromatin immunoprecipitation 
followed by hybridization to microarrays) and expression profiling analysis 
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(using microarrays) of SigF-mediated transcripts. Since SigF is not an 
abundant protein in the logarithmic phase of growth, a pristinamyin IA-
inducible system was used to control its expression. Experiments were 
performed using custom-made microarrays. Each array contained 43,450 
probes (21,725 probes on each strand), located, on average, every 203 bases 
and covering the entire M. tb H37Rv genome.  
 
Analysis of the ChIP-on-chip data revealed a total of 201 significantly 
enriched probes, which clustered in 67 distinct genomic loci. To understand 
SigF mediated gene regulation, transcriptome data were compared for sigF-
induced and un-induced samples. We found 138 probes, corresponding to 51 
genomic loci containing 33 protein-coding genes that were significantly 
upregulated upon sigF induction. No genes were found to be downregulated. 
On integration of the two datasets, we identified 16 genomic loci that were 
upregulated upon SigF induction and had a corresponding 5’ SigF-binding 
site. Thus, we could distinguish between transcripts that are directly 
regulated by SigF from those that are controlled indirectly, through a 
regulatory cascade, possibly involving other transcriptional regulators. 
Quantitative PCR confirmed the microarray findings and SigF-specific 
transcription start points could be mapped using 5’-RACE (rapid 
amplification of cDNA ends). A canonical SigF consensus promoter sequence 
GGTTT-N(15-17)-GGGTA was identified prior to eleven genes.  
 
The SigF regulon defined using these data confirmed that SigF controls its 
own expression, along with the expression of genes involved in lipid and 
intermediary metabolism, virulence (hbhA), and at least one transcriptional 
regulator (Rv2884), possibly acting downstream of SigF. In addition, SigF 
was also found to direct the transcription of the gene for small RNA F6.  
Genome-Wide Definition of the SigF Regulon in Mycobacterium
tuberculosis
Ruben C. Hartkoorn,a Claudia Sala,a Swapna Uplekar,a Philippe Busso,a Jacques Rougemont,b and Stewart T. Colea
Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland,a and Bioinformatics and Biostatistics Core Facility, Swiss Institute of
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InMycobacterium tuberculosis the alternative sigma factor SigF controls the expression of a particular subset of genes by alter-
ing RNA polymerase specificity. Here, we utilize two genome-wide approaches to identify SigF-binding sites: chromatin immu-
noprecipitation (ChIP-on-chip) andmicroarray analysis of SigF-mediated transcripts. Since SigF is not an abundant protein in
the logarithmic phase of growth, a pristinamyin IA-inducible system was used to control its expression.We identified 67 high-
affinity SigF-binding sites and 16 loci where a SigF promoter directs the expression of a transcript. These loci include sigF itself,
genes involved in lipid and intermediary metabolism and virulence, and at least one transcriptional regulator (Rv2884), possibly
acting downstream of SigF. In addition, SigF was also found to direct the transcription of the gene for small RNA F6. Many loci
were also found where SigF may be involved in antisense transcription, and in two cases (Rv1358 and Rv1870c) the SigF-depen-
dent promoter was located within the predicted coding sequence. Quantitative PCR confirmed the microarray findings and 5=-
rapid amplification of cDNA ends was used to map the SigF-specific transcriptional start points. A canonical SigF consensus pro-
moter sequence GGTTT-N(15-17)-GGGTAwas found prior to 11 genes. Together, these data help to define the SigF regulon and
show that SigF not only governs expression of proteins such as the virulence factor, HbhA, but also impacts novel functions,
such as noncoding RNAs and antisense transcripts.
Mycobacterium tuberculosis, the etiologic agent of human tu-berculosis, is a slow-growing pathogen that survives and
multiplies despite a huge barrage of stresses imposed by the
immune system. Resisting these stresses requires the bacterium to
be able to sense its environment and react accordingly. The com-
plete genome sequence ofM. tuberculosis (7) revealed at least 140
potential transcriptional regulators (36), and a total of 13 sigma
factors that can directly alter the promoter preference of RNA
polymerase. Among these sigma factors, SigA is the housekeeping
sigma factor that is responsible for general transcription, while the
other sigma factors (SigB to SigM) are nonessential but help fine-
tune gene expression in response to various physiological stresses.
SigF was first described inMycobacterium bovis BCG (BCG) by
DeMaio et al. (10) as a stationary-phase stress response sigma
factor that is also induced upon cold shock and nitrogen deple-
tion. Although some of these findings were partly confirmed in
BCG by others (34), they were not replicated in M. tuberculosis
(23), with only nutrient starvation showing some induction of sigF
(4). Although sigF is nonessential for bacterial growth in vitro and
found as a pseudogene in Mycobacterium leprae (24, 31), sigF is
conserved inmostmycobacterial species. Infection studies inmice
and guinea pigs show that M. tuberculosis lacking sigF is partially
attenuated (5, 14, 19).
To date, a number of genome-wide approaches have been used
to uncover the SigF transcriptome, but with contrasting results.
SigF-regulated M. tuberculosis genes have been studied by com-
paring the transcriptomes of wild-type and sigF knockout mutant
bacteria (14) and of wild-typeM. tuberculosis with a strain carry-
ing an acetamide-inducible sigF (20, 37). Alternative strategies
used to discover SigF-controlled genes were ChIP-on-chip (chro-
matin immunoprecipitation and hybridization to microarrays)
analysis of SigF-binding sites in BCG (30) and application of a
two-plasmid system in Escherichia coli to identify genes controlled
by SigF (16). Overall, there is little agreement between the findings
of these studies except for confirmation of the initial finding that
SigF controls its own transcription (18).
Here, a combination of both genome-wide transcriptome and
ChIP-on-chip analyses was used to detect SigF-induced tran-
scripts and identify SigF DNA-binding sites, respectively. The
findings were subsequently confirmed by quantitative PCR and
mapping the SigF-specific (or SigF-controlled) transcriptional
start sites with the combined results leading to definition of the
SigF regulon.
MATERIALS AND METHODS
Bacterial strains, reagents, and chemicals. All experiments were per-
formed in either M. tuberculosis strain H37Rv or its isogenic mutant,
H37Rv(!rsbW/sigF), lacking the rsbW and sigF operon, as described pre-
viously (15). These strains were transformed with either pMY769, an
empty pristinamycin IA (P-IA)-inducible integrating vector, or pMYsigF,
a pMY769 derivative with a P-IA-inducible sigF gene (15) to create
H37Rv::pMY769, H37Rv::pMYsigF, H37Rv(!rsbW/sigF)::pMY769, and
H37Rv(!rsbW/sigF)::pMYsigF. The strains were routinely grown in
Middlebrook 7H9 medium supplemented with 10% albumin-dextrose-
catalase (ADC), 0.2% glycerol, and 0.05%Tween 80. Bacterial growthwas
monitored spectrophotometrically at an optical density of 600 nm
(OD600).
P-IA was purified from pyostatin tablets as described previously (15).
Rabbit anti-SigF polyclonal antibodies were kindly provided by Ida
Rosenkrands (Statens Serum Institut, Copenhagen, Denmark), and a
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mouse anti-HbhA polyclonal antibody was provided by Giovanni Delogu
(CatholicUniversity of the SacredHeart, Rome, Italy). All other chemicals
(except when mentioned) were obtained from Sigma-Aldrich.
Protein gels and Western blot analysis. To analyze the total protein
content, bacteria were harvested, and the total cell extract was subjected to
SDS-PAGE for Simply Blue staining orWestern blot analysis as described
previously (15). Protein bands were excised from the gel and identified by
liquid chromatography-tandemmass spectrometry (LC-MS/MS) analysis
following trypsin or chymotrypsin digestion.
SigF chromatin immunoprecipitation experiments. Log-phase
cultures of H37Rv(!rsbW/sigF)::pMYsigF and H37Rv(!rsbW/sigF)::
pMY769 were diluted to an OD600 of 0.05. After overnight incubation,
P-IA (final concentration 2 !g/ml) was added to both cultures, and these
were incubated for 3 days at 37°C with shaking. Chromatin immunopre-
cipitation was performed as previously described (33), with some modi-
fications. Briefly, protein-DNA complexes were cross-linked using form-
aldehyde (final concentration, 1%; 10 min, 37°C) and quenched using
glycine (final concentration, 125mM). Bacteria were pelleted and washed
twice with Tris-buffered saline (20 mM Tris-HCl [pH 7.5], 150 mM
NaCl), and the pellets were stored at"80°C. The pellets were resuspended
in 600!l of immunoprecipitation buffer (50mMHEPES-KOH [pH 7.5],
150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxy-
cholate, 0.1%SDS, RocheAntiproteaseMini) and disrupted by sonication
at 4°C for 30min (30-s pulses with a Bioruptor, Diagenode) to shear DNA
to an average size of 200 to 400 bp. After centrifugation (2,000 # g, 15
min), the supernatant was diluted to 1.1 ml in immunoprecipitation buf-
fer and mixed overnight (4°C) with 20 !l of polyclonal rabbit anti-SigF
antibody. In parallel, per sample, 100 !l of protein A/G UltraLink resin
(Thermo Scientific) was washed in immunoprecipitation buffer and in-
cubated overnight (4°C) in 1ml of immunoprecipitation buffer with 1mg
of bovine serum albumin/ml and 0.1 mg of salmon spermDNA/ml. After
overnight blocking, protein A/G UltraLink resin was pelleted (2,000# g,
2 min) and mixed with the antibody and protein-DNA complex mixture
(rotarymixer, 90min, 4°C). The protein A/GUltraLink resin was pelleted
(2,000 # g, 2 min) and washed twice with immunoprecipitation buffer,
once with immunoprecipitation buffer plus 500 mM NaCl, once with
wash buffer III (10 mM Tris-HCl [pH 8], 250 mM LiCl, 1 mM EDTA,
0.5% Nonidet P-40, 0.5% sodium deoxycholate), and once with Tris-
EDTA buffer (pH 7.5). Immunoprecipitated complexes were eluted from
the beads by treatment with 100 !l of elution buffer (50 mM Tris-HCl
[pH 7.5], 10 mM EDTA, 1% SDS) at 65°C for 20 min. Samples were then
treated with RNase A, and cross-links were reversed by incubation for 2 h
at 56°C and 6 h at 65°C in 0.5# elution buffer plus 50 !g of proteinase K.
DNA was extracted twice with phenol-chloroform, precipitated, and re-
suspended in 20 !l of water. DNA obtained from immunoprecipitation
and total genomic DNA were labeled by Klenow random priming, with
Cy3-dCTP or Cy5-dCTP (GEHealthcare), respectively, and purified with
Qiagen MinElute kit, according to the manufacturer’s protocol.
Microarray analysis of the SigF transcriptome. Log-phase H37Rv::
pMY769 andH37Rv::pMYsigF cultures were diluted toOD600 of 0.05 and
split into two 50-ml cultures. After overnight incubation, P-IA (final con-
centration, 2 !g/ml) was added to one culture, and an equivalent volume
of dimethyl sulfoxide was added to the other. After 72 h of incubation
(rotary mixer, 4°C), the RNA was extracted using 6 M GTC (6 M guani-
dine thiocyanate, 0.75% sodium N-laurylsarcosine, 37.5 mM sodium
citrate, 0.75% Tween 80, 0.15 M "-mercaptoethanol) and TRIzol (Invit-
rogen) as described previously (28). Extracted RNA was treated twice by
RQ1 DNase (Promega) according to the manufacturer’s instructions and
cleaned up using an RNeasy minikit (Qiagen). RNA quantity and quality
were assessed by usingNanoDrop, agarose gel electrophoresis, andPCR to
confirm the absence of DNA. mRNA was reverse transcribed and cDNA
was labeled using RevertAID-H-minus reverse transcriptase (Fermentas)
according to the manufacturer’s instructions, using 1 to 4 !g of purified
mRNA, random hexamers, and either Cy3-dCTP or Cy5-dCTP (GE
Healthcare). Reverse transcription was performed using the following
conditions: 10 min at 25°C, 90 min at 45°C, and 5 min at 70°C. Labeled
cDNAwas treatedwith RNaseH andRNaseA (30min, 37°C), followed by
cDNA cleanup using a GFX purification kit (GE Healthcare).
Microarray design, hybridization, and analysis. The same microar-
rays were used for SigF ChIP-on-chip and transcriptome analyses, and
these were purchased from Oxford Gene Technology as described previ-
ously (33). Each array contained 43,450 probes (21,725 probes on each
strand) covering the entire genome, located, on average, every 203 bases.
LabeledDNAor cDNAwas hybridized tomicroarrays in an Agilent Tech-
nologies Microarray chamber at 55°C for 72 h in buffer composed of 1 M
NaCl, 50mMMES (morpholineethanesulfonic acid), 20% formamide, 20
mM EDTA, and 1% Triton X-100. The arrays were washed once in 6#
SSPE (1# SSPE is 0.18 MNaCl, 10 mMNaH2PO4, and 1 mM EDTA [pH
7.4])–0.005% N-laurylsarcosine and once in 0.06% SSPE–0.18% poly-
ethylene glycol 200, both times for 5min at room temperature. Finally, the
microarrays were dried in isopropanol and immediately scanned using an
Agilent Technologies microarray scanner, after which results were ex-
tracted using GenePix Pro 5.0 software.
For each ChIP-on-chip data set, the raw Cy3 and Cy5 intensity data
obtained from the GenePix software were median normalized. Since no
strand specificity is expected for ChIP-ed DNA (since the proteins bind
double-stranded gDNA), the average of the sense and antisense intensities
was calculated for each probe, and the enrichment was measured as the
ratio of the averaged Cy3 and Cy5 intensities. The enrichment ratios were
log2 transformed and further corrected using Lowess normalization in
order to eliminate intensity-dependent dye bias. Since the number of
enriched probes was low ($1%), the means and standard deviations of
the log2-normalized enrichment ratios of the whole data set were used as
a measure of variance of the data set. Using this, a Z-score and corre-
sponding probability (P value) was calculated for each probe to be signif-
icantly different from the mean.
In addition, since DNA fragments obtained from ChIP-on-chip experi-
mentswere between 200 and 400 bp, they are expected to hybridize to probes
adjacent to each other on the genome. Since the physical arrangement of
probes on the array does not reflect their location on the M. tuberculosis
chromosome, the data were reordered genomically. Putative SigF-binding
sitesweredefinedasa stretchof twoormoreconsecutiveprobeswithaPvalue
of$0.01 in at least three out of four data sets. Probe enrichment was calcu-
lated as 2(mean log2 normalized enrichment ratios). Positive probes were mapped to
the current M. tuberculosis H37Rv genome annotation, as described in Tu-
bercuList (http://tuberculist.epfl.ch).
For each cDNA transcriptome data set, a similar data analysis was
performed, but the sense and antisense probe intensities were kept sepa-
rate in order to determine the direction of transcription. As described
above, for each probe the raw Cy3 and Cy5 intensity data were median
normalized, the enrichment ratios were calculated, log2 transformed, and
Lowess normalized, and the statistical significance from the mean was
determined by calculating the Z-score and the P value. In experiments to
determine SigF mediated gene induction, (H37Rv::pMYSigF with or
without P-IA), the probes were considered significantly enriched if they
showed a P value below 0.005 in at least three of four data sets. In the
experiment to determine P-IA mediated gene induction (H37Rv::
pMY769 with or without P-IA), the probes were considered significantly
enriched if they showed a P value below 0.01 in at least two of the three
data sets and if they were also enriched in the H37Rv::pMYSigF experi-
ment, based on the previous criteria. To allow for the detection of smaller
RNA species, in contrast to the ChIP-on-chip data set analysis, singletons
(enriched probes with no genomically adjacent positive spot) were taken
into account for the analysis. Positive probes were mapped, in the correct
orientation, to the M. tuberculosis H37Rv genome annotation from Tu-
bercuList (http://tuberculist.epfl.ch).
All ChIP-on-chip and cDNA transcriptome data sets have been depos-
ited in NCBI’s Gene Expression Omnibus (12) and can be accessed
through GEO Series accession number GSE35080, with subseries
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GSE34919 (ChIP-on-chip microarray data) and GSE34922 (transcrip-
tome microarray data).
RNAextraction forQ-PCR.To confirm the transcriptional regulation
of genes by SigF, microarray data was confirmed by quantitative PCR
(Q-PCR). Briefly, 40-ml cultures of H37Rv(!rsbW/sigF)::pMY769 and
H37Rv(!rsbW/sigF)::pMYsigF were grown in the presence or absence of
P-IA (2!g/ml). After 0, 24, and 72 h induction, 10 ml of each culture was
pelleted, flash frozen in liquid nitrogen, and subsequently extracted with
TRIzol (according to the manufacturer’s instructions) using bead beating
to disrupt the bacteria, two rounds of DNase treatment to remove DNA
(confirmed by PCR), and ethanol precipitation to clean and concentrate
RNA (so as to retain small RNAs [sRNAs]). RNA was reverse transcribed
using random primers and RevertAID-H-minus reverse transcriptase
(Fermentas) according to the manufacturer’s instructions. Biological
triplicates were performed for each condition to allow for statistical anal-
ysis.
Q-PCR of purified cDNA was performed using SYBRgreen PCRmas-
termix (Applied Biosystems) and primer sets fromTable S1 in the supple-
mental material. Q-PCR for each sample was performed in duplicate on a
7900HT sequence detection system (Applied Biosystems) using the fol-
lowing protocol: denaturation at 95°C for 3 min, followed by 40 cycles of
denaturation at 95°C for 30 s and annealing/elongation with data collec-
tion at 60°C for 40 s. Melting curves were constructed to ensure that only
one amplification product was obtained. To calculate enrichment ratios,
mean threshold cycle (CT) values were normalized against sigA CT (!CT)
that was normalized against day 0 no P-IA !CT (!!CT). The statistical
significance was determined by comparing!!CT values using a nonpara-
metric paired t test (Wilcoxon test). The total fold enrichment was calcu-
lated as 2("!!CT).
Multiplex 5=-RACE. To determine the start point of transcription of
SigF-regulated transcripts,multiplex 5= rapid amplification of cDNA ends
(5=-RACE) was performed on RNA extracted from H37Rv(!rsbW/sigF)::
pMYsigF andH37Rv(!rsbW/sigF)::pMY769 induced with P-IA for 3 days
(see above). For the first step of multiplex 5=-RACE, reverse transcription
of purified mRNA was performed with sets of four specific primers for
four different putative SigF-regulated genes. Briefly, RNA (500 ng), gene-
specific primers (12.5 !M each), and deoxynucleoside triphosphates (10
mM)weremixed in 10!l and heated (65°C, 5min). After flash cooling on
ice, RT buffer (2 !l), MgCl2 (4 !l), dithiothreitol (2 !l) RNase OUT (1
!l), and Superscript III (1 !l) were added from the SuperScript III first-
strand synthesis system (Invitrogen). First-stand synthesis was performed
as follows (50°C for 1 h, 55°C for 1 h, and 70°C for 15 min). cDNA was
purified with a High-Pure PCR product purification kit (Roche) and then
used in the subsequent poly(A) tailing reaction (30 min at 37°C in the
presence of 0.2 mM dATP and 80 U of terminal transferase [Roche]). For
the amplification of specific genes, seminested PCR amplification was
performed with an oligo(dT)-anchor primer and a second gene-specific
primer. The products of the PCR were purified and sequenced by Sanger
sequencing on anABI 3130XL genetic analyzer (Applied Biosystems)with
the second gene-specific primer.
For sequence motif identification, the BioProspector tool was used
(21; http://ai.stanford.edu/#xsliu/cgi-bin/BPsearch.cgi), and the results
were entered intoWeblogo to generate a sequence logo (9; http://weblogo
.berkeley.edu/logo.cgi).
RESULTS
We sought here to use two different yet complementary genome-
wide approaches to identify genes regulated by RNA polymerase
containing SigF: chromatin-immunoprecipitation with SigF-spe-
cific antibodies and gene expression profiling of M. tuberculosis
cells that conditionally express this sigma factor.
Conditional overexpression of sigF. Quantitative reverse
transcription-PCR (RT-PCR) showed that the level of sigFmRNA
expressionwas the same in strainsH37Rv andH37Rv::pMYsigF in
the absence of the inducer P-IA and that no sigF transcript could
be detected in H37Rv(!rsbW/sigF) or H37Rv(!rsbW/sigF)::
pMYsigF without inducer. The addition of P-IA to cultures re-
sulted in an at least 256-fold induction of sigF inH37Rv:: pMYsigF
(after 3 days of P-IA exposure), whereas sigF transcripts were also
readily detectable in induced H37Rv(!rsbW/sigF)::pMYsigF cells
(data not shown). SigF protein induction could not be seen by
Simply Blue staining of protein lysates run on an SDS-PAGE gel
(Fig. 1A); however,Western blot analysis confirmed the induction
of SigF protein after P-IA treatment, as well as tight regulation of
sigF in its absence (Fig. 1B). As observed previously (15), the in-
duction of sigF in both H37Rv::pMYsigF and H37Rv(!rsbW/
sigF)::pMYsigF brought about a decrease in growth rate after 24 h,
whereas control strains were not affected.
Analysis of the total protein content of sigF-induced and unin-
duced strains using staining SDS-PAGE gels revealed induction of
a single protein band with an apparent molecular mass of #26
kDa that was too small to be SigF (Fig. 1A). LC-MS/MS analysis of
this band identified two proteins that were clearly induced in the
presence of P-IA, namely, the heparin-binding hemagglutinin
HbhA (Rv0475) and the phosphate-transport system regulatory
FIG 1 Protein expression profile of H37Rv(!rsbW/sigF), H37Rv::pMY769
(with orwithout P-IA), andH37Rv::pMYsigF (with orwithout P-IA). Analysis
of total protein expression by SDS-PAGE gel and gel staining by Simply Blue
(A) reveals the appearance of a protein band at#26 kDa, later to be identified
asHbhA by LC-MS/MS analysis. By LC-MS/MS analysis PhoYI was also found
to be upregulated in this band. Confirmation of SigF expression and induction
in the same set of lysateswas performedbyWestern blot analysis with anti-SigF
antibodies (B), while the induction of HbhA was confirmed with anti-HbhA
antibodies (C). Note that in the case of HbhA, induction of SigF seems to lead
not only to the induction of an HbhA band at 26 kDa but also the disappear-
ance of an HbhA band at 31 kDa.
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protein PhoYI (Rv3301c). Western blot analysis with a polyclonal
anti-HbhAprimary antibody confirmed the induction ofHbhA at
an apparent mass of 26 kDa but also revealed a decrease in the
intensity of a higher-molecular-mass form at !31 kDa (Fig. 1C)
that may be methylated, since this has already been described (25,
29).Western blot analysis was not performed to confirm the iden-
tity of PhoYI due to the lack of specific antibodies.
SigF-dependent gene expression. To understand SigF-medi-
ated gene regulation, we first looked at the changes in the bacterial
transcriptome after sigF induction by hybridizing cDNAs to mi-
croarrays. These experiments were performed using H37Rv::
pMY769 to control for P-IA-induced transcripts and H37Rv::
pMYsigF to analyze SigF-induced transcripts. P-IA alone was
found to induce six genes, i.e., Rv3197A (whiB7), Rv0341 (iniB),
Rv1258c, Rv1988, Rv2416c (eis), and Rv2725c (hflX), all of which
were not found to be preceded by a SigF ChIP-on-chip binding
site. Five of these genes are known to be induced by antibiotics
through WhiB7 (27) and were not considered when analyzing
SigF-induced transcripts.
When we compared RNA transcripts from uninduced and in-
duced H37Rv::pMYsigF, we found no genes to be significantly
downregulated, whereas 51 loci (represented by 138 probes) were
upregulated after sigF induction. Of the 51 loci, 25 represent oper-
ons containing 33 annotated genes, one of which was only anno-
tated in CDC1551 (MT1083.2) (see Table S2 in the supplemental
material). The remaining probes mapped to 20 intergenic regions
and to 6 antisense transcripts (compared to the annotated H37Rv
genome) (see Table S3 in the supplemental material). The highest
induction of an RNA transcript detected by microarrays was 19-
fold for Rv2884 (coding for a probable transcriptional regulatory
protein), followed by Rv1358 (14-fold) and Rv2268c (10-fold).
The induction of consecutive genes allowed some operons to be
identified, namely, Rv0941c-Rv0940c (Fig. 2A), Rv1823-Rv1825
(Fig. 2B), Rv1843c-Rv1841c, and Rv2268c-Rv2267c. Interestingly,
there were a number of transcripts, in particular Rv1358, where
the transcript seems to start within the annotated gene (Fig. 2C).
In addition, two examples of antisense RNA transcripts, found to
be highly expressed after sigF induction, are found in Rv1459c
(19-fold) and Rv0450 (8-fold) (Fig. 2D and E). Analysis of the
functional categories to which the enriched genes belong (6) re-
vealed no particular bias.
ChIP-on-chip analysis. To understand which of the genes
found to be upregulated after SigF induction were indeed con-
trolled directly by SigF, rather than by a SigF-induced transcrip-
tional regulator, ChIP-on-chip analysis was performed by com-
paring immunoprecipitated DNA from induced strains H37Rv
("rsbW/sigF)::pMY769 and H37Rv("rsbW/sigF)::pMYsigF.
Analysis of data from four independent biological replicates re-
vealed 317 probes that were enriched in at least three cases. Of
these probes, 116 were “singletons” and therefore discarded, leav-
ing 201 significant probes that clustered in 67 loci. Analysis of
ChIP-on-chip data showed that SigF-binding sites were evenly
distributed throughout the genome. Of these 67 loci, 40 were in-
tergenic, while 27 were intragenic (see Table S4 in the supplemen-
tal material). The biggest peak found by ChIP-on-chip analysis,
with an enrichment of 81-fold, was between the two converging
genes Rv0243 (fadA2) and Rv0244c (fadE5). Although no tran-
script was detected in this location by RNA microarrays, it is
known to encode an sRNA named F6 (2).
Integrating SigFbinding and transcription.On integrationof
the two data sets, 16 loci (representing 24 genes) were clearly iden-
tifiedwhere a SigF-binding site was followed by anRNA transcript
in the sense orientation, while nine regions were detected where a
SigF-binding site was associated with an antisense transcript (Ta-
ble 1). A Venn diagram showing the overlap between the two data
sets is presented in Fig. 3.
Of the 51 identified loci whose expression was upregulated
upon SigF induction, 26 were found not to have a corresponding
5= SigF-binding peak. Possible reasons for this include their indi-
rect regulation by other transcriptional regulators, such as
Rv2884, or, alternatively, the stabilization of RNA by sRNA.More
than 60% of the SigF-binding sites are not linked to genes display-
ing increased transcription. Reasons for this include additional
levels of gene regulation or the existence of short genes or sRNAs,
such as F6, which escape detection by the methods used.
Confirmation by Q-PCR. To obtain independent confirma-
tion data of the SigF transcriptome and binding analysis, a num-
ber of genes were selected and subjected to Q-PCR analysis. In
addition, a few loci were chosen that were previously reported to
be controlled by SigF (e.g., sigC) butwere not foundhere, aswell as
the F6 sRNA, forwhich no probe exists on themicroarray. Expres-
sion profiles of H37Rv("rsbW/sigF)::pMY769 and H37Rv
("rsbW/sigF)::pMYsigF were tested 0, 1, and 3 days after P-IA-
mediated SigF induction. The data revealed that at day 0 there was
no significant difference in the expression of any of the genes
between the two strains (see Table S5 in the supplemental mate-
rial). Likewise, after one or 3 days induction of H37Rv("rsbW/
sigF)::pMY769 no difference was seen for any of the genes tested
(see Table S5 in the supplemental material). One day after the
induction ofH37Rv("rsbW/sigF)::pMYsigF, significantly induced
expression of all of the selected targets was seen except forRv1870c
and sigC (see Table S5 in the supplementalmaterial), whereas after
3 days of induction all of the genes except sigC were upregulated
(Fig. 4). At 3 days after SigF induction, the fivemost induced genes
wereRv1284 (194-fold),Rv0941c (142-fold),Rv1358 (50-fold), F6
sRNA (35-fold), and Rv2884 (34-fold).
Localizing promoters by 5=-RACE. Since genes can be ex-
pressed from multiple promoters, care needs to be taken not to
confuse the SigF-specific transcriptional start point (TSP)with the
TSP of another sigma factor, such as SigA. Consequently, compar-
isons were made of RNA extracted from cultures of H37Rv
("rsbW/sigF)::pMY769 and H37Rv("rsbW/sigF)::pMYsigF at 3
days after induction. Multiplex 5=-RACE was performed for all 14
loci found to be regulated by SigF by Q-PCR, as well as for rsbW.
The 5=-RACE analysis was unsuccessful in four cases (Rv3254,
Rv2268, Rv2140c, and F6 sRNA) since the sequences obtained did
not map to the corresponding genes. For 7 of the remaining 11
genes, a SigF-independent TSP was identified in H37Rv("rsbW/
sigF)::pMY769, thus implying the existence of a second promoter
(see Table S6 in the supplemental material). The remaining four
genes may have SigF-independent TSPs far from the priming site
(as is true for Rv1358) or only be expressed from SigF-dependent
promoters. 5=-RACE sequences obtained from H37Rv("rsbW/
sigF)::pMYsigF RNA revealed both a SigF-independent TSP
(where there was one) and a SigF-specific TSP for all 11 genes. In
the case of Rv1358 and Rv1870c, the SigF-specific TSP was located
internally.
To identify the SigF promoters for the SigF targets validated
above, 40-bp sequences upstream of the identified TSPs were in-
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spected and, in all cases, the consensus sequence, GGTTT-N(15-17)-
GGGTA, was identified (Fig. 5).
DISCUSSION
We sought here to define the regulons of genes controlled by the
alternative sigma factor SigF. Expression of SigF is low during the
exponential growth phase, and the protein is likely to be largely
inactive due to its binding to the anti-sigma factor RsbW, which is
encoded by the same operon. Furthermore, there are no known
stimuli that specifically increase the level of SigF. After considering
these factors, we decided that in order to best study its role, sigF
expression should be artificially induced by using a tightly regu-
FIG 2 Representation of genomic regions identified bymicroarrays wherein a SigF-binding peak is detected, followed by anmRNA transcript. Examples include
the binding of SigF prior to Rv0941c-40c and the transcription on the reverse strand (A) and the binding of SigF prior to Rv1823-24-25 and the transcription of
the forward strand (B). An example of a case where there is an alternative start of transcription is illustrated for Rv1358, where the SigF-binding peak is located
in themiddle of the gene, with subsequent transcription of a “truncated”mRNA on the sense strand (C). Also, two cases are shown (D and E) where there is SigF
binding and subsequent RNA transcription in the antisense direction compared to the annotated genome. The data represent the mean of four biological
replicates, and these values are plotted against the location of the probes on the chips. The SigF ChIP-on-chip profile is indicated by solid line with black circles,
mRNA transcription in the reverse strand is indicated by dashed line with gray squares, andmRNA transcription in the forward strand is indicated by dotted line
with gray triangles. Genes are annotated along the bottom, with predicted regulated regions colored in gray.
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lated gene expression system. Consequently, we used the PipON
system (13) because the Pptr promoter shows no leakiness in the
absence of P-IA, as evidenced by our results.
At the protein level, which is relatively insensitive, only the
heparin-binding hemagglutinin, HbhA (Rv0475), and PhoY1
were found to be upregulated following SigF overexpression.
HbhA is a virulence factor that mediates extrapulmonary dissem-
ination through binding to epithelial cells (26, 29). As expected,
hbhA transcription was also upregulated upon SigF induction,
and a SigF-binding site precedes its gene, as was also found in BCG
(30). 5=-RACE analysis of the hbhA regulatory region revealed two
promoters: a proximal promoter that was SigF-independent and a
distal promoter that required SigF for expression. Curiously, two
forms of the protein were found by Western blot analysis, with
apparent molecular masses of 26 and 31 kDa. After SigF induc-
tion, there was an increase in abundance of the 26-kDa form but a
decrease in the amount of 31-kDa HbhA. Extensive methylation
of the heparin bindingC-terminal domain has been reported to be
important for its activity (17, 22), so SigF induction may lead to
TABLE 1 Summary of all SigF-induced RNA loci that are preceded by a SigF binding site, as determined by microarraysa
Locus
Strand annotation in
M. tuberculosis
genome
RNA ChIP-on-chip
Orientation according to
microarray
No. of
probes
Fold
enrichment
No. of
probes
Fold
enrichment
Rv0450c (mmpl4) Forward Antisense 1 8.6 2 21.8
Rv0475 (hbhA) Forward Sense 3 4.6 5 6.2
Rv0507 (mmpl2) Reverse Antisense 3 3.1 2 7.5
Rv0759c Reverse Sense 4 2.6 3 17.4
Rv0941c-40c Reverse Sense 12 3.2 4 10.3
MT1083.2 Forward Sense 2 4.5 2 15.7
Rv1206 (fadD6) Forward Sense 1 3.4 2 3.5
Rv1284 (canA) Forward Sense 3 5.7 4 22.3
Rv1358b Forward Sense 12 14.4 3 3.2
Rv1397c (vapC10) Forward Antisense 1 4.0 6 11.9
Rv1455 Reverse Antisense 1 7.9 2 4.3
Rv1459c Forward Antisense 2 19.4 3 9.8
Rv1823-25 Forward Sense 10 4.3 4 11.8
Rv1843c-41c (guaB1) Reverse Sense 2 2.4 4 21.6
Rv1870c-69c Reverse Sense 3 2.3 2 23.0
Rv2140c (TB18.6) Reverse Sense 5 2.8 2 4.8
Rv2268c-67c (cyp128) Reverse Sense 2 10.6 2 4.6
Rv2722 Reverse Antisense 1 3.8 3 16.2
Rv2884 Forward Sense 4 19.3 4 61.9
Rv3049c Forward Antisense 1 3.7 2 4.4
Region between Rv3210c and Rv3211 Reverse Antisense 1 8.1 3 5.0
Rv3254 Forward Sense 4 2.5 2 3.2
Rv3287c-86c (rsbW/sigF) Reverse Sense –d – 2 32.0
Rv3301c (phoYI) Reverse Sense 3 3.0 1c 3.7
Rv3347c (ppe55) Forward Antisense 1 3.0 3 5.9
a The data for SigF-regulated RNA transcripts come from a comparison of the H37Rv::pMYsigF transcriptome with or without P-IA. The data for the SigF binding sites come from
a comparison of immunoprecipitated DNA from H37Rv(!rsbW/sigF)::pMYsigF to H37Rv(!rsbW/sigF)::pMY769 (both cultures with P-IA). The data represent an analysis of four
biological replicates.
b Transcription of this gene appears to start within the annotated gene (5= truncated).
c For this ChIP-on-chip experiment, there was only one enriched probe.
d –, Induction of rsbW/sigF operon was observed, but the origin of the transcript (original genome or integrated pMYsigF vector) could not be deduced.
FIG 3 Venn diagrams illustrating the distribution of SigF-controlled loci, as
identified by RNA microarrays and by ChIP-on-chip analysis.
FIG 4 Q-PCR measurements for the fold induction of a number of genes in
strain H37Rv(!rsbw/sigF)::pMYsigF after 3 days of induction with P-IA com-
pared to no P-IA. The data represent the means and standard deviations of
three biological replicates.
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accumulation of an unmethylated form of the protein and possi-
bly also indirectly impact on the HbhA methylation status. It re-
mains to be elucidated whether SigF, through the modulation of
HbhA activity, is important in vivo, by playing a role inM. tuber-
culosis dissemination from the lungs.
Transcriptome analyses of SigF have previously been con-
ducted in strains CDC1551 and H37Rv using various approaches
but achieved very different results (14, 16, 20, 37). Our transcrip-
tome study revealed 51 loci containing 33 protein-coding genes
that were significantly upregulated on SigF induction, and yet the
data set shows little overlap with the genes reported by Geiman et
al. (1 of 99 genes) (14) or Lee et al. (1 of 5 genes) (20), someoverlap
(7 of 70 genes) with the genes identified byWilliams et al. (RsbW-
SigF, Rv1824-Rv1825, Rv2884, and Rv3301c-Rv3300c) (37), and
good agreement with the genes found by Homerova et al. (using a
two-plasmid system in Escherichia coli) (16). For the 60 genes that
were suggested to be transcribed from SigF-dependent promoters
byWilliams et al. (37) but not found in the present study, only the
regulatory region of Rv0542c is found to contain a SigF-binding
site fromourChIP-on-chip data. Some of these discrepanciesmay
be attributed to the use of different M. tuberculosis strains
(CDC1551 versus H37Rv), to the RNA sample time points (12 h
versus 3 days), and to the levels of sigF induction (acetamide ver-
sus P-IA). A particularly noteworthy difference is the negligible
effect of SigF on the expression of sigC, in contrast to findings of a
previous report (20). A full comparison of published SigF con-
trolled transcripts in M. tuberculosis is shown in Table S7 in the
supplemental material.
A strength of our study is the integration of two independent
data sets: the SigF transcriptomewith the SigF-binding sites on the
genome defined by ChIP. Knowledge of the SigF-binding sites
allows one to distinguish transcripts that are directly regulated by
this sigma factor from those that are indirectly controlled through
a regulatory cascade that may involve other transcriptional regu-
lators such as Rv2884, whose gene is SigF dependent. Using the
integrated approach we identified 16 loci where a SigF-binding
site is followed by an induced transcript. These loci include previ-
ously published genes, such as rsbW-sigF, MT1083.2, Rv1284,
Rv1823-25, Rv2884, and Rv3301c (16, 37). In addition, this work
has identified 16 genes that have not previously been described to
be under the control of SigF (Table 1). Furthermore, the regula-
tion of the majority of these genes has also been confirmed by
Q-PCR, as well as the identification of the SigF-specific TSP. 5=-
RACE, followed by identification of a !10 sequence and !35
SigF-bindingmotif, resulted in the following consensus sequence:
GGTTT-N(15-17)-GGGTA located before all of the SigF-controlled
genes, a motif very similar to the one described previously (3, 16,
20, 30, 32, 37). Themajority of these genes controlled by SigF have
no validated function, making it difficult to understand how they
mediate a response to extracytoplasmic stress.
Since sigF has undergone pseudogenization in M. leprae and
lost its function, it was of interest to examine whether any of the
genes orthologous to those in the SigF regulon of M. tuberculosis
remained active. M. leprae has undergone reductive evolution,
and its genome has"1,300 pseudogenes (8, 35), withmany others
lost through deletions. Of the 25 genes that could be compared, 5
were still intact, 14 were present as pseudogenes, and 6 othersmay
have been deleted. Interestingly, the genes that appear to have
retained their function in M. leprae, such as hbhA, are those ex-
pressed from promoters recognized by SigF and another sigma
factor.
A notable finding was the location of the biggest ChIP-on-chip
FIG5 SigF-binding consensus sequence. (A) After 5=-RACE for the identification of the SigF-specific TSP (indicated by boxed base), a!10 and a!35 consensus
(both shown in red) was identified using Bioprospector. The distance between the TSP and the annotated translation initiation codon is shown in brackets after
the TSP. In addition, a proposed SigF binding site is given for the genes where 5=-RACE was not successful, including the TSP for F6 sRNA (*) described
previously by Arnvig et al. (2). A graphical representation of the!10 and!35 SigF consensus sequence was generated using Weblogo (B).
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peak between two converging genes, fadA2 and fadE5 (Rv0243 and
Rv0244c), and this corresponds to the location of the gene for
sRNA F6 (2), which is also known as mcr14 (11). Q-PCR con-
firmed that this sRNA was indeed upregulated after SigF induc-
tion. Interestingly, overexpression of F6 has been reported to slow
the growth of M. tuberculosis (2), thereby mirroring what we ob-
served here when SigF was induced.
Our study revealed some regions where SigF-binding sites are
not associated with RNA transcripts, and these were either inter-
genic or in the antisense orientation based on the current genome
annotation. These regionsmay contain small open reading frames
that have escaped previous detection or, more likely, code for
sRNA. To test the latter possibility, we inspected the list of known
sRNAs inM. tuberculosis (1, 2, 11), but nonewas identified. In two
of the nine cases (intergenic peaks between Rv1396c and Rv1397c
and betweenRv3210c andRv3211), a SigF-binding site is also pres-
ent in BCG (30), and in seven cases a !10 GGGTA motif was
detected near the ChIP peak. It should also be noted that some of
the identified SigF binding sites may be artifacts of sigF overex-
pression, following its induction, due to higher levels than those
observed physiologically. More work is required to determine
whether these regions do indeed code for conditionally expressed
sRNA.
The presence of SigF-dependent promoters within the pre-
dicted coding sequences of two protein-coding genes, Rv1358 and
Rv1870c, is intriguing. For the latter, this is most likely due to
misattribution of the initiation codon since the mRNA identified
in our work begins with a GTG codon that probably encodes the
formyl-methionine. This example illustrates the utility of tran-
scriptome studies for the refinement of genome annotation. Gene
Rv1358 is predicted to encode a transcriptional regulator of 1,159
amino acids belonging to the LuxR family that is well conserved
amongmycobacteria, includingM. leprae. Translation of the SigF-
dependent transcript of Rv1358 would give rise to a protein lack-
ing some 250 residues from its N-terminal domain. Whether two
forms of the Rv1358 protein exist is currently unknown. In con-
clusion, our study has helped in defining the SigF regulon and
characterizing its components.
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4.2.3 Virulence regulator EspR of M. tb is a nucleoid-associated 
protein 
Contribution: Preliminary processing of the ChIP-seq data, qualitative 
analysis of the ChIP-seq peaks, and visualization and mapping in the context 
of the M. tb H37Rv genome annotation. 
 
The ESX-1 system is the most studied type VII secretion system in M. tb. 
Located in the region of difference 1 (RD1), loss of ESX-1 genes is a major 
cause of attenuation of the vaccine strain M. bovis BCG (Mahairas et al. 
1996; Lewis et al. 2003), and thus the principal virulence determinant in M. 
tb. ESX-1 secretion is required for early bacterial replication and virulence in 
mice (Siméone et al. 2009). Considering the role of ESX-1 in M. tb 
pathogenesis, much effort has been devoted to studying the composition, 
regulation and function of the ESX-1 secretion system. In addition to the 
genes encoded in the ESX-1 locus, an unlinked gene cluster, espA-espC-espD 
is essential for ESX-1 dependent protein secretion (Fortune et al. 2005; 
MacGurn et al. 2005).  
 
EspR is a DNA-binding protein that positively regulates the espA-espC-espD 
cluster, by controlling expression of EspA protein (Raghavan et al. 2008). 
Recent structural studies performed in our laboratory suggest that EspR is a 
nucleoid-associated protein (NAP) (Blasco et al. 2011). NAPs are the 
bacterial equivalent of histones that organize the chromosome and act by 
stabilizing long-range structures in the genome through cooperative binding 
to multiple sites (Dillon & Dorman 2010). EspR employs an atypical DNA-
recognition mechanism involving a dimer of dimers that can multimerize and 
recognize distal DNA binding sites in a cooperative manner (Blasco et al. 
2011).  
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In order to confirm the role of EspR as a NAP and gain a better 
understanding into the extent of EspR-mediated regulation in M. tb we 
performed ChIP-seq (chromatin immunoprecipitation followed by high-
throughput sequencing) analysis of EspR. Analysis and integration of data 
from two independent ChIP-seq experiments revealed 165 loci harboring 582 
EspR binding peaks that were significantly enriched (> 1.5 fold) compared to 
the control experiments. Mapping the peak locations to the genome 
annotation revealed that EspR binding was not restricted to promoter 
regions, but distributed almost evenly between genes (55%) and intergenic 
regions (45%). Along with EspA, the EspR regulon included EspR itself, the 
ESX-2 and ESX-5 systems, a host of diverse cell wall functions, such as 
production of the complex lipid PDIM (phenolthiocerol dimycocerosate) and 
the PE/PPE cell-surface proteins. A subset of the EspR-binding sites was 
validated experimentally and a binding motif, TTTGC[TC][GA] was deduced 
for EspR.  
 
The ChIP-seq findings confirmed that EspR acts globally as a NAP and plays 
architectural and regulatory roles that impact M. tb pathogenesis through 
multiple genes.  
  
Virulence Regulator EspR of Mycobacterium tuberculosis
Is a Nucleoid-Associated Protein
Benjamin Blasco1, Jeffrey M. Chen1, Ruben Hartkoorn1, Claudia Sala1, Swapna Uplekar1,2,
Jacques Rougemont1,2, Florence Pojer1, Stewart T. Cole1*
1Global Health Institute, Ecole Polytechnique Fe´de´rale de Lausanne (EPFL), Lausanne, Switzerland, 2 Swiss Institute of Bioinformatics, Lausanne, Switzerland
Abstract
The principal virulence determinant of Mycobacterium tuberculosis (Mtb), the ESX-1 protein secretion system, is positively
controlled at the transcriptional level by EspR. Depletion of EspR reportedly affects a small number of genes, both positively
or negatively, including a key ESX-1 component, the espACD operon. EspR is also thought to be an ESX-1 substrate. Using
EspR-specific antibodies in ChIP-Seq experiments (chromatin immunoprecipitation followed by ultra-high throughput DNA
sequencing) we show that EspR binds to at least 165 loci on the Mtb genome. Included in the EspR regulon are genes
encoding not only EspA, but also EspR itself, the ESX-2 and ESX-5 systems, a host of diverse cell wall functions, such as
production of the complex lipid PDIM (phenolthiocerol dimycocerosate) and the PE/PPE cell-surface proteins. EspR binding
sites are not restricted to promoter regions and can be clustered. This suggests that rather than functioning as a classical
regulatory protein EspR acts globally as a nucleoid-associated protein capable of long-range interactions consistent with a
recently established structural model. EspR expression was shown to be growth phase-dependent, peaking in the stationary
phase. Overexpression in Mtb strain H37Rv revealed that EspR influences target gene expression both positively or
negatively leading to growth arrest. At no stage was EspR secreted into the culture filtrate. Thus, rather than serving as a
specific activator of a virulence locus, EspR is a novel nucleoid-associated protein, with both architectural and regulatory
roles, that impacts cell wall functions and pathogenesis through multiple genes.
Citation: Blasco B, Chen JM, Hartkoorn R, Sala C, Uplekar S, et al. (2012) Virulence Regulator EspR of Mycobacterium tuberculosis Is a Nucleoid-Associated
Protein. PLoS Pathog 8(3): e1002621. doi:10.1371/journal.ppat.1002621
Editor: Eric J. Rubin, Harvard School of Public Health, United States of America
Received November 8, 2011; Accepted February 21, 2012; Published March 29, 2012
Copyright: ! 2012 Blasco et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The research leading to these results has received funding from the European Community’s Seventh Framework Programme ([FP7/2007-2013]) under
grant agreement nu201762, SystemsX.ch and the Swiss National Science Foundation under grant nu31003A-125061. F.P. is a Swiss National Science Foundation
MHV Post-doctoral Fellow. J.M.C. is a recipient of Canadian Thoracic Society and Canadian Institutes of Health Research Post-doctoral Fellowships. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: stewart.cole@epfl.ch
Introduction
Details of the genetic control mechanisms governing the
pathogenicity of the etiological agent of human tuberculosis are
starting to emerge [1]. It has been postulated that the DNA-
binding protein EspR [2] controls the virulence of Mycobacterium
tuberculosis (Mtb) by specifically regulating expression of EspA, an
exported protein [3,4], which is required for the ESX-1 system to
function normally. There are five genetically related ESX-systems
in Mtb but functional information is scarce for all of them,
although ESX-1 is by far the most studied [5,6]. ESX-1 is widely
considered to be the principal virulence determinant of Mtb since it
secretes the EsxAB (ESAT-6 and CFP10) proteins and ESX-1
secretion-associated proteins (Esps) [7]. Although mechanistic
details are limited, some of these secreted proteins act as effector
proteins that perturb host cell activities, permeabilize the
phagosomal membrane and allow the tubercle bacillus to escape
into the cytoplasm [6,8,9].
Structural studies revealed that EspR is a homodimer with two
domains: an N-terminal DNA-binding domain with a helix-turn-
helix (hth) motif and C-terminal domain that mediates dimeriza-
tion [10,11]. Removal of 10 amino-acid residues from the C-
terminus, as in the EspRD10 protein, does not affect DNA-binding
activity but prevents dimerization and ablates activation of the
espACD locus [2,10]. A model has been proposed, based on the
results of co-crystallization with DNA and molecular dynamic
simulations, wherein EspR employs an atypical DNA-recognition
mechanism involving a dimer of dimers. Since, for sterical reasons,
only one hth from each dimer is capable of inserting into the major
groove of DNA at a given binding site, the second hth of each
dimer remains free to act at other binding sites [10]. Consequent-
ly, dimers can dimerize then multimerize and recognize distal
DNA binding sites in a cooperative manner as has been observed
by atomic force microscopy (AFM) of EspR-nucleoprotein
complexes at the espA locus, where DNA bending and bridging
resulted in loop formation [10]. This behavior is characteristic of
nucleoid-associated proteins (NAPs) rather than that of a classical
gene activator protein [12,13]. NAPs are the bacterial equivalent
of histones that organize the chromosome and act by stabilizing
long-range structures in the genome through cooperative binding
to multiple sites. This results in modulation of the accessibility of
free DNA to the transcription machinery via the state of DNA
compaction. NAPs thus function in a quite different manner to
transcriptional activators, which typically recognize a limited
number of sites in the genome and promote transcription through
direct interaction with RNA polymerase.
To test the hypothesis that EspR might be a NAP and to gain
more insight into the extent of EspR-mediated regulation in living
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mycobacteria, ChIP-Seq analysis of the Mtb H37Rv genome was
performed. Unlike cDNA hybridization to micro-arrays, ChIP-Seq
generates quantitative information with single nucleotide resolu-
tion. The complete repertoire of EspR-binding sites across the
chromosome was established with the majority of the gene targets
appearing to impact cell wall function generally rather than ESX-1
expression in particular. The ChIP-Seq findings were confirmed
independently by ChIP followed by quantitative real-time PCR
(ChIP-qPCR), by gel shift and DNase I footprinting assays, as well
as by transcript analysis, and a binding motif was deduced using
bioinformatics. Finally, the expression levels of EspR and its
subcellular localization were monitored and quantified during the
growth cycle. Altogether, these data provide a genome-wide view
of EspR regulatory functions and place EspR firmly in the NAP
family.
Results
Genome-wide analysis of the EspR regulon
We investigated EspR-binding to the chromosome of Mtb strain
H37Rv during exponential growth by ChIP-Seq, chromatin
immunoprecipitation followed by ultra-high throughput DNA
sequencing [14]. Sequence reads obtained from two independent
ChIP-Seq experiments using EspR-specific antibodies were
mapped to the Mtb H37Rv genome. Based on the peak detection
criteria, we identified 165 enriched loci harboring 582 EspR-
binding peaks (Fig. 1, Table S2), that were enriched by .1.5-fold
and these were not present in ChIP-Seq datasets from control
experiments conducted without antibody or with unrelated
antibodies (data not shown). These 165 loci occurred across the
genome (Fig. 1 and Fig. 2A) and were sited both in intergenic
regions (45%) and within genes (55%) implying that EspR is not a
classical transcriptional regulator.
Diverse functions are encoded by genes where EspR bound
upstream and classification by functional category reveals over-
representation of cell wall/cell processes and the surface-exposed
PE/PPE proteins (http://tuberculist.epfl.ch/; Fig. 2B). Internal
sites were found within AT-rich genes encoding proteins belonging
to the PPE family (Fig. 1), like ppe24 (rv1753c), and some of these,
such as ppe58 (rv3426), also bind EspR at their 59-ends. Binding
sites were present within genes that are thought to have been
acquired by horizontal transfer [15] like the rv0986-rv0989c region.
A survey of the ten top scoring peaks (Table 1) highlighted the
major EspR-binding gene targets. Two of the top three sites (Fig. 1)
occurred at a locus encoding an enzyme system that produces the
complex lipids phthiocerol dimycocerosate (PDIM) and phenolic
glycolipid (PGL) [16,17]. The second highest scoring site overlaps
the translational start of rv1490, which encodes a membrane
protein of unknown function, and this was followed by three other
peaks of lower intensity, separated by,300–400 bp, spread across
rv1490 (Fig. 1). The fourth and eighth highest scoring sites affect
two genes, pe-pgrs19 and pe-pgrs20 [18], encoding mycobacteria-
restricted PE_PGRS proteins, while the espACD locus, which is
preceded by three EspR-binding sites (Fig. 1), occurred in the fifth
position of the top ten ChIP-Seq hits (Table 1). The ninth peak is
sited in the intergenic region between lipF (rv3487c), encoding a
lipid esterase, and rv3488, whereas the last peak of the top ten
ChIP-Seq list was found at the 39-end of fadB2 (rv0468) encoding a
beta-hydroxybutyryl-CoA dehydrogenase and upstream of umaA
(rv0469) coding for a mycolic acid synthase. EspR binds to multiple
sites in the ESX-1, ESX-2 and ESX-5 loci (Fig. S2), as well as to
two sites upstream of its own gene (Fig. 3), thus implying
autogenous control. Taken together, these data suggest that EspR
may be involved in regulating cell wall function.
Consensus sequence
An EspR consensus sequence was identified in the ChIP-Seq
peaks using the MEME suite [19] and the binding motif deduced
(Fig. 2C). FIMO (Find Individual Motif Occurrences) detected 736
occurrences of this motif (p-value#0.001) distributed among 80%
of the EspR peak sequences analyzed. Of these motifs, 59% were
localized within open reading frames (ORF). The entire Mtb
genome sequence was searched for potential EspR-binding sites
using the TTTGC[TC][GA] consensus sequence and 199
putative intergenic and 827 intragenic sites were identified, of
which 163 (43 intergenic and 120 intragenic) correspond to known
ChIP-Seq peak sites. Further experimental support for the
consensus sequence is available from footprinting studies of the
espA [10] and espR promoter regions (see below), which revealed
EspR protection from DNase I digestion at sites comprising at least
one TTTGC-like motif.
Confirmation of in vivo EspR binding
To obtain independent confirmation for selected parts of the in
vivo dataset, we initially focused on the EspR-dependent espACD
operon [2]. Our previous in vitro work revealed two EspR binding
sites separated by 19 bp and located between 506 and 444 bp
upstream of espACD [10], consistent with the presence of a ChIP-
Seq peak in this region (Fig. 1). On closer inspection, two
additional major peaks of EspR-enrichment were found further
upstream of espA (centered between 2857 bp and 2695 bp and
between 21214 bp and 21113 bp, respectively). While this work
was in progress, another report of the presence of two additional
sites upstream of espACD appeared [11]. The existence of these
sites also corroborates results we obtained previously using AFM to
visualize nucleoprotein complexes of EspR and a 1360 bp espACD
promoter fragment [10]. AFM revealed loop structures stabilized
by multiple EspR dimer of dimers suggesting the presence of
several distant EspR binding sites in the espACD upstream region.
The 59-end of the espA mRNA was located 66 bp upstream of the
translation start codon using 59 RACE (Fig. S3). Consequently, the
Author Summary
A major infection mechanism employed by the causative
agent of tuberculosis, Mycobacterium tuberculosis (Mtb), is
the ESX-1 secretion system. It has been postulated that the
DNA-binding protein EspR controls the virulence of Mtb by
specifically regulating expression of the exported EspA
protein, which is required for ESX-1 to function. Previous
structural studies indicated that EspR forms dimers
capable of multimerizing on DNA and forming loop
structures, thus bringing together otherwise distant
chromosomal regions. Such characteristics are reminiscent
of nucleoid-associated proteins (NAPs), the histone equiv-
alent in bacteria. Here we use ChIP-Seq technology to map
EspR binding sites on the Mtb chromosome in living
bacterial cells. Genome-wide analysis of EspR identified
hundreds of binding-sites, with almost equal inter- and
intra-genic distribution, and mostly found in proximity to
genes associated with cell wall function. We validated a
subset of EspR-binding sites experimentally and identified
a consensus motif required for optimal binding affinity.
Moreover, our study reveals that EspR expression varies
with bacterial growth and that intracellular levels are not
linked to EspR secretion. These findings corroborate the
NAP nature of EspR and its dual roles, architectural and
regulatory, that impact the Mtb chromosome and patho-
genesis globally rather than the ESX-1 loci specifically.
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Figure 1. Genome-wide mapping of EspR binding sites. UCSC Genome Browser (http://genome.ucsc.edu) view of EspR binding across the Mtb
genome as determined by ChIP-Seq. Peak height (y-axis) indicates the sequencing read depth at each genomic position (x-axis). Inset boxes show
major EspR binding sites identified over (from left to right) the pe_pgrs19 and pe_pgrs20 genes, the rv1490 gene, the ppe24 gene, the rv2929 and
fadD26 genes from the PDIM/PGL locus and the espACD operon promoter region.
doi:10.1371/journal.ppat.1002621.g001
Figure 2. Binding of EspR to the Mtb chromosome. (A) Pie chart of EspR-binding peaks annotated relatively to the nearest gene translation
start using the ChIPpeakAnno package [38]. (B) Bar chart displaying the percentage of genes of the EspR regulon compared to the Mtb H37Rv
genome belonging to functional categories defined in the TubercuList database (http://tuberculist.epfl.ch/). (C) Most significant motif derived from
ChIP-Seq binding sequences returned by the MEME tool [19]. The height of each letter represents the relative frequency of each base at different
positions in the consensus.
doi:10.1371/journal.ppat.1002621.g002
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nearest EspR binding site is positioned over 300 bp upstream of
the promoter.
To further validate EspR-binding peaks, with varying degrees of
enrichment, we performed ChIP followed by quantitative PCR on
11 selected sites (four located within intergenic regions, three
within ORFs and three overlapping a translational start) and two
non-peak regions (within rv0888 and sigA ORF) as controls. All of
the selected EspR-binding regions exhibited enrichment compa-
rable to that observed from ChIP-Seq analysis (Fig. S4), thus
confirming that all peaks were genuine EspR-targets.
To obtain further confirmation of the in vivo EspR binding sites,
we performed electrophoretic mobility shift assays (EMSAs) using
,100 bp DNA sequences covering the top five binding sites (Fig.
S5 and Table 1) and a DNA fragment of the same size from within
the espA ORF as a negative control. EspR was shown to bind to all
five sites in a concentration dependent manner, while the negative
control fragment remained unbound at an equal protein
concentration. However, clear differences in affinity between the
fragments were visible. For example, the top-scoring fadD26 peak
bound EspR less strongly compared to the four others suggesting
that other determinants, like long-range protein-protein or
protein-DNA interactions, could contribute to the high-affinity
binding observed in vivo.
Autogenous regulation at the espR promoter
The presence of twin peaks upstream of espR (a, b in Fig. 3A) is
suggestive of autoregulation. To test this possibility, we performed
EMSA, DNase I footprinting and 59 RACE analysis of the espR
promoter region. Peaks a and b were both shown to bind EspR
using EMSA (Fig. 3B). Two regions within peak a were protected
from DNase I by EspR; region I, covering 17 bp, and region II,
55 bp-long, are situated 101 and 76 bp upstream of the espR
translational start codon, respectively (Fig. 3C and 3D). This
binding pattern is reminiscent of that described previously at the
espA promoter [10]. When incubated with the dimerization
deficient EspRD10 protein, only part of region II and none of
region I was protected (IIaD10, 14 bp and IIbD10, 12 bp, see Fig.
S6). This implies that oligomerization enables cooperative binding
between multiple EspR dimers, leading to the formation of higher-
order oligomers. The zone protected by EspRD10 contains an
inverted repeat of two consensus motifs: CAGCAAA,16.
TTTGCTC.
59 RACE analysis was employed to localize the espR promoter
using RNA extracted from Mtb H37Rv grown to mid-log phase.
The espR transcript starts with a poly-G (7) sequence 144 bp
upstream of the translational start codon. The promoter is
therefore situated in a region between peaks a and b so
simultaneous occupation by EspR of both the a and b sites might
form a repression loop. Expression data presented below indicate a
negative effect of EspR on its own transcription.
Target gene regulation on EspR binding
To confirm the prediction that binding of EspR directly affects
target gene expression, we exploited a pristinamycin-inducible
system [20,21] to overexpress espR conditionally in Mtb (strain
H37Rv::pMYespR; Fig. 4). Compared to the controls, it is
noteworthy that espR over-expression significantly decreased
growth after 24 h (Fig. 4A) while espR transcript and EspR protein
levels were found to be ,8-fold and ,3-fold higher than in the
control after 72 h, respectively (Figs. 4C and 4B). When the
relative amounts of target transcripts in untreated and pristina-
mycin IA-treated H37Rv::pMYespR cells were measured by
quantitative RT-PCR, significantly increased transcript levels were
detected for rv1490, espA, and the ABC-transporter rv0986
(Fig. 4D). Conversely, repression of lipF transcription was also
observed upon EspR overexpression, whereas transcription of
some target genes appeared unchanged (Fig. 4D). Using a
discriminatory RT-PCR assay it was possible to measure the
impact of EspR overproduction on expression of the chromosomal
copy of espR and, again, this appeared to act negatively (Fig. 4C).
The combined findings suggest that EspR is capable of both
positive and negative transcriptional regulation. Moreover, the
inability to observe direct EspR-dependent regulation at some
major EspR binding sites suggests that EspR has no or little effect
on these genes in the conditions tested or that other regulators
counter-balance the effect of increased EspR levels.
Growth phase dependent expression of EspR
It has been proposed that intracellular levels of EspR are
regulated via its secretion by the ESX-1 system and that blocking
EspR secretion results in enhanced EspR-mediated transcriptional
effects [2]. This suggested that the intracellular requirements for
EspR could change during the growth phase of Mtb since the
secretion of other ESX-1 substrates, such as EsxA (ESAT-6), is
known to occur early in the growth cycle. To determine whether
levels were constant or variable during growth and to estimate the
number of EspR molecules per cell, kinetic experiments were
performed. We monitored EspR protein levels by quantitative
Western blotting at different time points corresponding to the
Table 1. Top 10 EspR binding loci from ChIP-Seq.
Gene Position Gene description Functional category
rv2930 inside FadD26, fatty-acid-CoA synthetase, PDIM production lipid metabolism
rv1490 overlaps start Rv1490, probable membrane protein cell wall and cell processes
rv2929 overlaps start Rv2929, PDIM production conserved hypotheticals
rv1067c overlaps start PE_PGRS family protein, PE_PGRS19 PE/PPE
rv3616c upstream EspA, ESX-1 secretion-associated protein A cell wall and cell processes
rv1753c inside PPE family protein, PPE24 PE/PPE
rv0986 inside ATP-binding protein of ABC transporter cell wall and cell processes
rv1068c upstream PE-PGRS family protein, PE_PGRS20 PE/PPE
rv3487c upstream LipF, probable esterase/lipase lipid metabolism
rv0469 upstream UmaA, Mycolic methyltransferase A 1 lipid metabolism
doi:10.1371/journal.ppat.1002621.t001
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early-log (day 2), mid-log (day 3) and stationary (days 4 and 5)
phases of growth. Analysis of equivalent cell numbers showed that
the intracellular concentration of EspR increases throughout the
bacterial growth cycle, ranging from ,20,000 molecules at early
log-phase (day 2) to ,100,000 molecules per cell at stationary
phase (day 5) (Fig. 5A). Peak cell concentration of EspR in
stationary phase is consistent with the growth arrest observed upon
its premature induction (Fig. 4A). To determine if this peak was
due to protein accumulation or to increased expression of the espR
gene, we performed quantitative RT-PCR on RNA samples
isolated from cells at different time points (Fig. 5B). Interestingly,
throughout the growth cycle, the levels of espR mRNA varied in a
manner inversely proportional to the amounts of EspR protein,
suggesting that EspR stably accumulates in the bacteria while
Figure 3. EspR autoregulation. (A) Pattern of EspR ChIP-Seq peaks (denominated peaks a and b) identified upstream of the espR start codon. (B)
EMSA showing concentration-dependent EspR binding of DNA fragments covering the center sequences of peaks a and b shown in (A). (C) DNase I
footprint from binding of EspR to peak a of espR. Red and black peaks represent DNA without or with 10 mM EspR, respectively. Both reactions were
partially digested with DNase I and analysed by capillary electrophoresis in a genetic analyser (Applied Biosystems 3130xl). The corresponding
nucleotide sequence is shown below. Regions I and II protected from DNase I digestion by EspR are denoted by black brackets and positions relative
to the translational start are indicated. (D) Analysis of the espR promoter. The 59 end of the transcript was determined by 59 RACE using RNA
extracted from Mtb H37Rv at mid-log phase. Translational stop of rv3848 and translational start of espR are highlighted in red with +1 corresponding
to the first base of the espR open reading frame. Transcriptional start mapped by 59 RACE is boxed and indicated by a bent arrow. 210 and 235
positions for putative sigma factor binding sites are indicated. ChIP-Seq peak sequences are highlighted in gray, EspR consensus motifs framed and
sites protected from DNase I cleavage bracketed as in (C).
doi:10.1371/journal.ppat.1002621.g003
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autorepression may limit its own gene expression at late time
points.
EspR is not secreted
To determine if the low intracellular levels of EspR observed at
the early and mid-log phases of growth were due to intensive EspR
secretion, we measured intra- and extra-cellular levels of EspR
from strains Mtb H37Rv and Mtb H37RvDRD1 cultured in
Sauton’s medium to mid-log phase. Under these conditions, we
were unable to detect EspR among the culture filtrate (CF)
proteins in either case, whereas EsxA was present in the CF of Mtb
H37Rv, as expected, but not in CF from the ESX-1 mutant
H37RvDRD1 that lacks esxA among other genes (Fig. 6A).
To investigate whether EspR was exported from the cytosol but
retained in the cell envelope, whole cell lysate (CL) was
fractionated by ultracentrifugation into the cell wall/cell mem-
brane (W/M) and cytosolic (CYT) components. Since the
chromosome is known to be attached to the plasma membrane
[22], half of the samples were treated with DNase I. EspR was
detected in both of the untreated fractions but was mainly in the
cytosol after DNase I treatment (Fig. 6B). Since previous studies
were performed with the Erdman strain of Mtb, this provided a
possible explanation for the localization discrepancy. Consequent-
ly, we repeated the experiment with the Mtb Erdman strain and
the ESX-1 mutant Mtb Erdman 36–72 that fails to secrete EsxA
[23]. Again, EspR was below the level of detection in the CF of
either strain, whereas EsxA appeared in the CF of Mtb Erdman
(Fig. S7). We then examined CF at different time points of Erdman
cultures for the presence of EspR and the cytosolic marker
GroEL2. EspR first appeared in the culture filtrate after 8 days of
growth when it was accompanied by GroEL2, indicating that cell
lysis had likely occurred (Fig. 6C).
Discussion
The EspR protein has attracted considerable interest because of
its role in the regulation of virulence in Mtb and the remarkable,
Figure 4. Gene expression associated with EspR binding. (A) Growth of H37Rv::pMYespR without (2P) or with (+P) pristinamycin IA. Growth
was monitored at the designated time points measuring OD600. (B) Immunoblot analysis of EspR expression in the absence (2P) or presence (+P) of
pristinamycin IA after 3 days growth using rat polyclonal antibodies specific for EspR. Equivalent amounts of total protein lysates were loaded. (C, D)
Quantitative RT-PCR analysis of relative mRNA levels extracted from H37Rv::pMYespR cells treated with 0 mg/ml or 2 mg/ml of pristinamycin using
primers specific for the following regions: (C) the espR coding region (annealing to both endogenous and vector copies of espR) or to the 59-UTR
region of espR (PespR) (specific to endogenous espR). (D) The coding regions of genes related to the top 10 EspR binding peaks as obtained in ChIP-
Seq experiments (see Table 1). Relative gene expression was normalized against sigA and displayed as fold-induction (log-2 scale) relative to the
untreated sample (0 mg/ml pristinamycin). Shown are the mean 6 s.d. of a minimum of duplicate measurements from the average of three
independent experiments. Statistical significance was evaluated using Students T-test. * indicates P,0.05, ** P,0.01 and *** P,0.001.
doi:10.1371/journal.ppat.1002621.g004
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and most unusual, property of being secreted by the very secretion
system ESX-1 whose expression it controls [2]. This has led to the
suggestion that a negative feedback loop modulates EspR secretion
and is critical to successful infection. Studies of the three-
dimensional structure of EspR and its truncated variant,
EspRD10, together with models of DNA recognition and AFM
analysis of single molecule EspR nucleoprotein complexes,
indicate that EspR employs an atypical DNA recognition
mechanism [10,11]. A dimer of dimers is thought to bind to
DNA via one monomer of each dimer leaving the second
monomer free to contact another site. Cooperative interactions
then lead to multimerization and the formation of looped
structures in which EspR acts as a bridge between two separated,
or even remote, sites on DNA [10,11]. Such structures are
typically formed by nucleoid-associated proteins (NAPs), like H-
NS and Fis [12,24,25]. Collectively, these features led us to
consider the possibility that EspR functions as a NAP rather than
as a specific transcriptional activator of a limited number of genes
required for pathogenesis.
To test this possibility, ChIP-Seq analysis was performed to
assess the genome-wide distribution of EspR and to identify the
sites and genes to which it binds. This resulted in the identification
of at least 165 loci, often containing multiple peaks of EspR-
binding, throughout the genome. Binding sites were distributed
more or less evenly between intragenic and intergenic regions. The
majority of the genes (,50%) were involved in cell envelope
functions. Among them were genes that contribute to ESX-1,
ESX-2 and ESX-5-related activities, and others that contribute to
mycobacterial virulence, such as lipF and the PDIM locus.
Surprisingly, the latter harbored the major peak of EspR binding
in the genome whereas the previously reported site preceding the
espACD operon was less prominent (Fig. 1 and Table 1).
Confirmation of EspR binding to a selection of major sites was
obtained in vitro, from a combination of studies performed with
highly purified EspR (Fig. 3), and in vivo, following overexpression
of the protein (Fig. 4). This resulted in the definition of a consensus
sequence, TTTGC[TC][GA], that agrees well with the motif
predicted previously by molecular dynamic simulations, involving
computation of the binding energy of the optimal interaction of
EspR with the intergenic region upstream of espA [10]. These
predictions were consistent with the findings of DNase footprinting
or EMSA studies of the same locus. Using an in silico approach to
scan the genome sequence .1,000 potential EspR sites were
found, of which 163 had been detected experimentally by ChIP-
Seq. While some of the in silico predictions may be fortuitous, this
does raise the possibility that occupancy of EspR-binding sites may
vary with growth phase or physiological conditions and that more
sites will be uncovered. Furthermore, the EspR-binding motif
deduced here should be considered as a core sequence for high
affinity nucleation sites from where cooperative binding between
EspR dimers can initiate and extend to form long oligomers and
hence reach more distant sites [10]. The number of such sites and
the distance between them most probably enables EspR to
structure the chromosome.
The number of EspR molecules per cell was estimated by
quantitative Western blotting at different stages of the growth
cycle. There was a steady increase in concentration until
,100,000 molecules/cell were found at day 5. These levels are
about 30-fold higher than those of well-characterized transcrip-
tional activators, like Fnr in E. coli, but are comparable to levels of
major NAPs, such as Fis or HU, during the exponential growth
phase of E. coli [13,26]. The intracellular EspR concentration is
clearly in excess of that required to occupy all the experimentally
detected (582) or computer predicted (1026) binding sites.
Figure 5. Growth phase-dependent variation of EspR intracel-
lular levels. Time course analysis of Mtb H37Rv at the following phases
of growth: early log (day 2), mid-log (day 3) and stationary (days 4 and
5). (A) Immunoblot analysis of cell lysates (CL) from equivalent amount
of cells (approx. 2*10‘7). For quantification purposes, the indicated
amounts of purified EspR were electroblotted onto the same
membrane as cell lysates. GroEL2 is used as a loading control and
corresponding Western blot signals are used to normalize small loading
discrepancies. The number of EspR molecules per cell was estimated
from Western blot analysis correlated to OD600 measurements,
assuming that OD600 0.2 = 10
8 cells [40]. The results are plotted in the
bottom chart, with solid circles representing optical density at 600 nm
(OD600) while open squares represent the total number of EspR
molecules per cell from one representative of four experiments. (B)
Relative espR transcript amounts measured in total RNA harvested at
the different time points by quantitative RT-PCR and normalized to sigA
expression. The means and standard deviations of triplicate measure-
ments are shown from two experiments.
doi:10.1371/journal.ppat.1002621.g005
EspR Nucleoid-Associated Protein and TB Virulence
PLoS Pathogens | www.plospathogens.org 7 March 2012 | Volume 8 | Issue 3 | e1002621
The results of subcellular fractionation of Mtb H37Rv cells from
mid-log phase indicate that EspR is predominantly a cytosolic
protein although it can be found attached to cell membrane-bound
DNA, a trait of the nucleoid. Prior treatment of this fraction with
DNase I releases most of the EspR to the cytosol (Fig. 6B). In
contrast to the findings of a previous report [2], we were unable to
detect the secreted form of EspR in the culture filtrates of ESX-1
proficient and deficient strains of H37Rv nor in the Erdman
strains at early time points. Since EspR is a relatively abundant
protein and only found in the culture filtrate together with the
cytosolic marker GroEL2, we conclude that it is released via cell
lysis rather than secretion mediated by ESX-1.
EspR seemingly acts as an activator or a repressor depending on
its binding position relative to the genes it controls. EspR
production appears to be autoregulated as the protein binds to
its own promoter region and downregulates expression in certain
conditions (Fig. 4C). Interaction at the espR regulatory site occurs
in a contrasting manner to that seen at the espACD locus where
there are three prominent binding sites situated far upstream of the
promoter (Fig. 1). Interestingly, some tubercle bacilli, including M.
bovis and M. microti, have incurred the RD8 deletion in this region
of the genome [27] that completely removes the three major
EspR-binding sites. Two EspR-binding sites flank the espR
promoter thus evoking an autoregulatory mechanism whereby
EspR forms a loop at the promoter that either occludes RNA
polymerase (RNAP) or traps RNAP that has already bound. In
ChIP-Seq experiments performed with RNAP-antibodies, a major
polymerase binding site was localized (data not shown) that
partially overlaps EspR peak a (Fig. 3), consistent with the
promoter prediction from 59 RACE.
Loss of EspR strongly attenuates Mtb [2], suggesting that this is
due to reduced functioning of the ESX-1 system as a result of
insufficient EspA levels. However, in light of the present findings,
this appears to be an oversimplification as expression of the genes
for several other known virulence determinants are clearly subject
to EspR regulation. Foremost among these is a major locus that
encodes an enzyme system required for synthesis of PDIM, and in
some strains PGL, both of which contribute extensively to
virulence [16,17]. Another enzyme that has an important role in
pathogenesis is the lipase, LipF [16], which has been implicated in
modification of the mycobacterial cell wall as an adaptive response
to acid damage [28]. LipF is also thought to degrade host lipids
during infection [16]. The EspR binding site (Table 1) located far
upstream of the lipF coding sequence overlaps the previously
identified 59 bp acid-inducible promoter region, situated 515 bp
from the start codon [28]. Occlusion of this site by EspR would
therefore explain the observed repression of lipF transcription
(Fig. 4D). The lipF gene, together with a number of other EspR
gene targets like fadD26 and espA, is also regulated by PhoP [29,30]
and CRP [31], frequently with opposite effects on transcription.
Regulation of transcription orchestrated by EspR seems to
occur at two levels. EspR binding at promoter regions, as in the
case of espR or lipF, resembles global transcriptional regulators
Figure 6. EspR is not a secreted protein. (A) Immunoblot analysis
of 10 mg of culture filtrate (CF) and 5 mg of cell lysates (CL) of wild-type
H37Rv (left) and H37RvDRD1 (right) strains grown for 4 days after
transfer into Sauton’s medium without Tween-80. GroEL2 was used as a
control for autolysis, SodA as a loading control for CF and CL samples
and EsxA as a control for ESX-1-dependent secretion. (B) Immunoblot
analysis of H37Rv CL shown in (A) fractionated into cell wall/cell
membrane (W/M) and cytosolic (CYT) components by ultracentrifuga-
tion. GroEL2 was used as a loading control. (C) Immunoblot analysis of
Erdman CF (20 mg) for each of the time points indicated.
doi:10.1371/journal.ppat.1002621.g006
EspR Nucleoid-Associated Protein and TB Virulence
PLoS Pathogens | www.plospathogens.org 8 March 2012 | Volume 8 | Issue 3 | e1002621
where repression of transcription stems from occlusion of RNAP
whereas activation of transcription occurs via favorable interaction
with RNAP and/or other proteins. On the other hand, our
genome-wide analysis revealed that more than half of the EspR-
binding sites are intragenic and this refutes, at least partially, the
hypothesis that EspR acts as a transcription factor per se. Moreover,
EspR overexpression had little effect on some major EspR-bound
genes (Fig. 4D), suggesting that EspR-binding does not necessarily
affect transcription locally but rather serves as anchoring points to
organize chromosome domains. NAPs with DNA-bridging
activity, such as EspR, are often located at the boundaries of
chromosomal domain loops [13] where they control gene
expression in a temporal or spatial manner. In many bacteria,
NAP expression levels are dependent on the growth phase [24].
This is true of Mtb since low EspR levels were detected at early-
and mid-log phase compared to stationary phase, and premature
conditional overexpression causes growth to slow down. The
interplay between different NAPs alters chromosome structure and
organization thereby influencing patterns of gene expression in a
temporal manner.
Lsr2 is a DNA-bridging protein that also performs NAP
functions in Mtb by recognizing AT-rich and xenogeneic regions.
Binding sites of Lsr2 in Mtb have been mapped by Gordon et al.
using ChIP-on-chip technology [32]. Comparison of the Lsr2
ChIP-on-chip and EspR ChIP-Seq results showed that 77% of the
genes in the EspR regulon are also likely recognized by Lsr2 [32]
owing to an extensive overlap between their repertoires (Fig. S2).
For example, all three genes significantly upregulated upon EspR
overexpression (Fig. 4D) also bind Lsr2 and major ChIP-Seq peaks
of EspR are located close to Lsr2 binding sites in the ChIP-on-chip
enriched regions (Fig. S2).
While Lsr2 and EspR are both subject to autoregulation there is
no evidence for cross-regulation and Lsr2 seems to impact many
more regions. Lsr2 has an N-terminal dimerization domain and a
C-terminal DNA-binding domain whereas in EspR the opposite
configuration exists. A further difference lies in the DNA
recognition mechanisms since Lsr2 interacts with the minor
groove while EspR binding is predicted to occur via the major
groove. Together, this suggests that EspR and Lsr2 may control
gene expression, including that of many cell wall functions, in a
divergent manner with EspR possibly replacing Lsr2 at certain
sites and vice-versa. It is striking that in all sequenced
mycobacterial genomes espR is very close to the hns gene encoding
another NAP [33] and this may also indicate functional interplay.
These hypotheses can be tested experimentally by using the
corresponding antibodies to perform ChIP-Seq experiments on
Mtb strains at different stages in the growth cycle to localize their
binding sites. The contribution of other global regulators that
intersect with the EspR regulon, like PhoP and CRP, should also
be examined. A regulatory scheme is emerging in which growth of
Mtb, and hence pathogenesis, is controlled by chromosome
remodeling, effected by different NAPs, thereby resulting in
pleiotropic regulation of gene expression. EspR may thus play a
central role in regulating virulence gene expression analagous to
that of H-NS in enteropathogenic bacteria [12,13].
Materials and Methods
Bacterial strains and culture conditions
Mycobacterium tuberculosis (Mtb) H37Rv and Erdman were grown
in 7H9 Broth (Difco) supplemented with 0.2% glycerol, Mid-
dlebrook albumin-dextrose-catalase (ADC) enrichment and 0.05%
Tween 80 or on solid Middlebrook 7H11 medium (Difco)
supplemented with oleic acid-albumin-dextrose-catalase (OADC).
Mtb cells prepared for secretion analysis and cell fractionation were
grown in Sauton liquid medium. Escherichia coli BL21(DE3) was
used for expression of His9-tagged EspR as described [10].
ChIP-Seq
Chromatin immunoprecipitation was performed essentially as
previously described [34] but with some variations. Briefly, Mtb
H37Rv cultures (50 ml) grown to OD600 0.4–0.6 were treated with
formaldehyde (final concentration 1%) for 10 min at 37uC. Cross-
linking was quenched by addition of glycine to a final
concentration of 125 mM. Harvested cells were washed twice
with Tris-buffered saline (20 mM Tris-HCl pH 7.5, 150 mM
NaCl), re-suspended in 600 ml Immunoprecipitation (IP) buffer
(50 mM Hepes-KOH pH 7.5, 150 mM NaCl, 1 mM EDTA, 1%
Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, mini-
protease inhibitor cocktail (Roche)) and sonicated to shear DNA to
an average size of 100–500 bp. Insoluble cellular debris was
removed by centrifugation and the supernatant used as input
sample in IP experiments. 300 ml of input was incubated with
either no antibody (mock-IP) or 20 ml of serum containing rat anti-
EspR polyclonal antibodies (kindly generated by Ida Rosenkrands)
and then with 50 ml of Dynabeads sheep anti-rat IgG (Dynal
Biotech) pre-saturated with 0.1 mg/ml salmon sperm DNA and
1 mg/ml Bovine Serum Albumin (BSA) in IP buffer. Washing and
crosslink reversal of protein-DNA complexes, as well as purifica-
tion of the resulting DNA was carried out as previously described
[34]. Prior to sequencing, DNA fragment sizes were checked and
enrichment was verified by gene-specific quantitative PCR (ChIP-
qPCR).
EspR ChIP-Seq library construction and sequencing
DNA fragments (150 to 250 bp) were selected for library
construction and sequencing libraries prepared using the ChIP-
Seq Sample Preparation Kit (Illumina; San Diego, California,
USA; Cat. No. IP-102-1001) according to the protocol supplied
with the reagents. Prior and post library construction, chromatin
immunoprecipitation products were quantified using the Qubit
fluorometer (Invitrogen; Carlsbad, California, USA). One lane of
each library was sequenced on the Illumina Genome Analyzer IIx
using the Single-Read Cluster Generation Kit v4 and 36 Cycle
Sequencing Kit v4. Data were processed using the Illumina
Pipeline Software v1.60.
ChIP-Seq data analysis
ChIP-Seq experiments, with two independent mid-log phase
cultures, generated 25.6 and 22 million reads, of which 95% could
be successfully mapped to the Mtb H37Rv genome (NCBI
accession NC_000962.2) using Bowtie [35] allowing up to 3
mismatches and up to 10 hits per read. As a control, input DNA
was also sequenced and mapped to the Mtb H37Rv genome to
identify sequencing artifacts and calculate enrichment values.
Since comparison of the two ChIP-Seq datasets showed excellent
correlation in binding signals (Fig. S1), sequenced DNA reads from
both experiments were pooled together. In order to estimate the
binding location in the enriched regions, we used a deconvolution
algorithm that models the expected tag distribution on both
strands [36]. Based on the deconvoluted profile, a score was
calculated for each peak that was proportional to the read density
in the peak. Considering the high genome coverage, only peaks
with more than 600 reads per position were selected. Reads
mapped to the forward and reverse strands were shifted (by 80 bp)
and merged together to generate single peak profiles, which were
visualized on the UCSC Genome Browser database [37].
Annotation of the peaks was performed using the ChipPeakAnno
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package from Bioconductor [38]. The read count at each binding
region (400 bp width) was determined as the total number of reads
mapping to the region divided by the length of the region
normalized to the total number of mapped reads across the whole
genome. The enrichment at each locus was obtained as the ratio of
the average read count from the ChIP sample (from two datasets)
to the read count from the input DNA sample. Peaks with an
enrichment ratio lower than 1.5 were filtered out. The ChIP-Seq
data files have been deposited in NCBI’s Gene Expression
Omnibus [39] and can be accessed through GEO Series accession
number GSE35149. Lsr2 data were retrieved from this database
(accession number GSE18652).
Motif detection
Sequences of 102 bp covering the center of the 582 peaks that
fulfilled the peak selection criteria were extracted and used for
motif analysis using MEME [19] with motif occurrence set as
‘‘zero or one per sequence’’, minimum width as 5 and other
parameters as default. Since many EspR binding sites are found
within the highly repetitive sequences belonging to pe and ppe
genes, the initial motif returned by MEME was biased and
reflected a pe-ppe motif. Thus, from the 582 sequences, those
belonging to the pe and ppe categories were excluded, leaving 416
sequences that were reanalyzed using MEME. This led to the
identification of an unbiased overrepresented motif shown in Fig. 2.
This motif was further used in FIMO (Find Individual Motif
Occurences) from the MEME Suite web server [19] to search for
motif occurrence in the entire set of EspR binding sequences
setting the p-value threshold to 0.001.
Electrophoretic mobility shift assays (EMSA) and DNase I
footprinting
EspR protein was produced and purified as previously described
[10] and used in EMSA, DNase I footprinting and quantitative
Western Blot experiments, as well as to immunize rats. EspR-DNA
gel retardation assays were performed as recently described [10]
using 59-biotin-labeled forward primers and unlabeled reverse
primers in PCR reactions designed to yield DNA probes of 99 to
120 bp encompassing selected ChIP-Seq peak sequences for
analysis. DNase I footprinting assay was carried out using 6-
FAM-labeled probes as described in [10]. 6-FAM-labeled forward
primers and unlabeled reverse primers were used to synthesize a
361 bp DNA fragment starting 208 bp upstream of the espR
translational start by PCR. The nucleotide sequences of protected
regions were determined by DNA sequencing.
59 RACE
RNA was extracted from Mtb H37Rv cells in the mid-log phase.
59 RACE was performed as previously described [34] using the
59/39 RACE kit (2nd Generation, Roche) and primers specific for
espA and espR for 59-end mapping (see Table S1).
Inducible overexpression of EspR in Mtb H37Rv
Construction of the pMYespR vector for pristinamycin IA-
inducible overexpression of espR was undertaken as previously
described [21]. Plasmids pMYespR and the control pMY769 were
transformed into H37Rv strain by electroporation, clones were
selected on 7H11 agar plates containing 100 mg/ml spectinomycin
and plasmid integration verified by PCR. The resulting
H37Rv::pMYEspR strain was grown to mid-log phase (OD600
0.4–0.6), diluted to OD600 = 0.1 (day 0) and split into two 30 ml
volumes prior to addition of 0 or 2 mg/ml pristinamycin IA. Cells
were harvested at day 3.
For whole cell Western blot analysis, bacteria were pelleted,
washed twice in PBS containing 0.05% Tween 80 and
resuspended in lysis buffer (10 mM Tris pH 7.9, 500 mM NaCl,
1 mM b-mercaptoethanol, 5% glycerol, 0.1 mM EDTA) prior to
sonication (15 min at 4uC). Cell debris was then pelleted and the
supernatant filter sterilized. After total protein quantification using
Bradford reagent (Sigma), 10 mg of cell lysates were separated by
SDS-PAGE, and specific proteins visualized by immunoblot as
described below.
Immunoblot analysis
Proteins were separated on NuPAGE Novex 4–12% bis-Tris
gels (Invitrogen) and transferred to nitrocellulose membranes.
Membranes were incubated in TNT blocking buffer (25 mM Tris
pH 7.5, 150 mM NaCl, 0.05% Tween 20) with 5% w/v skim milk
powder for 2 h prior to incubation with primary antibodies diluted
in TNT with 1% BSA overnight. Membranes were washed in
TNT five times, then incubated with secondary antibodies for 1 h
before washing. Immunoblotting were performed with rat
polyclonal anti-EspR antibodies (kindly provided by Ida Rosenk-
rands), mouse monoclonal anti-EsxA antibodies (Hyb 76-8), mouse
monoclonal anti-GroEL2 antibodies (IT-70), rabbit polyclonal
anti-EsxB and anti-SodA antibodies. All antibodies were used at a
dilution 1:1,000 except for anti-GroEL2 (1:5,000), anti-EsxB
(1:500) and anti-SodA (1:50). Horseradish peroxidase (HRP)
conjugated rabbit polyclonal anti-rat IgG, rabbit polyclonal anti-
mouse IgG or goat polyclonal anti-rabbit IgG secondary
antibodies (Sigma) were used at dilutions of 1:100,000. Secondary
antibodies were visualized using chemiluminescent substrates
(Sigma).
Quantitative RT-PCR
Quantitative RT-PCR reactions were performed with the
7900HT Fast Real-Time PCR System (Applied Biosystems) with
the following parameters: 50uC for 2 min, 95uC for 10 min,
followed by 40 cycles of 95uC for 15 s and 60uC for 60 s. Melt
curve analysis was used to confirm specific amplification for each
primer pair. Threshold cycle values were determined automati-
cally using the SDS software.
Enrichment of ChIP DNA samples was measured by quanti-
tative RT-PCR using peak-specific primer pairs (Table S1), IP or
mock-IP DNA as template and SYBR-Green master mix (Applied
Biosystems). To calculate the amount of amplified DNA, standard
curves were generated for each primer pair using 10-fold dilutions
of input DNA as template. All reactions were done in duplicate
and averaged to determine the enrichment ratio calculated as [IP
DNA]/[mock-IP DNA].
For gene expression analysis, RNA was extracted with Trizol
reagent (Invitrogen) and treated with DNase I (Roche) prior to
generation of the cDNA template. cDNA was synthesized using
the RevertAid First Strand cDNA Synthesis Kit (Fermentas)
according to the manufacturer’s instructions using random
hexamers primer. cDNA corresponding to 10 ng of input RNA
was used in each RT-PCR reaction supplemented with specific
primer pairs (200 nM each) listed in Table S1 and SYBR-Green
master mix (Applied Biosystems). Relative mRNA levels were
calculated using the DDCt method, normalizing transcript levels to
sigA signals and are average of three biological replicates.
Time course expression analysis
Mtb H37Rv cells were grown to OD600 0.6 and then diluted in
100 ml with a starting OD600 of 0.05 (day 0). At various time
points corresponding to the early-log (day 2), mid-log (day 3) and
stationary (days 4 and 5) phase of growth, the number of cells was
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estimated from OD600 and culture aliquots were pelleted by
centrifugation for RNA and protein analysis. For protein analysis,
400 to 100 ml cell aliquots were resuspended in a 16 NuPAGE
sample buffer (Invitrogen) and boiled for 45 min. For all time
points, equivalent amounts of cells were subjected to SDS-PAGE
together with purified EspR protein standards (40, 30, 20, 15, 10
and 7.5 ng) and proteins detected by immunoblotting. Quantifi-
cation was performed by densitometry of scanned blots using the
ImageJ software. A standard curve was made from the intensity of
the purified EspR bands and was shown to be linear in the 7.5 to
40 ng range. Quantification of expression levels at each time point
was estimated from the standard curve after correction for small
sample loading discrepancies using GroEL2 band intensity for
normalization. The experiment was repeated four times and a
typical immunoblot pattern of EspR expression is shown in
Fig. 5A. For transcript analysis, RNA isolation and quantitative
RT-PCR was performed as described above.
EspR secretion analysis
Mtb starter cultures were first grown in complete 7H9 broth to
late-logarithmic phase (OD600,0.8–1). These were then used to
inoculate Sauton’s medium supplemented with 0.05% Tween-80,
at starting OD600 of 0.1. Cells were grown to mid-log phase of
growth (OD600,0.6), centrifuged, washed once with phosphate
buffered saline (PBS), resuspended in a volume of Sauton’s
medium without Tween-80 such that the OD600 was again ,0.6
then grown further at 37uC with shaking. Cultures were harvested
at required times post-transfer by centrifugation to obtain culture
filtrates and cell pellets. Culture filtrates (CF) were filtered
sequentially through 0.4 and 0.2 micron filters to remove any
residual cells and concentrated in Vivaspin columns with 5-kDa
molecular weight cut-off membranes (Sartorius Stedim Biotech
GmbH, Goettingen, Germany). Cell lysates (CL) were prepared by
resuspending cell pellets in lysis buffer (PBS containing Roche
mini-protease inhibitor cocktail tablets) followed by bead beating
with 100 micron glass beads and centrifuged. Total protein
concentration of all preparations was determined using the BCA
assays (Pierce) with BSA as the standard. Equivalent total protein
concentrations of CF and CL were analyzed by SDS-PAGE and
immunoblotting. For cell fractionation experiments, CL samples
were split into two equivalent volumes and treated with either
50 ml PBS or 50 ml of 1,000 units/ml DNase I overnight at 4uC.
CL samples were centrifuged at 200,000 g for 4 h at 4uC in a
Beckman-Coulter ultracentrifuge (TLA-100.3 rotor) to obtain the
cell wall/cell membrane (W/M) fraction. Supernatants containing
the cytosolic (CYT) fractions were carefully recovered and the W/
M fractions resuspended in PBS with 0.1% Triton X-100 and
mini-protease inhibitor cocktail. Equivalent amounts of the
different cell fractions were separated by SDS-PAGE and specific
proteins were visualized by immunoblotting.
Supporting Information
Figure S1 Correlation plot showing the reproducibility of EspR
ChIP-Seq.
(PDF)
Figure S2 Comparison of EspR and Lsr2 binding sites on the
Mtb genome. (A) Venn diagram showing significant overlap
between the gene targets of Lsr2 [32] as obtained by ChIP-on-chip
and EspR as obtained by ChIP-Seq (this study). (B–F) UCSC
Genome Browser (http://genome.ucsc.edu) view of selected
binding profiles as determined by ChIP-Seq for EspR (green, this
study) and by ChIP-on-chip for Lsr2 (red, [32]). Shown are (B) the
rv1490 region; (C) the rv0986-7-8 operon region; (D) the espA-ephA
intergenic region; (E) the ESX-1 (rv3864-3883c) and ESX-2
(rv3884c-rv3895c) regions; and (F) the PDIM/PGL locus (rv2928-
rv2962c). The GC content of Mtb H37Rv genome (in 20 bp
windows) normalized to the median GC content (65.6%) and the
gene positions are indicated below.
(PDF)
Figure S3 Analysis of the espA promoter. RNA extracted from
Mtb H37Rv at mid-log phase was used for the 59 RACE.
Translational starts are highlighted in red with +1 corresponding
to the first base of the espA open reading frame. Transcriptional
start mapped by 59 RACE is boxed and indicated by a bent arrow.
210 and 235 positions for putative sigma factor binding sites are
indicated. ChIP-Seq peak sequences are highlighted in gray.
(PDF)
Figure S4 Validation of 11 EspR-binding sites selected among a
wide range of scores by quantitative RT-PCR. The sigA and
rv0888 genes, showing no peak in EspR ChIP-Seq, were used as
negative controls. Plot showing log2 enrichment calculated from
ChIP-Seq and ChIP-qPCR experiments shows a good correlation
between the output of the two experiments. The log2 enrichment
values have also been indicated in the table below along with
additional details about the peaks. The column ‘‘Peak feature’’
indicates where the EspR-binding site is located relative to the
known gene annotation. ‘‘NA’’ denotes not applicable.
(PDF)
Figure S5 EMSA showing binding to the top five ChIP-Seq
peak sequences related to the following genes: fadD26, rv1490,
rv2929, pe_pgrs19, espA. A DNA fragment from within the espA
coding region where no ChIP-Seq enrichment was observed was
used as negative control.
(PDF)
Figure S6 DNase I footprint at peak ‘‘a’’ of the espR promoter.
Red and black peaks represent DNA incubated without or with
10 mM EspR proteins, respectively. Both reactions were partially
digested with DNase I and analysed by capillary electrophoresis in
a genetic analyser (Applied Biosystems 3130xl). The corresponding
sequencing reaction of the DNA fragment is shown at bottom.
Regions I and II protected from DNase I digestion by EspR and
regions IIaD10 and IIbD10 protected from DNase I digestion by
EspRD10 are denoted by square brackets. Positions indicated are
relative to the translational start.
(PDF)
Figure S7 Immunoblot analysis of 10 mg of culture filtrate (CF)
and 5 mg of cell lysates (CL) of Mtb Erdman wild-type (left) and
36–72 (transposon insertion in the pe35 promoter blocking esxA
expression and therefore ESX-1 function [23]) (right); strains were
grown for 4 days after transfer into Sauton’s medium without
Tween-80. GroEL2 was used as a control for autolysis, SodA as a
loading control for CF and CL samples and EsxA as a control for
ESX-1-dependent secretion.
(PDF)
Table S1 List of primers used in this study.
(PDF)
Table S2 List of the EspR ChIP-Seq peaks on the Mtb H37Rv
genome sorted by score (highest to lowest). Peaks are numbered by
order of appearance in the genome. The column ‘‘Feature’’
indicates where the EspR-binding site is located relative to the
known gene annotation. The ‘‘Distance to feature’’ column
designates the distance (in bp) from the midpoint position of the
calculated peak to the closest translational start site. Values in the
‘‘Score’’ column are arbitrary units proportional to the peak
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density. The ‘‘Enrichment’’ column represents the ratio between
the average ChIP-Seq read count at a particular locus (400 bp)
and the input DNA read count at that locus.
(XLS)
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4.3  Whole Genome Re-sequencing 
Contribution: Mapping and assembly of the high-throughput sequencing data, 
detection of sequence variation in the form of SNPs (single nucleotide 
polymorphisms) and InDels (insertions and deletions), and characterization of 
the nature of the substitutions occurring in coding sequences, as synonymous 
or nonsynonymous, based on the M. tb H37Rv genome annotation.  
 
4.3.1 Spontaneous phthiocerol dimycocerosate-deficient variants of 
M. tb 
The cell wall of M. tb possesses a unique array of complex lipids and 
carbohydrates that play critical roles in host-pathogen interactions and 
virulence of M. tb. Glycolipids are major M. tb cell wall constituents, known 
for their toxic or immunological properties. The most abundant of these 
lipids, the phthiocerol dimycocerosates (PDIMs) have been linked to 
virulence. Previous studies have shown that spontaneously arising PDIM-
deficient strains were attenuated in guinea pigs and mice. Whole-genome re-
sequencing of a spontaneously arising PDIM-negative clone and comparison 
with a PDIM-positive clone led to the identification of a nonsynonymous SNP 
in the ppsD gene resulting in a glycine to cysteine substitution at position 44 
(G44C) in the PpsD protein. The ppsD gene encodes a modular polyketide 
synthase involved in PDIM biosynthesis (34). Further experimental validation 
confirmed that the spontaneous point mutation in the ppsD gene is in fact 
responsible for both the defect in PDIM production and attenuation of 
virulence in mice.  
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Spontaneous Phthiocerol Dimycocerosate-Deficient Variants of
Mycobacterium tuberculosis Are Susceptible to Gamma
Interferon-Mediated Immunity!
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Onset of the adaptive immune response in mice infected with Mycobacterium tuberculosis is accompanied by
slowing of bacterial replication and establishment of a chronic infection. Stabilization of bacterial numbers
during the chronic phase of infection is dependent on the activity of the gamma interferon (IFN-!)-inducible
nitric oxide synthase (NOS2). Previously, we described a differential signature-tagged mutagenesis screen
designed to identify M. tuberculosis “counterimmune” mechanisms and reported the isolation of three mutants
in the H37Rv strain background containing transposon insertions in the rv0072, rv0405, and rv2958c genes.
These mutants were impaired for replication and virulence in NOS2"/" mice but were growth-proficient and
virulent in IFN-!"/" mice, suggesting that the disrupted genes were required for bacterial resistance to an
IFN-!-dependent immune mechanism other than NOS2. Here, we report that the attenuation of these strains
is attributable to an underlying transposon-independent deficiency in biosynthesis of phthiocerol dimycocer-
osate (PDIM), a cell wall lipid that is required for full virulence in mice. We performed whole-genome
resequencing of a PDIM-deficient clone and identified a spontaneous point mutation in the putative polyketide
synthase PpsD that results in a G44C amino acid substitution. We demonstrate by complementation with the
wild-type ppsD gene and reversion of the ppsD gene to the wild-type sequence that the ppsD(G44C) point
mutation is responsible for PDIM deficiency, virulence attenuation in NOS2"/" and wild-type C57BL/6 mice,
and a growth advantage in vitro in liquid culture. We conclude that PDIM biosynthesis is required for M.
tuberculosis resistance to an IFN-!-mediated immune response that is independent of NOS2.
Pathogenic mycobacteria possess a unique array of complex
cell wall-associated lipids. The most abundant of these lipids,
the phthiocerol dimycocerosates (PDIMs) (Fig. 1), are among
the best characterized (23). PDIMs contain long-chain diols
esterified by methyl-branched fatty acid chains. As early as
1974, it was recognized that a spontaneously arising PDIM-
deficient variant of the laboratory strain H37Rv was attenuated
in a guinea pig model of infection (11). Shortly thereafter, it
was shown that the in vivo survival of an avirulent Mycobacte-
rium tuberculosis strain was enhanced by coating the bacteria
with cholesterol oleate and purified PDIM (16). A genetic link
between PDIM production and virulence was not established
until a quarter century later, when a large chromosomal locus
was identified as playing an essential role in the biosynthesis
and export of PDIM (3, 4, 6). Transposon insertions within the
fadD26, fadD28, mmpL7, and drrC genes, and in the putative
transcriptional promoter region upstream of the fadD26 gene,
were identified in strains deficient in surface-localized PDIM.
The fadD26 and fadD28 mutants apparently fail to synthesize
PDIM, whereas the mmpL7 and drrC mutants produce PDIM
but accumulate it intracellularly, thus implicating these genes
in transmembrane transport of PDIM to the cell surface.
Strains deficient in production or surface localization of PDIM
are markedly attenuated for growth in the lungs of intrave-
nously (3, 6) or intranasally (28) infected mice, and in gamma
interferon (IFN-!)-activated but not in nonactivated macro-
phages (28).
Mutant strains that lack surface-localized PDIM display en-
hanced membrane permeability (3), but the precise role of
PDIM in virulence of M. tuberculosis is unclear. The attenu-
ated growth of PDIM-deficient M. tuberculosis in IFN-!-acti-
vated macrophages is reversed by treatment of the infected
macrophages with N"-nitro-L-arginine methyl ester (L-
NAME), a small-molecule inhibitor of the mammalian induc-
ible nitric oxide synthase (NOS2), suggesting that PDIM might
play a role in countering the impact of this important host
antimicrobial mechanism (28). However, PDIM-deficient bac-
teria do not show increased sensitivity to reactive nitrogen
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species (RNS) in vitro (3), suggesting thatM. tuberculosismight
be sensitized to RNS during intracellular growth or that the
impact of L-NAME on intracellular bacteria might be indirect,
possibly via modulation of expression of host (9) or pathogen
(29, 35) genes that are RNS responsive. A detailed compara-
tive analysis of PDIM-proficient and PDIM-deficient M. tuber-
culosis strains in macrophages revealed that PDIM participates
in receptor-dependent phagocytosis and inhibition of phago-
some acidification (2). PDIM insertion in model membranes
caused alterations in membrane fluidity, suggesting that phys-
ical changes to the host cell membrane caused by interaction
with PDIM may influence the uptake and ultimate cellular
destination of M. tuberculosis (2).
Whereas all M. tuberculosis clinical isolates apparently pro-
duce PDIM, only a subset of isolates produce the closely re-
lated phenolic glycolipids (PGLs). The PGLs comprise a
PDIM lipid core that is terminated by a glycosylated aromatic
nucleus (26). A 7-bp deletion in the pks15/1 polyketide syn-
thase locus, resulting in a translational frameshift, is responsi-
ble for the lack of PGL production by the H37Rv laboratory
strain and all other strains of the Euro-American M. tubercu-
losis lineage (5, 10). This frameshift abolishes production of
the Pks15/1 polyketide synthase that is responsible for biosyn-
thesis of the PGL precursor p-hydroxyphenylalkanoate from
p-hydroxybenzoic acid (5). In the absence of Pks15/1 function,
glycosylated p-hydroxybenzoic acid methyl esters (p-HBADs)
accumulate and are released into the culture medium (5, 25).
Three glycosyltransferases, encoded by the rv2962c, rv2958c,
and rv2957 genes, are thought to add, successively, two rham-
nosyl residues and one fucosyl residue to the p-hydroxybenzoic
acid moiety (Fig. 1B) (25).M. tuberculosisH37Rv produces the
triglycosylated p-HBAD (p-HBAD-II). Disruption of rv2962
abolishes p-HBAD production entirely; disruption of the
rv2958c or rv2957 gene results in the production of monogly-
cosylated p-HBAD (p-HBAD-I) (25).
In M. tuberculosis strains that produce PGL, a role for PGL
in immune modulation and virulence has been reported (26).
Whether the p-HBAD moieties secreted by PGL-negative M.
tuberculosis strains might also play a role in immune modula-
tion and virulence is not known. Previously, we described a
FIG. 1. PDIM and p-HBAD biosynthesis in M. tuberculosis. (A) Genomic locus responsible for PDIM and p-HBAD-II biosynthesis. In M.
tuberculosis H37Rv and other members of the Euro-American lineage, a frameshift mutation (red triangle) disrupts the pks15/1 open reading
frame. Other M. tuberculosis lineages have an intact pks15/1 locus that encodes a functional polyketide synthase. (B) Structures of p-HBAD-II and
PDIM. The polyketide synthase Pks15/1 adds malonyl coenzyme A (malonyl-CoA) units to p-hydroxybenzoic acid to generate p-hydroxyphenyl-
alkanoic acid derivatives, which are precursors of PGL biosynthesis (5). M. tuberculosis 37Rv lacks Pks15/1 activity and produces tri-glycosylated
p-hydroxybenzoic acid (p-HBAD-II) and PDIM instead. The Rv2962c, Rv2958c, and Rv2957 glycosyl transferases add rhamnose3 rhamnose3
fucose to p-hydroxyphenylalkanoic acid (25), and the Rv2959c methyltransferase O-methylates the C2 ring position of the proximal rhamnosyl
residue (24).
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genetic screen that was designed to identify M. tuberculosis
genes involved in countering IFN-!-dependent host immune
mechanisms other than NOS2 (12). Disruption of these “coun-
terimmune” (cim) genes severely attenuated growth and viru-
lence in NOS2"/" mice but had little or no impact on bacterial
growth and virulence in IFN-!"/" mice. One of the cim mu-
tants identified in this study contained a transposon (Tn) in-
sertion in the rv2958c gene, suggesting that secreted
p-HBAD-II might, like full-length PGL, modulate the interac-
tion of the bacterium and the host immune response. Here, we
describe further studies to elucidate the role of the rv2962c,
rv2958c, and rv2957 glycosyltransferases in M. tuberculosis vir-
ulence and counterimmunity. In contrast to our previous re-
port, we find that these genes are dispensable for bacterial
growth and survival in wild-type (C57BL/6) and NOS2"/"
mice. We demonstrate that the phenotypes we had previously
ascribed to disruption of the rv2958c gene are attributable,
instead, to the spontaneous loss of PDIM production in the
rv2958c::Tn mutant. Whole-genome resequencing of a sponta-
neous PDIM-deficient variant that arose during in vitro culti-
vation of M. tuberculosis H37Rv identified a single-nucleotide
polymorphism (SNP) in the ppsD gene, which encodes a mod-
ular polyketide synthase putatively involved in PDIM biosyn-
thesis (34). We demonstrate by complementation and rever-
sion that the spontaneous point mutation in the ppsD gene is
responsible for both the defect in PDIM production and at-
tenuation of virulence in mice. We additionally show that the
spontaneous PDIM deficient variant has an in vitro growth
advantage that allows it to replace the PDIM-proficient paren-
tal strain during subculture. We suggest that spontaneous loss
of PDIM production is likely to be a common phenomenon
that calls for a reexamination of published genetic studies ofM.
tuberculosis in which complementation analysis was not done
or was unsuccessful.
MATERIALS AND METHODS
Bacteriology. M. tuberculosis strains from the McKinney lab were H37Rv
(parental strain) and Tn5370 (Tn) mutagenized derivatives rv0072::Tn,
rv0405::Tn, and rv2958c::Tn, described previously (12). M. tuberculosis strains
from the Guilhot lab were H37Rv (parental strain), #rv2957, #rv2958c, #rv2959c,
and #rv2962c, described previously (24, 25). Bacteria were cultured at 37°C in
Middlebrook 7H9 broth (Difco) containing 10% albumin-dextrose-saline, 0.5%
glycerol, and 0.05% Tween 80 or on Middlebook 7H10 agar (Difco) containing
10% oleic acid-albumin-dextrose-catalase (BD Biosciences) and 0.5% glycerol.
Cycloheximide was added at 10 $g ml"1 to prevent fungal contamination, as
needed. Kanamycin (15 $g ml"1), hygromycin (50 $g ml"1), and sucrose (2%)
were added to the growth media, as needed. Frozen stocks were prepared by
growing liquid cultures in 7H9 broth to mid-log phase (optical density at 600 nm
[OD600] % 0.5) and freezing in aliquots at "80°C after the addition of glycerol
(15% [vol/vol]).
Mouse infections. Male and female C57BL/6, NOS2"/", and IFN-!"/" mice,
5 to 8 weeks of age, were purchased from Jackson Laboratories and housed in
The Rockefeller University’s Laboratory Animal Research Center or the EPFL
Center of Phenogenomics under specific-pathogen-free conditions. Bacteria
were grown to mid-log phase (OD600 % 0.5) in 7H9 broth, collected by centrif-
ugation (2,500& g, 15 min), resuspended in phosphate-buffered saline containing
0.05% Tween 80 (PBST), and centrifuged at a low speed (150 & g, 5 min) to
remove clumps. The declumped supernatant was adjusted to an OD600 of 0.1
('108 CFU ml"1) and further diluted 2-fold before being loaded into the
nebulizer. Mice were infected by the aerosol route with '100 CFU using a
custom-built aerosol exposure chamber (Department of Mechanical Engineer-
ing, University of Wisconsin, Madison, WI) and an exposure time of 15 min, as
described previously (37). Infected mice were euthanized by CO2 overdose.
Bacterial CFU were enumerated by plating serially diluted lung homogenates on
7H10 agar and counting colonies after 3 to 4 weeks at 37°C. For survival exper-
iments, infected mice were monitored twice daily, and animals that showed signs
of illness (ruffled fur, immobility, hunched posture, labored breathing) were
euthanized by CO2 overdose and scored as “died.” The animal protocols for
these studies were reviewed and approved by the Institutional Animal Care and
Use Committee (IACUC) of The Rockefeller University and by the chief vet-
erinarian of the Swiss Federal Institute of Technology Lausanne (EPFL), the
Service de la Consommation et des Affaires Ve´te´rinaires of the Canton of Vaud,
and the Swiss Office Ve´te´rinaire Fe´de´ral.
p-HBAD-II glycosylation and PDIM production. p-HBAD-II biosynthesis by
wild-type and mutant strains of M. tuberculosis was analyzed by thin-layer chro-
matography (TLC) of extracted and purified glycolipids, as described previously
(25). PDIM biosynthesis was analyzed by growing bacteria to mid-log phase and
labeling 10 ml of culture for 24 to 48 h with 10 $Ci of [1-14C]-propionate (specific
activity of 54 Ci mol"1 [Amersham] or 55.9 Ci mol"1 [Campro Scientific]).
Apolar lipids were extracted essentially as described previously (32). Labeled
cells were collected by centrifugation (2,500 & g, 10 min), resuspended in 5 ml of
10:1 (vol/vol) methanol/0.3% NaCl, and 5 ml of petroleum ether was added.
Samples were vortexed vigorously for 4 min and phase-separated by centrifuga-
tion (750 & g, 10 min). The upper layer was removed, and the extraction was
repeated with an additional 5 ml of petroleum ether. Remaining bacteria in the
combined petroleum ether fraction were killed by the addition of an equal
volume of chloroform. Extracts were reduced to '10 ml by overnight evapora-
tion and spotted (25 to 30 $l) on a silica gel 60 F254 TLC plate (5 by 10 cm;
Merck). TLC plates were developed in petroleum ether/diethyl ether (9:1 [vol/
vol]), air-dried, and visualized using a Typhoon PhosphorImager (Amersham
Biosciences).
Whole-genome resequencing. High-quality genomic DNA was prepared from
PDIM-positive and PDIM-negative isolates of H37Rv by the cetyltrimethylam-
monium bromide (CTAB)-lysozyme method (17). Genomic DNA fragment se-
quencing libraries were prepared using a genomic DNA sample prep kit (Illu-
mina) according to the manufacturer’s instructions, with 5 $g of purified
genomic DNA. Each genomic DNA fragment library was sequenced on one lane
of an Illumina genome analyzer IIx sequencing chip using a single-read cluster
generation kit v2 (Illumina) and a 36-cycle sequencing kit v2 (Illumina). Image
analysis and base calling were done using the Illumina Pipeline software package,
v1.32.
A total of 6.2 and 5.3 million reads 36 bases in length were obtained for the
PDIM-positive and PDIM-negative H37Rv clones, respectively. These sequence
reads were mapped to the reference M. tuberculosis H37Rv sequence using Maq
v0.7.1 via ungapped alignments allowing up to two mismatches per read. This
method mapped 95% and 89% of the PDIM-positive and PDIM-negative se-
quence reads, respectively, to the H37Rv genome. Maq was also used for SNP
calling and filtering out low-quality SNPs using the SNP filter designed for
single-end reads (18). SNPs identified in the ppsA and ppsD genes were further
confirmed by PCR and sequencing using the primer pairs ppsAF/ppsAR and
ppsDF/ppsDR (Table 1).
Plasmid construction. Oligonucleotide primers used for plasmid construc-
tion are listed in Table 1. For complementation of the ppsD(G44C) mutation,
the full-length ppsD gene was amplified from PDIM-positive H37Rv genomic
DNA using primers ppsDF2 and ppsDR2 that contain EcoRI and HpaI
TABLE 1. Oligonucleotide primersa
Name Sequence (5( to 3()
ppsAF................GCGAGGACCTGGTCGGTATC
ppsAR ...............GGCCTTGTTGAGGTTGGTC
ppsBF ................GAACTCTGCCACGAGCTGG
ppsBR................GCACCGATGACGAGCTG
ppsDF................GTCTTAATTAAGGAAACCCTGGGACTCGAC
ppsDR ...............TAGGCGCGCCGCCAAGTGAATTGCCACCAG
ppsDF2..............CTGGAATTCTAAGAAGGAGATATACATATGAC
AAGTCTGGCGGAGC
ppsDR2 .............CTGGTTAACTCGGGGATGCTCACAGGTC
ppsDR4 .............AAGCTTGAGGGCGGATGTGAT
MVinsF .............AGCGAGGACAACTTGAGC
ppsDF4..............CGATTCGCGCTCAGCTAGAC
pJGR .................AAATGCCGATATCCTATTGGC
pJGF..................GTGGACCTCGACGACCTC
a Restriction enzyme sites are underlined. The strong ribosome-binding site in
primer ppsDF2 is indicated in italics.
VOL. 79, 2011 SPONTANEOUS PDIM DEFICIENCY IN M. TUBERCULOSIS 2831
 on M
ay 25, 2012 by BIBLIOTHEQUE CENTRALE DE L'EPFL
http://iai.asm
.org/
Downloaded from
 
restriction sites, respectively. The ppsDF2 primer additionally harbors a
strong ribosome-binding site immediately upstream of the translational start
site of the ppsD gene. The resulting PCR products were cloned in pCR2.1-
TOPO (Invitrogen) and sequenced. Clones were identified that contained
wild-type ppsD sequence between a unique NcoI restriction site and the 3!
end of the ppsD gene and between a unique HindIII site and the unique NcoI
site. The first 979 bp of the ppsD gene 5! to the unique HindIII site were
amplified by PCR from PDIM-positive H37Rv genomic DNA using primers
ppsDF2 and ppsDR4, cloned in pCR2.1-TOPO, and sequenced. The ppsD
5!-HindIII fragment was digested out of the pCR2.1 cloning vector with
EcoRI and HindIII and cloned downstream of the strong constitutive hsp60
promoter in pMV361, a vector that integrates at the attB site on the M.
tuberculosis chromosome and contains a Kanr marker for selection (33). The
resulting pMV361-ppsD 5!-HindIII construct was digested with HindIII and
HpaI, and the HindIII-NcoI and NcoI-3! fragments of the ppsD gene were
ligated together in the plasmid. The resulting full-length ppsD complemen-
tation construct, pAT223, was confirmed by sequencing.
For allelic exchange of the ppsD(G44C) point mutation, the wild-type ppsD
sequence approximately 450 bp up- and downstream of the point mutation
was amplified from PDIM-positive H37Rv genomic DNA using primers
ppsDF and ppsDR, which contain PacI and AscI restriction sites, respec-
tively. The resulting PCR product was digested with PacI and AscI and ligated
to PacI/AscI-digested pJG1100, a suicide vector that contains Kanr and Hygr
markers for selection of recombinants and the sacB counterselectable marker
that confers sucrose sensitivity, to generate pAT221. The construct was con-
firmed by sequencing.
Strain construction. Oligonucleotide primers used in PCR confirmation of
strains are listed in Table 1. For complementation of the ppsD(G44C) point
mutation with pAT223, the plasmid was electroporated into the PDIM-negative
H37Rv ppsD(G44C) strain, and Kanr colonies were selected. The presence of
pAT223 was confirmed by PCR using primers MVinsF and ppsDR4. Reversion
of the ppsD(G44C) point mutation to the wild-type sequence was accomplished
by a two-step homologous recombination method. The pAT221 allelic exchange
vector was electroporated into the PDIM-negative H37Rv ppsD(G44C) strain,
and Kanr Hygr colonies were selected. Isolates containing the pAT221 vector
integrated at the ppsD gene were identified by PCR with the primer pairs
ppsDF4/pJGR and pJGF/ppsDR4. These isolates were grown in 7H9 medium
without antibiotic selection to mid-log phase and plated on 7H10 agar containing
2% sucrose to select isolates that had undergone a second recombination. Ex-
cision of the plasmid in sucrose-resistant isolates was confirmed by PCR using
primers ppsDF4/ppsDR4, and the resulting PCR product was sequenced to
determine whether the wild-type ppsD sequence or the ppsD(G44C) mutant
sequence was present.
Statistics. Student’s unpaired t test (one-tailed) was used to assess statistical
significance of pairwise comparisons between groups of mice infected with
PDIM-positive or PDIM-negative bacteria. The Mantel-Cox log-rank test was
used for comparison of Kaplan-Meier plots of mouse survival. P values were
calculated using GraphPad Prism 4.0 software (GraphPad Software, Inc.). P
values of "0.05 were considered significant.
RESULTS
A strain of M. tuberculosis with a Tn insertion in the rv2958c
gene is attenuated in wild-type, NOS2!/!, and IFN-"!/!mice.
Previously, we reported the results of a pilot signature-tagged
mutagenesis screen to identifyM. tuberculosis genes involved in
countering the impact of IFN-#-dependent immune mecha-
nisms other than NOS2 (12). This was accomplished by parallel
screening of Tn-induced mutants in intravenously infected
gene knockout mice to identify mutants that were attenuated
for growth and virulence in NOS2$/$ mice but unimpaired for
growth and virulence in IFN-#$/$ mice. One of the mutants
identified in this screen contained a Tn insertion in the rv2958c
gene, encoding a putative rhamnosyl transferase involved in
biosynthesis of p-HBAD-II (25). To confirm the phenotypes
observed in the screen, we infected mice by the aerosol route
with the H37Rv parental strain or with the rv2958c::Tn mutant
derived from it. Consistent with the results of the screen,
growth of the rv2958c::Tn mutant was attenuated in C57BL/6
(wild-type) mice (Fig. 2A) and in NOS2$/$ mice (Fig. 2B). In
contrast to our previous results, however, we found that growth
of the rv2958c::Tn mutant was also somewhat attenuated in
IFN-#$/$ mice (Fig. 2C). We do not know the reason for this
discrepancy. A possible explanation is that screening and re-
testing of mutants in our previous report were done in mice
infected by the intravenous route (12), whereas the experi-
ments reported here were done in mice infected by the respi-
ratory route, which is the natural route of infection.
Role of p-HBAD-II inM. tuberculosis growth in C57BL/6 and
NOS2!/! mice. Concurrent with our report describing the
results of our pilot screen to identify M. tuberculosis “counter-
immune” (cim) mutants (12), another group reported the con-
struction of deletion mutations in the M. tuberculosis rv2962c,
rv2958c, and rv2957 genes and the roles of the putative glycosyl
transferases encoded by these genes in the biosynthesis of
p-HBAD-II (Fig. 1) (25). In a separate report, the same group
also described the construction of a deletion mutation in the
rv2959c gene, encoding a methyltransferase responsible for
O-methylation of the first rhamnosyl residue linked to the
p-hydroxybenzoic acid moiety of p-HBAD-II (Fig. 1) (24). In
order to elucidate the contributions of these genes to M. tu-
FIG. 2. Growth kinetics of M. tuberculosis strains H37Rv (wild type) and rv2958c::Tn in wild-type and immunodeficient mice. C57BL/6 (A),
NOS2$/$ (B), and IFN-#$/$ (C) mice were aerosol infected with M. tuberculosis strains H37Rv (squares) or rv2958c::Tn (circles). These strains
were described previously (12). Groups of mice were sacrificed at the indicated time points, and bacterial CFU were enumerated by plating lung
homogenates on 7H10 agar and scoring colonies after 3 to 4 weeks of incubation at 37°C. Symbols represent means (n % 4 or 5 mice per group
per time point); error bars indicate standard errors. Asterisks indicate a statistically significant difference (P " 0.05) between the groups.
Representative results of two independent experiments are shown.
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berculosis virulence and counterimmunity, our groups jointly
investigated the growth kinetics and virulence of the !rv2962c
(Fig. 3A and B), !rv2958c (Fig. 3C and D), !rv2957 (Fig. 3E
and F), and !rv2959c (Fig. 3G and H) mutants in aerosol-
infected mice. We found that none of these mutants was at-
tenuated for growth and persistence in aerosol-infected
C57BL/6 (Fig. 3A, C, E, and G) or NOS2"/" (Fig. 3B, D, F,
and H) mice. These results were in sharp contrast to the phe-
notype of the rv2958c::Tn mutant isolated in our screen, which
was markedly attenuated in both C57BL/6 and NOS2"/" mice
(Fig. 2) (12).
Loss of PDIM production in the M. tuberculosis rv2958c::Tn
strain. Analysis of bacterial cell wall lipid fractions by thin-
layer chromatography revealed that the rv2958c::Tn mutant
(12) was deficient in PDIM production (Fig. 4A, lane 3), com-
pared to the H37Rv parental strain (Fig. 4A, lane 2). Loss of
Rv2958c function per se was not responsible for loss of PDIM,
because we found that the !rv2958c mutant (25) produced
wild-type levels of PDIM (not shown). Two additional mutants
identified in our counterimmune screen (12), containing Tn
insertions in the rv0072 (Fig. 4B, lane 4) and rv0405 (Fig. 4B,
lane 5) genes, were also found to be PDIM deficient. We
speculated that loss of PDIM production might have occurred
during the isolation of the rv2958c::Tn, rv0072::Tn, and
rv0405::Tn mutants, which involves clonal selection and expan-
sion of bacteria arising from a single transposition event. We
therefore derived eight independent cell lines from our paren-
tal H37Rv frozen stock, which had been used to generate the
Tn-induced mutants that were screened in mice (12), by plating
for single colonies on nonselective media and analyzing the
clonal cell lines derived from randomly selected individual
colonies for PDIM production. Of the eight clonal cell lines
that we analyzed, four were PDIM deficient (not shown), sug-
gesting that our parental H37Rv stock (Fig. 4A, lane 2; Fig. 4B,
lane 1) comprised a mixture of PDIM-positive and PDIM-
negative variants.
Consistent with this interpretation, we found that PDIM
production was dramatically reduced in the McKinney lab’s
parental H37Rv strain (Fig. 4A, lane 2) compared to that in the
Guilhot lab’s H37Rv strain (Fig. 4A, lane 1). We also found
that PDIM production by the McKinney lab’s parental H37Rv
strain was undetectable after only four rounds of in vitro sub-
culture from frozen stocks (Fig. 4B, lane 2). These observa-
tions suggest that spontaneously arising PDIM deficiency
might confer a growth advantage in vitro, thus promoting re-
placement of the parental PDIM-positive strain with PDIM-
negative variants during in vitro passage. To test this idea, we
compared the in vitro growth kinetics of independently derived
PDIM-positive and PDIM-negative H37Rv clones (see above)
and found that the PDIM-negative bacteria had a significant
and reproducible growth advantage over the PDIM-positive
bacteria (Fig. 4C). We found that the in vitro growth advantage
of PDIM-negative variants was particularly pronounced during
the early outgrowth of cultures inoculated from frozen stocks
(data not shown), which might reflect differential recovery of
PDIM-positive and PDIM-negative strains from the stress
caused by freezing/thawing.
Growth kinetics of PDIM-negative H37Rv, rv2958c::Tn,
rv0072::Tn, and rv0405::Tn strains in C57BL/6, NOS2!/!, and
IFN-"!/! mice. Previously, we reported that M. tuberculosis
rv0072::Tn, rv0405::Tn, and rv2958c::Tn mutants were severely
attenuated for growth and virulence in intravenously infected
NOS2"/" mice but were only slightly attenuated in IFN-#"/"
mice (12). Our subsequent discovery that these strains were
FIG. 3. p-HBAD-II biosynthesis is not required for M. tuberculosis
growth and survival in wild-type or immunodeficient mice. C57BL/6 (A,
C, E, and G) and NOS2"/" (B, D, F, and H) mice were aerosol infected
withM. tuberculosis strains H37Rv (A to H, squares), !rv2962c (A and B,
triangles), !rv2958c (C and D, circles), !rv2958c (E and F, diamonds), or
!rv2959c (G and H, crosses). These strains were described previously (24,
25). Groups of mice were sacrificed at the indicated time points, and
bacterial CFU were enumerated by plating lung homogenates on 7H10
agar and scoring colonies after 3 to 4 weeks of incubation at 37°C. Symbols
represent means (n $ 4 or 5 mice per group per time point); error bars
indicate standard errors. This experiment was performed once.
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PDIM deficient (Fig. 4A), presumably due to selection of pre-
existing PDIM-negative variants in our parental H37Rv stock
during Tn mutagenesis, suggested that the attenuation of these
mutants in mice might be due, at least in part, to their PDIM
deficiency. To test this idea, we compared the growth kinetics
of these mutants with a PDIM-negative H37Rv clone in aero-
sol-infected mice (Fig. 5). We found that the rv0072::Tn (Fig.
5A to C), rv0405::Tn (Fig. 5D to F), and rv2958c::Tn (Fig. 5G
to I) mutants grew with kinetics similar to those of the PDIM-
negative H37Rv clone in C57BL/6 (Fig. 5A, D, and G),
NOS2!/! (Fig. 5B, E, and H), and IFN-"!/! (Fig. 5C, F, and
I) mice. These observations suggest that the in vivo phenotypes
we reported previously for these mutants (12) were probably
due to the spontaneous loss of PDIM production in these
strains, rather than disruption of the rv2958c, rv0072, or rv0405
genes per se.
Growth kinetics of PDIM-positive and PDIM-negative
clones of H37Rv in C57BL/6, NOS2!/!, and IFN-"!/! mice.
To further test the idea that PDIM deficiency might contribute
to the in vivo attenuation of our rv2958c::Tn, rv0072::Tn, and
rv0405::Tn mutants, we compared the growth kinetics of
PDIM-positive and PDIM-negative clones of H37Rv in aero-
sol-infected mice. We found that, compared to the PDIM-
positive H37Rv clone, the PDIM-negative H37Rv clone was
markedly attenuated for growth in C57BL/6 (Fig. 6A),
NOS2!/! (Fig. 6B), and IFN-"!/! (Fig. 6C) mice. Virulence of
the PDIM-negative H37Rv clone, measured in terms of sur-
vival time of infected mice, was also attenuated in NOS2!/!
mice (P # 0.0005) and, to a lesser extent, in IFN-"!/! mice
(P # 0.002) (Fig. 6D). Median survival time (MST) of
NOS2!/! mice was $200 days after infection with PDIM-
negative H37Rv, compared to 64 days postinfection for
NOS2!/! mice infected with PDIM-positive H37Rv (Fig. 6D).
The MST of IFN-"!/! mice was also longer for mice infected
with PDIM-negative H37Rv (MST, 82 days) compared to mice
infected with PDIM-positive H37Rv (MST, 59 days) (Fig. 6D).
These data strongly suggest that the in vivo attenuation of the
“counterimmune” mutants described in our previous report
(12) can be attributed to the fortuitous loss of PDIM produc-
tion in these strains.
Whole-genome resequencing of PDIM-negative H37Rv iden-
tifies a point mutation, ppsD(G44C), responsible for PDIM
deficiency. Since our results demonstrated a correlation be-
tween spontaneous loss of the ability to produce PDIM and
attenuation in the mouse model of infection, we sought to
identify the mutation responsible for PDIM deficiency in a
PDIM-negative clone. Analysis of the PDIM biosynthesis locus
(Fig. 1) by Southern blotting did not identify any major inser-
tions or genetic rearrangements (data not shown), suggesting
that a point mutation might be the cause of PDIM deficiency.
To identify putative point mutations that could contribute to
PDIM deficiency, we performed whole-genome resequencing
of PDIM-positive and PDIM-negative H37Rv clones using an
Illumina genome analyzer platform. In comparison to the
H37Rv reference sequence, our PDIM-positive H37Rv clone
had 161 putative SNPs and 15 putative small sequence inser-
tions or deletions (indels). The PDIM-negative H37Rv clone
had 151 putative SNPs and 15 putative indels. These sequence
alterations included 72 polymorphisms (57 SNPs and 15 indels)
that were recently identified by whole-genome resequencing of
six H37Rv isolates and that are likely to be errors within the
H37Rv reference sequence (14). Analysis of the remaining
sequence polymorphisms, excluding those in the highly repet-
itive GC-rich PE_PGRS coding regions, revealed 22 putative
SNPs unique to the PDIM-negative H37Rv clone.
Among the SNPs present only in the PDIM-negative H37Rv
isolate were two mutations in genes required for PDIM bio-
synthesis: a putative A to C at position 2544 in the ppsA gene
and a G to T at position 130 in the ppsD gene. Only the G to
T in the ppsD gene was predicted to be nonsynonymous, gen-
FIG. 4. PDIM deficiency confers an in vitro growth advantage in M. tuberculosis H37Rv. (A and B) Thin-layer chromatographic analysis of
PDIM biosynthesis. Bacteria were labeled with [14C]propionate, which preferentially labels PDIM (6), and cell wall lipids were extracted and
separated by thin-layer chromatography. (A) M. tuberculosis strains. H37Rv, Guilhot lab (25) (lane 1); H37Rv, McKinney lab (12) (lane 2);
rv2958c::Tn (12) (lane 3). (B) M. tuberculosis strains, McKinney lab (12). H37Rv (lane 1), H37Rv after subculture (lane 2), rv2958c::Tn (lane 3),
rv0072::Tn (lane 4), rv0405::Tn (lane 5). (C) Independently derived subclones of PDIM-positive H37Rv (squares) and PDIM-negative H37Rv
(circles) were grown in 7H9 broth with aeration at 37°C. Growth of the cultures was monitored by withdrawing aliquots and measuring the OD600
at the indicated time points (plotted on the primary y axis). The (PDIM-positive OD600)/(PDIM-negative OD600) ratios at each time point are
plotted on the secondary y axis (diamonds). Results are representative of three independent experiments.
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erating a glycine-to-cysteine transition at position 44 in the
PpsD protein. PpsD is a modular polyketide synthase, and the
G44C point mutation identified in our PDIM-negative clone is
located within the putative !-ketoacyl acyl carrier protein syn-
thase enzymatic domain (34). We reasoned that the G44C
mutation might interfere with the activity of PpsD, since an
additional cysteine residue could cause formation of aberrant
disulfide bonds, thereby preventing proper protein folding or
interfering with the function of the active site cysteine residue.
We confirmed that the ppsD(G44C) point mutation was
unique to the PDIM-negative clone by PCR and sequencing.
We were not able to confirm the point mutation in the ppsA
gene by sequencing of a PCR product, suggesting that there
are likely to be some false positives among the SNPs identified
by whole-genome resequencing.
We attempted to restore PDIM production to the PDIM-
negative H37Rv ppsD(G44C) mutant using two approaches.
We complemented the ppsD(G44C) mutation in trans by pro-
viding a wild-type copy of the ppsD gene under the control of
a strong constitutive promoter on the vector pMV361, which
integrates in the M. tuberculosis chromosome at the unique
attB site. We also reverted the ppsD(G44C) mutation in the
PDIM-negative clone to the wild-type ppsD sequence by a
two-step homologous recombination method. Both strains
were tested for the ability to produce PDIM in vitro by thin-
layer chromatography of extractable cell wall lipids. Produc-
tion of PDIM was restored by either complementation or re-
version (ppsD rev) of the ppsD(G44C) point mutation (Fig.
7A), confirming that this spontaneous mutation is responsible
for the deficiency in PDIM production of our PDIM-negative
H37Rv clone.
The ppsD(G44C) point mutation enhances growth of H37Rv
in vitro. Since the ppsD(G44C) spontaneous point mutation
was responsible for PDIM deficiency, we sought to establish
whether the in vitro and in vivo growth characteristics of our
PDIM-negative H37Rv clone could also be attributed to this
FIG. 5. Growth kinetics of PDIM-negative H37Rv and M. tuberculosis rv0072::Tn, rv0405::Tn, and rv2958c::Tn mutants in wild-type and
immunodeficient mice. C57BL/6 (A, D, and G), NOS2"/" (B, E, and H), and IFN-#"/" (C, F, and I) mice were aerosol infected withM. tuberculosis
H37Rv PDIM-negative variant (A to I, squares), rv0072::Tn (A to C, triangles), rv0405::Tn (D to F, diamonds), or rv2958c::Tn (G to I, circles).
The PDIM-negative variant of H37Rv is described herein; the Tn mutant strains were described previously (12). Groups of mice were sacrificed
at the indicated time points, and bacterial CFU were enumerated by plating lung homogenates on 7H10 agar and scoring colonies after 3 to 4 weeks
of incubation at 37°C. Symbols represent means (n $ 4 or 5 mice per group per time point); error bars indicate standard errors. This experiment
was performed once.
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point mutation. We compared the in vitro growth kinetics
of the PDIM-positive ppsD! clone, the PDIM-negative
ppsD(G44C) mutant, the ppsD(G44C) pMV-ppsD comple-
mented mutant, and the strain in which the ppsD gene was
reverted to the wild-type sequence (ppsD rev) in standard
liquid culture conditions. The PDIM-negative ppsD(G44C)
mutant consistently grew at a higher rate and to a higher cell
density in liquid culture than the PDIM-positive ppsD! clone
(Fig. 7B). Either complementation or reversion of the
ppsD(G44C) point mutation restored growth to a rate similar
to the PDIM-positive ppsD! clone (Fig. 7B). These data dem-
onstrate that the ppsD(G44C) point mutation is responsible for
the enhanced in vitro growth rate of the PDIM-negative
H37Rv clone.
The ppsD(G44C) point mutation attenuates replication and
virulence of H37Rv in mice. Next, we tested whether the spon-
taneous ppsD(G44C) mutation was also responsible for atten-
uation of the PDIM-negative H37Rv clone in the mouse model
of infection. For these experiments, we focused on the strain in
which ppsD was reverted to the wild-type sequence (ppsD rev),
because the complemented strain exhibited a moderately re-
duced in vitro growth rate (Fig. 7B). The PDIM-positive
ppsD!, PDIM-negative ppsD(G44C), and ppsD rev strains
were introduced into the lungs of C57BL/6, NOS2"/", and
IFN-#"/" mice by the aerosol route, and replication of the
bacteria in the lungs and survival of the mice were monitored.
Consistent with previous experiments, the PDIM-negative
ppsD(G44C) mutant was attenuated for growth in the lungs of
C57BL/6 (Fig. 8A) and NOS2"/" (Fig. 8B) mice. Virulence of
the PDIM-negative ppsD(G44C) mutant, measured by survival
time of infected mice, was likewise modestly attenuated in
IFN-#"/" mice (Fig. 8C) (P $ 0.0018) and dramatically atten-
uated in NOS2"/" mice (Fig. 8D) (P $ 0.0025). Reversion of
the ppsD(G44C) spontaneous point mutation to the wild-type
ppsD sequence reversed each of these phenotypes. The ppsD
rev strain replicated in the lungs of C57BL/6 (Fig. 8A) and
NOS2"/" (Fig. 8B) mice with kinetics identical to those of the
PDIM-positive ppsD! clone. In addition, reversion to the wild-
type ppsD sequence restored virulence in IFN-#"/" (Fig. 8C)
and NOS2"/" (Fig. 8D) mice. Survival times of IFN-#"/" and
NOS2"/" mice infected with PDIM-positive ppsD! H37Rv or
the ppsD rev strain were not significantly different (for IFN-
#"/" mice, P $ 0.159; for NOS2"/" mice, P $ 0.398). These
data confirm that a spontaneous point mutation, ppsD(G44C),
was responsible for both loss of PDIM production and atten-
uation of the PDIM-negative H37Rv clone in mice.
DISCUSSION
Long-term persistence in the face of innate and adaptive
immune responses is a hallmark of tuberculosis, yet little is
known about the “counterimmune” mechanisms that promote
the persistence of M. tuberculosis in immunocompetent hosts.
We previously identified the glycosyltransferase encoded by
the rv2958c gene as a putative factor required to counter the
FIG. 6. Growth kinetics of PDIM-positive and PDIM-negative sub-
clones of M. tuberculosis H37Rv in wild-type and immunodeficient
mice. (A to C) C57BL/6 (A), NOS2"/" (B), and IFN-#"/" (C) mice
were aerosol-infected with PDIM-positive (filled squares) or PDIM-
negative (open squares) subclones of M. tuberculosis H37Rv. Groups
of mice were sacrificed at the indicated time points, and bacterial CFU
were enumerated by plating lung homogenates on 7H10 agar and
scoring colonies after 3 to 4 weeks of incubation at 37°C. Symbols
represent means (n$ 4 or 5 mice per group per time point); error bars
indicate standard errors. Asterisks indicate statistically significant dif-
ferences (P % 0.05) between the groups. (D) Survival of NOS2"/"
(circles) and IFN-#"/" (squares) mice (n $ 5 or 6 per group) after
aerosol infection with PDIM-positive (filled symbols) or PDIM-nega-
tive (open symbols) subclones of M. tuberculosis H37Rv. This experi-
ment was performed once.
FIG. 7. The ppsD(G44C) point mutation is responsible for PDIM
deficiency and the in vitro growth advantage of the H37Rv PDIM-
negative subclone. (A) Thin-layer chromatographic analysis of PDIM
biosynthesis. Bacteria were labeled with [14C]propionate, which is pref-
erentially incorporated into PDIM (6), and cell wall lipids were ex-
tracted and separated by thin-layer chromatography. M. tuberculosis
H37Rv strains: ppsD! (lane 1), ppsD(G44C) (lane 2), ppsD rev (lane
3), ppsD(G44C) pMV361-ppsD (lane 4). Results are representative of
two independent experiments. (B) Bacteria were grown in 7H9 broth
with aeration at 37°C. Growth was monitored by withdrawing aliquots
and measuring the OD600 at the indicated time points. M. tuberculosis
H37Rv strains: ppsD! (filled squares), ppsD(G44C) (filled circles),
ppsD rev (open circles), ppsD(G44C) pMV361-ppsD (open triangles).
Results are representative of three independent experiments.
2836 KIRKSEY ET AL. INFECT. IMMUN.
 on M
ay 25, 2012 by BIBLIOTHEQUE CENTRALE DE L'EPFL
http://iai.asm
.org/
Downloaded from
 
impact of IFN-!-dependent immune mechanisms other than
NOS2 (12). Here, we tested mutants harboring targeted dele-
tions of genes that are required for biosynthesis of secreted
p-HBAD, including the rv2958c gene, for their ability to rep-
licate in the lungs of mice. Although none of the "rv2957,
"rv2958c, "rv2959c, or "rv2962c mutants were attenuated for
growth, it remains possible that secreted p-HBADs play a role
in virulence modulation that is not reflected in the bacterial
growth kinetics, as shown previously for PGL (26).
We attribute the discrepancy between the phenotypes of the
rv2958c::Tn and "rv2958c mutants in the mouse infection
model to the spontaneous loss of PDIM production in our
H37Rv parental strain and the rv2958c::Tn mutant derived
from it. Our observations demonstrate a role for PDIM in
countering the impact of an IFN-!-dependent, NOS2-indepen-
dent immune mechanism, in addition to the previously postu-
lated role for PDIM in protecting the bacteria from the cidal
activity of RNS (28). Consistent with this idea, we found that
the survival time of IFN-!#/# and NOS2#/# mice was not
significantly different (P$ 0.07) after infection with the PDIM-
positive H37Rv clone. In contrast, following infection with the
PDIM-negative H37Rv clone, NOS2#/# mice survived signif-
icantly longer than IFN-!#/#mice (P% 0.001). Our results are
also consistent with the results of a recent screen for mutants
that specifically alter growth of M. tuberculosis in NOS2#/#
mice, which identified two independent mutations in the drrA
gene encoding a putative PDIM transporter (22). The immune
mechanism responsible for this IFN-!-dependent, NOS2-inde-
pendent attenuation and the countermechanism by which
PDIM confers protection are currently unknown.
We demonstrated that a point mutation, ppsD(G44C), in a
PDIM-negative clone derived from our H37Rv parental strain
was responsible for both a defect in PDIM production and
attenuation in mice. To our knowledge, this is the first direct
evidence that PpsD is required for PDIM biosynthesis and
virulence. We consistently observed a low level of res-
idual PDIM production by the ppsD(G44C) mutant. The
ppsD(G44C) mutant was a clonal isolate from a single colony,
suggesting that weak PDIM production is a property of this
strain. It is possible that reversion of the G44C point mutation
or compensatory mutations elsewhere in ppsD that restore
PDIM synthesis occur spontaneously at some low frequency. It
is unlikely that such strains would become a significant fraction
of the population, however, since the ppsD(G44C) mutant
grows at a higher rate. We therefore favor the possibility that
the PpsDG44C mutant protein retains some residual activity
that enables weak PDIM production. The low level of PDIM
produced by the ppsD(G44C) mutant is apparently not suffi-
cient, however, to support normal replication in the lungs of
mice.
A correlation was previously observed between PDIM defi-
ciency and a growth advantage in liquid culture (7). Similarly,
our PDIM-negative ppsD(G44C) mutant had an enhanced in
vitro growth rate and grew to a higher cell density than PDIM-
positive clones. The in vitro growth advantage of such sponta-
neous PDIM-negative variants could explain why they are able
to supplant the parental strain during repeated cycles of
growth in vitro, for example, during mutant strain construction.
Indeed PDIM-negative variants were isolated with significantly
higher frequency in a culture that was serially passaged than in
a nonpassaged control (7). It has also been suggested that
spontaneous PDIM deficient variants might be selected by
genetic manipulations involving electroporation or bacterio-
phage infections (11, 26). Since our results indicate that these
spontaneous PDIM-deficient variants are attenuated for viru-
lence, care should be taken to minimize the number of pas-
sages during genetic manipulation of M. tuberculosis and to
ensure that strains used in animal infection studies are PDIM
proficient.
Spontaneously arising PDIM-deficient variants have been
described previously (1, 7, 8, 11, 15, 19–21) and are probably
more common than has been reported or realized. Although
spontaneous PDIM deficiency has most frequently been asso-
ciated with the H37Rv strain, it has also recently been de-
scribed for the M. tuberculosis Erdman strain and the clinical
isolate HN878 (7, 20). Many of the attenuated M. tuberculosis
mutants described in the scientific literature have not been
complemented, and in other cases, complementation restored
virulence only partially. Some of these mutants might have
acquired unrecognized secondary mutations causing PDIM de-
ficiency, which could be a factor contributing to their attenu-
ation. Moreover, a number of genes have been implicated in
PDIM synthesis, based on the PDIM-negative phenotypes of
the corresponding mutants, in the absence of confirmatory
complementation (for example, see references 13, 27, 28, 30,
FIG. 8. Reversion of the ppsD(G44C) point mutation restores wild-
type levels of growth and virulence in mice. (A to D) Mice were aerosol
infected with ppsD& (filled squares), ppsD(G44C) (filled circles), or
ppsD rev (open circles) strains of M. tuberculosis H37Rv. (A and B)
Bacterial growth in the lungs of C57BL/6 (A) and NOS2#/# (B) mice.
Groups of mice were sacrificed at the indicated time points, and bac-
terial CFU were enumerated by plating lung homogenates on 7H10
and scoring colonies after 3 to 4 weeks of incubation at 37°C. Symbols
represent means (n $ 4 mice per group); error bars indicate standard
errors. Asterisks indicate statistically significant differences (P % 0.05)
in comparisons of ppsD(G44C) versus ppsD& and ppsD(G44C) versus
ppsD rev strains. This experiment was performed once. (C and D)
Survival of IFN-!#/# (C) and iNOS#/# (D) mice (n $ 5 mice per
group). This experiment was performed once.
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31, and 36). Some of these mutant strains might contain un-
recognized secondary mutations that are the true cause of their
PDIM deficiency. This phenomenon might also explain the
observation thatMycobacterium leprae produces PDIM despite
lacking functional copies of certain polyketide biosynthesis
genes that were reported to be essential for PDIM production
in M. tuberculosis (discussed in reference 36).
Construction and characterization of random or targeted
gene-disrupted mutants is a powerful technique to assign bio-
logical functions to biochemical pathways in mycobacteria.
However, our findings underscore the idea that any functional
assignment must be tentative in the absence of complementa-
tion analysis, even in cases where the mutation is not polar on
the expression of neighboring genes.
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4.3.2 Sequencing of pyridomycin-resistant mutants of M. tb 
Pyridomycin is a naturally occurring antibiotic produced by 
Dactylosporangium fulvum with specific cidal activity against mycobacteria. 
The aim of this study was to determine the target and mechanism of action 
of pyridomycin against M. tb and assess its potential as an anti-TB 
compound. The strategy used to identify the target of pyridomycin was based 
on analysis of the genome sequences of pyridomycin-resistant isolates of M. tb 
in order to identify genetic mutations responsible for this phenotype. It is 
expected that these mutations are likely to occur in genes encoding the drug 
target, as these changes would directly interfere with the activity of the drug. 
Whole-genome re-sequencing of pyridomycin-resistant colonies of M. tb 
H37Rv and comparison with the parental strain revealed a nonsynonymous 
SNP in the inhA gene resulting in the replacement of aspartic acid by glycine 
at position 148 (D148G). Further genetic validation, followed by biochemical 
and structural studies confirmed that pyridomycin inhibits InhA directly as a 
competitive inhibitor of the NADH-binding site and thus prevents synthesis 
of mycolic acids in M. tb. Incidentally, InhA is also the target of isoniazid, a 
first-line anti-TB drug but the two molecules have different binding sites. 
Coherently, the most frequently encountered isoniazid-resistant clinical 
isolates remain fully susceptible to pyridomycin, making it a promising 
alternative for the treatment of isoniazid-resistant tuberculosis. In addition to 
the identification of the target of pyridomycin, this study revealed a new 
druggable pocket in InhA that can be exploited in research on TB drug 
development.   
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Tuberculosis, a global threat to public health, is becoming untreatable due to
widespread drug resistance to frontline drugs such as the InhA-inhibitor iso-
niazid. Historically, by inhibiting highly vulnerable targets, natural products have
been an important source of antibiotics including potent anti-tuberculosis
agents. Here, we describe pyridomycin, a compound produced by Dactylospor-
angium fulvum with specific cidal activity against mycobacteria. By selecting
pyridomycin-resistant mutants of Mycobacterium tuberculosis, whole-genome
sequencing and genetic validation, we identified the NADH-dependent enoyl-
(Acyl-Carrier-Protein) reductase InhA as the principal target and demonstrate
that pyridomycin inhibits mycolic acid synthesis in M. tuberculosis. Furthermore,
biochemical and structural studies show that pyridomycin inhibits InhA directly
as a competitive inhibitor of the NADH-binding site, thereby identifying a new,
druggable pocket in InhA. Importantly, the most frequently encountered iso-
niazid-resistant clinical isolates remain fully susceptible to pyridomycin, thus
opening new avenues for drug development.
INTRODUCTION
Today, infection with Mycobacterium tuberculosis accounts for
up to two million deaths annually (Glaziou et al, 2009). Major
confounding factors such as poverty, homelessness and the
prevalence of HIV/AIDS (Harrington, 2010) mean that tubercu-
losis will indefinitely remain an important cause of morbidity
and mortality throughout the world. Furthermore, despite the
small, but growing number of drugs that are effective at killing
M. tuberculosis, the current treatment is still burdened by its
duration (typically 6 months for drug-sensitive strains) and
the ever increasing number of multidrug (MDR) and extensively
drug resistant (XDR) clinical isolates of M. tuberculosis
(Cegielski, 2010). Together, this underlines the need for
alternative therapeutic entities that can be used both to shorten
the duration of therapy and to combat the growing problem of
clinical drug resistance.
Natural products have long provided a rich source of effective
anti-tuberculosis agents. Themost active of these in current use,
the rifamycins (rifampicin, rifabutin and rifapentine), inhibit
RNA polymerase and are crucial for front-line treatment of the
disease. Furthermore, several other natural products such as
the aminoglycosides (streptomycin, amikacin and kanamycin)
and the peptide antibiotic (capreomycin) are part of the current
portfolio of anti-tuberculosis drugs. The rich diversity of natural
products represents a powerful tool for drug discovery, firstly,
in the form of leads for potential anti-microbial agents and
secondly, as a means of identifying those targets that are most
vulnerable in the bacterium.
In 1953, pyridomycin was first described as an antibiotic
that exhibited specific activity against different mycobacteria
including M. tuberculosis and M. smegmatis (Maeda et al,
1953). Pyridomycin (Fig 1A) is produced by Streptomyces
pyridomyceticus (Maeda et al, 1953; Yagishita, 1954, 1955,
1957a,b) or Dactylosporangium fulvum (Shomura et al, 1986).
Its biosynthesis was first studied in 1968 (Ogawara et al, 1968)
and more recently in 2011 (Huang et al, 2011) when the
involvement of both non-ribosomal peptide synthetases (NRPS)
and polyketide synthases (PKS) was proposed. Despite this
body of work, the mechanism of action of pyridomycin
against M. tuberculosis is unknown, and its potential as an
anti-tuberculosis compound has not been assessed.
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The aim of this study was to determine how pyridomycin
kills M. tuberculosis and to identify its target. To achieve this,
a combination of approaches involving resistance mapping,
genetic validation, biochemistry, enzyme inhibition and X-ray
crystallographic analysis of the target are described. The
combined results unambiguously indicate that pyridomycin is
a competitive inhibitor of the NADH-binding site of InhA,
NADH-dependent enoyl-[Acyl-Carrier-Protein] reductase, the
target of the two anti-tuberculosis pro-drugs isoniazid and
ethionamide (Banerjee et al, 1994; Vilcheze et al, 2006).
RESULTS
Purification of pyridomycin
Several strains of Streptomyces pyridomyceticus (NRRL B-2517,
ISP-5024 and DSM40024) were initially tested for pyridomycin
production with limited success, likely due to the presence of
producing and non-producing populations in the same culture.
Pyridomycin (Fig 1A) was, however, readily produced by and
purified from Dactylosporangium fulvum (NRRL B-16292) with
a yield of 20–40mg/L at a purity >99% and with an NMR
spectrum as previously reported (Kinoshita et al, 1989).
Anti-bacterial properties of pyridomycin
Pyridomycin has been described to act specifically against
mycobacteria, with little or no activity against other Gram-
positive and Gram-negative species (Maeda et al, 1953).
In order to verify its spectrum of activity, the resazurin
reduction microplate assay (REMA) was used to determine
the minimum inhibitory concentration (MIC) for various
bacteria. From Table 1, it can be clearly seen that pyridomycin
is effective against all members of the Mycobacterium genus
tested including M. tuberculosis (strain H37Rv, MIC¼ 0.31–
0.63mg/ml) and M. smegmatis (strain mc2 155, MIC¼ 0.62–
1.25mg/ml). Pyridomycin, however, showed no detectable
activity against other bacteria, including the close relative
C. glutamicum (all MIC> 100mg/ml). These data therefore
agree with earlier observations (Maeda et al, 1953; Maeda,
1957) and suggest that pyridomycin targets a mycobacterial
component that is either sufficiently divergent or absent in
other genera.
To further understand the properties of pyridomycin against
M. tuberculosis, its minimum bactericidal concentration (MBC)
was determined and its activity against non-replicating and
intracellularM. tuberculosismeasured. MBC data demonstrated
that pyridomycin is bactericidal against M. tuberculosis H37Rv
at concentrations of 0.62–1.25mg/ml. Evaluation of pyrido-
mycin activity against non-replicating M. tuberculosis using
the streptomycin-starved 18b (ss18b) model (Sala et al, 2010)
revealed that pyridomycin is not effective, thereby implying that
it may target a function involved in active growth. Finally,
the intracellular killing activity of pyridomycin was assessed
ex vivo after infection of activated THP1-derived macrophages.
The results indicated that, when left untreated for a 7-day
period, intracellular M. tuberculosis grew by at least 3 logs,
whilst exposure to both pyridomycin (10mg/ml) and
rifampicin (1mg/ml) prevented any multiplication within the
macrophages (Fig 1B). Further controls showed that strepto-
mycin (10mg/ml) had no impact on the growth of intracellular
bacteria while isoniazid (1mg/ml) was able to reduce the
intracellularM. tuberculosis load by 1 log (Fig 1B). Pyridomycin
is therefore clearly able to enter macrophages and arrest
bacterial replication.
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Figure 1. Chemical structure and intracellular activity of pyridomycin.
A. Chemical structure of pyridomycin.
B. The activity of pyridomycin on intracellular M. tuberculosis was tested in activated THP-1-derived macrophages. Cells were infected at an MOI of 1:1
with M. tuberculosis Erdman and treated with isoniazid (INH) at 1mg/ml, rifampicin (RIF) at 1mg/ml, streptomycin (STR) at 10mg/ml or pyridomycin (PYR)
at 10mg/ml. Colony forming units (CFU) were determined after 7 days exposure to drugs. NT refers to the untreated sample and NT0 to untreated sample
at time 0. The experiment was performed in duplicate and results are shown as mean values and standard errors.
2 ! 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. EMBO Mol Med (2012) 4, 1–11
Cytotoxicity of pyridomycin on human cell lines
To determine whether pyridomycin is cytotoxic to human cells,
the concentration-dependent cytotoxicity of the compound was
assessed on two human cell lines. Data indicated that the
amount of pyridomycin needed to kill 50% of HepG2 cells
(human hepatic cell line) or A549 cells (human lung epithelium
cell line) was 100 and 50mg/ml, respectively. Pyridomycin
therefore shows higher selectivity for M. tuberculosis compared
to the human cells tested (selectivity index >100-fold), in
agreement with a previous finding that pyridomycin shows
low toxicity in an acute murine model following 800mg/kg
intraperitoneal injection (Maeda et al, 1953).
Identification of the pyridomycin target
The strategy to identify the target and mechanism of action of
pyridomycin was to raise pyridomycin-resistant mutants and to
pinpoint the genetic mutations responsible for this phenotype,
anticipating that these mutations would be in the gene for the
drug target. Resistant mutants of strain H37Rv were selected on
solid medium containing pyridomycin at 10! MIC (3mg/ml)
and arose at a frequency of around 10"6. Of the 10 colonies
selected for further analysis (PYR1 to 10), nine showed no
change in the MIC to pyridomycin when re-tested by REMA,
whereas mutant PYR7 retained a near 10-fold increase in its
resistance level compared to the parent H37Rv (Fig 2). This
phenotype was stably maintained and mutant PYR7 remained
fully susceptible to isoniazid, moxifloxacin and rifampicin like
wild-type H37Rv (Fig 2).
To identify the single nucleotide polymorphisms (SNPs) or
insertion/deletions (INDELs) responsible for the pyridomycin
resistance, the genomes of both PYR7 and the parental strain
were sequenced to near completion by the Illumina protocol.
Ninety-eight percent of the reads were successfully mapped to
the H37Rv reference genome (Cole et al, 1998) resulting in an
average 300-fold coverage. Comparison of the PYR7 and H37Rv
assemblies revealed 63 SNPs of which 53 mapped to the
repetitive PE and PPE gene families and were therefore
discarded. Of the remaining 10 SNPs, nine were synonymous.
The only non-synonymous mutation found was an a443g
transition in inhA resulting in replacement of the aspartic acid at
position 148 by a glycine (D148G). This missense mutation was
subsequently confirmed by conventional Sanger sequencing.
With reference to previously published structures of the
NADH-dependent enoyl-ACP reductase InhA, Asp148 was
found to be located near the NADH binding pocket (Dessen
et al, 1995; Dias et al, 2007; Molle et al, 2010; Oliveira et al, 2006;
Rozwarski et al, 1999; Vilcheze et al, 2006).
Genetic validation of InhA as the target of pyridomycin
To genetically validate InhA as the target of pyridomycin, we
evaluated whether over expression of inhA caused an increase
in resistance to the antibiotic in wild-type M. tuberculosis. For
this purpose, we transformed strain H37Rv with a plasmid
carrying the inhA gene under the control of the hsp60 promoter
(pMVinhA; Larsen et al, 2002). In Fig 2, it can be seen that
H37Rv::pMVinhA displayed a 15-fold higher MIC for pyrido-
mycin compared to the control strain H37Rv::pMV261 (from
0.31 to 5mg/ml). When the same experiment was performed
in the PYR7 background, no complementation of the resistant
phenotype was observed, indicating that the associated
mutation was dominant. Similar to the wild-type strain, we
noticed a four-fold increase in resistance in PYR7::pMVinhA
compared to the empty vector (PYR7::pMV261; from 2.5 to
10mg/ml; Fig 2). In control experiments, overexpression of
inhA also led to increased isoniazid resistance in both strains
whilst not impacting the MIC of moxifloxacin (Fig 2). Together,
these genetic data strongly suggest that InhA is the target of
pyridomycin.
To further corroborate that the D148G mutation in inhA
was indeed responsible for pyridomycin resistance, we over-
expressed this allele in H37Rv and compared its effect with that
of a well-characterized mutation associated with isoniazid
resistance, InhA (S94A) (Vilcheze et al, 2006). Results presented
in Fig 2 clearly show that, compared to overexpression of
wild-type InhA (pMVinhA), overexpression of InhA (D148G)
causes four-fold greater resistance to pyridomycin while
overexpression of InhA (S94A) conferred only two-fold
resistance. Furthermore, overexpression of InhA (D148G) had
no impact on the MIC for isoniazid compared to overexpression
of wild type InhA, while, as expected, overexpressing InhA
(S94A) increased resistance around four-fold (Fig 2). None
of the mutations affected the MIC for moxifloxacin (Fig 2).
Collectively, the data prove that the D148G mutation in InhA is
responsible for resistance to pyridomycin, whilst not noticeably
affecting isoniazid activity.
In addition to isoniazid, InhA is also the target of ethionamide
and triclosan. Susceptibility studies using these compounds
on H37Rv and PYR7 indicate that both strains are equally
sensitive with MICs of 2.0 and 12.5mg/ml, respectively. This
lack of cross-resistance indicates that D148G in InhA is likely
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Table 1. Bacterial susceptibility to pyridomycin as measured by resazurin
reduction microtitre assay
Bacterium Pyridomycin MIC (mg/ml)
Mycobacterium tuberculosis 0.39
Mycobacterium bovis BCG 0.39
Mycobacterium smegmatis 0.78
Mycobacterium marinum 3.13
Mycobacterium abscessus 6.25
Mycobacterium bolletii 6.25
Mycobacterium massiliense 6.25
Mycobacterium avium 12.5
Corynebacterium glutamicum >100
Corynebacterium diphtheriae >100
Micrococcus luteus >100
Listeria monocytogenes >100
Staphylococcus aureus >100
Bacillus subtilis >100
Enterococcus faecalis >100
Escherichia coli >100
Pseudomonas putida >100
Pseudomonas aeruginosa >100
Salmonella typhimurium >100
Candida albicans >100
EMBO Mol Med (2012) 4, 1–11 ! 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 3
to have no impact on the binding to InhA of either triclosan
or the active metabolite of ethionamide, the ethionamide-NAD
adduct.
Susceptibility of isoniazid-resistant clinical isolates to
pyridomycin
Since our findings indicated that pyridomycin has the same
target as isoniazid, we investigated whether isoniazid-resistant
clinical isolates of M. tuberculosis retained susceptibility to
pyridomycin. As isoniazid is a pro-drug, clinically relevant
mutations that confer resistance are frequently found in the katG
gene encoding the catalase–peroxidase required for isoniazid
bio-activation or, less commonly, in the promoter region of
inhA, which increases expression of the protein. Of the eight
independent isoniazid-resistant clinical isolates analysed, four
had mutations in katG (S315T), three in the promoter region
of inhA [c (!15)t] and one isolate carried both mutations
(Table 2). Analysis of the drug susceptibility of these isolates
confirmed that all strains carrying the katGmutation displayed a
high level of resistance to isoniazid (MIC >10mg/ml) and those
isolates carrying only the inhA promoter mutation showed
intermediate isoniazid resistance (MIC¼ 1.25mg/ml) compared
to H37Rv (0.16mg/ml; Table 2). On the contrary, isolates
carrying the katG mutations showed no resistance to pyrido-
mycin (MIC¼ 0.3–0.6mg/ml), while a mutation in the inhA
promoter resulted in increased pyridomycin resistance
(MIC¼ 2.5–5mg/ml; Table 2). For all clinical isolates tested,
the susceptibility to moxifloxacin was similar to wild-type
(MIC¼ 0.03–0.10mg/ml). Thus, isoniazid-resistant clinical iso-
lates carrying the inhA [c (!15)t] promoter mutation displayed
cross-resistance with pyridomycin, whereas the more common
katG (S315T) isoniazid-resistant mutants retained full sensitiv-
ity to the antibiotic.
Inhibition of mycolic acid synthesis by pyridomycin
It has been elegantly demonstrated that inhibition of InhA by
isoniazid in M. tuberculosis leads to the specific depletion of
mycolic acids from the bacterial cell wall without affecting fatty
acid synthesis (Vilcheze et al, 2006). To show that pyridomycin
inhibition of InhA also results in inhibition of mycolic acid
synthesis, the mycolic and fatty acid content of M. tuberculosis
was determined in the presence and absence of pyridomycin by
radiometric thin layer chromatography (TLC). We found that
pyridomycin caused a concentration-dependent reduction of
mycolic acid synthesis (alpha-, methoxy- and keto-mycolic
acids) whilst not affecting the fatty acid content (Fig 3).
Furthermore, when performing the same experiment on PYR7,
over five-fold higher pyridomycin concentrations were needed to
inhibit mycolic acid biosynthesis consistent with the resistance
level observed. Both H37Rv and PYR7 behaved similarly when
Research Article www.embomolmed.org
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Figure 2. Genetic validation of InhA as the target of pyridomycin.
A-C. The compound susceptibility of wild-type H37Rv transformed with the control vector pMV261 (filled squares), pMVinhA (open squares), pMVinhA (S94A)
(open triangle) or pMVinhA (D148G) (open circle) to: (A) moxifloxacin, (B) isoniazid or (C) pyridomycin.
D-F. The compound susceptibility of pyridomycin-resistant mutant PYR7 transformed with the control vector pMV261 (filled squares), pMVinhA (open squares),
pMVinhA (S94A) (open triangle) or pMVinhA (D148G) (open circle) to: (D) moxifloxacin, (E) isoniazid or (F) pyridomycin.
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the assay was repeated in the presence of isoniazid (Fig 3).
Indeed, the latter caused a concentration-dependent decrease in
the amount of mycolic acids in H37Rv and was equally effective
at inhibiting mycolic acid synthesis in PYR7. Taken together,
these data confirm that pyridomycin targets mycolic acid
synthesis and demonstrate that the InhA (D148G) enzyme in
PYR7 is much less susceptible to pyridomycin inhibition.
In vitro inhibition of InhA by pyridomycin
Inhibition of purified InhA by pyridomycin was studied to
investigate if pyridomycin alone can inhibit the enzyme or
whether in vivo bio-activation by an intracellular process is
needed. InhA, InhA (S94A) and InhA (D148G) were successfully
expressed and purified. All three enzymes were catalytically
active and oxidized NADH in the presence of the substrate
2-trans-octenoyl-CoA (OcCoA). Initial experiments determined
the NADH-binding constant (Km) and confirmed that for InhA
(S94A) it was around 6.5 times higher than for wild-type InhA
(Table 3) as reported previously (Quemard et al, 1995; Rawat
et al, 2003; Vilcheze et al, 2006). Surprisingly, we found that
the Km of InhA (D148G) for NADH was 14-fold greater than for
wild-type InhA (Table 3) suggesting a lower affinity for NADH in
the D148G mutant. All the enzymes had a similar Vmax (around
0.52mmol/min/mg) (Table 3). Enzyme inhibition studies
showed that pyridomycin was able to inhibit both wild-type
InhA and InhA (S94A) at a similar Ki (6.5 and 4.55mM,
respectively) (Table 3). InhA (D148G) could not be inhibited at
all by pyridomycin at concentrations below 18.6mM. Statistical
analysis of inhibition of bothwild-type InhA and InhA (S94A) by
pyridomycin favours a model of competitive inhibition with
NADH as indicated by similar y-axis intercepts on Lineweaver–
Burk plots (Fig 4). These data prove that pyridomycin is the
pharmacophore that inhibits InhA, and this activity is achieved
by competitive inhibition of the NADH-binding site. Addition-
ally, these biochemical and enzymological results confirm that
InhA (D148G) is more resistant to pyridomycin while InhA
(S94A) is as susceptible as the wild-type enzyme.
Crystal structures of InhA (D148G), wild-type InhA and
InhA (S94A)
To further investigate the mode of binding of pyridomycin
to InhA at the atomic level, we crystallized and solved the
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Figure 3. Inhibition of mycolic acid synthesis by pyridomycin. The fatty acid methyl ester (FAMEs) and mycolic acid methyl ester (MAMEs) profiles of wild-type
H37Rv and pyridomycin-resistant mutant PYR7 were evaluated by thin-layer chromatography. Both strains were treated with different concentrations of
isoniazid and pyridomycin for 3 h and labeled with [1,2-14C]-acetate.
A. 14C-labeled FAMEs and MAMEs were separated by thin-layer chromatography and detected by autoradiography.
B,C. Quantification of the MAME band intensity relative to the density of the FAMEs illustrates the inhibition of MAME synthesis by pyridomycin (B) and isoniazid
(C) in H37Rv (black squares) and PYR7 (open circles).
Table 2. Pyridomycin activity against isoniazid-resistant clinical isolates of M. tuberculosis
Isolate KatG
genotypea
inhA promoter
genotypeb
MIC (mg/ml)
Isoniazid Pyridomycin Moxifloxacin
H37Rv wt wt 0.16 0.31 0.03
1 S315T wt >10 0.63 0.03
2 S315T wt >10 0.50 0.05
3 S315T wt >10 0.50 0.05
4 S315T wt >10 0.31 0.03
5 S315T c (!15)t >10 2.5 0.02
6 wt c (!15)t 1.25 3.75 0.10
7 wt c (!15)t 1.25 3.75 0.06
8 wt c (!15)t 1.25 5 0.06
wt, wild-type.
aNumbering refers to the KatG protein sequence.
bNumbering refers to the inhA coding sequence, with þ1 corresponding to the first base of the ATG start codon.
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structures of wild-type InhA and InhA (S94A) mutant in
complex with NADH as previously published (Dessen et al,
1995; Dias et al, 2007; Molle et al, 2010; Oliveira et al, 2006;
Rozwarski et al, 1999; Vilcheze et al, 2006). In an attempt to
obtain crystal structures of InhA in complex with pyridomycin,
pre-crystallized InhA:NADH or InhA (S94A):NADH crystals
were soaked in a pyridomycin solution. On penetration of
pyridomicin, the crystals turned yellow but lost their ability to
diffract. This suggests that pyridomycin may induce major
conformational changes upon binding to the NADH co-factor
pocket of InhA. For control purposes, InhA:NADH crystals were
also soaked with triclosan, an inhibitor of the enoyl-ACP
substrate binding site of InhA, and the structure successfully
solved, thereby ruling out technical issues with soaking
(data not shown). As an alternative strategy to define the
pyridomycin binding site in InhA attempts were made to co-
crystallize InhA or InhA (S94A) in the presence of pyridomycin
alone or with the octenoyl CoA substrate; however, despite
testing over 1000 conditions, no diffracting crystals have been
obtained to date.
The D148G mutation leads to pyridomycin resistance as
well as to a decrease in NADH affinity (Table 3). To determine
the molecular basis for this resistance, we crystallized InhA
(D148G) in the presence or absence of NADH. As with InhA and
InhA (S94A), we obtained crystals only in presence of NADH
and solved the InhA (D148G):NADH structure to 2.54 A˚
(Supporting Information Table S3). By comparing the structure
of InhA (D148G):NADH with that of wild-type InhA:NADH
and InhA (S94A):NADH obtained in this study and elsewhere
(Dessen et al, 1995; Dias et al, 2007; Molle et al, 2010; Oliveira
et al, 2006; Rozwarski et al, 1999; Vilcheze et al, 2006),
we observed only one major effect, namely rotation of the
phenylalanine 149 (Phe149) side chain by 908 (Fig 5).
Otherwise, the positions of other active site residues as well
as the overall structure of the protein were identical (Supporting
Information Fig 1).
Interestingly, Phe149 in the InhA (D148G) mutant adopts the
same orientation as InhA and InhA (S94A) in complex with
INH-NADH (Dias et al, 2007; Rozwarski et al, 1999; Vilcheze
et al, 2006). Thus, in the InhA (D148G) mutant, Phe149 is
naturally placed for Pi-stacking with the INH moiety and this
explains the unchanged MIC observed for isoniazid against
wild-type InhA and the InhA (D148G) mutant in vivo (Fig 5).
Furthermore, rotation of the Phe149 side chain in the InhA
(D148G) mutant also results in opening of a water channel
allowing the addition of two water molecules in the active site as
well as increasing the distance between the nicotinamide ring of
NADH and the ring of Phe149, leading to a decrease in NADH
affinity as confirmed by kinetic studies (Fig 5). The same
structural changes most probably also explain the decreased
sensitivity of InhA (D148G) to pyridomycin compared to wild-
type as NADH and pyridomycin share a similar binding pocket.
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Figure 4. Inhibition of purified InhA by pyridomycin.
A-C. Lineweaver–Burk plot showing the competitive inhibition of wild-type InhA (A), InhA (S94A) (B) and InhA (D148G) (C) by pyridomycin in the presence of
NADH.
Table 3. In vitro kinetic parameters of M. tuberculosis InhA and its inhibition by pyridomycin
Wild-type InhA InhA (S94A) InhA (D148G)
NADH Km (mM) 13.5! 2.3 83.5!9.5 190!16
NADH Vmax (mmol/min/mg) 0.52! 0.03 0.50!0.02 0.54!0.3
Pyridomycin Ki (mM) 6.5!1.2 5.0!0.4 No inhibition at 18.6mM
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DISCUSSION
To inhibit or kill competing organisms, numerous microbes
produce and secrete natural products with antibiotic activity.
This rich source of chemically diverse compounds was
successfully exploited for the production of many anti-microbial
and anti-cancer drugs in the first decades of antibiotic
development but was then abandoned (Fischbach & Walsh,
2009). Since the selective pressure imparted by some antibiotics
with broad-spectrum activity may have led to naturally
occurring resistance in other bacteria that share the same
ecological niche, many potentially bio-active molecules may
have been overlooked (Smith et al, 2010). The ecological and
evolutionary forces that have shaped natural products,
particularly the selection and inhibition of vulnerable targets,
remain unknown but understanding this relationship is
important for drug discovery.
The treatment of tuberculosis is increasingly menaced by
the emergence of drug-resistant strains of M. tuberculosis and
this has led to renewed interest in finding new bactericidal
inhibitors. As in other anti-infective areas, target-based screens
have been unsuccessful prompting investigators to adopt whole
cell screening once more (Cole & Riccardi, 2011; Payne et al,
2007). Consequently, we are reinvestigating diverse natural
products for hit generation as these compounds have been
optimized by evolution as antibacterial agents. In this study,
we have used pyridomycin, a natural product with anti-
mycobacterial activity, to identify the intracellular target and
characterized its mechanism of action. Pyridomycin was first
described in 1953 (Maeda et al, 1953), shortly after the
introduction of isoniazid into clinical practice, but was then
apparently neglected. In a remarkable coincidence, we show
that, like isoniazid, pyridomycin directly targets the NADH-
dependent enoyl (ACP)-reductase InhA and causes inhibition
by competing for the NADH-binding pocket.
InhA (also known as FabI) is an essential component of the
type II fatty acid synthase system (FasII) involved in fatty acid
elongation and is required for mycolate production in
M. tuberculosis. The FasII system is highly conserved in bacteria
but absent from humans making it an attractive drug target
(Heath et al, 2002; McMurry et al, 1998; Vilcheze et al, 2006,
2011). Although isoniazid is certainly the most effective known
inhibitor of InhA in M. tuberculosis, it is a pro-drug requiring
activation by the KatG catalase–peroxidase to form an adduct
with NAD. Clinically significant resistance to isoniazid is mainly
attributed to loss or alteration of KatG activity. The INH-NAD
adduct acts as a slow, tightly binding competitive inhibitor of
the NADH-binding site of InhA (Rawat et al, 2003). Interestingly,
mycobacterial InhA is also targeted by the small molecules
ethionamide (Morlock et al, 2003) (also a pro-drug) and
triclosan (Parikh et al, 2000) whilst in other bacteria, FabI is
inhibited by the natural products vinaxanthone and cephalo-
chromin (Zhang & Rock, 2008). Other natural products with
broad-spectrum activity, such as thiolactomycin, cerulenin and
platensimycin, have been shown to target different components
of the FasII system in other bacteria (Zhang & Rock, 2008).
Our results suggest that pyridomycin is the most potent natural
product to inhibit FasII specifically in M. tuberculosis and
resistance arises due to remodelling of the NAD-binding site in
InhA, notably through mutation of D148G.
Pharmacologically validated drug targets are scarce in
M. tuberculosis with InhA being among the best (Lamichhane,
2011). For this reason, several attempts have been made to
develop heterocyclic inhibitors that differ from isoniazid and
ethionamide in their structure and activity. Examples include
heterocyclic boron containing compounds (diazaborine) that
react with NADþ ribose to form diazyborine-NAD adducts
that inhibit InhA similarly to INH-NAD (Baldock et al, 1996).
Triclosan analogues (Freundlich et al, 2009; Vilcheze et al, 2011)
and di-phenyl ether compounds (Sullivan et al, 2006) have been
shown to inhibit InhA with nanomalar Ki and micromolar
MICs and are both promising candidates as anti-tuberculosis
compounds. Further screening studies for Escherichia coli FabI
inhibitors have also revealed effective novel structures, many of
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Figure 5. Crystal structures of InhA (D148G) compared to wild-type InhA and InhA (S94A).
A. The 2fo-fc electron density map at 1 sigma of InhA (D148G):NADH structure (at 2.45 A˚) with Phe149 and NADH represented as sticks.
B. Superposition of InhA (D148G):NADH (blue) on InhA:NADH and InhA (S94A):NADH (both in green) clearly shows the D148G mutation and the resulting
908 rotation of Phe149.
C. Overlay of InhA (D148G):NADH (Blue) and InhA:NAD-INH (PDB code 1Z1D: Pink) shows that, in this case, Phe149 occupies the same position and explains why
InhA (D148G) is still sensitive to inhibition by isoniazid.
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which however do not have good MIC against M. tuberculosis
(Lu & Tonge, 2008; Payne et al, 2002).
It is noteworthy that, while the FasII system is present in most
bacteria, pyridomycin is a specific inhibitor of mycobacterial
species (Table 1). Amongst the mycobacteria tested here, the
InhA proteins share a high level of sequence identity (77%) and
both Asp148 and Phe149 (as well as other active site residues)
are strictly conserved, which may explain why all mycobacteria
were susceptible to the antibiotic. Additionally, other patho-
genic mycobacteria such as M. leprae and M. ulcerans also
share near identical InhA proteins (91 and 93% identity to the
M. tuberculosis ortholog, respectively) and are expected to be
susceptible to pyridomycin (Supporting Information Fig 1).
The level of sequence identity between M. tuberculosis InhA
and FabI from the different Gram-positive and Gram-negative
bacteria tested here is considerably lower, ranging from 27
to 33%. Neither Asp148 nor Phe149 are conserved in these
enzymes, which probably accounts for their pyridomycin
resistance. It is possible that through cohabitating with
producers of pyridomycin, or a related natural product, the
ancestors of these bacteria may have acquired resistance to the
antibiotic as has been proposed for arylomycin, a natural
product that inhibits signal peptidase I (Smith et al, 2010).
The increasing emergence of isoniazid resistance in clinical
isolates of M. tuberculosis is an important problem for
tuberculosis therapy and seriously compromises the effective-
ness of current treatment. In 50–95% of the cases, resistance to
isoniazid is caused by mutations in katG (Zhang & Yew, 2009).
Low-level resistance to isoniazid is also associated with
upregulation of inhA but mutations in the inhA gene itself
are much less common (8–43%) (Zhang & Yew, 2009). Our data
clearly show that pyridomycin does not require activation. This
is of particular significance because it means that pyridomycin
can effectively kill isoniazid-resistant M. tuberculosis carrying
katG mutations as demonstrated by our susceptibility testing of
isoniazid-resistant clinical isolates.
The pyridomycin resistant strain PYR7, that carries the
D148G mutation in InhA, is not cross-resistant to isoniazid and
ethionamide while, conversely, the S94A variant that displays
isoniazid resistance remains susceptible to pyridomycin (Fig 2).
This suggests that, while both pharmacophores are competitive
inhibitors of NADH-binding, they bind to the pocket in different
ways. Additionally, the lack of cross resistance with triclosan,
the scaffold for other InhA inhibitor programs, is promising
as it demonstrates that there are multiple ways of inhibiting
the same protein without cross-resistance occurring. These are
important findings for rational drug design and could lead to
the development of pyridomycin derivatives that kill multiple
mycobacteria unlike isoniazid, which is effective solely against
M. tuberculosis.
MATERIALS AND METHODS
General information
Bacterial strains, culture conditions, pyridomycin production and
purification, expression and purification of proteins and details of
materials are described in Supporting Information Materials and
Methods.
Determination of pyridomycin MIC
The drug susceptibility of all bacteria was determined using the
resazurin microtitre assay (REMA; Palomino et al, 2002). Briefly,
log-phase bacteria were diluted to an OD600 of 0.0001, and grown in
a 96-well plate in the presence of serial compound dilutions. After
10 generations (7 days for M. tuberculosis) bacterial viability was
determined using 10ml of resazurin (0.025% w/v), and calculated as a
percentage of resazurin turnover in the absence of compound.
Methodology for determining the minimum bactericidal activity
(MBC) and intracellular activity are described in the Supporting
Information Materials and Methods.
Isolation and characterization of pyridomycin-resistant
H37Rv clones
Pyridomycin-resistant H37Rv mutants were isolated by plating
109 CFU on solid 7H10 medium containing 3mg/ml of pyridomycin
(10!MIC). Following 4 weeks of incubation (37 8C), colonies were
picked and grown in 7H9 medium without pyridomycin. Colonies
were then retested for susceptibility to pyridomycin, moxifloxicin,
isoniazid and rifampicin. Pyridomycin-resistant clone PYR7 was
selected for whole genome sequencing using Illumina technology
and reads aligned to the genome sequence of the parent H37Rv
genome to identify SNPs (protocols described in Supporting Informa-
tion Materials and Methods). The SNP in inhA was validated by
conventional Sanger sequencing using an ABI3130XL genetic analyser
(Applied Biosystems).
Determination of MIC on isoniazid-resistant clinical isolates
Nine isoniazid-resistant clinical isolates that were ‘genotyped’ using
the Line probe assay (1st line drugs, GenoType MTBDRplus) were
kindly supplied by the Centre Hospitalier Universitaire Vaudois (CHUV)
and the Hoˆpitaux Universitaires de Gene`ve (HUG). Isolates were grown
to mid log phase in liquid medium and tested for their pyridomycin,
isoniazid and moxifloxacin susceptibility by REMA.
Over-expression of inhA in H37Rv and PYR7
To genetically validate that InhA was the target of pyridomycin, the
impact of over-expressing either wild-type InhA or the mutant forms
in strains H37Rv and PYR7 was determined. Briefly, Quick change
site-directed mutagenesis was used with pMVInhA [where inhA is
expressed from the hsp60 promoter in pMV261 (Larsen et al, 2002)]
to introduce t280g or a443g mutations thus generating pMVInhA
(S94A) and pMVInhA (D148G), respectively (primers in Supporting
Information Table 1). Plasmids pMVInhA, pMVInhA (S94A) and
pMVInhA (D148G) were transformed into H37Rv and PYR7. Transfor-
mants were selected using kanamycin, then verified by colony PCR for
the presence of the kanamycin-resistance cassette before determining
their MIC for pyridomycin, isoniazid and moxifloxacin by REMA.
Inhibition of mycolic acid synthesis by pyridomycin
The inhibition of mycolic acid production by pyridomycin and
isoniazid was determined as previously described (Vilcheze et al,
2006). Briefly, early log-phase cultures of H37Rv and PYR7
(OD600¼0.3, 4ml) were treated for 3 h with isoniazid (0.1, 0.4 and
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2mg/ml) or pyridomycin (0.4, 2, 5, and 20mg/ml) prior to labelling for
20 h with [1,2-14C] acetate (1mCi/ml; Perkin Elmer). Bacteria were
harvested and washed with double-distilled H2O to remove excess
[1,2-14C]-acetate. The bacterial pellet was then treated with 2ml of
20% tetrabutyl ammonium hydroxide overnight at 100 8C to extract
the mycolic acids from the cell wall. Mycolic acids were subsequently
methylated and extracted by incubation with an equal volume of
methylene chloride and 100ml of methyl iodide for 1 h at room
temperature with mixing. The organic phase containing the mycolic
acid methyl esters (MAMEs) was washed once with 3N HCl and once
with H2O, dried under nitrogen and resuspended in a smaller volume
of methylene chloride. Radiolabelled MAMEs were analysed by TLC.
For each condition 10,000dpm were loaded on a HPTLC Silica Gel 60
F254 plate and run three times with 95:5 v/v hexane/ethyl acetate.
The MAMEs were visualized using a TyphoonTM scanner (GE
Healthcare) and quantified with the software ImageQuantTM (GE
Healthcare).
Steady state kinetics and inhibition of InhA
Inhibition of InhA activity was investigated using InhA, InhA (S94A)
and InhA (D148G) as described previously (Dessen et al, 1995;
Quemard et al, 1995). Briefly, kinetic parameters were determined by
following NADH oxidation at 340 nm using a TECAN FL200 spectro-
photometer. All reactions were performed at 25 8C with 100nM InhA
(or mutants) in 30mM PIPES (pH 6.8), 150mM NaCl and 10%
glycerol. After addition of variable concentrations of NADH, reactions
were initiated by adding 2-trans-octenoyl-CoA (synthesized as
described in Supporting Information Materials and Methods) to a
final concentration of 250mM. Steady state Km for NADH was
determined by measuring enzyme kinetics at different NADH
concentrations (0–800mM). NADH Km and pyridomycin Ki were
determined by measuring enzyme kinetics with both different NADH
(wild type InhA – 10, 12.5, 16.7, 25 and 50mM, for both InhA (S94A)
and InhA (D148G) !50, 62.5, 83.3, 125, 250mM NAHD) and different
pyridomycin concentrations (0, 0.625, 1.25, 2.5, 5 and 10mg/ml).
Kinetic parameters were analysed and calculated using GraphPad
Prism 5.
Crystallization, data collection and structure determination
Crystals of the InhA:NADH complex, InhA (D148G):NADH complex and
InhA (S94A):NADH complex were obtained by vapour diffusion at
188C by equilibrating 2ml hanging drops containing a 1:1 mixture of
approximately 10mg/ml protein incubated with 5mM NADH and
crystallization buffer (10% v/v MPD and 0.1M TRIS, pH 8.0 for
InhA:NADH complex; 8% v/v MPD and 0.1M Bicine, pH 9.0 for InhA
(D148G):NADH complex; and 8% v/v MPD, 50mM Sodium Citrate,
pH 6.5 and 0.1M Hepes, pH 7.5 for InhA (S94A):NADH complex) over a
500ml reservoir of the same crystallization solution. Crystals were
stabilized by soaking briefly in a cryoprotectant solution (25% glycerol
w/v in crystallization buffer) and flash frozen in liquid nitrogen before
data collection. Diffraction data were collected on X06DA of the Swiss
Light Source (SLS, PSI, Villigen, Switzerland) and on ID29 at the
European Synchrotron Radiation Facility (ESRF, Grenoble, France). Data
were indexed, integrated and scaled with XDS (Kabsch, 2010). Both
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The paper explained
PROBLEM:
Even today, infection with Mycobacterium tuberculosis accounts
for up to two million deaths annually. The effectiveness of
current anti-tuberculosis drugs to combat these infections is
increasingly compromised by the escalating prevalence of multi-
and extensively drug-resistant tuberculosis. For these cases, the
most effective anti-tubercular compounds such as isoniazid and
rifampicin are no longer effective and this can result in mortality
rates approaching 100% for patients with extensively drug-
resistant tuberculosis. For these reasons, it is imperative to
ensure that the pipeline of drug candidates to treat tuberculosis
is well filled.
RESULTS:
We show here that the natural product pyridomycin is a
very selective bactericidal compound against mycobacteria
including Mycobacterium tuberculosis, the causative bacterium
of tuberculosis in humans. By selecting and isolating M.
tuberculosis mutants resistant to pyridomycin and sequencing
their genome, we found that a single mutation in a gene named
inhA is responsible for the resistance. InhA is already the target
of the current frontline anti-tuberculosis agent isoniazid.
However, most interestingly, no cross resistance was observed
between pyridomycin and isoniazid, both in laboratory strains
containing mutations in InhA or in the most frequently
encountered isoniazid-resistant clinical isolates that contain
mutations in katG (a gene required to activate isoniazid).
We then present detailed genetic and biochemical studies to
confirm that pyridomycin itself inhibits InhA and that in live
bacteria, this inhibition leads to the depletion of mycolic acids,
an essential cell wall component. Finally, studies of the crystal
structure of the InhA protein and the pyridomycin-resistant
form give valuable insight into the binding pocket of
pyridomycin.
IMPACT:
Inhibition of InhA is one of the most effective means of killing
Mycobacterium tuberculosis, and this is the mechanism behind
one of the most potent anti-tubercular agents currently used:
isoniazid. The increasing emergence of multi- and extensively
drug-resistant tuberculosis (both of which are resistant to
isoniazid) means that for these cases, this target can no longer be
effectively inhibited by current therapy. Our finding that
pyridomycin kills M. tuberculosis by inhibiting InhA (even in
isoniazid-resistant clinical isolates) provides a promising basis
for the development of pyridomycin or a related agent for the
treatment of isoniazid-resistant tuberculosis.
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wild-type InhA and its mutants crystallized in the P6222 space group
with unit cell dimensions of approximately a¼ b¼98 A˚, c¼139 A˚,
a¼b¼908 and g ¼1208, with one molecule per asymmetric unit
(Supporting Information Table 2). Phase determinations were carried
out by molecular replacement using Phaser (McCoy et al, 2007), part
of the CCP4 Suite, using as a search model the published structure
of the InhA:NADH complex from M. tuberculosis (PDB code 3OEW).
The initial molecular replacement models were manually adjusted
in COOT, part of the CCP4 Suite (Winn et al, 2011) and refined with
REFMAC5 (Murshudov et al, 1997). The refined structures were
evaluated with PROCHECK (Laskowski et al, 1996). Structure figures
were prepared with PyMOL (Molecular Graphics System, Version
1.5.0.1 Schro¨dinger, LLC). All crystallographic statistics are listed in
Supporting Information Table 2. Coordinates and structure factors
for the above complexes structures have been deposited in the
Protein Data Bank (PDB accession codes 4DRE, 4DTI and 4DQU,
respectively).
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5. Conclusion and Perspectives 
The work carried out in this thesis presents the successful application of 
microarray and next-generation sequencing (NGS) technologies in 
comparative and functional genomics research of Mycobacterium tuberculosis 
(M. tb), the etiologic agent of tuberculosis. We have established and 
employed computational strategies for the analysis, integration, and 
interpretation of genomic and transcriptomic datasets to improve our 
understanding of the evolution, physiology and virulence of the MTBC. We 
performed comparative genomic analysis to assess the genetic diversity in 
MTBC strains by means of SNP genotyping, automated Sanger sequencing 
and whole genome re-sequencing in order to reveal genomic differences that 
could have functional consequences. Our studies in functional genomics 
investigated the role of several transcription regulators in M. tb using ChIP-
on-chip or ChIP-seq, and determined the transcriptome profiles of M. tb in 
different conditions with the use of cDNA microarrays or high-throughput 
cDNA sequencing (RNA-seq). Some of our findings may have direct 
implications in the development of diagnostics, vaccines and new drugs for 
TB control. 
 
This chapter will recapitulate the major findings of the studies presented in 
this thesis and comment on other areas of TB research that could benefit 
from the applications of NGS (in addition to those summarized in section 
2.2.4). When applicable, there will be a discussion of cutting edge NGS 
methodologies that could further our efforts to uncover novel aspects of M. tb 
biology and pathogenesis. Finally, the potential utility of NGS in the clinical 
setting will be discussed along with the bioinformatics challenges associated 
with the interpretation of data generated by these technologies.  
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In order to promote the development of TB vaccines, it is necessary to 
improve our understanding of the genetic mechanisms contributing to BCG 
attenuation and to the variable efficacy among individual vaccine strains. 
Using high-throughput SNP genotyping we were able to identify a minimal 
set of 115 nonsynonymous SNPs that distinguish attenuated M. bovis BCG 
vaccine strains and virulent M. bovis strains. Two follow up publications by . 
have characterized the functional effect of some of the nsSNPs identified in 
our study (Mendoza Lopez et al. 2010; Chen et al. 2012). We also identified 
strain-specific SNPs among BCG strains that could be studied further to 
determine their functional consequences and possible contribution to the 
variation in protective efficacy of different BCG vaccines.  
 
Identification of immunodominant M. tb antigens and studying their 
interaction with the host immune cells is crucial for the development of an 
effective TB control strategy. In order to evade the host immune system, 
variants of pathogens emerge, with alterations in epitope regions recognized 
by critical host immune cells. We characterized the sequence diversity in the 
highly immunodominant esx gene family among clinical isolates of M. tb in 
order to identify sequence polymorphisms that may affect their 
immunogenicity. Our work has led to the identification of non-synonymous 
mutations affecting known T-cell epitopes in EsxB (CFP-10) and EsxH 
(TB10.4). EsxB peptides are used in commercially available diagnostic tests 
for TB and the nonsynonymous substitutions may influence responses to 
EsxB peptides in such diagnostic tests. As EsxH has been used to obtain a 
fusion protein-based subunit vaccine failure to consider mycobacterial strain 
diversity could have a significant negative impact on vaccine efficacy.  
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We exploited the power of NGS by performing whole genome re-sequencing 
to detect sequence variation among M. tb strains, which could result in 
phenotypic differences. In one study, genome comparison of drug-resistant 
mutants with the sensitive wild-type strain we identify InhA as the target of 
the anti-TB drug, pyridomycin. Our finding that pyridomycin kills M. tb by 
inhibiting InhA (even in isoniazid-resistant clinical isolates) provides a 
promising basis for the development of pyridomycin or a related agent for the 
treatment of isoniazid-resistant tuberculosis. Using a similar approach we 
identified a spontaneous mutation that makes M. tb strains incapable of 
producing PDIMs (phthiocerol dimycocerosates), which are cell-wall 
associated lipids involved in M. tb virulence.  
 
We applied two high-throughput approaches for detection of sequence 
variation - SNP-genotyping arrays and whole genome re-sequencing. NGS 
offers unprecedented coverage and resolution for detection of rare genetic 
variants, which is especially useful in case of genetically monomorphic species 
such as M. tb. As NGS becomes more affordable it is likely that whole 
genome re-sequencing will replace array-based SNP detection. In M. tb 
research, whole genome re-sequencing has been mostly used to study 
pathogen evolution and population structure. The ability to discriminate 
between closely related strains using NGS has provided us with an enhanced 
view of pathogen biology and allowed reconstruction and refinement of the 
existing MTBC phylogeny (Comas et al. 2010; Schürch 2011). NGS has also 
been valuable in TB drug discovery; re-sequencing of drug resistant mutants 
has been successfully used for identification of the targets for two anti-TB 
drugs, namely, TMC207 (Andries et al. 2005), and pyridomycin (Hartkoorn et 
al. 2012). Whole-genome comparisons surpass traditional typing methods in 
assessment of genetic diversity. Based on NGS data, Niemann et al. (2009) 
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uncovered significant genomic differences in drug sensitive and MDR-isolates 
of M. tb exhibiting identical IS6110-RFLP patterns, which may have 
important clinical implications.   
 
It has been established that different M. tb strains have distinctive 
epidemiological and clinical characteristics (Lopez et al. 2003). The impact of 
differences in virulence and immunogenicity between M. tb on the outcome of 
disease is yet unclear. M. tb specific CD4+ T-cell signatures have been shown 
to vary significantly among patients with active disease, latent infection, and 
upon initiation of anti-TB therapy (Harari et al. 2011). Our laboratory has 
started a collaborative project that involves detailed profiling of M. tb specific 
host cellular immune response associated with different disease outcomes, and 
in response to therapy. The immunity profiles will be correlated with 
genotypes of M. tb clinical isolates, which will be determined by whole 
genome re-sequencing.  
 
In addition to the characterization of individual isolates, NGS can also be 
used to reveal the taxonomic and functional diversity of microbial 
communities. This will help us understand the impact of genetic diversity of 
M. tb diversity on immune response before and after anti-TB therapy. 
Metagenomics has been widely applied for profiling microbial communities 
from different habitats, such as aquatic ecosystems, soil, bioreactors, etc. The 
human microbiome project is an international effort that aims to characterize 
microbial communities at five different sites on the human body (gut, nasal, 
oral, vaginal, skin) and to correlate changes in microbial communities with 
disease states (Gevers et al. 2012). Metagenomic data analysis involves 
mapping of the reads directly against an entire database of complete or draft 
genomes. The results are represented as the relative abundance of different 
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species in the sample. Recent metagenomic studies of the lung microbiome 
revealed alterations in the lung flora of people suffering from respiratory 
diseases such as asthma and cystic fibrosis, compared to healthy individuals. 
A similar approach could be applied to understand the interaction of M. tb 
with the lung flora, and compare the lung microbiome during active disease 
and in response to therapy. The resulting information may promote the 
development of microbiome-based biomarkers for diagnosis and follow-up of 
anti-TB treatment.  
 
In order to determine their biological significance, genomic differences need to 
be studied in a functional context. Gene expression and its regulation by 
transcription factors contribute to the complexity of biological function. 
Within transcriptional regulation the interactions of transcription factors 
(TFs) with DNA are of central importance. Using a combination of the two 
high-throughput approaches, we characterized the transcriptome of M. tb and 
studied the genome-wide dynamics of two key components of the 
transcription machinery, RNA polymerase (RNAP) and NusA, in exponential 
and stationary phases of growth. We demonstrated that NusA interacts with 
RNAP ubiquitously and that its profile mirrors RNAP distribution in both 
the exponential and stationary phases of growth. Differential binding of 
RNAP and NusA in the two growth conditions correlated with transcriptional 
activity as reflected by RNA abundance. By systematic integration of the 
ChIP-seq and RNA-seq data, we identified a set of transcription units (TU) 
in the M. tb genome, and mapped their putative promoters. Analysis of 
RNAP and NusA binding across the promoter and the body of TUs and their 
correlation with transcription offered new insights on the biological roles of 
RNAP and NusA in promoting transcription. The high resolution and 
accuracy offered by RNA-seq helped us uncover novel anti-sense and 
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intergenic transcripts and enabled refinement of the M. tb genome 
annotation. Our catalogue of the gene expression and the genome-wide 
dynamics of the RNA polymerase and NusA in exponential and stationary 
phases of growth is a valuable resource to the TB research community. 
 
We also exploited the ChIP-on-chip and ChIP-seq technologies to define the 
regulon of a specific sigma factor, SigF, and gain a better understanding of 
the role of virulence regulator EspR. In the case of SigF, integration of the 
genome wide binding profile with transcriptomic data provided a complete set 
of genes whose expression was directly regulated by SigF. Our results 
confirmed that SigF controls its own expression, and regulates transcription 
of genes involved in lipid and intermediary metabolism, virulence, and even a 
small RNA. Together with the 3D-structure of EspR (Blasco et al. 2011), 
ChIP-seq data support its role as a novel nucleoid-associated protein (NAP) 
that plays architectural and regulatory roles that impact M. tb pathogenesis 
through multiple genes . The EspR regulon comprised genes encoding a host 
of diverse functions such as production of the complex PDIM lipids, the 
virulence-mediating ESX-1 cluster, PE/PPE cell-surface proteins, etc. 
 
M. tb possesses a vast repertoire of regulatory elements as it encodes 13 sigma 
factors directing the specificity of the RNAP core enzyme to a defined subset 
of promoters and over 200 potential transcriptional regulators. In addition, a 
number of NAPs contribute to shaping the chromosome and impact 
transcriptional activity in M. tb. The studies mentioned above have been a 
major step towards our ultimate goal of generating a complete regulatory 
map of the M. tb genome to fully understand transcriptional control and 
uncover the role of diverse regulatory elements in different conditions.  
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As a continuation of our efforts, generation of ChIP-seq datasets using 
specific antibodies against several regulatory proteins, including the two-
component response regulator PhoP, termination factor Rho, topology 
enzymes TopA and GyrA, and various sigma factors (SigA, SigB, SigE) will 
be carried out in the near future. When available, isogenic mutants will be 
used as a negative control in ChIP-seq and for comparison in RNA-seq. The 
ChIP-seq results can be integrated with the RNAP, NusA and RNA-seq 
datasets in different growth conditions in order to correlate the presence of 
specific regulatory proteins with transcriptional activity. Integration of 
binding profiles for sigma factors and RNAP with transcriptional activity will 
allow definition of promoter features and correlation of promoter strength 
with utilization of specific sigma factors in both exponential and stationary 
phase.  
 
NAPs are the bacterial equivalent of histones and act by stabilizing long-
range structures in the genome through cooperative binding to multiple sites. 
New technologies based on chromosome confirmation capture (3C) can be 
used to probe this higher level of regulation by NAPs (Dekker et al. 2002). 
The carbon-copy chromosome confirmation capture (5C) technique allows 
identification of physical interactions between distant DNA regions and can 
be used to generate a conformational map of the chromosome (Dostie et al. 
2006). More recently, chromatin interaction analysis by paired-end tag 
sequencing (ChIA-PET) has been developed and applied in eukaryotes to 
capture associations among genomic regions mediated by a particular protein 
through a ChIP step (Fullwood & Ruan 2009). As these technologies mature, 
they will be adapted to M. tb to elucidate spatial and temporal aspects of 
gene regulation by NAPs (EspR, H-NS, HupB, etc).  
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Generation of a regulatory map of the genome will require integration of the 
numerous NGS datasets using sophisticated data-mining, clustering and 
network biology approaches to identify interactions and dependencies within 
the transcription complex. Machine learning techniques, notably Bayesian 
networks can be used to integrate data from different kinds of experiments, 
and to find associations among diverse kinds of data. A better understanding 
of the molecular mechanisms at the basis of M. tb multiplication, survival and 
control of gene expression will underpin future translational research. 
 
It is clear that genomic, transcriptomic and metagenomic data sets produced 
by NGS can provide us with unprecedented opportunities to address 
fundamental questions related to genome function and disease. NGS 
applications also hold great promise in the clinical and public health domain, 
particularly in areas of diagnosis, molecular epidemiology, and treatment 
control. Researchers have exploited the discriminatory power of whole genome 
sequencing in a number of recent outbreaks to investigate the real-time 
evolution of disease-associated clonal isolates, tracing person-to-person 
transmission and identifying sources of outbreaks. Some examples include, the 
cholera epidemic in Haiti (Chin et al. 2011) 
Chin et al. 2011), the E. coli O104:H4 outbreak in Germany (Grad et al. 
2012), MRSA (methicillin-resistant Staphylococcus aureus) cases in a hospital 
in Thailand (Harris et al. 2010), and  a TB outbreak in British Columbia 
(Gardy et al. 2011). Whole genome sequencing offers a resolution superior to 
all existing molecular typing tools.  
 
Drug susceptibility testing for bacterial pathogens can provide clues to the 
potential for disease progression and aid further investigation and clinical 
management of the disease. The use of whole genome re-sequencing as a 
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diagnostic method is appropriate only in organisms that exhibit a high 
correlation between phenotype and genotype. In this respect, M. tb represents 
an ideal candidate due to lack of heterogeneity between MTBC strains and 
the fact that many of the drug-resistance traits arise through point mutations 
or indels in single genes. Moreover, due to the slow growth rate of M. tb, the 
turnaround time for phenotypic susceptibility is too long. At present, the 
WHO endorsed genotypic test, namely the GeneXpert MTB/RIF assay, can 
rapidly distinguish MTBC from other acid-fast bacteria and detect rifampicin 
resistance (Helb et al. 2010). This test could be complemented by whole 
genome sequencing of the organism which could, over time, replace the 
remaining diagnostic functions including the precise species identification, 
susceptibility testing for remaining antibiotics, and epidemiological typing, 
which are currently achieved using a number of different techniques at 
reference laboratories.  
 
NGS has the potential to transform clinical and public health microbiology 
but there are certain challenges that need to be addressed. The capacity to 
generate NGS data greatly outpaces our ability to analyze it. The lack of 
standardized and automated data interpretation represents the major hurdle 
to clinical implementation. Since the introduction of the first NGS platform 
in 2004, the field of NGS has been developing at a tremendous rate. Major 
advances include, reduction in the sequencing costs and turnaround time, and 
improvements in sequencing read length, depth and data accuracy offered by 
various NGS platforms.  
 
The massive data produced by NGS presents a significant challenge for data 
storage, analyses and management. The development of a customizable data 
analysis pipeline for interpretation of NGS data is time and labour intensive, 
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and depends on a complex set of choices from among the many bioinformatics 
and statistical tools that are available. A variety of open-source and 
commercial data analysis tools for NGS are being developed. NGS data 
analysis is a multi-step process and the tools generally fit into the following 
broad categories: (1) quality control of raw data, (2) alignment of reads to a 
reference or de novo assembly in absence of a reference, (3) base-calling and 
detection of variation (i.e. SNPs, insertions and deletions), (4) method-specific 
data analysis (i.e. peak calling for ChIP-seq, analysis of differential gene 
expression for RNA-seq, etc.), (5) visualization and analysis in terms of the 
genome annotation.  
 
The challenge for bioinformaticians is to create tools that are easy to use and 
provide output that can be readily interpreted by bench scientists and 
clinicians with no specialist knowledge of NGS analysis techniques. An ideal 
software would be platform and organism independent, able to support 
analysis of different types of NGS data and perform downstream tasks 
ranging from epidemiological tracking to drug susceptibility testing. This 
needs to be supported by comprehensive databases that would enable 
retrieval and comparison of sequence data from clinical isolate(s) with 
existing strains in the database. One must stress the importance of genome 
annotation for interpretation of how genetic sequences translate to resistance 
phenotypes. The reliability of NGS as a means of predicting antimicrobial 
susceptibility is critically dependent upon the availability of a current and 
curated database of reference sequences. In order to address the present 
challenges, future advances in NGS should focus on improvements not limited 
to but including the following areas: (1) reducing the quantity of starting 
material required in order to save time and effort needed for culturing, (2) 
decreasing costs of DNA library preparation prior to sequencing, (3) 
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improving our understanding of variation between different sequencing 
platforms, especially in terms of error profiles, (4) developing easy-to-use, 
standardized and replicable data assembly and analysis workflows, (5) 
constructing and maintaining accurate and readily accessible annotation 
databases for  reference genomes, and, (6) maintaining public data 
repositories to allow easy retrieval of raw and pre-processed NGS data.  
 
In conclusion, high-throughput approaches for comparative and functional 
genomics based on NGS offer new hope in the fight against M. tb. On the one 
hand, we have been able to obtain novel insights into bacterial evolution and 
disease etiology that will promote identification of new drug targets and 
antigens for vaccine development, and on the other hand we have the 
potential to develop tools to detect, monitor, and control pathogen threats in 
real time.  
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